From cab5b175060ac57c8ce77271fd4ee43228dc25ab Mon Sep 17 00:00:00 2001 From: Ruben Date: Sun, 30 Nov 2025 00:08:22 +0100 Subject: [PATCH 01/50] Add translation support for FAQ summary and answer links Use translations for FAQ summary label and read full answer button text while falling back to default Norwegian text if translations are not available --- custom/templates/list-faq.php | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/custom/templates/list-faq.php b/custom/templates/list-faq.php index a7e2bbd..d2b7984 100644 --- a/custom/templates/list-faq.php +++ b/custom/templates/list-faq.php @@ -14,9 +14,9 @@
-

Kort oppsumert:

+

- Les hele svaret +
From a273a7a7a0ee6835f10308fe41582d99b1b360d4 Mon Sep 17 00:00:00 2001 From: Ruben Date: Fri, 12 Dec 2025 21:51:37 +0100 Subject: [PATCH 02/50] Add language switching and improve table styling Add h4 styling Improve footnotes styling Add table styling with alternating row colors Make site multilingual with language switching Update footer to use translations Improve language handling in navigation links --- custom/styles/base.css | 41 +++++++++++++++++++++++++ custom/templates/base.php | 64 ++++++++++++++++++++++++++++++++------- 2 files changed, 94 insertions(+), 11 deletions(-) diff --git a/custom/styles/base.css b/custom/styles/base.css index 8ff1228..478a4f6 100644 --- a/custom/styles/base.css +++ b/custom/styles/base.css @@ -28,6 +28,7 @@ h1, h2, h3, h4, h5, h6 { margin-top: 1.3em; text-wrap: pretty; } +h4 { font-weight: 700} a { color: var(--color-green); @@ -113,6 +114,10 @@ main { font-size: 1.2rem; line-height: 1.35em; } + .footnotes { + margin-top:1rem; + hr {border: 1px var(--color-grey) dashed} + } } .button { @@ -121,6 +126,42 @@ main { } } +table { + margin-top: 1.3em; + border-collapse: collapse; + width: 100%; + + thead { + tr { + background-color: var(--color-green); + color: white; + + th { + padding: 0.6rem; + text-align: left; + font-weight: 600; + } + } + } + + tbody { + tr { + &:nth-child(odd) { + background-color: white; + } + + &:nth-child(even) { + background-color: oklch(0.96 0.005 173.93); + } + + td { + padding: 0.5rem 0.6rem; + border-bottom: 1px solid oklch(0.9 0.01 173.93); + } + } + } +} + /* BUTTONS */ .button { display: inline-block; diff --git a/custom/templates/base.php b/custom/templates/base.php index 40be390..4a1771f 100644 --- a/custom/templates/base.php +++ b/custom/templates/base.php @@ -13,7 +13,7 @@ function getActiveClass($href) { return rtrim(parse_url($_SERVER['REQUEST_URI'], ?> - + @@ -81,16 +81,42 @@ function getActiveClass($href) { return rtrim(parse_url($_SERVER['REQUEST_URI'],
@@ -102,15 +128,31 @@ function getActiveClass($href) { return rtrim(parse_url($_SERVER['REQUEST_URI'],
- -

Følg oss på Facebook, Instagram og Mastodon

- -

Nettsiden er håndkodet av Ruben Solvang ved hjelp av HTML, CSS og minimale doser PHP. Det tok ms å generere siden.

- -

Follow us on Mastodon

- -

This website was hand-coded by Ruben Solvang using HTML, CSS and minimal doses of PHP. It took ms to generate this page.

+ +

+ + +

+ +

+ $lang) { + $url = $langUrls[$lang] ?? '/'; + + // Get language name: use language_name from that language's translations + if ($lang === $currentLangCode) { + $langName = $trans['language_name'] ?? strtoupper($lang); + } else { + $langName = $trans["language_name_$lang"] ?? strtoupper($lang); + } + + if ($index > 0) echo ' | '; + echo '' . htmlspecialchars($langName) . ''; + } + ?> +

From f949439ebff4a8c0de14fc7e951d4c9d191cedf1 Mon Sep 17 00:00:00 2001 From: Ruben Date: Fri, 12 Dec 2025 21:53:19 +0100 Subject: [PATCH 03/50] Add content and translations --- content/00-hero.en.html | 5 + content/00-hero.html | 5 + content/01-intro.en.md | 5 + content/01-intro.md | 5 + content/02-brosjyrer.en.html | 6 + content/02-brosjyrer.html | 6 + content/03-goals.en.md | 27 ++ content/03-goals.md | 27 ++ content/artikler/pasientinfo/article.md | 271 ++++++++++------- content/faq/Hva-er-MC/article.en.md | 45 +++ content/faq/Hva-er-MC/article.md | 30 +- content/faq/Hva-er-MC/metadata.ini | 3 + content/faq/dokumentasjon/article.en.md | 37 +++ content/faq/dokumentasjon/article.md | 15 +- content/faq/dokumentasjon/metadata.ini | 4 + .../faq/et-politisk-sporsmal/article.en.md | 24 ++ content/faq/et-politisk-sporsmal/article.md | 15 +- content/faq/et-politisk-sporsmal/metadata.ini | 5 +- content/faq/forerkort/article.en.md | 51 ++++ content/faq/forerkort/article.md | 90 ++---- content/faq/forerkort/metadata.ini | 3 + content/faq/historie/article.en.md | 11 + content/faq/historie/article.md | 18 +- content/faq/historie/diagnoser-Norge.jpg | Bin 199990 -> 0 bytes content/faq/historie/metadata.ini | 3 + content/faq/resept-norge/article.en.md | 67 +++++ content/faq/resept-norge/article.md | 56 +++- content/faq/resept-norge/metadata.ini | 3 + .../article.en.md | 30 ++ .../typer-medisinsk-cannabis-norge/article.md | 25 +- .../metadata.ini | 3 + content/frontpage.php | 42 --- content/kontakt/00-some.en.md | 7 + content/kontakt/01-kontaktskjema.en.php | 277 ++++++++++++++++++ .../article.en.md | 17 ++ .../2025-09-26-banebrytende-studie/article.md | 10 +- .../{cover.jpg => cover-old.jpg} | Bin .../2025-09-26-banebrytende-studie/cover.png | Bin 0 -> 85465 bytes .../article.en.md | 19 ++ .../article.html | 19 -- .../article.md | 19 ++ .../metadata.ini | 1 + content/om-oss/historie.en.md | 35 +++ content/om-oss/historie.md | 34 ++- content/om-oss/metadata.ini | 1 + content/om-oss/vedtekter/vedtekter.en.md | 68 +++++ content/om-oss/vedtekter/vedtekter.md | 68 +++++ custom/languages/en.ini | 13 + custom/languages/no.ini | 13 + 49 files changed, 1192 insertions(+), 346 deletions(-) create mode 100644 content/00-hero.en.html create mode 100644 content/00-hero.html create mode 100644 content/01-intro.en.md create mode 100644 content/01-intro.md create mode 100644 content/02-brosjyrer.en.html create mode 100644 content/02-brosjyrer.html create mode 100644 content/03-goals.en.md create mode 100644 content/03-goals.md create mode 100644 content/faq/Hva-er-MC/article.en.md create mode 100644 content/faq/dokumentasjon/article.en.md create mode 100644 content/faq/et-politisk-sporsmal/article.en.md create mode 100644 content/faq/forerkort/article.en.md create mode 100644 content/faq/historie/article.en.md delete mode 100644 content/faq/historie/diagnoser-Norge.jpg create mode 100644 content/faq/resept-norge/article.en.md create mode 100644 content/faq/typer-medisinsk-cannabis-norge/article.en.md delete mode 100644 content/frontpage.php create mode 100644 content/kontakt/00-some.en.md create mode 100644 content/kontakt/01-kontaktskjema.en.php create mode 100644 content/nyheter/2025-09-26-banebrytende-studie/article.en.md rename content/nyheter/2025-09-26-banebrytende-studie/{cover.jpg => cover-old.jpg} (100%) create mode 100644 content/nyheter/2025-09-26-banebrytende-studie/cover.png create mode 100644 content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.en.md delete mode 100644 content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.html create mode 100644 content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.md create mode 100644 content/om-oss/historie.en.md create mode 100644 content/om-oss/metadata.ini create mode 100644 content/om-oss/vedtekter/vedtekter.en.md create mode 100644 content/om-oss/vedtekter/vedtekter.md diff --git a/content/00-hero.en.html b/content/00-hero.en.html new file mode 100644 index 0000000..b9b9e63 --- /dev/null +++ b/content/00-hero.en.html @@ -0,0 +1,5 @@ +
+
+

"We are the patients lost in the shuffle"

+
+
diff --git a/content/00-hero.html b/content/00-hero.html new file mode 100644 index 0000000..7e09c6a --- /dev/null +++ b/content/00-hero.html @@ -0,0 +1,5 @@ +
+
+

«Vi er pasientene som faller mellom alle stoler»

+
+
diff --git a/content/01-intro.en.md b/content/01-intro.en.md new file mode 100644 index 0000000..a20dd43 --- /dev/null +++ b/content/01-intro.en.md @@ -0,0 +1,5 @@ +# About us + +We are a voluntary advocacy organization working to ensure that patients who could benefit from medical cannabis receive equitable and safe treatment with medical supervision. This medication group should be financially accessible through public reimbursement programs, and patients should not lose fundamental rights when receiving legally prescribed medicine! + +Read our story diff --git a/content/01-intro.md b/content/01-intro.md new file mode 100644 index 0000000..01853b0 --- /dev/null +++ b/content/01-intro.md @@ -0,0 +1,5 @@ +# Om oss + +Vi er en frivillig interesseorganisasjon som arbeider for at pasienter som kan ha nytte av medisinsk cannabis skal motta likeverdig og trygg behandling med oppfølging fra lege. Medikamentgruppen skal være økonomisk tilgjengelig gjennom offentlig refusjonsordninger og pasienter skal ikke miste grunnleggende rettigheter når de mottar lovlig medisin! + +Les vår historie diff --git a/content/02-brosjyrer.en.html b/content/02-brosjyrer.en.html new file mode 100644 index 0000000..842d44d --- /dev/null +++ b/content/02-brosjyrer.en.html @@ -0,0 +1,6 @@ +
+
+

Help us spread knowledge and open doors! We've created simple brochures that can be shared with patients, professionals, patient organizations, and politicians. Download, print, and share!

+ View brochures +
+
diff --git a/content/02-brosjyrer.html b/content/02-brosjyrer.html new file mode 100644 index 0000000..bd1b58b --- /dev/null +++ b/content/02-brosjyrer.html @@ -0,0 +1,6 @@ +
+
+

Hjelp oss å spre kunnskap og åpne dører! Vi har laget enkle brosjyrer som kan deles med pasienter, fagpersoner, pasientforeninger og politikere. Last ned, skriv ut og del!

+ Vis brosjyrer +
+
diff --git a/content/03-goals.en.md b/content/03-goals.en.md new file mode 100644 index 0000000..90d94d7 --- /dev/null +++ b/content/03-goals.en.md @@ -0,0 +1,27 @@ +# What are we aiming to achieve? + +Our goal is to address the challenging situation facing Norwegian patients, doctors, and researchers regarding the use of medical cannabis (MC) in treatment. We aim to do this by establishing a registry study and trial program in Norway, along with several implementation criteria that must be met for the study to be realized: + +## 1. Registry study in collaboration with international partners + +We are working to ensure Norway implements Europe's largest medical cannabis registry study, developed at Imperial College London. The study tracks all medical cannabis users—regardless of their condition or the type of cannabis they use. This will help us determine which variants of the medication work best for different conditions, along with any side effects that arise. We are already in discussions with several Norwegian researchers who want to contribute to this effort. + +## 2. Broad indication for evaluation + +For the study to expand our knowledge, we need to change the current situation where it is nearly impossible for patients to obtain a prescription for medical cannabis in Norway. This is despite the medication already being considered low-risk in medical terms. We want it recognized that cannabis affects the body's endocannabinoid system, meaning it can help with many different conditions. Therefore, we believe doctors should be able to prescribe medical cannabis for any condition where the patient hasn't received adequate help from other medications—as long as there are no medical reasons to avoid it. + +## 3. General prescribing rights for all doctors + +We want doctors who can already prescribe strong medications (A- and B-class drugs) to also be able to prescribe medical cannabis to their patients. We advocate for the doctor who knows the patient best—and who follows up with them regularly—to be the one making the decision about medical cannabis. We believe this will lead to better follow-up and more holistic treatment for patients. It will also relieve pressure on a specialist healthcare system that is already overworked and has long waiting lists. + +## 4. Coverage of medication costs + +A medication isn't truly accessible if patients can't afford it. Everyone who receives a prescription for medical cannabis should have their costs covered by the public system, just like other medications. Currently, patients mostly have to pay for it themselves, creating a two-tier system where only those with financial means can access treatment. This leads to many patients buying cannabis illegally, where it's cheaper but lacks quality control and safety. + +## 5. Continuing education for doctors and healthcare professionals + +It's crucial that the prescription of medical cannabis is handled in a safe and responsible manner. This means doctors need access to courses and training on how medical cannabis is used to treat various conditions. Doctors themselves admit they lack knowledge in this area, which is also confirmed by studies. Without sufficient expertise, doctors can't provide the best treatment or feel confident prescribing medical cannabis. + +## 6. Review of driver's license health requirements + +For patients to participate in the study, we need a thorough review of the regulations surrounding driver's licenses and medical cannabis. As the only country in Europe, Norway has rules that result in most patients losing their driver's license when they receive a prescription for medical cannabis. This happens even when they use variants and doses that don't impair driving ability. For other medications that may temporarily affect driving, Norway operates on a trust system. The current regulations therefore discriminate against patients using medical cannabis. diff --git a/content/03-goals.md b/content/03-goals.md new file mode 100644 index 0000000..56ca391 --- /dev/null +++ b/content/03-goals.md @@ -0,0 +1,27 @@ +# Hva ønsker vi å oppnå? + +Målet er å finne en løsning på den utfordrende situasjonen som norske pasienter, leger og forskere står overfor når det gjelder bruk av medisinsk cannabis (MC) i behandling. Dette søker vi å gjøre ved å opprette en registerstudie og prøveordning i Norge, sammen med flere gjennomføringskriterier som må være oppfylt for at studien skal kunne realiseres: + +## 1. Registerstudie i samarbeid med utlandet + +Vi jobber for at Norge skal implementere Europas største registerstudie på medisinsk cannabis, utviklet ved Imperial College i London. Studien følger opp alle som bruker medisinsk cannabis - uansett hvilken sykdom de har eller hvilken type cannabis de bruker. Slik kan vi få oversikt over hvilke varianter av medikamentgruppen som virker best for ulike tilstander, sammen med bivirkninger som oppstår. Vi er allerede i dialog med flere Norske forskere som ønsker å bidra til dette. + +## 2. Bred indikasjon for vurdering + +For at studien skal kunne gi oss utvidet kunnskap, er det behov for å endre dagens situasjon der det er nesten umulig for pasienter å få resept på medisinsk cannabis i Norge. Dette til tross for at medikamentgruppen allerede ansees som lite risikabel i medisinsk sammenheng. Vi ønsker at det skal bli anerkjent at cannabis påvirker kroppens endocannabinoide system, som betyr at det kan hjelpe ved mange forskjellige sykdommer og plager. Vi mener derfor at leger bør kunne prøve ut medisinsk cannabis for alle tilstander der pasienten ikke har fått god nok hjelp av andre medisiner - så lenge det ikke er noen medisinske grunner til å unngå det. + +## 3. Generell forskrivningsrett for alle leger + +Vi ønsker at leger som allerede kan skrive ut sterke medisiner (A- og B-preparater), også skal kunne skrive ut medisinsk cannabis til sine pasienter. Vi jobber for at legen som kjenner pasienten best - og som følger dem opp til vanlig - også skal være den som tar avgjørelsen om medisinsk cannabis. Vi mener dette vil gi bedre oppfølging og mer helhetlig behandling for pasientene. Dette vil også være en viktig avlastning for en spesialisthelsetjeneste som allerede er overarbeidet og har lange helsekøer. + +## 4. Dekning av medisinutgifter + +Et medikament er ikke reelt tilgjengelig hvis pasienten ikke har råd til det. Alle som får resept på medisinsk cannabis bør få dekket kostnadene gjennom det offentlige, slik som med andre medisiner. I dag må pasientene stort sett betale alt selv, noe som skaper et todelt system der bare de med god økonomi får tilgang til behandlingen. Dette fører til at mange pasienter kjøper cannabis illegalt, der det er billigere, men uten kvalitetskontroll og trygghet. + +## 5. Etterutdanning av leger og helsepersonell + +Det er viktig at foreskrivningen av medisinsk cannabis foregår på en trygg og forsvarlig måte. Det er derfor behov for at leger får tilbud om kurs og opplæring om hvordan medisinsk cannabis brukes for å behandle ulike sykdommer. Legene sier selv at de mangler kunnskap på dette området, noe som også bekreftes i studier. Uten tilstrekkelig kunnskap kan ikke legene gi pasienter den beste behandlingen eller føle seg trygge på å forskrive medisinsk cannabis. + +## 6. Gjennomgang av helsekrav til førerkort + +For at pasienter skal kunne delta i studien er det behov for en grundig gjennomgang av regelverket rundt førerkort og medisinsk cannabis. Som det eneste landet i Europa, har Norge et regelverk som fører til at de fleste pasienter mister førerretten når de får resept på medisinsk cannabis. Dette selv om de bruker varianter og doser som ikke påvirker kjøreevnen. For andre medikamenter som kan ha en midlertidig påvirkning av kjøreevne operer Norge med et tillitssystem. Dagens regelverk diskriminerende derfor pasienter som bruker medisinsk cannabis. diff --git a/content/artikler/pasientinfo/article.md b/content/artikler/pasientinfo/article.md index f6460ac..242bad8 100644 --- a/content/artikler/pasientinfo/article.md +++ b/content/artikler/pasientinfo/article.md @@ -1,159 +1,204 @@ # Informasjon til pasienter -Denne artikkelen tar for seg en kort introduksjon til hva medisinsk cannabis er, hvilke diagnoser som er aktuelle for resept i våre naboland og muligheter for å få resept i Norge. Medisinsk cannabis kan være en trygg og effektiv løsning for mange ulike helseutfordringer. Det er ikke én medisin, men en gruppe medikamenter som kan tilpasses akkurat dine behov. I Norge er det nå 19 ulike varianter tilgjengelig, og forskning viser at pasienter som får effekt opplever bedre livskvalitet, mindre smerte og bedre søvn. Under her kan du lese mer. +Denne artikkelen tar for seg en kort introduksjon til hva medisinsk cannabis er, hvilke diagnoser som er aktuelle for resept i våre naboland og muligheter for å få resept i Norge. Medisinsk cannabis kan være en trygg og effektiv løsning for mange ulike helseutfordringer. Det er ikke én medisin, men en gruppe medikamenter som kan tilpasses akkurat dine behov. I Norge er det nå 19 ulike varianter tilgjengelig, og forskning viser at pasienter som får effekt opplever bedre livskvalitet, mindre smerte og bedre søvn. Under kan du lese mer. # Hva er medisinsk cannabis og hvordan virker det? -Medisinsk cannabis (MC)er ikke én medisin men en medikamentgruppe. Medikamentene kommer i administrasjonsformer som kapsler, oljer, tabletter, tørket plantemateriale (damping) og munnspray. Hvert av produktene i disse kategoriene har en unik kombinasjon av virkestoffer og administrasjonform. En pasient som ikke får effekt av en variant av medisinen (eksempelvis Sativex) vil likevel kunne få god effekt av en annen variant og/eller administrasjonsform. I Norge har vi nå 19 varianter av MC. +Medisinsk cannabis (MC) er ikke én medisin, men en medikamentgruppe. Medikamentene kommer i administrasjonsformer som: +- Kapsler +- Oljer +- Tabletter +- Tørket plantemateriale (damping) +- Munnspray -De mest kjentevirkestoffene i MC er THC og CBD. THC kan øke appetitten og redusere kvalme. Det kan også lindre smerte, betennelser og problemer med muskelkontrollen. Ved overdosering kan THC gi en euforisk virkning (ruseffekt). CBD er ikke rusgivende, men kan virke avslappende. CBD kan redusere smerte og betennelse, kontrollere epileptiske anfall, og være til hjelp i behandling av psykisk sykdom og avhengighet. CBD er for øvrig tilgjengelig som helsekost i våre naboland.  [I tillegg til dette](https://www.mdpi.com/1420-3049/26/9/2774 "https://www.mdpi.com/1420-3049/26/9/2774") finner vi mindre mengder av andre cannabinoider som eksempelvis CBG, CBN og THCV og også ikke-cannabinoide fenoler, flavoriner, terpener og alkaloider. Disse virker sammen i en entourage-effekt og bidrar til at hver variant av medisinen har unike virkninger. MC er dermed ideell for persontilpasning. +Hvert produkt har en unik kombinasjon av virkestoffer og administrasjonsform. En pasient som ikke får effekt av én variant (f.eks. Sativex) kan likevel få god effekt av en annen variant eller administrasjonsform. I Norge er det nå 19 varianter av MC tilgjengelig. -Virkestoffene i cannabis virker på et stort reseptorsystem i kroppen som kalles det endocannabinoide systemet. Dette består av tre hovedbestanddeler: +## Virkestoffer i medisinsk cannabis -- endocannabinoider (som Anandamide og 2-AG) +De mest kjente virkestoffene i MC er **THC** og **CBD**: -- CB1 og CB2 reseptorer +- **THC** kan: + - Øke appetitten + - Redusere kvalme + - Lindre smerte, betennelser og muskelkontrollproblemer + - Gi ruseffekt ved overdosering -- regulatoriske enzymer. +- **CBD** er ikke rusgivende, men kan: + - Virke avslappende + - Redusere smerte og betennelse + - Kontrollere epileptiske anfall + - Hjelpe ved psykisk sykdom og avhengighet -Det endocannabinoide systemet er et stort reseptorsystemsom har som hovedoppgave å opprettholde den naturlige balansen i kroppen, eller homeostasen. Det virker som en dirigent som koordinerer alle de viktige kroppssystemene vi har. Det er sentralt i regulering av mange viktige prosesser som angst, smerte, betennelser, stress, immunreseponser, humør og appetitt. Dysreguleringer i systemet er også antatt å påvirke utvikling av symptomer ved Huntington’s, Alzenheimer, Parkinson og MS. +CBD er tilgjengelig som helsekost i våre naboland. I tillegg finnes mindre mengder av andre cannabinoider (CBG, CBN, THCV) og ikke-cannabinoide forbindelser som fenoler, flavonoider, terpener og alkaloider. Disse virker sammen i en *entourage-effekt* som gir hver variant unike egenskaper. -![](./endo.jpg) +## Det endocannabinoide systemet -Effekten på det endocannabinoide systemetforklarer også hvorfor cannabis har effekt på så mange symptomer og diagnoser.Cirka 50 % av [reseptene som nå skrives ut iEngland](https://www.bbc.com/news/articles/crgkxv6ljp4o "https://www.bbc.com/news/articles/crgkxv6ljp4o") skrives ut mot all typer langvarig smerte, 40 % skrives ut mot ulike mentale helsetilstander, 6 % mot nevrologiske tilstander og 4 % til andre diagnoser.  +Virkestoffene i cannabis påvirker kroppens **endocannabinoide system**, som består av: +- Endocannabinoider (f.eks. anandamid og 2-AG) +- CB1- og CB2-reseptorer +- Regulatoriske enzymer +Dette systemet har som hovedoppgave å opprettholde kroppens naturlige balanse (homeostase) og regulerer prosesser som: +- Angst og stress +- Smerte +- Betennelser +- Immunrespons +- Humør og appetitt +Dysregulering i systemet antas å påvirke symptomer ved sykdommer som Huntingtons, Alzheimers, Parkinsons og MS. -De vanligste diagnosene under hovedkategoriene i UK er: +![Endocannabinoide systemet](./endo.jpg) -![](./diagnoser-UK.jpg) +## Bruksområder +Omtrent **50%** av reseptene i England skrives ut mot: +- Langvarig smerte (50%) +- Mentale helsetilstander (40%) +- Nevrologiske tilstander (6%) +- Andre diagnoser (4%) +![Vanlige diagnoser i UK](./diagnoser-UK.jpg) -Tilstander som har fåttgodkjenningsfritak i Norge per 2023: +### Godkjente tilstander i Norge (per 2023) -![](./diagnoser.jpg) +| Diagnose/tilstand | CBD | CBD/THC | THC | +|----------------------------|-----|---------|-----| +| ADHD | ✓ | | | +| Apetitt | | | ✓ | +| Autisme | ✓ | | | +| Blodtrykksykdom | ✓ | | | +| Crohns | | | ✓ | +| Cluster/migrene/hodepine | ✓ | | ✓ | +| CRPS | | | ✓ | +| Epilepsi | ✓ | | | +| Fatigue/ME | | | ✓ | +| Fibromyalgi | ✓ | | | +| Hicka | ✓ | | | +| Kreftrelatert | ✓ | | ✓ | +| Kvalme | ✓ | | | +| Lindrende | | ✓ | | +| ME | ✓ | | | +| MS | ✓ | | ✓ | +| Muskeldystrofi | | | ✓ | +| Palliativ | | | ✓ | +| Parkinson | ✓ | | | +| Psoriasis | ✓ | | | +| Psykiske tilstander | | | ✓ | +| PTSD | ✓ | | ✓ | +| Reduserte blodplater | ✓ | | | +| Restless legs | ✓ | | ✓ | +| Reumatisme | ✓ | | | +| Sammensatte tilstander | | | ✓ | +| Schizofreni | ✓ | | | +| Skjelving/tremor | ✓ | | ✓ | +| Smerte | ✓ | ✓ | ✓ | +| Spasmer/kramper | ✓ | ✓ | ✓ | +| Stress/uro/angst | ✓ | | ✓ | +| Sårbehandling | ✓ | | | +| Søvnproblemer | ✓ | | ✓ | +| Tics | | | ✓ | +| Tourettes | | | ✓ | ## Er medisinsk cannabis trygt å bruke? -### Bivirkninger og sikkerhet: +### Bivirkninger og sikkerhet -Medisinsk cannabis regnes som et legemiddel med få alvorlige bivirkninger. Dette fremkommer gjennom studier og uttalelser fra erfarne fagpersoner. Det moralske og etiske knyttet til å teste ut medikamentgruppen i Real Life bør derfor være mindre problematisk. +Medisinsk cannabis regnes som et legemiddel med **få alvorlige bivirkninger**. Tidligere medisinsk fagdirektør i Legemiddelverket, Steinar Madsen, uttalte i [et intervju fra 2019](https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/): -Tidligere medisinsk fagdirektør i legemiddelverket, Steinar Madsen, har allerede i 2019 sagt følgende i en [intervju med Fagbladet](https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/ "https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/"): +> *"Det er en utbredt feiloppfatning at cannabis er et medisinsk risikabelt stoff. Cannabis er et legemiddel med få alvorlige bivirkninger."* -_«– Det er en utbredt feiloppfatning at cannabis eret medisinsk risikabelt stoff, sier Steinar Madsen til Fagbladet Journalen. Hanunderstreker at cannabis er et legemiddel med få alvorlige bivirkninger.»_ +**Studier og evalueringer**: +1. **Danmark (2024)**: 8 785 pasienter, 68 082 resepter over 6 år. + - *"Ingen sikkerhetsproblemer identifisert"* ([kilde](https://www.ism.dk/Media/637643720599030745/Evaluering%20af%20fors%c3%b8gsordningen%20med%20medicinsk%20cannabis%20-%20November%202020.pdf)). +2. **UK (2025)**: 40 000 pasienter over 2+ år. + - *"Godt tolerert, forbedret livskvalitet, angst og søvn"* (Erridge et al., under publisering). +3. **Nature Medicine (2025)**: 800 ryggpasienter over 1 år. + - Bivirkninger: Milde og forbigående (tretthet, svimmelhet). + - *"Ingen tegn til avhengighet eller abstinens"* ([kilde](https://www.nature.com/articles/s41591-025-03977-0)). -[Evalueringen av den Danske forsøksordningen](https://www.ism.dk/Media/637643720599030745/Evaluering%20af%20fors%c3%b8gsordningen%20med%20medicinsk%20cannabis%20-%20November%202020.pdf "https://www.ism.dk/Media/637643720599030745/Evaluering af fors%c3%b8gsordningen med medicinsk cannabis - November 2020.pdf"), som ble gjennomført i 2024, har på 6 år behandlet 8.785 pasienter og skrevet ut 68.082 resepter og konkluderer med følgende: +### Rus og avhengighet +- **Ruseffekt**: Ved medisinsk bruk regnes dette som en uønsket bivirkning ved **overdosering** av THC. + - Medisinsk dose: 0,5–20 mg THC **per døgn** (avhengig av diagnose). + - Startdose: 0,5–2,5 mg THC/døgn. + - Rusdose (uerfarne): ~15 mg THC; erfarne: >50 mg **per dose**. + - Varianter med <1% THC gir **ingen ruseffekt** (f.eks. isolert CBD). -_"Lægemiddelstyrelsen har på baggrund af bivirkningsindberetningerne **ikke identificeret signaler om sikkerhedsproblemer** ved brug af cannabis slutprodukter omfattet af forsøgsordningen." (vår utheving)_ +- **Avhengighet**: + - MC regnes **ikke** som fysisk avhengighetsskapende i medisinsk bruk. + - Studier viser **ingen abstinensproblemer** etter: + - 3 års bruk av Sativex ([kilde](https://pubmed.ncbi.nlm.nih.gov/21878454/)). + - 5 ukers bruk ved revmatisme ([kilde](https://pubmed.ncbi.nlm.nih.gov/16282192/)). + - 1 års bruk (Nature Medicine, 2025). + - Ved rekreasjonsbruk utvikler ~9% avhengighet ([kilde](https://pubmed.ncbi.nlm.nih.gov/17382831/)). + - Symptomer ved seponering: Søvnproblemer, rastløshet, irritabilitet (varer noen uker). -Evalueringen fra UK Medical Cannabis Registry, som da hadde fulgt 8.945 pasienter over 2 år finner (_Erridge et al. 2025: UK Medical cannabis registry: an updated clinical outcomes analysis across all conditions. Nylig akseptert for publisering i ICRS, men ikke trykket enda):_   +--- +## Tilgjengelige varianter i Norge (per 2025) -_“..medical cannabis was largely well-tolerated. Moreover, there was an improvement in health-related quality of life, anxiety and sleep.”_ +### Registrerte cannabis-legemidler (RCL) +- **Sativex**: Munnspray (27 mg THC + 25 mg CBD per ml). +- **Epidyolex**: Munnspray (100 mg CBD/ml). -Ifølge Mikael Sødergren (som er forskningsleder for denne studien ved Imperial College) inneholder studien per juni 2025 data fra 40.000 pasienter og han skriver følgende i en mail til oss i Stopp lidelsen: +### Cannabis-based Medical Products (CBMP) med GMP-standard -_“...we now have >40,000 with similar safety profile seen”_ +#### Tørket plantemateriale -En helt [ny stor randomisert studie](https://www.nature.com/articles/s41591-025-03977-0), publisert i Nature Medicine, har fulgt 800 ryggpasienter over ett år og oppsummerer med følgende: +- Bediol: 63 mg THC + 80 mg CBD/gram. +- Bedrocan: 220 mg THC + ≤10 mg CBD/gram. +- Bedica: 140 mg THC + ≤10 mg CBD/gram. +- Bedrobinol: 135 mg THC + ≤10 mg CBD/gram. +- Bedrolite: ≤10 mg THC + 75 mg CBD/gram. -*Bivirkninger var hovedsakelig milde og forbigående (f.eks. tretthet og svimmelhet). Ingen tegn til avhengighet eller abstinens ble observert.* +#### Dråper (oljer) -Cannabiser beheftet med en del misforståelser og stigma knyttet til at virkestoffet THC i cannabis også kan brukes som et rusmiddel. Ved medisinsk bruk regnes ruseffekt som en uønsket bivirkning som kan oppstå ved overdosering av THC. I så henseende er ikke medisinsk cannabis alene. Vi har flere medikamenter som kan gi ruseffekt ved overdosering. Alt handler om dose, opptrapping, tilvenning og innhold av virkestoffer. Opptrapping av THC foregår gjennom en tilvenningsperiode, tilsvarende det man gjør ved eksempelvis bruk av Lyrica og Benzodiazepiner. THC brukt medisinsk, ligger vanligvis på doser mellom 0,5 - 20 mg **i døgnet**, men dette avhenger av diagnose og individuelle forhold. Startdoser ligger gjerne på 0,5 - 2,5 mg THC i døgnet. Til sammenligning regnes èn rusdoseå ligge fra 15 mg THC blant uerfarne brukere, og gjerne over 50 mg **per dose** for erfarne brukere. Varianter som inneholder under 1 % THC kan man ikke oppnå ruseffekt av. Dette er typisk isolert CBD (som i Epidyolex) eller helplante CBD med GMP-standard. +- **Glostrup**: + - ≤1 mg THC + 20/50/100/300 mg CBD/ml. +- **Adven**: + - ≤1 mg THC + 10/50 mg CBD/ml. + - 10 mg THC + 10 mg CBD/ml. + - 20 mg THC + ≤1 mg CBD/ml. +- **Stenocare**: + - 2 mg THC + 20 mg CBD/ml. + - 15 mg THC + 22,5 mg CBD/ml. + - 30 mg THC + 0,1 mg CBD/ml. +- **Stenocare Asturm**: 10 mg THC + 10 mg CBD/ml. -Avhengighetspotensiale er en annen faktor som mange er bekymret for. Dette er forståelig gitt erfaringene med oxicontin og den aggressive markedsføringen som ble ført i den forbindelse. MC regnes i liten grad å være fysisk avhengighetsskapende. En RCT-studie som ser på hva som skjer ved en rask seponering av Sativex, finner [ingen abstinensproblemer](https://pubmed.ncbi.nlm.nih.gov/21878454/) etter 3 års bruk. En annen RCT-studie, som [følger revmatismepasienterover 5 uker](https://pubmed.ncbi.nlm.nih.gov/16282192/), viser ingen problemer knyttet til å avslutte behandling. Det samme viser RCT-studien fra Nature Medicine som gikk over ett år: [det var ingen tegn til avhengighet eller abstinenser](https://www.nature.com/articles/s41591-025-03977-0). Ved rekreasjonsbruk er det anslått at cirka [9 % utvikler avhengig](https://pubmed.ncbi.nlm.nih.gov/17382831/)het. Symptomer på dette er eksempelvis søvnproblemer, rastløshetog irritabilitet som oppstår ved seponering, og vedvarer i noen uker. Avhengighetsbegrepet bør for øvrig brukes med forsiktighet når vi snakker om medisinsk bruk. Å avslutte behandlingen vil ofte medføre at symptomene MC brukes for, vender tilbake. Det kan oppstå toleranseutvikling (at dosene må økes), men dette reguleres ved at lege følger doseutvikling og gjennomfører nedtrappingsperioder dersom dette er nødvendig. +#### Andre legemidler (krever godkjenningsfritak) -### Hvilke varianter av MC er tilgjengelig på resept i Norge per 2025: +- Cesamet og Marinol (isolert THC). -**Registrertecannabis-legemidler (RCL)** +--- +## Priser +- **Dråper**: 4 000–6 000 kr/flaske (noen dyrere). +- **Tørket plantemateriale**: ~900 kr for 5 gram. +- **Selvtilvirket CBD-olje** (fra Bedrolite): ~300 kr/flaske (9% CBD, <1% THC). -- Sativex: munnspray ekstrakt med 27 mg THC og 25 mg CBD per ml. +**Refusjon**: +- **Registrerte legemidler** (Sativex/Epidyolex): Kan skrives ut på vanlig resept. +- **CBMP**: Krever [søknad om godkjenningsfritak via DMP](https://www.dmp.no). -- Epidyolex: munnspray ekstrakt med 100 mg/ml CBD. +--- +## Hvem kan skrive ut resept? -**Cannabis based medical products med GMP-standard (CBMP)** +**Forskrift om rekvirering av narkotika** ([Lovdata](https://lovdata.no/forskrift/2022-09-22-1630/)) fastsetter reglene: -- Bediol: tørket plantemateriale; 63 mg THCog 80 mg CBD per gram. +### **Fastleger kan skrive ut** (uten refusjon): +1. **Godkjente legemidler**: Sativex, Epidyolex. +2. **CBMP med <1% THC** (via DMP-søknad). +3. **Produkter med <10 mg/ml THC** (regnes som <1%). +4. **Attest** for vurdering av utenlandsk lege ([mal her](https://www.dmp.no/globalassets/bilder/godkjenning-av-legemidler/narkotika/legeerklaring-eksempel-2024.png)). -- Bedrocan: tørket plantemateriale; 220 mgTHC og ≤ 10 mg CBD per gram. +### **Spesialister (sykehusansatte)** kan skrive ut: +- **Alle produkter** (inkl. THC >1%). +- **Refusjon**: Kun ved resept fra **offentlig sykehus** (H-resept). + - *Merk*: Mange offentlige sykehus skriver ikke lenger ut resepter pga. refusjonsordningen. +- **Privat sykehus**: Pasienten må dekke kostnadene selv. -- Bedica: tørket plantemateriale; 140 mg THCog ≤ 10 mg CBD per gram. +**Refusjon gjelder for**: +- Sativex (fra 1.2.2021) og Epidyolex (fra 1.8.2018) **kun ved resept fra offentlig sykehus**. -- Bedrobinol: tørket plantemateriale; 135 mg THC og ≤ 10 mg CBD per gram. - -- Bedrolite: tørket plantemateriale; ≤ 10 mg THC og 75 mg CBD per gram. - -- Glostrup dråper:  ≤ 1 mg THC og 20 mg/ml CBD - -- Glostrup dråper: ≤ 1 mg THC og 50 mg/ml CBD   - -- Glostrup dråper: ≤ 1 mg THC og 100 mg/ml CBD   - -- Glostrup dråper: ≤ 1 mg THC og 300 mg/ml CBD   - -- Adven dråper:  ≤ 1mg THC og 50 mg/ml CBD   - -- Adven dråper: ≤ 1 mg THC og 10 mg/ml CBD   - -- Adven dråper: 10 mg/ml THC og 10mg/ml CBD - -- Adven dråper: 20 mg/ml THC og  ≤ 1 mg CBD - -- Stenocare dråper: 2 mg/ml THC og 20 mg/ml CBD   - -- Stenocare dråper: 30 mg/ml THC og 0,1 mg/ml CBD - -- Stenocare dråper: 15 mg/ml THC og 22,5 mg/ml CBD - -- Stenocare Asturm dråper: 10 mg/ml THC og 10 mg/ml CBD - -I tillegg kan legemidlene Cesamet og Marino (isolert THC) også søkes godkjenningsfritak for, men de er ikke registrerte cannabis-legemidler i Norge i dag. - -Priser; - -De fleste dråper ligger mellom 4-6.000,kroner per flaske med olje. Noen er enda dyrere. - -Tørket plantemateriale koster cirka kroner 900,- for 5 gram. - -Det er mulig for pasient å gjøre Bedrolite (tørket plantemateriale) om til olje. Da får man CBD-olje for cirka kroner 300,- per flaske, med 9 % CBD og mindre enn 1 % THC. - -- Registrerte cannabis-legemidler kan skrives ut på tradisjonelt vis. - -- Cannabis based medical products(CMBP) krever søknad om godkjenningsfritak via DMP. - -### Hvem kan skrive ut resept?: - -**_Forskrift om rekvirering av forbudt narkotikum og bestemte legemidler til humanmedisinsk bruk kapittel 3_** _angir rekvireringsregler for cannabinoiderog cannabisholdige legemidler. [Forskrift om rekvirering av forbudt narkotikum og bestemte legemidler til humanmedisinsk bruk - Lovdata](https://lovdata.no/forskrift/2022-09-22-1630/)_._ _Forskriften § 3-2 angir rekvireringsrett:_ - -_Leger som kan rekvirere cannabisholdige legemidler er leger som har rett til å rekvirere legemidler i reseptgruppe A:_ - -- §  _alle leger kan rekvirere cannabisholdige legemidler som er godkjente eller harmarkedsføringstillatelse i Norge. - -- §  _alle leger kan rekvirere cannabisholdige legemidler med THC-innhold under 1 % som ikke er godkjente eller har markedsføringstillatelse i Norge. - -- §  _lege med spesialistgodkjenning som er ansatt i det offentlige helsevesenet eller i privat sykehus, kan rekvirere cannabisholdige legemidler med THC-innhold over 1% som ikke er godkjente eller har markedsføringstillatelse i Norge._ - -Dette innebærer at fastlege kan skrive ut følgende produkter (uten refusjon): - -- Sativex og Epidyolex (registerte cannabis-legemidler). - -- CBMP-produkter med mindre enn 1 %THC (godkjenningsfritak via DMP). - -- Produkter med mindre enn 10 mg/mlTHC (dette regnes som mindre enn 1 %). - -- Fastlege kan også skrive attest som pasient kan ta med til utenlandsk lege for å få en vurdering knyttet til om medisinsk cannabis er en egnet behandligsform. Forslag til attest finnes på DMP sine nettsider og [kan lastes ned her](https://www.dmp.no/globalassets/bilder/godkjenning-av-legemidler/narkotika/legeerklaring-eksempel-2024.png "https://www.dmp.no/globalassets/bilder/godkjenning-av-legemidler/narkotika/legeerklaring-eksempel-2024.png"). - -Spesialist som jobber på sykehus kan skrive ut resept på alle produkter. Dette gjelder både private og offentlige sykehus. En resept via offentlig sykehus fører til refusjon av kostnader på H-resept. Noe som har gjort at de fleste offentlige sykehus nå har sluttet å skrive ut resept. Er resepten skrevet ut av en spesialist som jobber på privat sykehus må pasienten dekke kostnadene selv. - -Både Sativex og Epidyolex er markedsførte legemidler i Norge. Indikasjon for Sativex er spasmer ved MS, og for Epidyolex er indikasjon Dravet syndrom, Lennox Gastaut syndrom og anfall ved tuberøs sklerose. Disse preparatene kan også skrives ut utenfor indikasjon til andre tilstander. Kostnader til medikamentet dekkes på H-resept (Sativex ble overført til H-resept 1.2.2021 og Epidyolex 1.8.2018). Det vil si at dersom en spesialist på offentlig sykehus skriver ut resept, blir kostnadene dekket. Dersom en annen lege skriver ut resept, må pasienten dekke kostnadene selv. - -Sentrale kilder: - -- [Forskrift om rekvirering avforbudt narkotikum og bestemte legemidler til humanmedisinsk bruk](https://lovdata.no/dokument/SF/forskrift/2022-09-22-1630) - -- [Direktoratet for medisinskeprodukter: Behandling med cannabisinnenfor dagens regelverk](https://www.dmp.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak/behandling-med-cannabis-innenfor-dagens-regelverk) - -- [Direktoratet for medisinskeprodukter: Legemidler på reise inn til Norge](https://www.dmp.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-inn-til-norge#CBD-(cannabidiol)-4) - -Her er det spesielt kapitlene som omhandler «Legemidler med narkotiske virkestoffer» og «CBD (cannabidiol)» som er av størst interesse. +--- +## Sentrale kilder +1. [Forskrift om rekvirering av narkotika](https://lovdata.no/dokument/SF/forskrift/2022-09-22-1630). +2. [DMP: Behandling med cannabis](https://www.dmp.no/godkjenningsfritak/for-leger-og-tannleger/legemidler-det-ofte-er-sporsmal-om-ved-godkjenningsfritak/behandling-med-cannabis-innenfor-dagens-regelverk). +3. [DMP: Import av legemidler](https://www.dmp.no/tilvirkning-import-og-salg/import-av-legemidler-til-personlig-bruk/legemidler-pa-reise-inn-til-norge#CBD-(cannabidiol)-4). diff --git a/content/faq/Hva-er-MC/article.en.md b/content/faq/Hva-er-MC/article.en.md new file mode 100644 index 0000000..4435e29 --- /dev/null +++ b/content/faq/Hva-er-MC/article.en.md @@ -0,0 +1,45 @@ +# What is medical cannabis? + +Medical cannabis isn’t a single medication but rather a category of medicines. These products come in various forms, including capsules, oils, tablets, dried plant material, and oral sprays. There are three main types of medical cannabis products available by prescription: + +- Approved pharmaceuticals (currently Sativex and Epidyolex in Norway) +- GMP-standard medical products, collectively referred to as *Cannabis-Based Products for Medical Use* (CBPMs). The GMP standard ensures precise, consistent levels of active compounds in each product. +- Compounded medications prepared to GMP standards (pharmacy-produced). + +![](./mc.jpg) + +Each product in these categories has a unique combination of active ingredients and delivery methods. A patient who doesn’t respond to one formulation—such as Sativex—may still benefit from another variant or administration form. Norway currently offers 19 different medical cannabis products, while the UK provides over 200 options. + +The most well-known compounds in medical cannabis are THC and CBD. THC can stimulate appetite, reduce nausea, and alleviate pain, inflammation, and muscle control issues. At high doses, it may produce euphoric effects (intoxication). CBD, however, is non-intoxicating but can promote relaxation, reduce pain and inflammation, manage epileptic seizures, and potentially aid in treating mental health conditions and addiction. [Beyond these](https://www.mdpi.com/1420-3049/26/9/2774), cannabis contains smaller amounts of other cannabinoids—such as CBG, CBN, and THCV—as well as non-cannabinoid compounds like phenols, flavonoids, terpenes, and alkaloids. These components work together in an "entourage effect," giving each product its distinct properties and necessitating personalized treatment tailored to individual patient needs. + +The active compounds in cannabis interact with the body’s **endocannabinoid system**, a vast receptor network comprising three key elements: endocannabinoids (e.g., anandamide and 2-AG), CB1 and CB2 receptors, and regulatory enzymes. This system plays a crucial role in maintaining the body’s natural balance (homeostasis) and regulates essential processes such as anxiety, pain, inflammation, stress responses, immunity, mood, and appetite. Dysregulation in this system is believed to contribute to symptoms in conditions like Huntington’s, Alzheimer’s, Parkinson’s, and multiple sclerosis. + +![](./endo.jpg) + +This broad influence on the endocannabinoid system explains why cannabis can address a wide range of symptoms and conditions. In England, roughly [50% of current prescriptions](https://www.bbc.com/news/articles/crgkxv6ljp4o) target chronic pain, 40% address mental health disorders, 6% treat neurological conditions, and 4% cover other diagnoses. + +Medical cannabis often faces stigma due to THC’s recreational use. However, products containing less than 1% THC (such as isolated CBD in Epidyolex or whole-plant CBD with GMP certification) cannot produce intoxication. With higher THC concentrations, intoxication is considered an unwanted side effect of overdose—similar to other medications that may cause impairment at excessive doses. Effective medical use depends on proper dosing, gradual titration, and adaptation to the patient’s needs. Typical therapeutic THC doses range from [0.5–20 mg **daily**](https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-021-00073-1) after a [titration period](https://pubmed.ncbi.nlm.nih.gov/39781623/), comparable to medications like pregabalin or benzodiazepines. Starting doses are usually 0.5–2.5 mg THC per day. For context, a single recreational dose begins at around 10 mg THC for inexperienced users and often exceeds [50 mg **per dose** for regular users](https://www.liebertpub.com/doi/10.1089/can.2023.0209?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed). + +Dependence potential is another common concern, understandable given past issues with drugs like oxycodone. However, medical cannabis carries a low risk of physical dependence. A randomized controlled trial examining abrupt discontinuation of Sativex found [no withdrawal symptoms](https://pubmed.ncbi.nlm.nih.gov/21878454/) after three years of use. Another RCT tracking arthritis patients over five weeks reported [no issues upon stopping treatment](https://pubmed.ncbi.nlm.nih.gov/16282192/). A [recent double-blind study](https://www.nature.com/articles/s41591-025-03977-0) following 800 patients for a year detected no signs of dependence or withdrawal. While recreational use carries an estimated [9% risk of dependence](https://pubmed.ncbi.nlm.nih.gov/17382831/), this term requires careful interpretation in a medical context—discontinuation may lead to the return of symptoms the medication was addressing. Tolerance can develop (requiring dose adjustments), but this is managed through physician oversight, including periodic dose reductions when necessary. + +### Side effects and safety + +Medical cannabis is considered a medication with few serious adverse effects, supported by research and expert statements. + +In a 2019 interview with *Fagbladet*, Steinar Madsen, former medical director of the Norwegian Medicines Agency, stated: + +> *“There’s a widespread misconception that cannabis is a medically risky substance,”* Madsen told *Fagbladet Journalen*. *“In reality, it’s a medication with few serious side effects.”* + +A [2024 evaluation of Denmark’s medical cannabis pilot program](https://www.ism.dk/Media/637643720599030745/Evaluering%20af%20fors%c3%b8gsordningen%20med%20medicinsk%20cannabis%20-%20November%202020.pdf), which treated 8,785 patients over six years (issuing 68,082 prescriptions), concluded: + +> *“Based on adverse event reports, the Danish Medicines Agency **has not identified any safety concerns** related to cannabis-based products covered by the pilot program.”* (emphasis added) + +An analysis from the UK Medical Cannabis Registry, following 8,945 patients over two years (*Erridge et al. 2025: UK Medical Cannabis Registry: an updated clinical outcomes analysis across all conditions*, accepted for publication in ICRS), found: + +> *“...medical cannabis was largely well-tolerated. Moreover, there was an improvement in health-related quality of life, anxiety and sleep.”* + +According to Mikael Sødergren, the study’s lead researcher at Imperial College, the registry included data from over 40,000 patients as of June 2025. In an email to *Stopp lidelsen*, he noted: + +> *“...we now have seen more than 40,000 [patients] with a similar safety profile.”* + +A [new randomized trial](https://www.nature.com/articles/s41591-025-03977-0), published in *Nature Medicine*, involved over 800 patients with chronic lower back pain followed for one year. Side effects were more common in the whole-plant extract group (83.3%) than the placebo group (67.3%), but most were mild and temporary (e.g., fatigue, dizziness). No signs of dependence or withdrawal were observed. diff --git a/content/faq/Hva-er-MC/article.md b/content/faq/Hva-er-MC/article.md index be6a702..978153c 100644 --- a/content/faq/Hva-er-MC/article.md +++ b/content/faq/Hva-er-MC/article.md @@ -1,30 +1,22 @@ -# Hva er medisisk cannabis? - -## Spørsmål - -Hva er egentlig medisinsk cannabis? - -## Svar +# Hva er egentlig medisinsk cannabis? Medisinsk cannabis er ikke én medisin men en medikamentgruppe. Medikamentene kommer i administrasjonsformer som kapsler, oljer, tabletter, plantemateriale og munnspray. Det finnes tre kategorier av medisinske produkter som skrives ut påresept: - Legemidler med markedsføringstillatelse (I Norge er dette idag Sativex og Epidyolex) - -- Medisinske produkter med GMP-standard. Dette går under fellesbetegnelsen Cannabis Based Products for Medical Use, forkortet til CBPM’s. GMP-standarden holder så høy kvalitet at man vet eksakt innhold av virkestoffer i alle disse produktene. - +- Medisinske produkter med GMP-standard. Dette går under fellesbetegnelsen Cannabis Based Products for Medical Use, forkortet til CBPM’s. GMP-standarden holder så høy kvalitet at man vet eksakt innhold av virkestoffer i alle disse produktene. - Magistrelt fremstilte medikamenter med GMP-standard (apotekfremstilt). ![](./mc.jpg) Hvert av produktene i disse kategoriene har en unik kombinasjon av virkestoffer og administrasjonform. En pasient som ikke får effekt av en variant av medisinen, eksempelvis Sativex, vil likevel kunne få god effekt av en annen variant og/eller administrasjonsform. I Norge har vi nå 19 varianter av MC. Tilsammenligning har de i England over 200 varianter. -De mest kjente virkestoffene i MC er THC og CBD. THC kan øke appetitten og redusere kvalme. Det kan også lindre smerte, betennelser og problemer med muskelkontrollen. Ved overdosering kan THC gi en euforisk virkning (ruseffekt). CBD er ikke rusgivende, men kan virke avslappende. CBD kan redusere smerte og betennelse, kontrollere epileptiske anfall, og muligens være til hjelp i behandling av psykisk sykdom og avhengighet. [I tilleggtil dette](https://www.mdpi.com/1420-3049/26/9/2774 "https://www.mdpi.com/1420-3049/26/9/2774") finner vi mindre mengder av andre cannabinoider som eksempelvis CBG, CBN og THCV og også ikke-cannabinoide fenoler, flavoriner, terpener og alkaloider. Disse virker sammen i en “entourage” effekt og bidrar til at hver variant av medisinen har unike virkninger. Noe som også gjør at MC bør person tilpasses, til hver enkelt pasient sitt behov. +De mest kjente virkestoffene i MC er THC og CBD. THC kan øke appetitten og redusere kvalme. Det kan også lindre smerte, betennelser og problemer med muskelkontrollen. Ved overdosering kan THC gi en euforisk virkning (ruseffekt). CBD er ikke rusgivende, men kan virke avslappende. CBD kan redusere smerte og betennelse, kontrollere epileptiske anfall, og muligens være til hjelp i behandling av psykisk sykdom og avhengighet. [I tilleggtil dette](https://www.mdpi.com/1420-3049/26/9/2774) finner vi mindre mengder av andre cannabinoider som eksempelvis CBG, CBN og THCV og også ikke-cannabinoide fenoler, flavoriner, terpener og alkaloider. Disse virker sammen i en “entourage” effekt og bidrar til at hver variant av medisinen har unike virkninger. Noe som også gjør at MC bør person tilpasses, til hver enkelt pasient sitt behov. Virkestoffene i cannabis virker på et stort reseptorsystem i kroppen som kalles det endocannabinoide systemet. Dette består av tre hovedbestanddeler: endocannabinoider (som Anandamide og 2-AG), CB1 og CB2 reseptorer og regulatoriske enzymer. Det endocannabinoide systemet er et stort reseptorsystem som har som hovedoppgave å opprettholde den naturlige balansen i kroppen, eller homeostasen. Det er sentralt i regulering av mange viktige prosesser som angst, smerte, betennelser, stress- og immunreseponser, humør og appetitt. Dysreguleringer i systemet er også antatt å påvirke utvikling av symptomer ved Huntington’s, Alzenheimer, Parkinson og MS. ![](./endo.jpg) -Effekten på det endocannabinoide systemet forklarer også hvorfor cannabis har effekt på så mange symptomer og diagnoser. Cirka 50 % av [reseptene som nå skrives ut i England](https://www.bbc.com/news/articles/crgkxv6ljp4o "https://www.bbc.com/news/articles/crgkxv6ljp4o") skrives ut mot all typer langvarig smerte, 40 % skrives ut mot ulike mentale helsetilstander, 6 % mot nevrologiske tilstander og 4 % til andre diagnoser.  +Effekten på det endocannabinoide systemet forklarer også hvorfor cannabis har effekt på så mange symptomer og diagnoser. Cirka 50 % av [reseptene som nå skrives ut i England](https://www.bbc.com/news/articles/crgkxv6ljp4o) skrives ut mot all typer langvarig smerte, 40 % skrives ut mot ulike mentale helsetilstander, 6 % mot nevrologiske tilstander og 4 % til andre diagnoser.  Cannabis er beheftet med en del misforståelser og stigma knyttet til at virkestoffet THC i cannabis også kan brukes som et rusmiddel. Varianter som inneholder under 1 % THC kan man ikke oppnå ruseffekt av. Dette er typisk isolert CBD (som i Epidyolex) eller helplante CBD med GMP-standard. Ved høyere mengde THC gjelder følgende; ved medisinsk bruk regnes ruseffekt som en uønsket bivirkning som kan oppstå ved overdosering av THC. I så henseende er ikke medisinsk cannabis alene. Vi har flere medikamenter som kan gi ruseffekt ved overdosering. Alt handler om dose, opptrapping, tilvenning og innhold av virkestoffer. Vanlige doser av THC til medisinsk bruk ligger gjerne mellom [0,5 - 20 mg **idøgnet**](https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-021-00073-1) etter at man har gått gjennom en [tilvenning](https://pubmed.ncbi.nlm.nih.gov/39781623/), tilsvarende det man gjør ved eksempelvis Lyrica og Benzodiazepiner.  Startdoser ligger gjerne på 0,5 - 2,5 mg THC i døgnet. Til sammenligning regnes èn rusdose fra 10 mg THC blant uerfarne brukere, og gjerne over [50 mg **per dose** for erfarne brukere](https://www.liebertpub.com/doi/10.1089/can.2023.0209?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed). @@ -34,20 +26,20 @@ Avhengighetspotensiale er en annen faktor som mange er bekymret for. Dette er fo Medisinsk cannabis regnes som et legemiddelmed få alvorlige bivirkninger. Dette fremkommer gjennom studier og uttalelser fra erfarne fagpersoner. -Tidligere medisinsk fagdirektør i legemiddelverket, Steinar Madsen, har allerede i 2019 sagt følgende i en [intervju med Fagbladet](https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/ "https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/"): +Tidligere medisinsk fagdirektør i legemiddelverket, Steinar Madsen, har allerede i 2019 sagt følgende i en [intervju med Fagbladet](https://www.lmi.no/2019/06/26/cannabis-er-ikke-medisinsk-risikabelt/): -*«– Det er en utbredt feiloppfatning at cannabis er et medisinsk risikabelt stoff, sier Steinar Madsen til FagbladetJournalen. Han understreker at cannabis er et legemiddel med få alvorligebivirkninger.»_* +> *– Det er en utbredt feiloppfatning at cannabis er et medisinsk risikabelt stoff, sier Steinar Madsen til FagbladetJournalen. Han understreker at cannabis er et legemiddel med få alvorligebivirkninger.* -[Evalueringen av den Danske forsøksordningen](https://www.ism.dk/Media/637643720599030745/Evaluering%20af%20fors%c3%b8gsordningen%20med%20medicinsk%20cannabis%20-%20November%202020.pdf "https://www.ism.dk/Media/637643720599030745/Evaluering af fors%c3%b8gsordningen med medicinsk cannabis - November 2020.pdf"), som ble gjennomført i 2024, har på 6 år behandlet 8.785 pasienter og skrevet ut 68.082 resepter og konkluderer med følgende: +[Evalueringen av den Danske forsøksordningen](https://www.ism.dk/Media/637643720599030745/Evaluering%20af%20fors%c3%b8gsordningen%20med%20medicinsk%20cannabis%20-%20November%202020.pdf), som ble gjennomført i 2024, har på 6 år behandlet 8.785 pasienter og skrevet ut 68.082 resepter og konkluderer med følgende: -_"Lægemiddelstyrelsen har på baggrund af bivirkningsindberetningerne **ikke identificeret signaler om sikkerhedsproblemer** ved brug af cannabisslutprodukter omfattet af forsøgsordningen." (vår utheving)_ +> *– Lægemiddelstyrelsen har på baggrund af bivirkningsindberetningerne **ikke identificeret signaler om sikkerhedsproblemer** ved brug af cannabisslutprodukter omfattet af forsøgsordningen." (vår utheving)* -Evalueringen fra UK Medical Cannabis Registry, som da hadde fulgt 8.945pasienter over 2 år finner (_Erridge et al. 2025: UK Medical cannabisregistry: an updated clinical outcomes analysis across all conditions. Nylig akseptert for publisering i ICRS, men ikke trykket enda):_   +Evalueringen fra UK Medical Cannabis Registry, som da hadde fulgt 8.945pasienter over 2 år finner (_Erridge et al. 2025: UK Medical cannabisregistry: an updated clinical outcomes analysis across all conditions. Nylig akseptert for publisering i ICRS, men ikke trykket enda):_ -_“..medical cannabis was largely well-tolerated. Moreover, there was an improvement in health-related quality of life, anxiety and sleep.”_ +> _«...medical cannabis was largely well-tolerated. Moreover, there was an improvement in health-related quality of life, anxiety and sleep.»_ Ifølge Mikael Sødergren (som er forskningsleder for denne studien ved Imperial College) inneholder studien per juni 2025 data fra 40.000 pasienter og han skriver følgende i en mail til oss i Stopp lidelsen: -_“...we now have >40,000 with similar safety profile seen”_ +> _«...we now have seen more than 40,000 [patients] with similar safety profile»_ En [helt ny randomisert](https://www.nature.com/articles/s41591-025-03977-0) studie, publisert i det annerkjent tidsskriftet Nature Medicine, har over 800 pasienter med korsryggsmerter inkludert. De har fulgt pasientene i ett år. Bivirkninger var vanligere i gruppen som fikk helplanteekstrakt (83,3 %) enn i placebogruppen (67,3 %), men hovedsakelig milde og forbigående (f.eks. tretthet og svimmelhet). Ingen tegn til avhengighet eller abstinens ble observert. diff --git a/content/faq/Hva-er-MC/metadata.ini b/content/faq/Hva-er-MC/metadata.ini index 2e6f2cb..69c6bcc 100644 --- a/content/faq/Hva-er-MC/metadata.ini +++ b/content/faq/Hva-er-MC/metadata.ini @@ -1 +1,4 @@ summary = "Medisinsk cannabis er en stor medikamentgruppe med ulike produkter (oljer, spray, tabletter) og virkestoffkombinasjoner (mest kjent er THC og CBD) som virker på kroppens endocannabinoide system. Forskning viser få alvorlige bivirkninger og lavt avhengighetspotensial, men effekten krever individuell tilpasning. Produktene brukes mot en lang rekke tilstander som smerte, mentale helseutfordringer og nevrologiske tilstander." + +[en] +summary = "Medical cannabis encompasses a broad category of medications available in various forms (oils, sprays, tablets) with different active compound profiles—most notably THC and CBD—that interact with the body's endocannabinoid system. Research indicates minimal severe side effects and a low risk of dependence, though effectiveness often requires personalized adjustment. These products are used to address a wide spectrum of conditions, including chronic pain, mental health disorders, and neurological diseases." diff --git a/content/faq/dokumentasjon/article.en.md b/content/faq/dokumentasjon/article.en.md new file mode 100644 index 0000000..b036b19 --- /dev/null +++ b/content/faq/dokumentasjon/article.en.md @@ -0,0 +1,37 @@ +# When doctors say there’s "no evidence of effect" for medical cannabis, what do they mean? + +When physicians claim there is "no evidence of effect" for medical cannabis, they aren’t suggesting the treatment doesn’t work. Instead, they’re referring to a lack of the specific type of research that medical professionals traditionally rely on most heavily. Medical science evaluates treatments through different research approaches, with two primary categories standing out: + +1. **Randomized Controlled Trials (RCTs)** + These are considered the gold standard in medical research. In an RCT, participants are randomly assigned to one of two groups: one receives the treatment being tested, while the other gets a placebo (an inactive substance). Neither the patients nor the researchers know who is receiving which—this "blinding" helps eliminate bias and ensures the results are as objective as possible. +2. **Real-World Evidence (RWE) – Practical, Everyday Studies** + Unlike RCTs, these studies examine how a treatment performs in actual clinical practice over time. They track outcomes in large groups of patients using the medication in their daily lives. Examples include long-term observational studies following thousands of patients over years or comparative analyses between those who use the treatment and those who don’t. + +### Why Are There So Few RCTs on Medical Cannabis? + +Several challenges make it difficult to conduct RCTs for medical cannabis: + +- **High Costs and Logistical Hurdles** + RCTs require large participant groups, extended follow-up periods, and tightly controlled conditions—all of which are expensive. Since medical cannabis is difficult to patent, pharmaceutical companies have little financial incentive to fund these studies, leaving a significant research gap. +- **Small Studies Yield Unreliable Results** + Even when RCTs are conducted, limited funding often restricts them to small sample sizes. A study with too few participants may fail to detect a true effect, even if most patients benefit. For instance, if 80% of a small group experience improvement, the study might still conclude "no effect" due to statistical limitations. This is a major issue for cannabis research, where large-scale trials are rare. +- **Single-Strain Testing Doesn’t Reflect Real-World Use** + Medical cannabis isn’t a one-size-fits-all medication—it encompasses a wide range of strains and formulations. RCTs typically test just one variant, but in practice, treatment must be tailored to the individual. For example, the UK has approved over 200 different medical cannabis products, each with unique properties. +- **Study Participants Aren’t Always Representative** + RCTs often enroll patients with single, well-defined conditions and few comorbidities. However, many real-world patients have complex, overlapping health issues. This discrepancy means RCT results may not accurately predict how cannabis will work for the average person. + +### What About Other Types of Evidence? + +Given the challenges of conducting RCTs, researchers often rely on alternative study designs, such as Real-World Evidence. These studies can demonstrate clear benefits and, according to regulatory standards, should be considered valid documentation. Yet, they are frequently overlooked or dismissed by medical authorities. + +Examples of Real-World Evidence include: +- **Longitudinal studies** tracking thousands of patients over years. +- **Case-control studies** comparing outcomes between those who use cannabis and those who don’t. + +While these studies can show meaningful results, they are often deprioritized simply because they aren’t RCTs. + +So when doctors say there’s "no evidence of effect" for medical cannabis, they’re not claiming the treatment is ineffective. They’re pointing to a shortage of the *preferred* type of research. Many patients—such as those with arthritis—report significant relief from medical cannabis, and studies support these experiences. However, because not all medical communities acknowledge this evidence, cannabis is often rejected as a treatment option, even when it works for patients. The phrase "no evidence of effect" becomes a default response, despite real-world success. + +To ensure more patients can access medical cannabis when other treatments fail, we’re actively working to improve education, expand research, and foster transparency around what "evidence of effect" truly means. Through pilot programs and registry-based studies, we aim to gather practical insights into how medical cannabis performs across a broad spectrum of conditions. This knowledge is critical for giving patients and doctors confidence in their treatment decisions. + +But change doesn’t happen in isolation. Your voice and involvement matter. As more people understand the challenges and opportunities surrounding medical cannabis, progress becomes possible. You can help by sharing information—with friends, family, colleagues, or anyone who might benefit. Feel free to use our brochures as conversation starters to spread awareness. diff --git a/content/faq/dokumentasjon/article.md b/content/faq/dokumentasjon/article.md index 624ee77..7cc9eea 100644 --- a/content/faq/dokumentasjon/article.md +++ b/content/faq/dokumentasjon/article.md @@ -1,15 +1,8 @@ -# Hva betyr det når leger sier "ingen dokumentasjon" for effekt? - -## Spørsmål - -Mange pasienter har hørt legene si at det ikke er dokumentasjon for effekt av medisinsk cannabis. Hva betyr egentlig dette? - -## Svar +# Mange pasienter har hørt legene si at det ikke finnes dokumentasjon for effekt av medisinsk cannabis – men hva betyr dette egentlig? Når leger sier at det ikke finnes dokumentasjon for effekt av medisinsk cannabis, betyr det ikke at medisinen ikke virker. Det betyr at det ikke finnes nok av den typen forskning som leger og fagmiljøer tradisjonelt stoler mest på. I medisinsk forskning er det flere måter å undersøke om en medisin virker. De to viktigste typene er: 1. **RCT-studier (Randomiserte, kontrollerte studier)** Dette er den typen studier som leger og forskere stoler mest på. I slike studier blir pasientene delt tilfeldig i to grupper: En gruppe får den nye medisinen, og den andre gruppen får en placebo (en medisin uten virkestoff). Verken pasientene eller legene vet hvem som får hva. Dette gjøres for å unngå at forventninger påvirker resultatet. - 2. **Real World Evidence (RWE) – eller "hverdagsstudier"** Dette er studier som ser på hvordan medisinen virker i virkeligheten, over tid, på pasienter som bruker den i hverdagen. Eksempler på dette er oppfølgingsstudier der tusenvis av pasienter blir fulgt over flere år, eller studier der man sammenligner pasienter som bruker medisinen med pasienter som ikke gjør det. ### Hvorfor er det så få RCT-studier på medisinsk cannabis? @@ -17,11 +10,8 @@ Når leger sier at det ikke finnes dokumentasjon for effekt av medisinsk cannabi Det er flere grunner til at det er vanskelig å gjennomføre RCT-studier på medisinsk cannabis: - Det er dyrt og vanskelig å gjennomføre RCT-studier. De krever store pasientgrupper, lang oppfølging og kontrollert medisinering. Dette koster enorme summer. Medisinsk cannabis er vanskelig å patentere, noe som betyr at det er få bedrifter som er villige til å betale for slike studier. - - Små studier gir usikre resultater. RCT-studier som lykkes med å få finansiering, får som regel ikke nok penger til å lage store studier. Små studier gir mer usikre resultater, og selv om 4 av 5 pasienter opplever god effekt, kan studien likevel konkludere med "ingen effekt" hvis gruppen er for liten. Dette er et stort problem for cannabis, siden det er få store studier. - - RCT-studier tester bare én type cannabis. Medisinsk cannabis er ikke bare én medisin – det er en stor gruppe medisiner med mange varianter. I RCT-studier testes ofte bare én type cannabis, men i virkeligheten må behandlingen tilpasses den enkelte pasient. I England er det for eksempel godkjent over 200 ulike varianter av medisinsk cannabis. - - Pasientene i studiene er ikke alltid representative. Pasientene som deltar i RCT-studier er ofte silet og har ofte bare én diagnose og få tilleggslidelser. Men i virkeligheten har mange pasienter komplekse og sammensatte tilstander. Derfor gir ikke studiene alltid et godt bilde av hvordan cannabis virker på "vanlige" pasienter. ### Hva med andre typer studier? @@ -31,7 +21,6 @@ Siden RCT-studier er vanskelige å gjennomføre, bruker man ofte andre typer stu Eksempler på Real World Evidence: - Oppfølgingsstudier der tusenvis av pasienter blir fulgt over flere år. - - Kasus-kontroll-studier, der man sammenligner grupper av pasienter som bruker medisinen med grupper som ikke gjør det. Disse studiene kan vise at medisinsk cannabis har god effekt, men siden de ikke er RCT-studier, blir de ofte ikke tatt like alvorlig. @@ -40,4 +29,4 @@ Når leger sier at det ikke finnes dokumentasjon for effekt av medisinsk cannabi For å sikre at flere pasienter får tilgang til medisinsk cannabis når andre behandlinger ikke hjelper, jobber vi aktivt for å skape bedre utdanning, mer forskning og større åpenhet rundt hva "dokumentasjon for effekt" egentlig betyr. Gjennom prøveordninger og registerstudier vil vi samle inn verdifull kunnskap om hvordan medisinsk cannabis virker i praksis, mot en lang rekke tilstander. Dette er viktig for å kunne gi pasienter og leger trygghet og gode beslutningsgrunnlag. -Men forandring skjer ikke alene. Din stemme og ditt engasjement betyr mye. Når flere forstår utfordringene og mulighetene knyttet til medisinsk cannabis, blir det lettere å skape endring. Du kan bidra ved å dele informasjon videre – med venner, familie, kollegaer eller andre som kan ha nytte av å vite mer. Bruk gjerne brosjyrene vi har utarbeidet som samtalestartere. +Men forandring skjer ikke alene. Din stemme og ditt engasjement betyr mye. Når flere forstår utfordringene og mulighetene knyttet til medisinsk cannabis, blir det lettere å skape endring. Du kan bidra ved å dele informasjon videre – med venner, familie, kollegaer eller andre som kan ha nytte av å vite mer. Bruk gjerne brosjyrene vi har utarbeidet som samtalestartere. diff --git a/content/faq/dokumentasjon/metadata.ini b/content/faq/dokumentasjon/metadata.ini index 26c64e4..8e002ca 100644 --- a/content/faq/dokumentasjon/metadata.ini +++ b/content/faq/dokumentasjon/metadata.ini @@ -1 +1,5 @@ summary = "Når leger sier at det "ikke finnes dokumentasjon for effekt" av medisinsk cannabis, betyr det ikke at medisinen ikke virker. Det betyr at dagens system for godkjenning av medisiner i hovedsak vektlegger bestemte typer studier, selv om det allerede finnes god dokumentasjon for effekten av medisinsk cannabis mot mange tilstander." + +[en] +summary = "When doctors claim there is 'no evidence of effectiveness' for medical cannabis, it doesn’t mean the treatment doesn’t work. Rather, it reflects how current drug approval systems prioritize specific types of studies—even though substantial evidence already supports the benefits of medical cannabis for many conditions." +slug = "documentation" diff --git a/content/faq/et-politisk-sporsmal/article.en.md b/content/faq/et-politisk-sporsmal/article.en.md new file mode 100644 index 0000000..62615f3 --- /dev/null +++ b/content/faq/et-politisk-sporsmal/article.en.md @@ -0,0 +1,24 @@ +# Why does access to prescription medical cannabis require political engagement and parliamentary support? + +When patients find relief from symptoms through medical cannabis but face barriers in the healthcare system, the issue isn’t about lack of effectiveness—it’s about a system that wasn’t designed for this kind of medicine. Medical cannabis differs from most pharmaceuticals in key ways, and these differences explain why political action is necessary to ensure patient access. + +### Why doesn’t medical cannabis fit the current system? + +1. **No patents, no financial incentive.** Most medications are developed by pharmaceutical companies that patent isolated compounds, conduct expensive trials, and recoup costs through exclusive sales rights. Medical cannabis, however, can’t be patented because it involves the whole plant with over 100 active compounds. Without financial incentives, the industry has little motivation to fund research, educate doctors, or pursue approvals. As a result, the medicine remains outside the established system. +2. **Knowledge comes from the ground up.** Unlike traditional drugs, which move from labs to patients, medical cannabis knowledge has grown from patient experiences. Many have turned to it after conventional treatments failed, finding relief and sharing their stories with doctors and fellow patients. This has built a strong foundation of real-world evidence (RWE), demonstrating effectiveness and safety across thousands of cases. +3. **Regulations aren’t adapted for medical cannabis.** Real-world studies and patient experiences are often overlooked because current rules were designed for patented, single-compound drugs. Even when RWE provides valuable insights into practical use, it’s not always accepted as sufficient proof. This leaves patients and doctors without clear guidelines, even when benefits are evident. + +### Why must politicians get involved? + +This isn’t something medical professionals can fix alone—it requires political will. Lawmakers must step in where the pharmaceutical industry typically would, taking responsibility to: + +- Fund and launch studies to identify which patient groups benefit from medical cannabis and how it should be used. +- Establish reimbursement schemes so the medicine is accessible to all who need it, regardless of financial barriers. +- Train doctors to prescribe medical cannabis safely and responsibly. +- Review regulations to ensure RWE and patient experiences are properly considered. + +Norway is lagging behind. Across much of Europe, medical cannabis is already part of healthcare, while Norwegian patients still lack access—despite existing evidence and proven benefits. This is about systemic fairness and political action. + +Your voice and experience are crucial for driving change. You can help by reaching out to local politicians, health policymakers, or patient organizations to explain why this matters—for you, for others, and for a fairer healthcare system. Sharing your story can raise awareness and build support. You can also back *Stopp lidelsen*, which advocates for better access to medical cannabis. + +Medical cannabis isn’t just a medical issue—it’s a political responsibility. Together, we can create the change that’s needed. diff --git a/content/faq/et-politisk-sporsmal/article.md b/content/faq/et-politisk-sporsmal/article.md index 3ee26b0..5b6b508 100644 --- a/content/faq/et-politisk-sporsmal/article.md +++ b/content/faq/et-politisk-sporsmal/article.md @@ -1,19 +1,11 @@ -# Hvorfor er medisinsk cannabis et politisk spørsmål? - -## Spørsmål - -Hvorfor krever tilgang til medisinsk cannabis på resept politisk involvering og stortingsflertall? - -## Svar +# Hvorfor krever tilgang til medisinsk cannabis på resept politisk involvering og stortingsflertall? Når pasienter opplever at medisinsk cannabis lindrer symptomer, men møter vegger i helsevesenet, handler det ikke om manglende effekt – men om et system som ikke er bygget for denne typen medisin. Medisinsk cannabis skiller seg fra de fleste andre legemidler på flere avgjørende måter, og det er disse forskjellene som gjør at politisk handling er nødvendig for å sikre pasienters tilgang. ### Hvorfor passer ikke medisinsk cannabis inn i dagens system? 1. Ingen patenter, ingen økonomisk drivkraft. De fleste legemidler utvikles av legemiddelindustrien, som patenterer et isolert virkestoff, gjennomfører dyre studier, og tjener inn kostnadene gjennom enerett til salg. Medisinsk cannabis kan ikke patenteres, fordi den består av hele planten med over 100 virkestoffer. Dette betyr at industrien ikke har økonomisk insentiv til å finansiere forskning, opplæring av leger eller søke godkjenning. Uten denne drivkraften blir medisinen stående utenfor det etablerte systemet. - 2. Kunnskapen kommer nedenfra. I stedet for å følge den tradisjonelle veien – fra laboratorium til pasient – har kunnskapen om medisinsk cannabis vokst fra pasienter og oppover. Mange har prøvd medisinen etter å ha opplevd lite eller ingen effekt av andre behandlinger. De har opplevd lindring, og delt erfaringene med leger og andre pasienter. Dette har skapt et solid grunnlag av erfaringsbasert kunnskap, støttet av store oppfølgingsstudier (Real World Evidence, RWE), som viser effekt og sikkerhet hos tusenvis av pasienter. - 3. Dagens regelverk er ikke tilpasset medisinsk cannabis. Oppfølgingsstudier og pasienterfaringer blir ofte oversett fordi dagens regelverk er laget for patenterbare, isolerte virkestoffer. Selv om RWE-studier gir verdifull kunnskap om hvordan medisinen virker i praksis, blir de ikke alltid godkjent som tilstrekkelig dokumentasjon. Dette gjør at pasienter og leger står uten klare retningslinjer, selv når effekten er tydelig. ### Hvorfor må politikere handle? @@ -21,15 +13,12 @@ Når pasienter opplever at medisinsk cannabis lindrer symptomer, men møter vegg Dette er ikke et problem fagmiljøene kan løse alene. Det krever politisk vilje og handling. Politikerne må gjøre den jobben som legemiddelindustrien vanligvis gjør og ta ansvar for å: - Finansiere og initiere studier som gir kunnskap om hvilke pasientgrupper som har nytte av medisinsk cannabis, og hvordan den best kan brukes. - - Sikre refusjonsordninger slik at medisinen blir tilgjengelig for alle som trenger den, uten at økonomi blir en barriere. - - Opplæring av leger slik at de får den kunnskapen de trenger for å skrive ut medisinsk cannabis trygt og ansvarlig. - - Gjennomgå regelverket for å sikre at dokumentasjon fra RWE-studier og pasienterfaringer blir tatt på alvor. Norge henger etter. I store deler av Europa er medisinsk cannabis allerede en del av helsetilbudet, mens norske pasienter fortsatt står uten tilgang – til tross for at dokumentasjonen finnes, og effekten er reell. Dette er et spørsmål om system, rettferdighet og politisk handling. Din stemme og din erfaring er avgjørende for å skape den endringen som trengs. Du kan bidra ved å ta kontakt med lokale politikere, helsepolitikere eller pasientforeninger for å fortelle hvorfor dette er viktig – både for deg, for andre pasienter, og for et mer rettferdig helsevesen. Ved å dele din historie med andre, kan du hjelpe flere til å forstå behovet for endring. Du kan også støtte Stopp lidelsen som jobber aktivt for bedre tilgang til medisinsk cannabis. -Medisinsk cannabis er ikke bare et medisinsk spørsmål – det er også et politisk ansvar. Sammen kan vi skape de endringene som trengs. +Medisinsk cannabis er ikke bare et medisinsk spørsmål – det er også et politisk ansvar. Sammen kan vi skape de endringene som trengs. diff --git a/content/faq/et-politisk-sporsmal/metadata.ini b/content/faq/et-politisk-sporsmal/metadata.ini index dfc1232..cabf4dc 100644 --- a/content/faq/et-politisk-sporsmal/metadata.ini +++ b/content/faq/et-politisk-sporsmal/metadata.ini @@ -1 +1,4 @@ -summary = "Siden medisinsk cannabis ikke kan patenteres, finansierer ikke legemiddelindustrien forskning eller opplæring – noe som gjør politisk handling nødvendig for å sikre pasienters tilgang til en medisin som allerede har dokumentert effekt. " +summary = "Siden medisinsk cannabis ikke kan patenteres, finansierer ikke legemiddelindustrien forskning eller opplæring – noe som gjør politisk handling nødvendig for å sikre pasienters tilgang til en medisin som allerede har dokumentert effekt." + +[en] +summary = "Because medical cannabis cannot be patented, the pharmaceutical industry has little incentive to fund research or education—leaving policymakers responsible for ensuring patients can access a treatment with proven therapeutic benefits." diff --git a/content/faq/forerkort/article.en.md b/content/faq/forerkort/article.en.md new file mode 100644 index 0000000..3d3d951 --- /dev/null +++ b/content/faq/forerkort/article.en.md @@ -0,0 +1,51 @@ +# Do you lose your driver’s license if prescribed medical cannabis in Norway? + +In most cases, patients in Norway automatically lose their driver’s license when prescribed medical cannabis. However, there are exceptions, and it is possible to apply to the county medical officer for an exemption. Below, we explain the current regulations in more detail. + +When discussing medical cannabis (MC) and driving privileges, it’s important to distinguish between **"registered cannabis medicines" (RCL)** and **"cannabis-based medical products" (CBMP)**. Currently, only two RCL products—Epidyolex and Sativex—are available on the Norwegian market. CBMPs are medical cannabis products that meet strict standardization requirements, including **Good Manufacturing Practice (GMP)**, meaning their active ingredient content is precisely known, similar to RCL medications. Illegally sold CBD products online do not meet GMP standards, are not prescribed, and fall under health supplement regulations in neighboring countries. The following discussion focuses solely on prescribed medical products. + +Below is a list of medical cannabis products currently prescribed in Norway [^1]. **THC** is the compound that can cause intoxication at high doses and is the primary concern for driving regulations, while **CBD** has no psychoactive effects. Both compounds have medical benefits. + +**Registered cannabis medicines (RCL)** + +- **Sativex**: Oral spray extract containing 27 mg THC and 25 mg CBD per ml. +- **Epidyolex**: Oral spray extract containing 100 mg/ml CBD. + +**Cannabis-based medical products with GMP standard [^2] (CBMP)** + +- **Bediol**: Dried plant material; 63 mg THC and 80 mg CBD per gram. +- **Bedrocan**: Dried plant material; 220 mg THC and ≤ 10 mg CBD per gram. +- **Bedica**: Dried plant material; 140 mg THC and ≤ 10 mg CBD per gram. +- **Bedrobinol**: Dried plant material; 135 mg THC and ≤ 10 mg CBD per gram. +- **Bedrolite**: Dried plant material; ≤ 10 mg THC and 75 mg CBD per gram. +- **Glostrup drops**: ≤ 1 mg THC and 20 mg/ml CBD +- **Glostrup drops**: ≤ 1 mg THC and 50 mg/ml CBD +- **Glostrup drops**: ≤ 1 mg THC and 100 mg/ml CBD +- **Glostrup drops**: ≤ 1 mg THC and 300 mg/ml CBD +- **Adven drops**: ≤ 1 mg THC and 50 mg/ml CBD +- **Adven drops**: ≤ 1 mg THC and 10 mg/ml CBD +- **Adven drops**: 10 mg/ml THC and 10 mg/ml CBD +- **Adven drops**: 20 mg/ml THC and ≤ 1 mg CBD +- **Stenocare drops**: 2 mg/ml THC and 20 mg/ml CBD +- **Stenocare drops**: 30 mg/ml THC and 0.1 mg/ml CBD +- **Stenocare drops**: 15 mg/ml THC and 22.5 mg/ml CBD +- **Stenocare Astrum drops**: 10 mg/ml THC and 10 mg/ml CBD + +Patients prescribed **Sativex or Epidyolex** may retain their driver’s license if the prescription is issued by a hospital specialist (the regulation specifies *"registered cannabinoid medicine"*). However, if the same medication is prescribed by a general practitioner, the license is revoked under current rules. + +There are **11 CBMP medications** with THC levels equal to or lower than those in Sativex, including several CBD-dominant products (≤ 1 mg THC) that cannot cause intoxication. Yet, under current regulations, all patients using these medications lose their driving privileges. The regulation states: *"Any other use of cannabinoid medicines is incompatible with operating a motor vehicle,"* which applies to all CBMPs. + +Revoking a driver’s license is a severe measure. Seriously ill individuals, already facing social isolation, become even more cut off when denied the ability to drive. It is crucial to carefully assess whether such restrictions are necessary. **Stopp lidelsen** advocates for revising Norway’s driving regulations on medical cannabis to align with other European countries and evidence-based research. + +Emerging [research](https://icadtsinternational.com/Fact-Sheets) suggests that regular medical cannabis use, including THC, is generally compatible with driving in most cases. Neighboring countries address this by advising patients not to drive if they feel impaired and to wait several hours after consuming high-THC products—similar to Norway’s approach with other medications. + +**Stopp lidelsen** has consulted two researchers specializing in cannabis and driving impairment. They highlight the following key studies: + +- [Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance](https://jamanetwork.com/journals/jama/fullarticle/2773562) +- [Does acute cannabidiol (CBD) use impair performance? A meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38528133/) +- [ICADTS-FactSheets](https://icadtsinternational.com/Fact-Sheets) + +Norway’s current regulations can be found [here](https://www.helsedirektoratet.no/veiledere/forerkortveileder/midler-som-kan-pavirke-kjoreevnen-35-37#legemidler-som-kan-pavirke-kjoreevnen). Unlike in neighboring countries, Norwegian doctors are legally required to report patients using medical cannabis to authorities—even if it does not impair driving ability—risking their medical license if they fail to comply. + +[^1]: Data from the Norwegian Medicines Agency, autumn 2024. +[^2]: The first five CBMPs listed are whole-plant materials measured in grams, though many patients use far less than 1 gram daily. diff --git a/content/faq/forerkort/article.md b/content/faq/forerkort/article.md index 11c5f70..f81ff9a 100644 --- a/content/faq/forerkort/article.md +++ b/content/faq/forerkort/article.md @@ -1,66 +1,39 @@ -# Mister man førerkortet om man får resept? - -## Spørsmål - -Får man beholde førerkortet om man får resept på medisinsk cannabis i Norge? - -## Svar +# Får man beholde førerkortet om man får resept på medisinsk cannabis i Norge? Som hovedregel mister alle pasienter i dag førerkortet når de får resept på medisinsk cannabis i Norge. Men det er noen unntak og det er mulig å søke fylkeslegen om dispenasjon. Under her vil vi beskrive dages regelverk i mer inngående detalj: Når det gjelder medisinsk cannabis (MC) og førerrett, er det først nyttig å definere forskjellen på "_registrerte cannabis-legemidler"_ (**RCL**) og det som kalles "_cannabisbased medical products"_ (**CBMP**). Munnsprayene Epidyolex og Sativex er de eneste to **RCL**-produkter som vi har på det norske markedet i dag. **CBMP** er medisinske cannabisprodukter som har høye medisinske krav til standardisering, og innehar en GMP-standard (Good Manufacturing Practice). Det vil si at de er så standardiserte at man vet eksakt innhold av virkestoffer, tilsvarende som for RCL-legemidlene. CBD-produkter som omsettes illegalt på nettet innehar ikke GMP-standarden og skrives heller ikke ut på resept, men omfattes av regelverk knyttet til helsekost, kosttilskudd eller lignende i våre naboland. Idet følgende er det kun de medisinske produktene som omtales. -Under her legger vi ved en liste over de medisinske cannabisprodukter som skrives ut på resept i Norge i dag[[1]](#_ftn1) THC er det virkestoffet som kan gi ruseffekt ved overdosering, og som er mest sentralt vedrørende førerkort. CBD har ingen euforiserende virkning, og gir ikke ruseffek. Begge virkestoffene har medisinske egenskaper.   +Under her legger vi ved en liste over de medisinske cannabisprodukter som skrives ut på resept i Norge i dag [^1] THC er det virkestoffet som kan gi ruseffekt ved overdosering, og som er mest sentralt vedrørende førerkort. CBD har ingen euforiserende virkning, og gir ikke ruseffek. Begge virkestoffene har medisinske egenskaper.   **Registrerte cannabis-legemidler (RCL)** -•       Sativex:munnspray ekstrakt med 27 mg THC og 25 mg CBD per ml. - -•       Epidyolex: munnspray ekstrakt med 100 mg/ml CBD. - - - -**Cannabis based medical products, med GMP-standard [2](#_ftn2**) (CBMP)** - -•       Bediol: tørket plantemateriale; 63 mg THC og 80 mgCBD per gram. - -•       Bedrocan: tørket plantemateriale; 220 mg THC og ≤ 10 mg CBDper gram. - -•       Bedica: tørket plantemateriale; 140 mg THC og ≤ 10 mg CBD pergram. - -•       Bedrobinol: tørket plantemateriale; 135 mg THC og ≤ 10 mgCBD per gram. - -•       Bedrolite: tørket plantemateriale; ≤ 10 mg THC og 75 mgCBD per gram. - -•       Glostrup dråper:  ≤ 1 mg THC og 20 mg/ml CBD - -•       Glostrup dråper: ≤ 1 mg THC og 50 mg/ml CBD   - -•       Glostrup dråper: ≤ 1 mg THC og 100 mg/ml CBD   - -•       Glostrup dråper: ≤ 1 mg THC og 300 mg/ml CBD   - -•       Adven dråper:  ≤ 1 mg THCog 50 mg/ml CBD   - -•       Adven dråper: ≤ 1 mg THC og 10 mg/ml CBD   - -•       Adven dråper: 10 mg/mlTHC og 10 mg/ml CBD - -•       Adven dråper: 20 mg/mlTHC og  ≤ 1 mg CBD - -•       Stenocare dråper: 2 mg/ml THC og 20 mg/ml CBD   - -•       Stenocare dråper: 30 mg/ml THC og 0,1 mg/ml CBD - -•       Stenocare dråper: 15 mg/ml THC og 22,5 mg/ml CBD - -•       Stenocare Astrum dråper: 10 mg/ml THC og 10 mg/ml CBD +- Sativex:munnspray ekstrakt med 27 mg THC og 25 mg CBD per ml. +- Epidyolex: munnspray ekstrakt med 100 mg/ml CBD. +**Cannabis based medical products, med GMP-standard [^2] (CBMP)** +- Bediol: tørket plantemateriale; 63 mg THC og 80 mgCBD per gram. +- Bedrocan: tørket plantemateriale; 220 mg THC og ≤ 10 mg CBDper gram. +- Bedica: tørket plantemateriale; 140 mg THC og ≤ 10 mg CBD pergram. +- Bedrobinol: tørket plantemateriale; 135 mg THC og ≤ 10 mgCBD per gram. +- Bedrolite: tørket plantemateriale; ≤ 10 mg THC og 75 mgCBD per gram. +- Glostrup dråper: ≤ 1 mg THC og 20 mg/ml CBD +- Glostrup dråper: ≤ 1 mg THC og 50 mg/ml CBD +- Glostrup dråper: ≤ 1 mg THC og 100 mg/ml CBD +- Glostrup dråper: ≤ 1 mg THC og 300 mg/ml CBD +- Adven dråper: ≤ 1 mg THCog 50 mg/ml CBD +- Adven dråper: ≤ 1 mg THC og 10 mg/ml CBD +- Adven dråper: 10 mg/mlTHC og 10 mg/ml CBD +- Adven dråper: 20 mg/mlTHC og ≤ 1 mg CBD +- Stenocare dråper: 2 mg/ml THC og 20 mg/ml CBD +- Stenocare dråper: 30 mg/ml THC og 0,1 mg/ml CBD +- Stenocare dråper: 15 mg/ml THC og 22,5 mg/ml CBD +- Stenocare Astrum dråper: 10 mg/ml THC og 10 mg/ml CBD **Sativex og Epidyolex** kan man i dag kjøre med (ordlyd i forskriften er _"Registrert cannabinoid-legemiddel"),_ dersom en spesialist som jobber på sykehus skriver ut resept. Men om det eksakte samme preparatet er utskrevet av fastlegen, mister man førerkortet ifølge reglementet. -Vi har videre hele 11 CBMP-medikamenter som inneholder samme, eller har et lavere innhold av THC i forhold til CBD, enn det Sativex har. Flere av produktene er CBD-medikamenter (≤ 1 mg THC) som det er umulig å oppnå ruseffekt av. Men ifølge reglementet fratas alle disse pasientene i dag førerkortet. Ordlyden i forskriften er: _"All annen bruk av cannabinoid-legemidler er uforenlig med føring av motorvogn_".  Dette omfatter alle CBMP-medikamentene.  +Vi har videre hele 11 CBMP-medikamenter som inneholder samme, eller har et lavere innhold av THC i forhold til CBD, enn det Sativex har. Flere av produktene er CBD-medikamenter (≤ 1 mg THC) som det er umulig å oppnå ruseffekt av. Men ifølge reglementet fratas alle disse pasientene i dag førerkortet. Ordlyden i forskriften er: _"All annen bruk av cannabinoid-legemidler er uforenlig med føring av motorvogn_". Dette omfatter alle CBMP-medikamentene. Det er et svært inngripende tiltak å frata mennesker førerkortet. Alvorlig syke mennesker som allerede er sosialt isolerte, blir enda mer isolerte når de blir fratatt førerretten. Det er derfor viktig at det vurderes nøye når, og om, det er nødvendig å frata mennesker denne viktige funksjonen. Stopp lidelsen jobber derfor for en revisjon av førerkortreglementet når det gjelder medsinsk cannabis, slik at det harmonere med andre land i Europa og kunnskapsbasert forskning. @@ -68,18 +41,11 @@ Vi begynner å få en god [forskningsbase](https://icadtsinternational.com/Fact- Stopp lidelsen har vært i kontakt med to forskere som jobber spesifikt med cannabis og påvirkning på førerevne. De fremhever følgende studier som viktige: -- [Effect of Cannabidioland](https://jamanetwork.com/journals/jama/fullarticle/2773562) [Δ](https://jamanetwork.com/journals/jama/fullarticle/2773562)[9](https://jamanetwork.com/journals/jama/fullarticle/2773562)[-](https://jamanetwork.com/journals/jama/fullarticle/2773562)[Tetrahydrocannabinolon Driving Performance](https://jamanetwork.com/journals/jama/fullarticle/2773562) - +- [Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance](https://jamanetwork.com/journals/jama/fullarticle/2773562) - [Does acute cannabidiol (CBD) use impair performance? A meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38528133/) +- [ICADTS-FactSheets](https://icadtsinternational.com/Fact-Sheets) -- [ICADTS](https://icadtsinternational.com/Fact-Sheets) [-](https://icadtsinternational.com/Fact-Sheets) [FactSheets](https://icadtsinternational.com/Fact-Sheets) +Link til dagens regelverk i Norge finner man [her.](https://www.helsedirektoratet.no/veiledere/forerkortveileder/midler-som-kan-pavirke-kjoreevnen-35-37#legemidler-som-kan-pavirke-kjoreevnen) I håndhevingen av regelverket er norske leger, til forskjell fra leger i naboland, pålagt en meldeplikt. Det vil si at en norsk lege er pålagt å bryte taushetsplikten og rapporterer at pasienten bruker medisinsk cannabis til myndigheten, selv om bruken ikke påvirker kjøreevne. Dersom dette ikke blir overholdt risikerer legen å miste sin legelisens. -Link til dagens regelverk i Norge finner man [her.](https://www.helsedirektoratet.no/veiledere/forerkortveileder/midler-som-kan-pavirke-kjoreevnen-35-37#legemidler-som-kan-pavirke-kjoreevnen) I håndhevingen av regelverket er norske leger, til forskjell fra leger i naboland, pålagt en meldeplikt. Det vil si at en norsk lege er pålagt å bryte taushetsplikten og rapporterer at pasienten bruker medisinsk cannabis til myndigheten, selv om bruken ikke påvirker kjøreevne. Dersom dette ikke blir overholdt risikerer legen å miste sin legelisens.  - - - -* * * - -[_**[1]**_](#_ftnref1) _Tallmateriale fra Direktoratet for medisinske produkter høsten 2024._ - -[_**[2]**_](#_ftnref2) _De første fem medikamentene på CBMP-listener er helt plantemateriale og er oppgitt i gram, men mange pasienter bruker langt mindre enn 1 gram i døgnet._ +[^1]: Tallmateriale fra Direktoratet for medisinske produkter høsten 2024. +[^2]: De første fem medikamentene på CBMP-listener er helt plantemateriale og er oppgitt i gram, men mange pasienter bruker langt mindre enn 1 gram i døgnet. diff --git a/content/faq/forerkort/metadata.ini b/content/faq/forerkort/metadata.ini index ab1a46d..c7c1140 100644 --- a/content/faq/forerkort/metadata.ini +++ b/content/faq/forerkort/metadata.ini @@ -1 +1,4 @@ summary = "I Norge mister pasienter som får resept på medisinsk cannabis vanligvis førerkortet, unntatt for Sativex og Epidyolex utskrevet av sykehusspesialist. Regelverket er strengt, selv for produkter med lavt THC-innhold. Det jobbes for å endre dette basert på ny forskning." + +[en] +summary = "In Norway, patients prescribed medical cannabis typically face automatic driver's license suspension—except when using Sativex or Epidyolex prescribed by a hospital specialist. The regulations remain rigid, applying even to low-THC products. However, ongoing efforts aim to revise these rules in light of emerging research." diff --git a/content/faq/historie/article.en.md b/content/faq/historie/article.en.md new file mode 100644 index 0000000..8541e42 --- /dev/null +++ b/content/faq/historie/article.en.md @@ -0,0 +1,11 @@ +# Is medical cannabis a new class of medication? + +The use of cannabis in medicine dates back more than 5,000 years, and in Norway, doctors could legally prescribe it until as recently as 1965. + +The plant likely originated in Asia but spread early to much of the world. Traces of its use in Norway go back to the Viking Age. One of the women buried in the Oseberg ship was found with a leather pouch containing cannabis seeds in her grave. According to Ellen Marie Næss, a university lecturer at the Museum of Cultural History, these seeds may have been used for pain relief—or to help communicate with the gods. The fibers of the cannabis plant were also put to practical use, such as making ropes, clothing, and sails. + +Hemp cultivation was widespread in Norway until the early 20th century. The fibers were used to produce textiles, ropes, and clothing, while the seeds were eaten by people, birds, and livestock or pressed into oil. Then came the "war on drugs," and overnight, growing hemp became illegal—despite the plant having been part of Norwegian agriculture and folk medicine for centuries. + +Medical use was also halted. Until 1965, Norwegian doctors could prescribe cannabis tinctures for conditions like pain, rheumatism, and insomnia, with patients picking up their medication at pharmacies—completely legally. But with the new drug policies, this too was banned. The decision went against the wishes of medical professionals and put an end to all medical cannabis prescriptions in Norway. Doctors risked fines and losing their licenses if they continued writing prescriptions. The drug class was removed from the Norwegian Pharmaceutical Handbook and eventually faded from memory. + +Today, patients still suffer from the abrupt policy shift of the 1960s. While neighboring countries have begun embracing medical cannabis for various conditions, Norway lags behind—not due to a lack of evidence, but because the knowledge, will, and courage to change the system remain insufficient. Stigma and prejudice continue to block access for patients in need of relief. diff --git a/content/faq/historie/article.md b/content/faq/historie/article.md index 6638882..7fe03a9 100644 --- a/content/faq/historie/article.md +++ b/content/faq/historie/article.md @@ -1,19 +1,11 @@ -# Hvor lenge har cannabis blitt brukt medisinsk? +# Er medisinsk cannabis en ny medikamentgruppe? -## Spørsmål +Cannabis har vært brukt medisinsk i over 5000 år, og var fullt lovlig å skrive på resept i Norge helt frem til 1965. -Er medisinsk cannabis en ny medikamentgruppe? +Planten har trolig sitt opphav i Asia, men spredte seg tidlig til store deler av verden. I Norge finnes spor av bruk helt tilbake til vikingtiden. En av kvinnene gravlagt i Osebergskipet hadde med seg en lærpose med cannabisfrø i graven. Ifølge universitetslektor Ellen Marie Næss ved Kulturhistorisk museum kan frøene ha vært brukt som smertestillende – eller som hjelp til å komme i kontakt med gudene. Cannabisplantens fibre ble også brukt til praktiske formål som tau, klær og seil. -## Svar - -Historien om medisinsk cannabis i Norge - -Visste du at cannabis har vært brukt medisinsk i over 5000 år? Og at det var fullt lovlig å skrive ut medisinsk cannabis på resept i Norge helt frem til 1965? - -Planten har trolig sitt opphav i Asia, men spredte seg tidlig til store deler av verden. I Norge finnes spor helt tilbake til vikingtiden. En av kvinnene gravlagt i Osebergskipet hadde med seg en lærpose med cannabisfrø i graven. Ifølge universitetslektor Ellen Marie Næss ved Kulturhistorisk museum kan frøene ha vært brukt som smertestillende – eller som hjelp til å komme i kontakt med gudene. Samtidig ble hamp, en variant av cannabis med lavt THC-innhold, brukt til praktiske formål som tau, klær og seil. - -Hampdyrking var utbredt i Norge helt frem til 1965. Fibrene ble brukt til tekstiler og tauverk, mens frøene ble spist direkte eller presset til olje. Men så kom «krigen mot narkotika», og over natten ble det ulovlig å dyrke hamp – til tross for at planten hadde vært en del av norsk landbruk og folkemedisin i århundrer. +Hampdyrking var utbredt i Norge helt frem til ut på 1900-tallet. Fibrene ble brukt til å lage klær, tekstiler og tauverk, mens frøene ble spist direkte av mennesker, fugler og husdyr eller presset til olje. Men så kom «krigen mot narkotika», og over natten ble det ulovlig å dyrke hamp – til tross for at planten hadde vært en del av norsk landbruk og folkemedisin i århundrer. Også medisinsk bruk ble stoppet. Frem til 1965 kunne norske leger skrive ut resept på cannabis-tinkturer mot blant annet smerte, revmatisme og søvnproblemer. Pasientene hentet medisinene på apoteket – helt lovlig. Men med narkotikapolitikken som kom, ble også dette forbudt. Vedtaket ble gjennomført mot fagmiljøenes vilje, og det satte en stopper for all forskrivning av medisinsk cannabis i Norge. Legene risikerte bøter og å miste lisensen om de fortsatte å skrive ut resept. Medikamentgruppen ble også tatt ut av Legemiddelhåndboken og gikk etter hvert i glemmeboken. -I dag lider vi fortsatt under ettervirkningene av denne politikken. Mens nabolandene våre har begynt å åpne opp for medisinsk bruk av cannabis til ulike sykdomstilstander, henger Norge etter. Ikke fordi dokumentasjonen mangler – men fordi kunnskapen, viljen og motet til å endre systemet fortsatt er for svak. Stigma og fordommer står i veien for pasienter som trenger lindring. +I dag lider pasienter fortsatt under denne pluttselige politiske endringen på 60-tallet. Mens nabolandene våre har begynt å åpne opp for medisinsk bruk av cannabis for ulike sykdomstilstander, henger Norge etter. Ikke fordi dokumentasjonen mangler – men fordi kunnskapen, viljen og motet til å endre systemet fortsatt mangler. Stigma og fordommer står i veien for pasienter som trenger lindring. diff --git a/content/faq/historie/diagnoser-Norge.jpg b/content/faq/historie/diagnoser-Norge.jpg deleted file mode 100644 index 61db0ccc87044b36e875f1e305837bd092103d0a..0000000000000000000000000000000000000000 GIT binary patch literal 0 HcmV?d00001 literal 199990 zcmd?QS5#AN6gC(-NR!@#C?KFT=~5&h(nJJAdWnh(NRuW3V(7htfYKrzsnQiN^d>63 zg%T1_q$kt}Az2CFncR%~t&%T(uSOHzWuV<(SqM)Dv zr2>DTiv^Glh>DW(zYlOx10NcC8X9V9noD$awDe4un3xzZF)}i zjf0bmi;IbshnJg^mz|S~^S_5sPyzo#O~XJ#!@$YR$jtdaeO+{c*yyP$sIXKN!XQdE z3Mw{=i#`w-1frk;to_g6|Kp;d1ZhV=GKi9bii(n&>OZT2U%v&u2T`-p zuwRqYrsXhuN+;~iDIb?f+*Vc7 zxu>hAZ(w-e{IP|lm9>qn)AJWEon2gC`TF_434jF#MMOqL$Hd0Pr)Rv&%*uZMA*ZOg zq_nKO;!|ZqV^ecW>zA)>J-vPX1A{}u-zO%gre|j7=FwQ(>e}x=>wh;k3Ht|!N5?0` zf2aTXMFFDv-`)B@J^R1;#Rm9ANli^fP4}N)6qEtLO~pn{b4`wxUE7TAsW*qPd>B3F z-L%5`ZUzyBM|iGhKI50TMHR8v3IDnFKRo+?=2-auE6@H<$Nn$B&>$u%3gG2Yv4J3< zbMvBj3DEzq?+)m3`+12}=ZlbVwYp>(_vlYS4cD`BpN!Uf%9Q--cbeC-dNX)iC)usL zsg996?|7AHN7rXY2+*4B(DrsZ|HRWfjjw4(bKdwP-R_Y0UG!>LSgJr0@lU8Gwg_c% zo__)I+M_4kJI}gKY+c=og^LI!1u5nSZ{tn8Ij!yuuoWk9t=+hqBTp;fD#f5~WEJRk z<^yLy5mP)?j6&kn9xRJ}`QU+T)qU49$q~kbRt~&20&izr*KpD>rE4>DG+f1?2eGm} zd)%93UV?Lydy}A-;Ute$drL?B3r6=}71ec(&l7E?=*JrK);%ezpbVX^dr_TNI+Uv2 z$d?HD(RHORn^3b4Ge(w;T70b|SH365Mf&iC(z!jsyHHKJ)Ugp?oVmd{h{LO$L>&#m z)h%h~zN9~aZ;ZUWd64xs$nSw7kFzgTV?o$%?LQ68U}}mKV4PsH~&*p@3osy6wbWV zviA!%;6k-rQO8e&o;@S+6GvCwkn}`_!8XKK952_xw)dbS!o|_LZ#O;zByW;s7ix0< zJ0WCe9xu{mg%WOu~)|$S$POLcJOsm!{rMlAb^qqIQygbF;W2@1e zbrL7laWH;2s_4~8C#NE^-tDI2=r+N``-W-1VYjcL zRWgG8sC#yNfPQG|BvU`iuTU{GY^pV?lvG1r!cc0cRBx*3l@nNgOb9_q!xKBHT)A_P(2Z6Liuh*+-TkqoFhiYGNk*&T5Fzyvyml#mmp}%eYIF!^<}ZK#eoXX_UZuWvhO6q;62C8}>aBOJ9Q1>NcDV56+p>gm zOCs{jj6AXImE@&iva+Cl7I>(wTymmpdAuV%z`w|SGxo9UQrA`1`^QP@b|AZ>8F9>kDiRhw1du4b;za*W-PM z#h>-ak$5Gkon~$EOAKAqr&fK?hCLGJLNA67r3_o>Mu<%{<*R-7@K(G4Q5coGX7@Ne zTPn@hd1x0ju)w{9^5&6OxpEn#xmAP;CS?B?B5(1m3A-9{H6)|SouevO^bG7t^VhG* zd=@PY8ujm1`A(H``0%FOSlI;KiYM=cL`kw;Wc4d+a6^f6>L-UV$$y z>`qbyXwrqtZ$En+4?3%iCqSc-Eg{{|L{0VVZWJpqtlUjg)cCji#El}39qQH$(b!MQ zAnCIfPl`LVt`{IahCwvjDYDG6Km*?|vJD$hGWLi|lavtI5+N#8q5K zqI8I-*Swc@M8EBnnouLw;_KAm&=G?r`qZ3eSl;-uM}xA(Lu-!II}%iTXvrx2-oOQj z8rFyli6ske*d7KT4@?F0CZ!jbizKEUeq=3osmt$lMJ5#7Aih20aO=G6$E@qF zVdGUe@2KHZL64!-kXL)mi*N|>S_$z2)PGG=gm|Le{H@tg zO7z~8n9IPvkVGU~y*sI-P86id2Rc=YKY;L){P4<21om01#d^HmeZp>Q>F8T0XPS}; zgH$PB1(QEFc_&?>Eh*;M%|TZZNz$vMU<}cS%#gb(dl|;FdJ>NkhnB~Fv?jT!EclIV zy`AO$K2!ez`s?u}-;-EPCyKBx(794kr$&bx!D=82*%Yw-w5%JqX62_(rvV%hQq$QmEdr_}ZNLDunAc7eAe zS0h)Vhpa?B+|MUNS&fQ1sCuBSon7E7L>!pjrIY<|q~=W^YLv-@rtj9zYquG$?CaI5 ziiT2tT{PjVdr3ehDyGDs*k?41ag3dxU4nG0vs+so&4+*M@Mpb2hc-T;eEkurttFsn zwLZFiegUF!$MeJvCR~89901Fikv!#D4yNrLEvLm>}b z>T){-&&*%~D}&q3c;CKGE|O=?i{)0VgG@*h=0k0rY?<=wrUrN2z~}0D-0nj5&kyWX zc60#K`0>uYDf7D{gAk?;onjc$erDGeqtl9NXb%pKU`jo&dCvH|$>WNzq(@q6elJCv zDcwA9o>}1Eu@M2t8&7M>=m?IP>0zENpJ-dzLfbL#uFN=kYd?ZAB8p zX5)4Ny1d=AZ~dV?DJ%6^&dyc#w5in#Sa2qUsSSXl22^dI0t6)2~31zlWxDMe3G8)(M ztY!Rry0Hdv0GHZVBSMju&O;?~$AxM_qD~sGzXQRy;~>2b0fWo@gs6f#tivU=-M2@( z^uO6{`Z+yBno>F0>xQbkI7gg9-DI)rJ4tviTxVhv@)FEwP&o$^>uA2sZLW2oqTy=JuFC7e;b$uHN7`y8xMd@k^iGj&SvusQ#Xq5askG^j3KR zGbrc<*FkMA5EIPj`Tkx!ve7lD8?O51f$+@0r(crCb6aF`kT4MJDx1K!OC)O(xqG4J>A9Ud-MIqf9g~Us3B~@L$NS;)3%~nC-9*0vS=O?~5m=4Y!O%_@FpF_52|~Eu8hbb- zwl4;IWKa_Qz}c-|xT;KhXtDTC1r@3YC3pb}PlsC&=z8|9Ab#y{Xi87PB}I}O7gU+g`e)bLuuV}`nw4(WPA&=;VUy+JVdGR(P)toC`@pZ9vS3gf2xo{i3mwB1#P;5Fb=|Qcx*7(%Q zbr`@3epdOUYv+ZULhvB+k|v07r!&r6=Zl@)Kj~+gk5qZt+ij-r#ox`7=QdAfh6C7% zhWflt@yrWN*M+&{j=JI2$*Lh&zSs!EJjM@wZAG;#)^|uWl)QNFu6jO0_@MdZ4K5UN z-=%I8iLP2jM!^}eDUqkr$iZQ!=)niBbu~(YPL}mk%@xi~(0YeO2iKMfd%eFQL1yFB zxny^5ht8A`_a*Ta$hIzak9UI%nE(<(o0~+_j*4Z$49?EO&eRwM%XC7Ir{>PZ@hfzV zigQvNzvcQ@NQfa{s{6Rv+2CKZ9uD{QD2DrdX{k?NHEA5%6%uewjP*?8|HBhm0lmf4 z?md<5^6WOU)#-Z`AFxr^hoOrCH>KA5T+VAdQhjq z4?4an`CU^PF%7*G;%rm>kr=ZoX~OETT%Jo)o}u)!x6A@|2g|yX zfDc}6aNCDT4y3+%{g=Dvz`S7d*Pj7NgNJ*|>WjMkJOAuNg+RmopkO7ggU%QrKnlT) zgK;D%INI+56wmLp*Y6&5A;ml{Z5o0_^Zs7T45U%YeS;1vkE;bi- zclqpoeT-?khngy->(c^>ICL_FuX#egHX-Or^WWgN<_bzLeFN#s!ODNTdlZxUkt@V;~?h&lLe8L*)HZFL5{%!wZ?J(I8(!8 z`knRm51i+d!rB7wyRRe>hk%_isvDT~?aYWIk6-U55FQ@%&-lPV@4IHIi?ep+9kuyu zhcc1sLyweyKlDxH|9u#;kiDYUN#MqGp#%DA#P<4H*{d&i^N*|J3%&XJwVt-13*}F)l>(0Qb`&*i-3C99 zRtVQ=oKiAjw{I@{@G>jFNU9-PGTJhhH|)vXrd%DT-(neqkk*(klW4L^c8}&YVp_S4 z+t|pOiPse#jzQ`V-G(ocm6PRJsTG(40E2&XtwT54-V5S8$weFYL@8fL3i(j3JR|J*M{K|TC!p7wrNL|!O^Q1BTY zVmZia#|-O7lVWBRxHVjL`e7SD2C|mk@&Fc_a-& zig*g8AsXRWK2#IaRNNcmuInOQq?RAlhO2(2fV96{;TSWeYcg|G07|F@Z z?d@se=Okz%+dn%!q5o%1yXHOgk%b&j7>$6o&;c0Kx>Z!*eCrVZ6OeWZ++_+PqN6GB#MFib~vu@|5Qr=LZ(!@=S)O6?w=f9M}K z=K9CO1VgXnce=2=<+47mMd|@rFB;DN`5Y;hW*w=WUw&L@hUjbMASWq5!mMk9?B*dv_G&LbadrfT&+b zx&=H~hq!qG>Qgp%oh0V=y|Jw+t?A)Rwf#3!ueV*E)-kZHFnzxux&0jZf2;ZTS$YKBv8rjKQV4LXr}GuLs41C$+K0kQ9pl+Fn`c_^I#!;27pln3SLCUh=uEdS#4m zoo;)cU~Ueu1!q{dWm@9Via@syTCA$b?yf(CmFi0ShaBN$n>py~moFuLF_?l> zAkXU(ml^*f(|}TTLCho;b+r+nm#ukSEh)dHh-`oIxn`zNd{;!{d%t*8rj=BWmX>g* zHXMu(?t-$)?#gyZuB5QQULLQoDg8<*SwI^~h>QE`g%-Sh>$9P1< zCs_IzP3w%z;n4MtNR}|M7cyUl2be(!Ws*u976=tBl0))6mo<~v%T*#wT-W@5gi9_! zJdm_5x5&RR^+%DmN{Pz8j;^VOOqQGR<3GI^@0U{**GnyzXJkN&_u&F~Y83wzNsUa4 zUm%8gKAPZ4Ec zGY2`ns!j&&6x^)aHp1@6TA#Ody4fY1D^DE5njwvY*ZUYnq#ljFzOH3(+v-wbj82nt z>03-Ck+s)$FZQtR@}{HUL^E^9eI~_o%guosp4GifDjAYDT=vy=L==};yM%c017EA% zY*nHUlfO46phHIm#cEO1`nJ> zyr`eAAF_5s=-~|b8JiM(On8Sn)<&E+^U(Mvqr%nIJ>GHOG5^CVvLK!=igc~gO|2jT z`%UEDl>aBxWTm6)jGW!i5E+|};U!K!JDGJ~cAuS1V6~yxXInWYJCbMmu4?OpI|3_u z^?`N2Jf9J~V%(J|s?i#g?--S~B-kRK3oD7L4V6&Rn4H~(E8^FCI*Heh3evEUSR;ah zR>oj>@LNww+Q!JsjryWy#p=Ix2G(CckAh@ApH1tge6l;pZZJC4-e4s zDN^8NclNMLlD$Hb=Sj&aW#|p46XANzx6ZjjYxw)VmIrKa!a@a7=@73VEX2_sXY_G|3E=%>L)4H9dqA=(sDE#P)x)aZzo86he#nTCzuxF zDpOz9`(|b*)t4{LP$yN*sT71TCedci4g>}4OhbAWBqJw|?%euWY-?@TBy(JMeUgIH zdXeg$9X;*qE(-K#5;Hc1kz{(Fe8|k$k7*u^f?vl{N)jLTq?b-r zKQwt?EW;a-YEU=#jkOEGhaae~e02(m@yi#tn1*-mFm4I(78V?gQ0xC`t8i5g*IIl? zf%}Xja^PoJIlyfFfRky&$l*WvHi|}1-#}HD{%m9NLVfeb=uEKR#Ej{B+Z;bgFJ|x0 z+xEMk_#|rlzI@}2P)#DT1`$l|URK7RgkFH$q3BT^f>>+$U$tM~R`2mYL{==8a9}cm zD^joOT^;gP)W5{aQeId$UisUT%n1_);Q1|B+j=*eW-xxGJHa8_D6Foyt7}2kVU;Qw zI5_oTlgF_H)&Z|DBwy`ONZc|D5mMG$;b^UoPaf@6_Q7m6D9_O3cftir-dN^Spf|VQ z5FQfOL)`q&D9J+^Td`h>e~+?_Dk6hN7D^g!7*`Gdc|^ zxx&eNa(P^=;j~ys|CQCcznv{9JK|1NB-jLk>Q!5Gqg0v+u7+~Z)Y#6%wOmfv81}th zxM%DsCz;>?)3hGkL`DJYCf?28zgvUF(7Eu_R=q_wLtTUHxhEH&ul-Ao=li;z{tChm zzlIm@`>?Z42mnq5+=rThYZ zmBu6sw;MZ7K2%mF7``t~=Ph1dsc;$bv_uEwv6P%d%*co=ObiuU;u_3mT$ns>k2I<_;iPD7`}?SN>fi*y*r zo@wS*8kYCWD$6}dO8su-=NA1m>gp4uEeL-Biqe!Is)n3BCs~h^6tMYsdvQNYqZ(le zw#b0_x@!w8{Rs-UXaaQF*~(t4x?52Ib-w=vC_`bob6f7|1*n+$t#>(5ytmCH&R>?z z`Y*o&GFC~{V6WLN`1Wdh+hbncEYtQp8CoiiL^IqT4J;T(n;@2gOQL%~5K9xOPI+22 zKj=>-pI61Z_NXLc=r+I!+y;pE-6cd2>h2$owg~5&RGqZ-%!tW_ z_RL$TO6FAng!&Jl7;x(i0(w}Q5{SVZ@hJZmJSO&tmAVv#tgKvHcra7R^-W*H^Gf2H z56w#$k3(We_ias8(zOYV+sk~!UhEBhk|^50Wv_Yjasn~&8{H{ODiTSlwfDG`Z~jGI8vkd((X z3@<)S!nI}^GAzO6r(e)sh$>;Mu27P(O~s1ixw0`yLq^yUIo{|g{_^|LPr*Ilcp#UE0onn~qwXVqs&y0MpE%sHdPvZ1{`RLB zyJgN*R$+;oYF?Hbd75d{;M;7%hlV_W>)?I6G-bvPfATosA<;)QV57LFpC^w5#g>DE z4W{o_>IxJ-Hm&?f1BgO)?39;T$J{$qfimI<6<4nPF;EY@T~Q-q2bDT9kzj5&DU;Iz zgWv(@)rS~5@<0gPI-YAbvcm*ETH5kmqNEKSkG~d@(}%m*g<~ z8qV(Q0z|wq*qxh;OtLi@STe9)v|DsLl}U1QqG@Zc!JNu$`3x&_jd=dDf?Z*QmbW=~ zd&RVgNA1Ct%3&P6%0gFAA@W=L&Eq?(jbA)zH?BRV9}F9&D;0~un_w}~o`<I`z6j}Ns!Xb&Q`A-XaC@GTSxouN_ycO zn8ot#-vul8;|+#bxO6CHsg(9ZBK?*uLx^HAgSmIORnY^ZIO<1>3wD$i(%IYH$>XG} z)%Q-RsqweZ^TtRN*c2wWoPp+In3utXf6~*woUB48Cr%Zf9}L&Z(jF^Da(h}Al+P67 zM|(pUV6w(jihHauJKZtAb3Lnqg^CbKo z3~Js%Orz@&P)}j1wv|ov&lh68|7&UX=YfdD7h#FvmrtNq>)u093a8Ah+b8&j1--8m z*NCnw#HQR26Pv-*V;=X|e|%jK(Gx-ckbm9x{AHUgFOjMj%%(U!*J8^yIXqc$|9ai`{0WzzFmGqL-|f7pcN!c}gq`8~~qh;Kp#5yJ4m z^UMp-D=#Mdg}<6&1eNHbNo@9@BV(wj?M~4Wt9q~mcLAome4y<#gHiFkfKq&2c*mU;2SGn1^ItXRn5I(E1i_oX z)Lkg^>z}l8_oO>Rlp}J~x`-u6`Z0}49y5`${T*Q(tdth!aC2!p2ynQffC2Pqyd26<1Q zeiKweHRM+9YHqIgX$njzZRLx3``O_X&c6A;E7SbzYnafxR{#hYsK?c) z^v#k5CS*Gd%S7~@s_p0cum3Lkd@bune72U3^4+xj!I@BqB>5_0T=Ob12iasCb<)pD z2WK2R%&j`VO%#MHI0sa~GE;Jr{_uH=42v)+rbXZUWd{P8))tHRaYb{*%&{V#pC{k^5aQ^+3oEaT<9!#MR?(Kz2AhB_g#7LOPwz0Y<5c}9>oq57_@CJ`-C&0g$4Ji<$vsN-mNOt_Ei+A z8`_PmTY0q`1EA&}GH=7Q`(X(42ETDxjYhU@)VHKW)4@Q+2zEpH$}o}7AO&SZK^Lk6 zw^g2GlIm&*QS^FrCUz&_;jEGg>tC`^idDm8?W4e^KPqe$JoF{+o^h7s(d`rG)nRC;) zyKrOF+EvQmA{I2CLBABbKC=E~U7%aFz;t1V5>d19if`?Dm${~j@b=td2ZJp;7BL2-3^Z!JVvrL2cO#t2J}gP)VW^$#^6Bf zMV$27<1}Hm9_wA*MJhby%3D%%|a`65LDYhCf+OWWt&52~9xI5wO{QEY+PG@z@3z*54US4YMJKj{?P=Dt;%qRS+G z$^2~1{bAqW$`dD5DGDIAcJ2_IR`!yBmR25;rGs_l-2C1Q+*wpj3H1THbE~8+ssIyz(r$(IMK0tlIB(}ovi|CdZ!T8nj?+}GH~v>B8lk*@d^f}NM^)@1}K6%iW(`(9uP+mH}^mwy72c*4Xfw6jB2cwA)*! zvOC3RhI0UyFQkYJMb{QqkBFKRtF-E;I4md8u0ISi9ObJGJ~#2|LOQG*S+nGhFtMFZ zDO|+C;|k(iTzfel8jWIytET{5kW-@73??L9}Mc9a@bbp|Iol#_dqB#)1O~jOPm=W$CgyYbz zlUw^u&bP8WcMn{~4tM=9liA+u$BHjnZ~Twad>gT(DLB!gdIm;}m~Ys6l;z$*6_)&y zN8hbiM7+rUaP85@%Qn;21=|!Fvm2UKcubG&UZj4MzbvCmTTE1!F8}ozBvXr)B(2$+ z{5x!@NHYCTg+4G-haheV{9wX=l;LmCugua8A8YGPes_g#m%r_1Mf#5_EDS*vyjL!P zh$gEl34SKgKsRBO5*E>))0`dM#Eo|67E4H>17Dl@iMTw{cfx(@ z*%;`aZjTPMeAA$_*6utaZ0OJm2%kh(oVq(-)G!}m!T{k+2N$jrZKp+4Yz@j>YK`r< zhD%|xws&+$kFS&a@-7UDbuuPFa{7T!5jLl(bkl>GpYj6O_Z+?e<=D{u3+ zMb7r_ern|eXVPQtYmd1HUKdZ)lXUUw*ujJ&Y^@uHl_XuWr9=J7HaWq=+edElBsr?n z7Fau+ez$Cl9AdPy(LWN>B$kg&VJE&4sIlwTyhWf%U$EXZ`q{l^S_A5r+CKt}1imafMET}t7U5!)GtVbKt*Rc`(Whu~Xcs_Uiv1yytbDZc2s=uoUc zUcvcKm`uVM|MDUksEIjI(y&@EGc2Y{NE%O4yQe0&X6!4M#@=n1!zaAo^5-WZ+UY=+ zDh~v|0G;vax~@W!AT6?SBt{o#muvme3dk2T`O)NEkJHC`$(mxi{<8E4}=w-1W8Hl0Bsk zn`lKLQk2rimLxH%LFuqek4W%EdpJ zw>F(G^r}I)?lpT#t*4`6NxnckhM@Vi#LadTXvf%Dk1r0FZSu^>8GAqL3%BLtGtx7( z_-*hP5Mmxo9z%&SD|->hmXjS*poQQ3O}6LsxUe#=$qmEyD>X1DAm3*}ICF^C#c`CL z#lRG#{_r+rezMz<2}pt6NHqDRFK4lUp2&r(~Ke-N1-U!slO?uQeKEE;yLBWXJ@Jt zKPv^GvS$UB$~(scfT4TGYQ$-rEHioHl&)(F!w!>NRRPil^AH-6tRd^g_GMB!4Hj-A z{5=%jq-URz6`L)Z1}#<^fr(?S!cqL!dtf@MdR%oEqf=<3EDUGV|O8ANBo znO^6#1`X~^5HV@e-2uAO(bBcfEc&QY?FM@8*~cqage1Qog%EFKZ;uzf3Q*<&b4r&K zEPYp>->^E7;~@X2*BV+~vW^FxBH{^kv7IgA-J_Aqy!bzzxXvp!8)^Zu)wn6e&mQYp zxIfFfOz8=*RaXmxrz2OpS5^`&2V)?v&}c^)qInhEa2)R7TnUpk3}*~0Rb+Oe2M2wUBA)=9Snaok+p6aEt%ln?ftvbpfKZC#>hO? zlf>#$UguQFVBPa36a%2c2q&peY6`nrp`-(on%;ObJa}ZB7wGEUI2?U-RfM>zeg-5 z>>XQyY02V__J6aNWtG*=le4{jUmVAx_e^w+ssiYLB-Y$^*a~M{{RTp$jXSCnijO;q zch2s-nn6QTNM6o`o7rq}kNTz8+w-pd5-bi^d2SvN-bIxx`MuKvlWf_B*=Ai0iG?u2 zoy7*Y!Ovz%cY^REd}^6ZJ~xLV)s$zRzgXGV=A=0K#&uA)y?SOy)PICWc8|ui?Zy9T zBNo>X1@6xnmmaFHDs48$4~q_9Gn~H8OM>(2(S6CxK@P2hbree^=oErS2S*(u=!%9- z%PJOnDPL{r5!_K8mGBmI_9S7$`auDQ!01E3{}_FkhQBUgZzdL&3|9}U%umWaY^f7_ z4Qi8%WibK8bniGo`@!fstbR9?3(QQ!3|OKBXY?}9o1}L?<}$nfQG7Z*eTiEpvFKJn z`fYP9p?Y07BO&BC<}0CmC*n+M84e-Tei9GWu;BVJVK;AYZ)dwHA()|{wGeRmaiYOj z>Nj;&r0Zt}BxS;Ek_Hs(z}l~Tayl4kI$TQ={=Bswl)A8MLoH6NeD|w}oAYiSD9C|p zMTq_U8yQ4gAG}P|(IsY=Ik+|cJcd1k$y|$eW#}?kPgjZ?76ozr!ohyR0{*AfSfOB; znMKo*9>!|2#;Zp3z{9i15S!uZFx16$`?ko{E-2W63(rI12wCNcIYLG`iV@ZmG;b3#`cBW2 zN_>eez5M|bNeXx6jUlOHd}d|=CC|aqbIw$Z`|+n#*u9-~JO>V$cn#kgO%`=M30m6^ zyk%#?E)6<&bJC0uPs?wzb-n`(#2W*!TW=)B8K(hx#T=FP`;ST!2tkFpx0VTF& zMF$%M?^lf4e9!9hn!;K_ee5)5TVFx&rmXXO_X)kk`&+o^457v=7-zVyx^2maZrZYOcJW6P1h%5w)Bp{F~`wNaK~N zioU%_|1YKHDG?ZdD#i-bp?muam}Z)j#740e&DF2}1|6zd{QK566*8W=lJai@N+)dSa?C?_`FUwiiPN0C&QJnQLLp6_H1=u|%b-}>Nve2MAr8Xv zs-;aVrhM?vBF53M;r8rpzB@qZ(}|{nL}%BtfgR`#lzRq5Ex--U8%rPb6Ki&k+}?@> z=WDt?z5crK9!@!3*hlqIB*4s;a$5aRqnRndv<}93=ntIxT!0?&Q{G2#-O2wxXCs~s zI=lbFB(-l%bFA>-#=p<>HO5ZlO9E%=E}GI_%*!OxN%O~s@EAEe`w{n)bb7bQ*q&S3 z!?IxjYZ_nFfx*r0@Zo1yoc~j#UWTpqAM=Z4Rvb8~jH){%QoVPIvsnYlr$4?-#cF2n z+{?PqxZ*Y75VWU<4@rhJA4wYVHQy*yGd>iM#({>;O2Zznuyv{43H!(zT!ixc0+6za zXMSkYtLq~eAfC}G_Gsh)6q>F|#Yur4cT~W;{SSSfmYe*B5EY=$Yp&9( z2HK2S3_CJ{S|jrM8ZN&;YngO{Tj~Ryt&pyi7=&gv%+ajjJ-0;c!7LUNBHGUwbdPB#PU>=CSf)l{|T2sx>CpAWIbCgxZsM`kAh=$I#3|W}Y|;;x5hm2u z7rOw}*p}N*bMwh<51E?nohBlm@9W9?j!G0ZMu@|La*(r76c$R90B`?Wh4L-HtPF@B z%1vtQe@L$++u6OpmUUO_vCUfCvuB1N5GezgU;Jw;`5ko~F@?E=Vj*_HpaUp{2K;i1 zU*}FC&7n`FfQei&i|G94dcPNJyUPYx6E2l*S+p}Ydxy`p!UVt9-+~h14>a??)GOUF zw)<h+GECb2Bsg)SvT!^{;VREg2)-E$C z^s)mD+Xo##wjn!_WVf>ObcBkH3;6SBXh#SEGC(U4l^A{IFzbmnyzbTXJ?`sVR@%^| zk3NIRO%zAWT&tZl7oh*r38qP=#dj5QTH|hEQ z)Ypc1?uBvZjF0~zM!5=ADh=W{8r;dZtEK2+2+Ra<-`~As*bbpYM(94Ic@kmw_3rU`^ zHvolu@w>WiBuK0foH187o!?Q#N;qwW$ci@gaxBP%s6 z#n=&Z>>l@4kZw!4vna&5nUx9Z`jqopiCxB@=qpvSq$btP4lus17eRHN19AK51kj6o zO?wF^{C_f}a!O8RQiPB%-2AS7dGma~1ZF=ZM*Yv)tcj{X?&RleH-u_SlWD9&7RSoC zAtX8BXJ_CcEj+t@?c1gLqM|&563?E*oS6oI2fd@xVwV$eQgnnu%#)vBN6eObGkO7*-FA5 zjqb`8lFo%k=yHr#_D7@At{H~tWjRl)5niwNPlFC-sh{NDR_GP$7pZ0`+w zmkoxL_p8m{52c3beA=IXeanj4DIP?WF_7I2S*hye!cHVGKQxJXm=(ps`@m!8?vvBq zewbGmYaGzf*N_Cfm?W02baFdv+#()tdOXCOQSM&$ztPN{;_IKNqy5)h9Ic6QxaJv+`IU;J` z*ws=wU5;-`R!d%Dr}d{}zMY`K=qK_Vgj17?^zghX>dmgNe0MqPvLam^Dc9rF#q;)u?E37IZMV8~+7ud7LI2zi z8wY^Q3}+?WT0ru`6ne>$%8Oe5KV=w4CC@QR0$%15HBk6%e8DFy9X@|O>d>u|QLPdc zqlsjk`)tMXvCHZy#k*Up;S`&I$tM3Bd+#0A)E2J|1`t8%y%Q7=lqS8J2uKqV1*Jn& zL^_BF1PFxQi-5url_-dylt@QFLPtb;?<62dPe5P`AyWiY<&Y8LAKF{3w?wx1; z*pHZJLH1tzw|?ta-uGR5VS~R5S?otiIG5yebgm81JeMGU>|$z;?RgKvows{-A-V99 zra}rU(%S*(BeLu@06PVf2vaO_ZR5Z{Chfc`bmC)DrBC$YrcN4{Af{rT1u-OJiQkI$ zo1-_tUovjhfW5)H;1gz)G>ho-%dPS{pGKTC3paP$;BA_ePr8j`M4DeAUXS(61p*8{ z_A3Q@wlKkstBl=|UQI3yq-}^~%WGqQ`$A~PlOU*WFp=A3TtU;f0^#}u&lh@Qxws{5N7E*;( zlKbKdQ=K2`wBlb1cCnY4KM4{{8k;RcodVqH;#1=YKp@_btaE?odU3Y+$9lP!n>+sA zy_eN{-Q9MYgn5QhcO3~+Sf&*o*oBW#Q#S4yR&D#EB-Z&(!S4aNX<`^j5!7$g?oQ&~ zHsGiPuR^Tv%wu9ICIRYA6U7@<14~1mqmmxtj}|%gc(p&JUQkeFSEsHurCuvb1tjP? z;ZYg}u>!4dUX-{bxUIanUOlt-S%(eHma~##tPy8nHBEhsmbaxY;mCRfY`LbgA``EY zPQJ(YNSKXPzM7jj$e&3vo3Y+JoV`|@pVt@i_7;dyV%CyyT@b)=H{(P2p^# zFTuDPbEGA=XCKy2JdC?|9d;W;9Q~4b4emcU5J3b&9b$qc;?W**j4L)K*;cRM%|s-u z%`NEm<^VMP9bfv&xF(lETD+Qnudl;CDYZRYt`!bQS%y`CPMbSas6RDg7QSKc@VL50 z+Ki-s-$PQoc2!*@fNO6ygD8iu4kwrbhL3Tvja);1M-=D1l6Q%oT%%iCfgi#vwzB*G z-Nr+hJQfBAs5=RmSeT$OK@E*pBys2X*-M!iI{EmyaqI6`+}7n4xcfBBik)?y|NAk- z)AW~8YU13UG~yWYBeR%=CG=a?KBj7~f>hL=rSX{Lnte-yC-QNRR+)-QJ+wE|BR5=B zse<;lH1*f%jHKY%s@xTd=%BY!iA~GYt--CcF0vljyVh@VRCw<{zH|F&g!T!Lm$X>Z z(W7cV44+TNox&KT5R5hL&Cc(7i@vVh!QSE#8ooAq3`rT9tY-lvP20R<(1M}7C{AK( zvkXFi4CO@;si3q}_KO+R4wazddAc7ycSjj|cIiV>rPE>Ni2MV1loFH$=>=tRwK@0d zoeOKn-NdUEl_^rUbc`g+Bu{guBWVP)+ljHw7?1|YQl-8NWkB+@I`9umoG=c^TjAbI z|H5*kkDuCi(}e~P7Y5x0t{nFF#R!TwHR&FBoWZPr%>9bEh6V){C2(_eT0C6XXy;)rnPTaPwnAjsZKYd_k`x2{6HfcnVFas15$Inn<=uS2hqyIWo~(<#?6p){P&xT z6>X)pvl>*rp_NqI4*8^jj=2+!w4q(0^sY)!YPZRasBg0{lEo{oiT=B;Tu=1H1sq}K zZMObu^vo9xv-YIMoEt%d%?4HxfVB#O>unvexXd0|aeeUh(EKo;O`oP?to*BJ>cE8S z8_&CXLjM3-n{xPp=zR18uro7h8UJ{unbKKotrx(I@BarLprz zH2TBy6_mb&ebXV42$zk3t!=IWUHX006xCFYPc{TNq%eryEp`a)QhBrzuQ*`?WcGTR ze(j~jWjstk9AVVw$yX07qe4M}2W}W6%8(?tzU59FJ=7oB71Fe*IO)l)Eah~kk2hx0 z!htQ^?263Jxlz1t-)cwRyGeI$9&XjWkFyhYXA<1q|7c758g-}W{0UYAM?0siCU}g7 zSC;3yNt8PAS?MeHpzI{>hd=z^GpZWW8x5R5T61#5(md>He$A5fGk8S_2S|0c1%L6( z*|SAc#ivgy#yrau&|wXJ=}5w6G@c~~kHM5eyI}IeRo;m(2IBQs%Eyq25*WjeP`(Nd zqjHxCJ3};@TORifk~))C%MpI4%mP}b_W~c;mM7+CT!W<+^{Bm{^gW(I-40RLy{+@x z*ss@NH&?8(;M6dF2e-P+0w0j=kg;m>(wl2{FKO&m8^Qyff+k$W-twUrtxtZRn%vZ>&?jApc#AA^JAF&h&*K1GHjp zJ(jRRv#^}hsEo26ZBYM!Y;6k)*fV!&^5)(G|st`;VN54{Vr=clmG#nMcmPrr?Koe!_f`GfEgh4vH9BI5Q=lXw!_(orfy z`FbM-pH3PZ+V+OMc@`Wl=yh3yTsY7Cno_iK3^`5adW%$9XyJza#^*{r6nfC_`SXit z*;DoIm@rA*+U-Z`TNbIUTMSV8PP{q3L*O(z^e?C9u0jEAUNFwbZxJi$JU4 z(NmN*Nwfof8WjEzAn?RAm=n}3+vZM_P2D-i`qZDdePN~SrrFhYovsyy-GyL=F(=3u ziQcVN60t49?EMW=jEj7Z14`o_qdFSgY#)}fL3ygprm*WXNi?wAbU-rHCLDxv)d&& z9uxT!b7~r}>1@ds&x-N7=i)rz`SXWkd8UehH9u=TpW!?RJmsX?-Xe48&Toa0H4kOU zmq=*mP>ZU<|7qW}Vp2gc)}mzc###~s?q1eIkMntY$RkJRu^+@!=p!3JBv;UU9@ z0fi02{H2Lp?c*U9X26#$qY8(j;OjrFa+W2#h-5{-@_xg}DY-aO!DWZK4XD6qwe)Vxd*--tgsxNJE%Uza{dC)(}G z`D{5yzQ?u#K;uK;ZIhU|4V3CzTV(95IBj&1?p=2KnGOh*_*2nSHw;wE zap4#e2j!t~BV+bkFdU^yP`YoUa5mH#cU~T!jmw#RVvdg7JGHl(m>46MS7D1~fabiA zVhaawy{}nVu##B0&G(>xe$aEU!$7TDiAsh2p}OeDqFF{D0B;)0kIEEg2l;9EU_OE1 zDVJ(C>$aX%3*{T864?;);gDmLa*K5QEt47MbOR*NOmQL8Z zRHm6dE&VC<;#XehQrN?z_Y_%VWGAj-tQEoPHYbQuB)l>U(UH*yA#$+|mz+Ij1*bT} zD*A-)n-t&FdJkc?yEx6te^l7t$cE%;IoQlA`7z5t+{-9lH5`~-RnfS`I&Ck-YVDME zLowpAn7n%X{mw%TvSh;O-UN&nP?o{IwJv>QPu(xx7G6X5BoO(4>5GJfRzDq>feKd! zGX+x^n26_w%*tzqWzcxmOz*QxXU=*jD+h{tzID8?TFi3q^fe_-Gr0CQ{uLjk(cEE=g4o}xo z6Gx6Y+cw=uLEmSy30Kllufun0-skp#Y1mN1-4MbQf@y_&_5v=-)_(2Dcw5#O8zjs? z3?EPzE{HxahD!VaT8AlKwcRu_8w_E(JA@g=ydV26eEL4jb9mY?(oL?=``qNbK{9Y< z`xp|ue@pbd`Uwl~4r7xWlqPt&#cSE`Lt64q#k~hPZ%1|ZX1jX2!Us1?c5DpRzYW<-1RYhdHszE9n=H1UiF%NAzZjD{lfqg4grTFQ6v zO2n#~*vcX_<68%vA7$28s*QzxKkD$@vD-T!v z$aB-I)fj~9#1xl2$eCIn+)A(6eOkqqkL9PQcWN z#Qi=W=oxKUFt4(WbbnD)AjA7mM`h8xmXS1yyR5}QjBUa&Ic1yDgGI?ku5_Px#FfF< z6$;ESQZmmaI>c2R9s@x-He1@1^u>ZN#6?x3a%t_xi)&>G6IV+5bL4IE&Z*DYleAU|9R8*GKA5n zEM^|VyaE#+ZqRdl?dl&YGMpybI8w5{kg~aQ<1V+g&gR2fUdHS4wznWR^*I0k>;L^Z zp!!t=+V)eRY#}xJ7(y(B$Gmi-evYqKRYfEF z7mmVdx&e}Sw14|nz(@2LvN#Fyw`2pz1MovIP}_(OjRTWp1F|G$YM&Ab_5$HVg26GQ zs}kK3e}qH-fRkvzgiQ=het~!mK4oXx&*>+xb_&M?(4 zUocLR*gHCgfC*$93t27g7_#jNCFY{N=MGrNV577(9(oKpH@5Z}tcI}t7akm#)f^JM zSAFybR}IG_$l5?S*pI&-2=@Xde4cB{B}nL% zzgW{>Ew1WdOYgtONMn*SA*To|*MN#e0kNLzo4Xh;w_aI`U7<`S*;!GU>F%m5mPr0H z_w-ljn3AAouUWpN0yp6`TSs&h5j4In6(r=kfJ|PF!_Z?$Kbk;C5d@R`Un)5JAO9tX zx_`sf;M~0ddj#=49DnEcqKpPz#bq>Ll79@rc!S0H(nHf{l!B#0$_x@aeU%K7TVH}( zG3J0rlBO4gwO*mj;eJ8^5K0`&4yTyp{f$>T@*MGgacyu*j(w1Dw1E$dF3F9_zW3pJ z8{=hZpRiLjVvnSnB#z4Ssz{y%(cb}elDhI?y^-AOj~XGd&&BA!VnvQ2CLJ^isU2az z$pC+u+`qg5_ua&n$wjbjz8mvi_F19JBYS-@Pt99bj9>U3O>pr&RUL@iFR_7;y`&}nl^v?ZxM$Gri(6qU~IOc)B^H?G6Z$f7rghv|$ zTo)t&9}<6Svnst4Of*YBBG~Yr#hH8`+P3r)W+j>9m)nC+7LaVO#cC5%s`6Y9u!%ph z>~oV7lQV$-*v8Ff!TD$PFBb#-SLymBGy|By0CN9t?i>DR3&V~DfkQ?AyA0i)n-m3I z3bDSq?k;iW^Q*1I-J^SbIs=}5Cj!DZC7zsgrBO)CQ#ZnSlB;@jjfY@tWTU{J-Md46Ji!dCndYp;SN>=ayK8SXFU%4I0i^!X7yp;A zKT;yWG74<8V4`5Bhf%hKIbM*%in>$~h<0lLOE^D!zW+*>Hrh7u?|rnH7Z$Wg$}ng} zoT5y@c^bG1kToq17lH61Wbn-$Sa%@UJXneSw!P?rSxn!syE_mo^7zZbNt`x(9&|O^ zP6#&irqD5@K*|O_{{jmBpBc9aMwFm>I|ydo9Pq=j z+9M-xnFzO<_TNdcUaWl_a5LU1*=L(=zam|2RbMp{?Z(0kWOQ;nFpd6X;Xu-~9YkoZ zOrjH&zE@NF=~dxr(%xd%Z#}vN+w!WU`Ze-*Zt8Es%+;Le1;j=l9}?4g3>nv$#T-S0 zVE*hm>t7Zcv9I{hKaB#Qs@)wEY64c_J&&LM*A7Yl=K20ZVf2bz4CVZ4qtwwGE&KT? zhF}$9O*E)!Sm?lst`suEC&izx-l*rE(Y-i%eT66O{{xZEf2*i0_b7oJK$>d>p}g>u zWECK90n2M|N;d_sd@N($R^i6I@#;cwTur!Q8<}_d(LlTodD3Tw_h@#0Uk=8 zei+=^B{u;g`L8ZAm}W*SqkA}xA+>Xqamydcp#kV-U))msF=QI7L3>F3)DMG&997{K zUm-Oqoyj!E5M#4CrxawJ#6xb8L4*LiY@aqsi|9Q_JD1IZ&K{B6L0= z4;f%L!qkCzJAH!6K}=Gx{C?Dq&>ouk;zcR~>>gH1XOu2uAo+mknRVCliS9ZjE>WReOlvK&< z7EJq6-$MFKU9H$B0ec1}rVKVhN>7k;n>RK1gdAir)1_Z6x6^&M z=C3erXXNs=;;do5kxp~i-Iqxbio^Wd407Y0trf084-yHc0>E;|EbmYzS8QwcW)bVq z#J$eUaszKh2e;CZUv}jrkd`6`=n>>NR#XsW51#pca8vo{mTi$+vv&_as9Bp~y}XiLKHyB4YGN@RWvAgra!alC1{*eeZWuljY*|A-U62wP{z=FY9hcOGS=} zCT!2R?}-sJD?qrEz9~0y%7mEnS^V3+Fz?6FD?un<)7pl#_er(C#=nR;dl(@nswGLpvM~8D--v6W)cwl1Npw3H zFZy{p6Ic?plnVggcFP=|L8a8wZW{&p<&#ksIrfnX4M|gB8IQtK=(U1Dpa+G=70z0P zrE?22JNYnPkI{Nj2LQ&O_V&ypmo zV%C?%>xbJb{>Rg?KtJxHk@zjS|Ie?Hucl5%Kia6BfpfW<%4kUD& zve@YnIuzG}1jlH(=Ba-$s*GqdCVdt5*lcP!V(~rH`jLrXu7uJ8rgkKj))_gyjBnL1 zTK2mcH?MCHEYif-H)X#~4X1bd`&y5p%d^5`TXF120}K9w_sV77{66)kHse zr{7=hwNtyT|I6{#jj%`VqgpgXZup6{y}GL9RFwC^sr7-uK`7fQ!R5|$z0riAPrQJu z=;QkF`!5%lihqE$$JAylEt29*YcuOUIa^lf7Al_5vP}@*sbWa#TFiTrkd}2i&u3oP zs-KRI_%byCQMufP6E5R$g>j|8Pq=(jM<~m~-iU0}_qY(gY_QP{Hb!HWj$Tms>`-R` zIXs5hO>Wseo~nLiS+1cQt;ttvRYMBhou>Ig=k~Mi-|URPcgf!sJ704O`iC8MNaNp> zIezvwhLBXr7|U?ny1@wiXX#{PM5)Fh-s@Q*%4#rFq{|0cH~J#q&V|@iig9*%kS6xP zX{xqXzLfsXMbndETF@InSMZ@G`4%waNGLJeF(0ti1DDKlYkZ--R_$%XxuvgX*Zspa zIxLi%ZpuES>ha~Teolhw5^?K8_{86ne`XNeyzKQ!4Z82eyRsiWsK_Q5%AZ?2nq3eK zG!vCf%DW&{b@Tzol9~+V12G%U+KqMPL%W*E#ulTZ@$GLdA|$B^MPNt0qjfsg9F^mOv> zrE7B)*v>gt;2xCA9h5!%+!rpVWhsmyT+-g!T;JSqI<0f{7^0S-C*}!Cn>q4g1&Dod zp=!uZe04O529%|1H?i#8Upe`n>090)3y0o&b8?~U+@~Ivz01V?7`De7 zq8&LJLs}vke2yRxqt^U-63?`w4o9C=SKk-$sjh{L%ff3Mifu_h9Pd#{8j711aIXHJ zI?OEJ`u=Ba#1Lfy>Paktk&;6?h+R90Q^hSS!DxT*Rqj0)r z^XPIjEH@11d-SFu@bw(|GASemv%r#6*BSS?HVs`7DlpYM%Fmf&cz!uhvPeqtfj)ah zlFBqh-db1;*!X~qoCj%yOt3>0$smz@i7w8`y6Q8}l@Ush<9oHs(QgG9a}L1v)5dB)O>hin`dAps_gRqOOK7qisfFPfi)~ri6UWD5MS3dTDWgFGq>U z)5H=D=!+Xe*sX5Y0F|0#>PuzSG+sJi;V55G)^D~lov+EXL~H^I zQHZ)au*(-JqD{oy9&{Y~iC_3-x>qwPX3hN_zZ3r4k-jTc6Q~0Z=Nt3GO@LjDy8Y%k zW|T^8{qT@>zxlP4No0PKU2U05w$S>G_kHR0AM@1JraB;6<(qRh;IabgNLPs=TS;VH zy!UBR6%oQZ(TYx)h2ozOA83hyM zxByM-h)%sRulwKs9v~Ul>zP{GoV2A_8oplFNOb|C4^@6Ns*##WnHYj82O!X{ zFjyhNGd*6xNHDE&`lZTDYYLJJmT{BU)T=ut@O$mUS;y*rfrld4?j)bf!n8aci7Zj*6R?YJvjU?iv}#JFkjklL;#gba zbJ@+upX@4qrVW<7SOoY~+0!-H*ym+KJ#e(mBoIA|07Fs^U7#$$2bS-aBbL>Eu$$cb z%+FDRhh4n9w}sBWdFboyCOg5g0T|cOb5K`v5-9QOo^kH1X_Tz6*R&W$nfuF1;M_7cDLomQn73-`$@5C~6=QO35=Kh0 zt>t3Ueg8YxrScm@3Al}Cu5R=%t^kNUf%gVCkFbT*Wf2-2Lgk9g^WQG{Iuzj1(UX>u z4S@?7UTfoE*n7f?%(=!GSJt+e$!TrgI9l3AA5Km8bgj~HbyB{;S^Tz60;)EnT8*v8>pX{^&Zjn2&%K}#iHS75l)}z(s zUk8^~Uo;bTm3xlcnG`@4(MZA44wd}8X{(+|IJz&>kntd4YTHQRKF4VNR3FnC80+KQ zaB-n*Sp>R-N*4N+Z06L*pd9wi;6P#LL!B7wU&t6LY0(S!&oHoaoSX{_Wl1*Jn+K9f z=R8jy8V^-&C=8jD*Ve}`#NKGk6g$+LhJ?{uPnQiU#!*DbS^&?&9Mk05WNLiX zkpSTW5_*lq#%5BeT>MUj_Bk>2(T6SGfTrnNFCCR9|HF~g_&UxB)S<-CVJQN}1$J{T zHqosJ2YdS&%{jZ-idfZDIMedhZO>NdV@6Lx36gGJI`q`ohM#+%FvtMsn8?e23lkk_ z>u>(#pHZ&1z^*c=zY_4VOTDWH67=kUBxX=Wbh8oI{{7kr0<)$yk0IABD$&g5By-yZ=1HR4$)28f9{%2)9$N5Jelom4ZfLN%7Gx}Yh?y=Jo?k3tjdF9~0Q-yl7BT?4)gr&$>3ZP18 z{ecq*<*bSF!z2Y9$i?ld3{^3t#@*RLM&4&OkduvI`QzVOHe2dZ{lbU z=JBYTfq3`fhC%&LMQ;aeqvIF0tEI0Nzf}{DQ$QuCE{KGo+DTc2TcP5^Fcn)j92eR1 zHA-(t+5MGba}FOdGtbwX>1!t=+SzKMh7b^F9hD#N@{9Kx|O zQcM<4yj;%S>g;V}i~`FgN`StL_OJM<{(wID5~OWM5X*WIv;%0ALzXXemi@Q^yaA;+ zkGRc9#T~;|3tzYQs+%q|y%gNTzQ^HjxX6(t97x4WOP~^!?ZBJ<()EJ-?iSU_i#}0P zFKe=!zQ>6QGW#xpIlV-rXR&9cR4NCu&zvY;*{uYlZyZJSoYDFCIO$!pR9i6>TSHRg z>wY=`Ql~k|zYL2+wAT%gb}=pSWJRu#uPCiX_u$W(Hy+4|)fn+{7}LkS7EqC9BafSskWI1wPrB1jEKQ-hX?0o75R(OwD%mU)YE=AM#{tI0qGT;_SH-(3T#~w)s zea9v}zQkZcoB=D|(aLh1t52raSdI4hzJ2w&^X!jbkIpJ+3bh8zs`2i!glAvFu)tWG zNm3o4at2FWDYikA8Czsjgvczf)~0`+#0pK9`EYgd(Rereb@%sW0M$Fac@|#4){LZ@ zpmjyd@~-TQ!qv&%T#0(t208At0w-?Xz5j^1aw2(PuUroXows zc74DvaYZ&S#nzr*<{d%D$ZWHVHPwv~qx2HO4B^?+Aa3kpTi6I2UQnsF9L+{dyG_Is zU+CoZA7__eicxbxel}wt6>e-0Dr*wxMXlb%>xj8rAEEn>AoFNaTrfu<&~C2@i#&~QrOvn^GQ*g?ldX)Wp)vfX>wl1;47FT|iZKC6idfhBp zo-`YtNYh?4_r=~yb8$2sb!UkFRrA5h!&SDL!N9Jh@W8;V`s-KJ@v4DdD$guVKn#?q)`LLM zEtYXSamLZCV$kDTS(B_>fuW;<=7}rQZA{`+A zaM;o)Jm&YAec5E>N6xgdHWt4Py?Q*sRW%wbgrV5#rQX} zqNJ-dk3yxo#NCUWG9P|q@UF{Ok!NhEUKfrCyVRIKN(D_>py4hlMMlCd1OF{ZB7FCS ze#6ji6^W6@e0{#-T=gws+l%X^hlXc9y7y}Fkak)zbhrm4nr)5zK!~4vo@!!2e@D2} zdm}&CFXi)h(_LouWWai<4_j0B2}U|4s$D-W0_^nB>jvFG65<*WnnDronYY)q8(JQI zY#UzGUTEO|@!8IsjCR;6o~qqh-}j^ zci(!$bp6|!tDBsy3D2p$XEm}nt~vH@L_d3~BL77Hk(5rO_pqOp5_AfS7~a%<;Vu`= zI{o#meeZ2$%@{SB_f1+BTP^66SuLRA%@mN(jraSEiQY9)u{{#Fkmc|4iYjI-`R8W#MH#6y{KbYzAPkNZ+ zVfuEWVK*1~pvjQn5w0Cd4Jfu#w@kpKYSGPOqXUFxh8x7i-_$l_*(7ufEaVJoMt3)O zTzOl6w&P9sxb<@?>bF^Y^#gAK4t!sniZFE8yULVx_52&xMjqz08RHLp4jgX1a~C#{ zZ^iorEY(0H>Xa;5H{bODEW*#Y`TI|n=9YhcmNZ76F(ZAM@0!c?WqLkiPdb4ZpX`2Y z>Mm3eiET$zt2PzEd6C@Sv~JZZu(N4bf|7!wUkyL9)sEy`Ei^u#6lR(B@WU9HGuuUzgqXORndt&bf*4`iyP*6s|7n&qXaY2c_@v zQw$}(MkXwlnIdC0k1cgpWajGPbqam9Dnn=?ZUcV8}E5= z@<(14^t`N<&!<~YqzpRHl{qCWsk>ln8OhLm5$HHis~vn(U-RUKC0j1P_fn4a1|I^Q;H^E~q`?dnUv6a0{a)r4Q}%@`q+ z3^8xs;xiUNH*;9&nv5chUjZ>g3Sm!J! zQ7)!|3Iy#~+V{U5kxpmQlUa!BAf4-aH5`>BRi?1`@ZKsFwR->n=bI}&^62+&A`ZbOKr)o_Ei znCfJ7VIZofd(S`37E;*uyd{ZkYK*M62M1hICyWnaLx-@|LmI^4rGjjyZP7!foVMBN z>Vfc#E>O~A^@3C@j4!l5=R8n_6?jF1?|eQlKH~MbU~GBpwQ=nvoy)92`NT8(wXk<4 zz?tehV>E}CP}hJ8EIAM;dgl(~jIrkz@}CsIsC+8IlPyQ2BXFyoNmb~t@0s2U4iQNW*VJ!K#;ZNd;g)Bnq@(dwPAkIx8NU?W+dfYxUAucWM!U+1o$ns~IAn7VD*=pey3gT(u_ z&URrD1QU3uneGMg?^R3PVFM|r>rZ)-aSb1IW2Yg_kOSF-B?@#6CN|cfE;N@wR%MA+ zjub6gsXj=b%PoXUox07TE~GyYne*Ay=>O<0{!5qfA9WfJob?_-d0`^xmO{Xmfa42^ zJTyOKFu~k703J~`uYJccrl1rj}V zPHk;^%_ZI#V3-OH95j--e?d^}!zsyjtBXvL z5iGh6rX;$(@DZiHxJ(!=kuFl8b5=a#D*w!QhPjExU~doRzQ>LN%zm7;kVlPAjM=?O zOOCJsw;~2?1cJz6GI|N5l0RFY;hNU8;8 zL|Q#;)rbv4@y%mS$i+42mi|Cbj_&bfx47<&j`~R7iG28DLo{NQ`U6Lp)jZ>Hs0Qg$ z((EPRlrPwCRK_JL%Usw6t*hxKF5nTLxpPmLsu!;)C)L(1%ib(R6;soUTD2V-u~4JlcE!&D(oyO~zIqaRfV|Janj zd!g9#@Hu3<*BIgmdDE-2;-EaTyEPfmWC3Swb_lOAZsZz9sfDmJkNZ&TY_bnq#M&Ga#ak zhj*bdCWS!6m8yuZ9j$FQ?F4EkSvytC`)0)b)SqZ-q(BQ@XO3*+ zkbrIG%&yYVhR3?@FL&vTa=7d<t*-M$m#OK#UjEsK>rAQy%!b|qhHFK&ku}mJM0nY3XsfzQ8JqUb z^9glSJk@rWP60?Cl7DGwo=+JIYETX39tM?W)&bw<9Px&lvhtBEL`_{oP5OMemsjzC zcAUBhd+DKqD##Xm{#CG)YkTr-kt*#B)a?zU}mN!Q7M+OHcWHx1T|4^IZ zJ9l$Q%_>HhK9T2IxC800KJQ=qzkm5T)C)jU%)>!!4mH@0a~WIV`qL-#|gvPU#ph>HcLkS(?$^uhlwnW&v-e<{_k;Hr{1;L9MXntdvP$em!7)UCLzTkD59*Z*=TQW7_lCg3nfzaXsF7s% zV@T=^x?-Sy&yGYp7e%33%gUi1)CviipF7?BdTsX9NadC6DuC_B{ghF< z7$Nsk&>1+ppqz;X1m{>!3i}Tz?Oa>7;ZO2Lzs$vM9~AIi7;9&Vg7FZQK%&OuBgP+Nlg4fV+wP+~ z42xBtqOvOW?pCtqxb7r;ye;|Ro3?N(G`!(vK6oaA2C2O|A#2iPEVB6L5jXVtRAvdJGw;2OF(X`XIKTv+(b}it6C@pEB@@zxmaoCbSa^N9Z8B z;&x4fEQmj_v?b9tep2!uOJ9X?4wqV-_gKt1m&_;*aZ3AcV4lt=-+bZ*-P#xkFQKU!-VD}Xp3JOei|;*WOb;0je2pB&+_AFk<6jO3Y3VvgnLkZw-4HAJ0HP&o%& zaYvAY!e9-<4Ge@A@W}#O(r#u#b_}>_o!+~2b|hz0ExP9bVS2GfUHl2x{a;_X1nQsY z1#Y#NMp2|Ifc>|~B16Daq8Y(x;O&pn%Wp58nz32SF#IF7yQ=0vic0b}#g)E|sTNE7 zcN6&+`#qp(f>8sX=KC1PHb6*$%lWrLW?*4|MC;PRAG?NHPxi0fud#^YP%z}{wS6!$ z^~98K8*!TQbym)smn=0J+ft&dJ=y>#2ncMkA~S4BoqNRx5h8b`({z_AgB4?>Z;Rn? z--sArLjSw-@ddaIGA$jzgDOD$j^( z&U}1=V+qZNYN*QLw#bWs+A zPPJ_);K?#&N=cpsWvG;~luHJGaW=16@xi%P04KX%aOVhPzs;YjK zXg}L7-o{oK*ib!wdxGnxqpW_1to}UROAt<4{=KgiOc`vv@(y80U&01>a)P~E5F$S3 zpm+9GOn_|lzOm0vB%hdflA0)>E%#Qj&4L1LGRa%PDEEM6@kd7>w}f>Q!D)K zjU^{D6lC6EWZJ9BJ2@{*+4t8OQk`nD`)D`TulyfcR(hdsVAJ~FI(Yb>UKS+u*-bw{e^v6Z__N6&8AHzeoQpk z0RLjchRuilD4W3q=MwU*3HD8xH60zrKd&KC?^OUy1uKc zj5xgd{N5?)>#}i{@d>fC%myOwSG6Mlx?zH0?_d2a%@0$4@+p!unu)@<=DAMXrXU1xY^+nNiKY&K@@K< zp+8*AKEC?VepXNV9Xmf-rkecyVUh4ru8MT)Lz<4oLnM+_NjzkwnsC(ZJ;-Aw zx#pT6laXZ%baOMu-QRG}YxZ!LAhqd+cSyd}8ZwW6UEHDuP!vO`!R!MH@&PBx3c?FB2qh4FYn*?MSv05|1%4X>wlt<6tV3{vdN)Q&!LSS$}x4mv>Igg z%DhQf3gJVYe=p#Yn?7jFyXfM(^r22yc2q8c)TqE&xWDzMH*#6Hbv`v3&iNQKzTbg3 zvCBdehy8g(cXO!n)dLxuk=LWb*5VhVOb&C!?e2G1QeOgo_88y;;!9z2p?x-!uAhdq z&gZU4XT}7(CrzY5i+1VA@+Rgt|UA@PDmW5c;293p3sP{21k~`*Z&7dC(J5VkY z&^pFrF4e9Up=qgu=Y48{6k?vI@AVl{(ef)mxdUSaL{!Eqny~~0%|p7kk7{&$$XKf$ z3y^h8x$Syyd&)aKeEd#^D36`U={7+1pE+tQ(7osO34AuNF(w3Lug#anlJc}kPHn1t zLneN%w0qAK+SsjL+OuLgxR_51rf8cF`wNQ#5~VYM#Qdww*!fG)7SA`p!B`up-SlQg zZ_g7pV6m_5Ak|DfA#M6pBLM*Y(Visww*W#MFi=q zQ+eoL@xi6WBGZ5Np25;r(vzZ3Uv8!crPF=(L2xy4122B})fk-Lt+Xtm833%|@UGL& z0;0mU*;VUNqjd~fv9RU-%m0nL_YQ0F+tx*cC|!Dyu2hw#2%@xDDIx|`x)7C4gs8M2 zfdEpZ3n(Z`ks_T)30;sbAktf?2}Nm=AcPMI`JK;o*STjO@t))!mfhAiGxglK`{E&_>GGH|8|s%9-|1s~KcX1ZkcHH#~F zvSHV<%x%0f%2Cs-XPN_JKdJjcj2B08E80;-ood4mg)TeQA+>h1OwIDDw%vP#L#s_$ zbmni~drk;N5&mIJ(S8NWUZWq7YAGSFh_ZobVS(s!Lqs#l$s4a#k$E7bH7fC2H(Rd5 z?Px($rkkS8f{+bO>$Jw$h~$xGCA(?MpV_%sEN6<8P(LIdAAX&N@m1G7oM10(d2d^2l#-+y?SoCv#p0~VPZ)ePJ zWWYCpk{aoO|HI_Wj>-sL+GlzMsdpNN@A4+CgtsZ6q+cLC!TkAlT&OT( z%nOMG5Rk`U(ek^m&>RFf4~U^TEaP1Z<0dVcGn2Y(HDefnv1g>_H>%`@Kb!$5={jax z8T+JRi~TRi!1E$;l3^_PISjtV_4D%(+GOVft#=yd*gE~#MuyZ7MPsn}YQtY0qUb4l z4QvOgSas#A%e!x<+$AY-bp5=;oq*aJPyTu)^!?r9`h94nJ~T7PmIX5cle&JDG>wn1 zu9F;!w+=4!NOf1o^})I&=|V*4Mv5SQ2PW=6|AxCO|*V@#?WoRL;OWh1&x@4^+y-+*k)FYcsmjLM5z94y;#+t ztE7OsYs>iTYeD8%@6Ifp`9qG-V}}Z1^t2xTGj+fza&0rWb3dSTiEI*S379qFW8SGA z$*depk^0nWZ5v}D$P_IYbl}W#1o&(Ia@hYa{d!1V3#mVa1|@U}hJtkhxhRM4mj>lC z!HeA;qOY%Sv{&0vmd5)RfUc357D-_t zesaF>jecjL%G>0-_cq4kamwgcaae0TguK>_jR6ri@CpwYYCb^z)Q~+@@U_InXzbQ_ z-NWs^37zjJqDSJRs`uaKO5QH`)8u%_;2hYi#zd6W5B4{eOyQ*52! z^6|2{9(11ls+~^pmE!fno30XN{sL%*S68b^6)y|?yXp`2Z(6G(ZZ?n|$5*EMg74Ma zch^XiFX*sX7!TcVv45wG{^K-#B{l@kvAK4TiU9~9?Z18Hhf=s=xsOUgn)>OT3ynEh z$|?D+3HJi9pBNs*#dZ7g{Y%~G{@F+Kf9n0%WV;rOQrp)KG*DUpf*5C-fQ;Gy87Fd2 zE47YoT?>bjZh#=|MIewgZ9%F?Cw05$$F9hAX;>Y7rC(EC5l3BZQ;jPcGf8>(xme&W zgmES07vNXSgq%RTqVyqcN8}r3Q*0P9gy^hS#&lc;z=luTlpb0pzWY%T#1<%MQ)dkH z@KHr_FDE0z%5y)O)epJNRs`yQW&L;|CKdPcE!BdgT}H6#;aQ|9lXka43!ip)7LL0- z)py(%W1!hN&&zTBGMbQy^1TX>cYM(Xk!`1qmMzViRweatz2(v8_gCaS!0_BMKuO#- z$)e*w@#QV!eJ1>F8BG|t(FiT|Zd-*lPYL&z%k7$7V8v*^ault#_PL5Kllh>=_g#Gd z_s~{|uVWDHG+G0Q%Qd(|P!a=dTh;nxUrJX*7LHF{iQFZY)N*PqDIKDE0SMBXIjw^X zZ-KIa#r*YQ#v)3#QLw#IGITe#vF7}x z`U?H$`tj%V*g(mOrDz_T0Zqf~@g+;`Oy~T?5!M>vF2P|ZJF)yFJ;|>wn`l?UM@{IC zl0Tj%)29L}L)j84pJ+0wMX9=;mR>I`->Ef-RW!)$MVAy@Oj*jOJI--i?rUsFS~*8E zHoAYw7{$~20~sMTka)V*ikbD$#c!ilhdoE9 zB)u-G^WLwI{Jm!v#aMR1lhFwl|%l&`n-;1$8-!(FM=Air<&nEtcyqT zN1mhHY1h(-;=AFgpl)^ls#k!PX*Em;ZApSQ`>ft3BcrHLf^+e9Wvu1U;WFpy_K#AY zlRep#_e~ z6r6ba1wJ;Is-J~QgPEPgO+{n)CeDYMC<&kFsX)vrjmupkr8U90{JSeGy@SlUoz^`iLuwC)x~@I3j18kgJxRmDvCI}$YN4t{ z$2NRdZS1PNUC&w86dQ9TijMY(Le3r**Nep)5QGt~nH&-REb29%hP!iOIq`n!SC|=2 ziNCD9e>kY>^W{g!-`VfyJU_=ZRj<4o3d*@D5oJFp@r|R>nvzd9@J&ZDG!d5ec007pKBWZ;SE_ltO5SfZCh=8_VMztXlO++)^FFW!zSs zruPq})$rb?J12%K^dD&8K%XMBwxsfq8Qwb+a!AzEFuy{Cw-@EnqaLr)I{pIr_cV5q}A4t)lqyuUNOZ*l5;{0{2zJ8v^8T$i%SxX(cz>SNFB z#!wG(MEZkGkl$N>XubbdL>9M5YhA}Loseo`vfq}sr3-{8 zkbCyBNRfA6Zzpd`4E?d=qldZLRY2FQWSv^iJS*p#B9KS@7Dlo9>Z-_XR{qKfsc4k- z%&)Kr_wN3OE$kDhBQmB!oP~DGzc1NuIvD+cC{P7N`rVf$HH5lt>T&u!P#lTpJp!Nq zJn)%GYZ>fJ8OlXD&Ole=$UMyz$ra&w*l>sVPOWPlt4jCg;ye4Ly+h9l3bL*>vw!Gi z92ZJz>j`_L7Qq;b;}8Sxwzt@Y2x)yTL5fbn&d-&Ftu9(;qs$t?B-M-%8(Po&)#gww z$t#S=Zgf8V<7~Lbdn{lEt=Ime+3`eN-S)Q{y{M>L|xtK`z z;WJ9L&4M=Aa9~roO2O4%5#U}}@;1*166YS%__%UEKVP~7bjcD$^y2(D49N%5aYHIQ z)>lSPJUBQfcic^seR#iPLeG12QtlioU{=mr}TRA^BPX5TgSTe~<5) z1(Xty6k!f@fQ%gn@QBDdWd;Uw|6%AlLR=8Ka&;K95$dvOxu+-g->OIaqp#&U>(2fK zk%f^tXe~VlF^gWcKVK5B($>oA;p2qo{Jp%W~ShvRg3!FF(*p0EWW!ab3U?e zi(7G9ZQ*3Pn>(4E zDVgNfJg&kB%*ZX`kJ2~O*w9R%CnZ^_1;Y!zZ^K}(bx4uL<*c@v%Vp((Da9~V7iwU3Eez0=tMu{^lt<}{?nFl z+q-F+z8<^{;zz>4m=TPReXNRwAk?4zcwZ4o{8Ecc(@Axhl)rDVPft3`Yk{dV%Tc%{ z@kc}iWIJqDsZl9P3|a<2v3M67w!u2@nQkw?yPJyLL!qzKYxMGXt+;&{T0L%6PT{Sh zh&Z$;$%?2Jsjc}{oY()DHDJ^9rCHr|I4#p@iYtBrH9E1%W1#sx%f8;EDI=Z!Y>&t; z&t(WYkc64(0e$ccnjcMr)jYLkrImtJcca0XVdS?>=5MzRUM8P2EdB80Q+jMtH@#L5 z8WYjL*g!D$@A<*;VO89+b{K6>k@Y32_g1^vNH7} z83A(6HJ-(>IhLTLN#d|qi4^DgLrv{M0r}~VAP}tlZkj*WvN(&9_Hl!PiO~tAh&rSn z(dvl3WJwI($+eH$`eW78Lsmz;*|kD~fN(n8+TH@>t_UpCvOyXMdk?+dnhb3T*eGoUmztFBC<;x1tbs6fk?TJjAR!pm+c)biO zkEp^oapzn+QP-OfeZd)%uq$8(5-ASt3+Gc!d_zbJS9|bc)zuDj*0sJ-w6H+N=m5Ha z^JXRJ(HZ#7!-%nKnxkHr)-TS4mcBEi#bE>Z5aI03CyHX86BYcFG6rwsj4Py)@zN(h zfu@>TKpW`&qGF9U9jKFKx?qQ_&o9UU?KGbsY4B2Um*o+@qSg zdd@^TFh9t@$W}C0?HOy^!t+Uo?JG-ZklMa;A|pLwCxG`e*vH}|BP7qVw%W7B(>wsj zHC&`kV)uMynY;IWF9YSg^-Hf%vMjA9u6aG4rD=!Pod?aKM{LdxsMHoIHPTLyxm|=< zCalUCD15$pQ)J28Ocq(DxApdethosg&UJ|mv1|`P>l2+c?VVCZNZ<2agm8nWtnfjt z&)Kf)MU)jNKP}?A-*TJV1r`b|-)e?NsZ)Olgw$PC^!)f{M}I(R#m!?UDKhF~+^u$D zz1OiX&x>qg6?Q9CxZa=)2x4XIfv2-)Fbt?3!$Htg{Az{s<@z+S3@$olR1>IX@)#$oNge^khO}MM2gOT8Zm+^d_ z)B&jgP`3XT5WZtYJx21cE<%CiqPAg*wj?g9QTwB#ll+2*wxyv*?w!Dnw*B$PKFht> zeO|BTJPa-K{(uDxsRo{&M9iVF?3CwiZ@yT=a;*<|ADM4<$LUWVfq+)Hpp+am(uNbP z{9vLmZ2m_qY$m7|>&d5aDD;^cu$9nXB4V-2s)r>+PFdYmIK1h=c0^$E{6;|t=xkfN zBZxjXI9ml{0nBcO&RV_?Wqf8n-nIXu?9;L~OGZR{%Zfrnh3!Fo?#fi$`$*E}} z6OSh@(yqQ9lkZ|RSa2O{i7BY``sNxflRhEz+kr#F=saoDU*MMe1ar*b>?8Poy`?uX3VV*KoNk;J& zcdPWxFB#u8HE;T8Vl@B6OC&ZIF;_*Ca1v+6AY+9ZiQ}^wX@Y?F#fo03RDqLAJi01m zP2 z$SVDArk(Cb_({==T{tVj>$?VZOvPUc9r{qdD#g=OkgNWR3D@ zew}r^>TP{9!-AnMNMLxYJ?b%~002EonE_0TWlnf^cI*?)o|Rhn9BbU>RFkP;;$6uH z>rcJ?*XGwEwv(FDI6$WKa>F~vP_)$@Fh*G`kC>{R_I462dK;^!tW(H-zwg93EkOo# zmeu;Bs4g8qVCTU&0P+!z`kiV_&I#fHt(puqmGvF(ppv4chQD=YUFerQ!Zv!a(n&V% zocKkMP(D6`j7&XLM`jGs)OXHzHoew2b!9x=SIxLO5jD?3dV2QA(6zJJ7k@#VVdEMf zQcnW5qDjrjCpTJ&GGvCQ@47%*)TBQ{O%)e@#Lp45GCPsE=YP zIC4(2mi7k7MV>lT*017=tMJ7DdPs%Uc^-p(XRdeQTJ~KyF_)4RfJgzxcg~|#fY_ZA zR8>-Jh^w2b0!DvGQ-iNHO8x2+(5-6Hs#Rj5?68&B=Q}Ly<_(ZyJ;=^740uT>xAScQR1tSgCVKNH)2oL&7?QuyM=(|GKs;JkwYFxAf}uxJ+sQZ{?WYgb9S@ z*&Vf&Pjy&rtv6|;Pu)!}mIheKuUZ?JHSZa&MQFl&9}u;8+LBmz)_ASfZH}eo;1$f~ z*GE_+A^EvWJ)?3&nZP@QHBPErZT;y6P8ApzqEZbnLaH(3RmjyStSe?w?iLe1b9NRK z1uOcQyZ;d+_ue#s<$s0i{oDWBb7A<28ULDyrL!-$)hqYWL;+oMGV}=&TDGAjF>EkC zjy*QN{^or3tGf&iA4GY1R&5@<@gJFHq#Dlpaxgomo++&z_7oIiRd{+$!EGM?o>%Si zer`RE1AJZdZKqn#@3>$(vd}glymu@;1nbjN)v)4+S_J{ros+{2DWswS=ToOL|4Q zx0_mLNbKQQ5`qV7o|@f><#wr�zHisVpv3`&u}JKfHNyA(NBtsNGj4)g^WBRxAV6 zez)FV5TVVY@2RED!HPJ&4#aB+L=5i+R!W?CYtMj`^Omx|*$I*Q2BBXBE1#fmhz=!UbBME!gI0j2oi?2r$mA4MxxkTp4Hw%y}wE|Xb_==#IJ&W@Z7$_oBo zn~UsC>0WL}%D-#Ovl2a$Q|WwH!y9s?ChS(;%0cudSjLlNJ>nwTyr`(9lW3jT z>*T{>&51ue`mL=m-nTz7(Xwy#1fOf$^~MW9`in2n81S1cfHcxFMS_(2m?(^8MyTgJ zRw^pmjJzgQ;ZDd}o{;lvlVszI=@;G)@e?L*QTj*?&1-?FXUR#AaZH=51{Z1)bSu33 zk&Xj%gK-9jlFj=};x1Gy@}CQc&Tc$xRzMX6TEP@H+J;YPBrK;k^{B<|YPCn!L!o1J zI4_nYu1sa>?82?shv%`+Rk6IFl>aCzv9h`7RFggdDTCcN=|`@UcX?$kkfz2%o%%}^o5!NZGrCa zXsZ4N$;PifD)KQ4gU&6|j(|mlmjvvt;>d3R1~LqE*OM1(f;^r(|%Sa>mk{CZsF zy`q6fRhl}(yPP{!iAO_w4Mh8uSRNz|Lw|iPV#q0- z<2d-;9mKUCN1&h|hDP%=6_-g9kd18k8vIlI{=*svW_|d*>CadT+)4#|PBM7NpbRQ~ zoz`EFF3W%7BSB@mG;MiQM)QY9g+}N@|El13RaK2lhm$3c zJiEJv%edGySAZr|K*=JlI$eTuW6K4o)l9& zGSeO-Rh86aBNo15`u)Q9Hzsw%5g%KY?yyvQvG8>{$WG+52>b}zTe&EQ{5qKC4VT3cEY7K#wyJLZ$cztH2alN-MxkKzq;gTGXxu9J7rTdhWYm6w-c%VdZOZ`7Tj#f83ndU-kk&+tK zv5|FVxzV!C_*-|ax|-P%e6E-u)sQsx+J3G*I5yLt`3hRbDB7gASW}m9p2`6+-p01 zm`^^+B*m-b=XTx;G7#%k5%r2dBPpSk#`IIHh)k~smI)pkq#5pD(g=(7Jqt&yX>dx- zw>J0aX6=j`C06PcGBUJIHEWT62GhbCn1jFQB%_upX1&9yxPn25I108Q@E}6|U*q^r z0`Kq*kzz*&L22^{N|HE(=7a3<9)g19F{R=)6`9a6%g;u355(SnGdbVE6gA4oa*b}I z;dcilLVQ~_HY$xGgMj|Hs0y-o{_uo)Lr$1|8%Vl7a>@EykIC?6ir31Rvk?1ZXUePP z?dPneZNd2g`OFSpCdPwNL(?H?Jaa%w&h#zV%rq}>-1lrS%#rwNe?{WesIchF_)DH! zre`!ogdiaB_|M3lY6XBu!W0Nof!{lqdrCM*dFK0f; z)Li+`k2e4JC4&Do($)VBqb$Y{)WUJ%eE$7#ZpBR~^RgIw6^t3>CS5W-UmEYsYl8^Z zJDA@vXdl73vdwh`aiVp)cYCO1GIs9%Pi|(q-8@N=A>Sb39*Bfr|o_ z6c1p8tPGE&ohcoriWZ_0znm*C9kP_OLan&TKEM0&?9P>n{#W*$`3Fo)=w_@?h@WiKUx_v)jD+EG{ zFhM-VU$oITzany$S=AZ&P0XqLlcTY+5ABAJuNg9VTusiFUZc7@mYdd7FG_|z))qrK zEPcNb2_tFeWxL=Jjq-Ob><7qm@-1x_kA0ZnJ*E}W%h)B(qkROmOsrg$BSV`iewei$ zyx26w%Fln=EA8NBt?S{!?^fYisS9Sw$E5CBF$Fwhc_}HAL#~XdSN+;hsuUtY7RxI} z$+Z{EPHO1khKlDy)*MQFH?4dWgV}ALy%;mSBzx}_`^-gd|0m?FmFhRBE+St~j7KaF zfF*22V2d)!2XP$CF3iZ?Y+lS#NXx@kDK{f-K1wKk)a<@uu;5q*58a#&d&Kb=>xtx? zv~U(0s;IBrdK6y$zNRL0b`{dC(mDS;Etl^88S8X52zq44lJ>a*6q0Oc>{26x{)!6r z-~461CSpDFfQ$uwvsLa4%_rySMA>|2?IA7w+TH0hF8+Ow)*@))sA&SM5zc&zdSRp- zF)pfWGNhJJS|Io^FJaq7frPA;HFz zjk%UC>Q{-ZwQ{*|^o1XJnB_~}~%RQC+v!br2bi`bzCa&ZyT zw*WuM>Rbo3ep0S2m6LZ1iJAYBywNi{^5I7(Sj=*45$8s2wQ4Jp86z~+Y<)Z#3UbRv zFGz6huwiFlL3q^m*>5lo3viZ>zV z`D{-ipHaMY4Zr9L{=Z^{d$}(^1H&&Vc`sxB?{vJtDlOgK(1iuz@X&jj&IDK6W_+QJ zpOR@=a?`iN59$StGK+of%_F{pn)<(RHhpI~m>2yuNySBkZkLHkXQ86PL~ov#IAM(rl{4GWHjU@de-HME!a1Dq{AI4l%*7uJg_OI)&MJUN$AY4H z8#`0*UCr{Si~O^Lb^jhZcrhxp8G2eLJo^T>*w6E>Bh{m0-nMf)p0^+=3@2-UOIo1v(|S1H~ELK zGcyph5ZZuze3ru7-{5S}6DfAQiahn|zw;T?&vXieQ6BMYihUpd(IHU&5ul1i6HD!{6coZo5Ml8>9El(V8;;%Rdu*~#cY z2mgl$e9!L2Yl>m)rvanCAb9mrQrMVwJEcz(iX8j0y*)ke<1^X*qt3SS(J)Z9a|VSW zHbi*D@-~wZ@7+TkW)-^ciUmYylo<1F zjJ9^=lXg&zXg8JzMo@sasJ~W5gu8qUNi=xne5g$K@O_b#)?0S3A6QXZ0YUc+|7MyN znZ1%M&^9GI;wHa>(`cwbT+a?pczIJjJ0niyzPKiBZeM2Sll88u-BW&`U5t8r<6jVd zs@71QKC#Gcr1f}L-m>M}w~C&O(k2f#=x`0W&K!_s?@JI_m+_t7zmo=fL=iE)l>;G%t=Vk8L!YBCq0maS{a*ocs#;WvsU zyO~7_RRMKREpORqkG>4P!kZBCDHz?Z>PvB{1eH$LqRT99fpeu5+bp~)p<4weoYBQr zE@k+oV-njAQ}(I)7t{sVqVy){4q>m=?IzTzVX5*sl5RNFfH*C{DtbZ7%#h4pl!v9% zzj7DKZoR(rb4dp1o7HG30bS{j4oT`EvN&!b+u zKlCW^$;p#%Z@ob)s@Wb6c;xvD#r|(LI6wc*$82TbFNoB#83?!bw5I)dx}>^<+XJ`# zc5{QbOS9YOA6WyXM&x*`xbVIg z7g}NULN`S`Nt5T&gPOBO2hN;5wAKq?A~4QSahC>qj8hsTs;vp6q?iI2LR(FO3F-Yx z(D1x$rFYQM(7IH3{ROXt=O4eErT@AX3Ek(>5Gj-xTOiH}fVy%=`mdW8siv_m>GTus zKFy1lH8qR5B+a?%agT5R-RdGW$|aI3Xgwkh*tqJ#hmdHWd&5&l$T~UbN}=~(Pab;q z(&DsYir;bq3p?d; z3-uSbQBm+CkkpXM?`gV#=WZ>@j8ZY|FOF%lCt?Iq2F4^|py)PPI~^a=jhj=;b0Z!z zx4(WVL4$$!#0*`4R$7}ly$XlWB8Ed=sTjwUPSP%MELwa!b@QM+rMH6(aq_755exID zwfcu|2R=pWlVWufX6?jz4|Z=+sM=x)%?9_RV5P4ds||wYz1+U5wJ~_l?x$8S1VFXw z1ZR;kP+@Hz*_I*>1K_>;Y_~~HL*JT;pH~wHTWf_Qm(_0ImwkE=qbR$mkL?e7uKeI2 zdWf9@UhQ0?o*?6L@-?X?sG<2h{OBSvoo~t z2V}%0Ak?wm&{40?vA3uw(PZajkcDL2%fRdNjp64sN`f9T&q2^>1^%CZ_<^3#i`ieV z1G7Yybl~oY15KQ7vK7_Mw_8r9Id{8BjovrCsXVw^u&_r2*lBM#qz$Fs=(Fvo9iIje zO=?e_g^`uY8$HVTg8w!6~=~>VFbmv@WJYq>HV!A9enha|P4RXv{{AEa( z@Qp}|dpy@kt?O0>51b_#e0{vz2v18xXBZftUUme=DW<(>P~yy(Tpvcn@>4a*G6lRw zOCvU1gSM5{#&?D9s&RGkKKWFz9>!A0D45PVU5Z<4G3W_ORz_bhsVODmS!i{v$P!=F|Qs$hwVM5;WHfQ~k4T?#Kj#!D5x2z{+#Ohwi0L z>CIoe>4;#9di+#ReVWw$)9E(7;iql(&vMJ$5=i&@wUYx9iI6*%+&%Xm)dmacSB%>uk`*6%p_wb)>9vvW$>?f|>tODrLfzUf!`paoV*^nqW>7bVJ~0 zIU!8E1xii%I|%+C80dEx$caXi>WgNyOno-tB9b|gXqel9%2?c}z`aMSRF^C5kJ3wS z9(W!7xiuy7)G6`Yy=204`aJ{F-7|UVyTzW}y3Np1@Y14XrPom1k28R>Pj$Qc+Ml|p z!p-!eAT#fPx!C#rT-Q;yR)cO0_J*?N$+QJSOW1){udQx5LA>qVLm%O1r)yKjKKrCI zg6a={GMCS&XLfTv(t^cHb3UZ_wvPx=YI9N8Yh@({T_`+lX<@TS$YeV4yOa-`uK?YP z+FVU;T|c5Yz83T+2|=r33IT&QAxyZYzPsw%gqfrPuFbBTNR7^>`0_jZ2$AK15c>|n zR>-}*>sp|80}v)HUv3zX_vGM5eQw&i`8@qyMKve^tSdbckv%41+Hhd>co}E);eC%- z`hm+kI^fa#w(!C*?A;C2$_+;&zSO_Sg^$%a8Te#TO=Y$ST zeZnNvlmv^_RLBA%jbaV@(Yn~L7`uUQ#daSB*uR{5{rs7TxEcg zHUp>-HfVuU>8&3CO*X!iU{{}yL z#!|%#trk}ctYJh0Rs&yO#JR#tpF2EOj7kqRUcN07@Zd8`;lf`M? zVu_@4fbZ;fxp1v>arrbCEK|xa@$V(rJ<;qpQvtTM(Rcob25JTtvC6)L%1Z`o=i^*=5J;wv1s30cyHALtuPBM zj}-*kn=H*9gNAk-+^Fk>JA)hGY3sE7utWH~NY@$n<8Pa!@VxKhUW&VLo;oKA+jFe^ z=1kVL-?<9t-U75Tsk)@iib`UUxY<*yG4rpF?2^>hd#Z;rPQ+Gyw7uWjnZGJkal%DB zbh`XYnD*f%|D*lL4LB#jV?&xucCn0!BX&tuq{xq+w0eHBLqZcHxzD6y|LwqY{C~6` z@{^jNc$?-~#XP%YSfHl++pm_{S3-+o%?O2d-6NwtxKMnG$ z=`go#fFLLZoPr`#}%K?C`?S&jQiZ1R(>W)o_z>2$;^`V#QfM9h}iQ#S({sH zVbFUR2GH>t^fUYMHTC#F`5Mm^3Qe4>lbQ8GCB??%`p)5}pw7|Di^`|k@@MSz_dDvg z{{_MEhtEt4F4^$(YaSzleVVicHg6$Z&f|@i8d|qLZ~0xvc)bzdqZ5+XKkKkh7%{~D z$v>LaG!&%?8Vr z=r5jvFAtMiDZ+VgqEitFGi7@DxR4|DMuG3t76QP6=|A2{x7GqN;4ylTdY+UGl6=Y= zm{7AcE`%@d`-)-Vi;j`T4jxhC_$;?|gQIbj`>*s(kAF(XIiodpb5)R{=!=n!Lb1VU z_zaZW+Co2fky0-|aDCK;Q|E(TZ{5R>S;h0xhYBF>5s==!N$2lEkM=MW2|wVRMoQ{% zB`Aq3o7%7sAyu$k(~FPP4UyTx&dJAQ5@9Ozf}{PASFdFR;~t*M%kdxgryl}SiCR4m zEH4(cRm+u0$OMM{j%4&HVMXFZPIi8hlKyxE-nBmZIP}aJ$TH@SjzM8iFbS6wrYTHT zvH<*$gfxC2r%l~81qae#&BDrCt9_ryu%lbtB{GiRql+qhtbEwI<+U|wdKFIk-U4M% z#f10dT07Ci`f?I`OezOgE#<~pt0s+Cr337P$5VJE=Hi#5=8O*X>7ai7tFOFSbddW*yyZ43p$y54y z5-d&84>_ipkek#|l`WJRE7Xp4pjUhGbX!)TcRnlMIg5`ID;A?=r%wL9g8VOdnEtIO zJodfmhtkS88E#ZLgnl61niGseJn3I+$FF{p?{bubko6yRNX$Kq$u_s+JTLKHX>Y2u zw;||{lP`tcYP4SgN(K|kWdlUsBEg$h4a}3LTWPYSWfgC)2ivkMc?%hdp=V{z_y`=h z5GCdUJA?{?2Ea>`V(XkixxOhy;El)+>!EK6`8@@#*l6|hu1BomD?ed_fwv8{gYv7Au7+>Thl&*v&vw4p zs-Lax`rsyjLtfmu1(+()O#|&WL4skV%0XsD*Hw=^RjtEW_?-!E1zICZnf{Rk5xM-+ zOw#8T0zeC_KiRqYmCZ=J)nzis>y#zMWD;U|0mhatJN)zdSHxweRm=4ubGa`1cB#0k z3tiRT48nnuf~p1t?^Re98a}cyj^seewsR1=4d3#Movi8`){>ahDIRZ0b$sz;%Ibi3 zv`M%TySW{`)t4wD8WD%tE``8P=jSy~fTz6>* z!?>h~w`rgD<7uX`kn5|nbn~^Nl_Kwzhqy{;JbT)HSXpp?2v?)&Qyn8t|9kroFLtpU zRCx?1RS}S5myT>x$1kbRS?f}?Q%x5<(GN59_j5g-ejrv(H`%(QhEhkxo8z$J`og*P z9zYzC`;b_$c;&-mU=Q3L%wU*=Y)fHn7w4;&Kx@CNY>2fasZqQsuSd8t#=9t^LMU`1 zyT!Zwi*6>3i>bKQrRfUUKo6zh&r<=w=xwmdmC&Q*nsZv{!PExV8Q$2%XAe~^bDv6gY>XU6O8 zE8m-H4Sk?mLP-@32sn7RF0(~}WE|JsFhj~8=3m#(aQCf?zC$ZIfvPdb#j8{(O^cTx6+%At#( z-nl-ZAq2`*h-Q9}4ywG_$PI!)`Ol> zbzER75h^B6{unuET-y^Vjsf^W-ae!KzQYFSN7ymvPt&)x{4X>OKrp9-6w^`UF9`-9oL5XQQnli zKC11kBUntC!3r-YUwV}JwI8VH(lhOstk!3HNPpz1p0Nm@^L~3e#)S_u0pQB~$u=+e z=+90YoH{{9uBwqi1+ARGI%mblws~M9(LL83^Q=eQ`c6V-wVr7{`f%kuh8yo<1ip<7 zd;Fw_?b!*xne_iV(X&4vXh9laIOC@Q>Q5%ML_@Du4=WbUlafNe32wf3+cJ4^vTlSo zP+_99rkEEU81y)v!93yrKfeN%vnpITg~GIo?_XO{QMlMLav%8YnrxFKU2_YTLT`TK z-Gl+}MJMT)MS+kr9UnkI^j8w@&vsO^KOo_r6DzpJxt>zVRF4@xPm%2cckM zFdX(k8OgR?jJ2}Lz#zrk;052|GvA)MT`1;RU~zxk|6X`6>-9H0ItV$1r$qqY z-agGw>jN9nHXGY+2qkB|3cM8}aWF<0gZ> zybf|bTz-lCK*H>KzggBN#b=_H1OmGD!xEY@e7I&(_t{37Vq2hGaI`7OEt>%2rS-r$ zRSoH{n;6tWSFKsNju#Y!D2NpoMRzLG&Dn_rUG_Lhy-mJ#vhV?wk-RPukYC_S=!J+v z#PQ{HB!@QySVS6^M^9Li`VXoXnK4>H6P9TMBp42Fd@RyD>u`M?s!9l#5PSGWs-Wc) zAD#Co1LIg42lZs31#JxMNcHTBK2ABvztvpB%U=^!@vUNuTgR=gCFa8ETE+PZIw?27 zw#%N-z1!*61?^>QYvA@!;zFs-2*fJP_j!VJgCT$I9=}X^e$=4-#oWT)Th62_#)_iB zm(pcz6)B$?bTg^@$d50QzZeZ^A8VhDOp8eF36mMvFwpXC8pa#q+Fsq8LX#|Y4|F$a zW{+8XiVwQ~7;^VL>+Izs&;>w?{@Q?NLlBgAqbo&`rUkn?v;m5DQj&%R^a=~)uSegU zS@i;ilX@frW84W_ppxSO6lJ`vrm`6poyLhaws%!XP0K}9+K`6YDd_97-JH7onY>Q7 zj)%HtKRNXIOgg*!j7f1>I@OJonnFry#_(v0lUiwGvf*`SXWuJZ`N_gA3adzbnBZPK z@*;5lL$?^SCOgc1M{aT%&Q6m=o00h6&rEZV^%S6%Ey)U@H7Xs#da0fB!{)D6G57U{ z&~=HQ&$K;Q{7t0VJGJ?JHYR&E%x|c~kVi#e6UUz{)<5-$d)tEc5Jj;nyq9A zs5Q1RRz&}S5(u&Kj210~e7R8IQ^Xe+KG?+faD`Vc@e{22Ca)sh=7IkTzxsdn823V; zTWvyb^WFevrh_Whhk!6M94;PVE$zlXF{PJ(rA6wt2`g6sj9zo(^MAZyAVB*b@Wx(g zRg!#z;7~Ht5G;0*q!zmY;~HBMYKW{mpCNk8Rb_NbIMTanGO~1*DL3@;++42gX*4~# zc#WX6D!Zd64{DCViQUS}Hl-*mS~f@Yay-Ff6#78^sCRqS?ZV)DOU$>}cKP;-i#jaC4n3J6-OI2B1IBDgV>@RVrDuT z!;G<;X4lPH{4o;d8SULBU^x;|q$%mlpIP86WIs4?)fN|CDt7tPk&00JiBU#|l%2DH znoVDW)0!Yqv!esxh)AX`5`edwLhD!P4kG6a+PrZgr*$|_$l57~JTxe2Doy_3`)7v? ziDPVO#JZQJ1|ST8J8#feNbOC0WpzkSuxrg@v1r9(VeHk-0n0DSq2Kk{;>s@ZNV#{P zC-j8*AC06jkCCmKZvc*_FwUtoo>$hQE7Ah)+m%TQ>>s_>TxSXt89y;ep5@z6`;!Kx za=Hbmh^8RcrJiH=#hudLP1f;f;dY^e!&!-xSV{9n(dV6AQjO==`^ME6)4~L59=Dv_*RJq>kpH2a&QjNUZQk{UmXnV+ z|EOE4oNh+_FG%BjKj`H5d032%#28+#aC(4P^tRe3%cXE@q=J7AE>Kf*e|`H-q-07@ zuyTl$>LbS02rHuKS~EOo_%FyA^5?3uWhMoIndZ#q5l>1$>ADP;B{8&eVB$830YAr08BU)RS$_Kn5ahQ^Z zvvXSs(`;~Th^9f#Vl>6trAg1u{Eb7j7wez{OW*FIHgK>@+;vYd+)IuQ&}=Zm0hu#c zK(^@2dp>%ok`xb%(juq9JmUX$jutHtZBgyeKDxNMG&Arx!E!@+;=(J~S=^UcK zof$Z%1$y6Z&c^sO$C8l^!bXl9-In60^*T~|<5U=Dot~Mpd|J~@&aqk5SF^DYAaR)@ zzniLZv`!DBkF&+FAE}O$@NV-rlY1?ey8UL-1^=_r z3VopxkR+>aVmU|0oVSb&@=*82+eJ&Bw%Hozg|eZCCk(hgd=U8p79oD=fJo=q2dI*E zKG;YBMKinCnhDspSFUEdsa7RRRwngj=sW_9j4?YPz>~&Eds~RtnDig1Z zSG&G#cQ7cOZ@X0cE?`emvL4cu+_~OEP};u)M{al;zsBH+i; zu4LFJe32`!T3KS;g!^;D$G5v2`94v_D~C4V(KejrfCd2;PGcgeYg zE9rJ#|Bb!(j%u=P)4hWz9qC;N3W`coX$nZN&_qNmbcjj~p@;|sh%}`)fd>#!iWKQc zuM$cKAOg}M)FhzN6Onief#>6E7H^?)=18mYlDQUl|YoRuD`nK_}0mi2TTg4WKg z|52?ceR8_gdFo|+lGK|*G|NDz8{UTaxsw@^sQ+^dUSsGmA@{H1Bac-n`1hnJiNxW>6TL z-;AFl48+zzCx)$t-Dn&o6R3n8VhXkR%Yz}kH?jQV5=k#z;2GjU>3#GFqk7Ti@v(s4 zxkfxYaMW$=FdTiFvJpyC^B~d9yK%?dHu~s%pk}5sr%m#lo@=ybg6a3rJKa(h#D>gT zB#4b)lO-49ysTL$Do@cz$?LMlUpI{@UTJvCagP}bChl1#TWq>!Z&MPBS0G1u*>#UscG~crnApS(`)RQEmdYC*}NSDH2EYo&acCv6(NAe!L-YiPB*V zWJ~u^%h?g;&c=J(rU|4+Op!SMk>E2;S6zn`Y$PCQJ9F(BYGWV*0d$o%3asvcZV#=Y z(g&55)v=(MYw>=l5=$iWXvBFi1y`z2a;$v+ZVd7$MNDu^gt|RUyQ)|`O!x*kcz~J` zs`t*x2GtU7CiJw+CX2N4htH6g51J)NI$>LehtcPDYvpS$@*^$SUB3=KUaDc5os}N- zlXmo;YG_S*78Amvi-24iiQJCbw|X{kM5%^+$7RwvS#wfUTIIus5h}A53g*ih&`^|Z ztX9GWn|M#>oZ{DSC5B%HYe7%}?Q#50(v)#RZ8;^MM3hvaw!84O#ewq#9$^f3ZVW^I z7_zXk6q2((`97F<97j9Z`(QJ_BA@0uET_Q&=n&(AYh(>O^;9Cim3r$XKv}KK6~or* z{PJYEuf121wov{oX{Wc;02ZHp^Is9?IDn_v40>Rb!XLn4NPTx~xU)r)Jla{4)OsuG ze5~wc*f}lZdtwF)w($c>>%Vx3={{*NHI0E$1Ctm5liOss2)D;^(7xES9Lia-u7_vb`t%;K)=$zNZ@}nW&ZCGf&cs`cvk+G zc@#gBUjLdytSRb^-3V88YmW=_m!xD=@O{{}etKUy$Ad3T`U3?Ql6q6&q>N^35B){m za#aAnV_--zy!A1s2GF4hTpg+j*TM>~SJ>EzMqV9E<(kQ9@}>)gw2PTOUWV=q90HT~ zYd+%;>dfS?Fm8m#p*pe&O=8U7sz0g7y0?&b=d_O`mbxM+wK%OZ?-BixVFMe7e~4n8 z*T7I@012x);TwgAUp$6$>g=YwYwQ3ew5{`r-yQlkxhggbpxzh6=HRbjyl9;=pkt4D ziIQezXz^}Do&Y?RO{$rp^*#D{HAAx2^tqeV!ll5%myk1Oq(^9egaKavJ`DdJ+X_FF zrx{NCM)8ig-2qBlhz3_Jr>vN>lR7_e9%6R3aoh|KE@OF$dqhVS<@*Z4Az4sy#5Y}- zXyN1<3bd2rn88J9@5%)N3`cE)N4VUO(zz3oz4VYG@$)g>*EDBN=o}||cZkXD=7W)2 zE0`Gbl+HOJ6cW3Qp~g@X?Xs6YOcLAv)SVP~*#M5TMs` z8rUE?1Y&HX0Clq>l+<0yyHTv_%vj`Adrx8X?0v46Z~7`yS*4jKlSb^c5TK$aEOH%# z$P`8&O(b!|b#?3*uykSLb#~tl6h-7Gm|nkPbk9N8L+D9lYhtx6q%BZm;x*>tn*VXM zCONLHI6!0;)nqv?4qT*Mxk;urD2}_rO+VfutyW$fI?AdTUs6%;U@XxqJAUGwD?B0v z1Qz#EsyaPT%ir5E>>3~j5)I?eL8_!WHvTcVTl8tC=SPB>%V3rkTM6?6h+3?sMrpYU z;6MpSYXLzNl@916Z1QuPZ(d6}wY>TV#(C4lCewfBX>V6*oscu>!e@Gt{6X}CC#;~M zlYwksM`<$p*lbwTl3r*@(+i$o60YX9(53V`51+h~WOap(JL@!uAm1R6(*>S{J6xox zc#2fW`dEi`#po(~-rybkh;+l6%iU#~2*?8?Lu33Ik6^m*NgiT!lyRC=t!n82O#;6W z=HFI0jcB=nv7?&Fp_8Ym;o77Y#^pF1q5ly2F4>h`0?fe@2udN;fiQ_V&St4MODZNU zC-+7v{8?1xy70j#Np>dq4BP0Tu-f~90&3dQb1<7Zo)xi^!!7d4RYkMQefKE}Sk)&v za7%UEEM6^8B1DC!R*{kAY2bM# z-&S_IzpaQw6+U_pteixRetEK|Yth=~uOZUkpnL({6(s@VFXy)DeinAiJKsS`b?s~P zU1^8jt(C=l$=o8r_L2;&B}lMHG3Bb=c#LDIQ&%Vc zUG2MEv}x0D^*i0!YhNcV%9XkzAL=SDfKk~8PWn46pcg>x3jsM>Y{#}h@4|~ zY8;PNoDp31lJV9N?OYpiX;7%u5_#(ET+AoL@Q#rh@{R&;+u%W;0xl9nZHPLNCCx_4 zAcDKj%Xj+G%6Be{4u0AB<_23XZL_EfV`IpDrhbqxFDy;U3{C_)BiI1G)vZ_3U1=sk z0v&x%URwbhrgbAqYWj#apy|ZVF`k(M z_|B}EX~cJYs;bpY$#;HgpNniQOT(!%vTF9m5BusJAoSm?o975BxT6#uEQVV#ZZ&ST zV}65EIqdV3H+?(S;*oADA_5NEGfj`?yusHOr>^f-hW6hrr8&%tlnaAYrWPKu@zXam zR}cg%y>F9l>+2t)9TIGRq;lO9k6T|Ck|@v+wWDx!f=1o2R?zQPe0SKhDUJ(h@9lcK zl#E~OtiEjTL#zmLK(%tE@<|S8=CyW1z}&}NUXu^4>9ze0Z|YNQfv$sD1xCLg+P zjCjbtBH);~%oRUhq^mo!sR`Ai9oenYfTEoZ!@X5CM-}^|S}CRdIYrB49lmO6DK%K` zo^5>ZRpT+^-qSB#&VMRFEAAGq?wwl3%lMjf1cV!>F;ufI?VZF7-nyuaqNeESGe=k8 z=IzXNM~;*i48+km0a-!_Fb<|}25HFjMNBG)y{z<&;jv15nrFT1U*sN!ndc1=#*LHUQ`yK5xFdXdNM_d|Qu7Gm!# zYJ0uy?!IvFDcG6&t0eSifzs-;g+{D#)B9?H>sN2b0qR^B)>6Tpt_wdRVkYQ zWy1sV?Y{D1CDvv#kJC@ei2F<^#vCy!I`sf@=xvT9-N1cIj^9y8L2Q(36Fz%a~@140`=$JAJz zBU1e``BxatTPzwt{9*Lj&RX%JdV`8n9sC!hG6H?HKyQx1{Ex+PnQwCfsFjWk&T%=r z#*t=`9HhT?;=`c?`qxGrbv- z-GkoPbZqobyQOBwFj@M{HIMmZ!Stcij~Mih7>9yFVx3|CGe{`+vHEu|-gky%tIe`} zcvgE4p6fYwu56~QC#h1OEAR~C1#lJkooA2@#zi|q{@y+igb|V{`S#8M$DeUB1*Ftd zqYLC*UDxHg()5v!BhO68hFl80pJBRH=0|nheWAF)zK3fx?0^bS=y}S$%kP0j98K0S z%WY`XEpUPmu3^Zxn}hF7HMwva4XNImWi&Vqk7@XI%?7Mt@DzbJtEP za$3d^nzUGQx+M4f@d=?vk?J470{h-5tm*@qCIY;JJ$+nif!*$k-EvVd8eJ7nR&EGA zDK;azD!{xm5=(bXy5a}!5$g8JZ|S5)=r+SZ_96c?8bRhkgB#)y5<_6hIZPBsr%!cz z{83A74wl2ZqNZCV(El0J&A($_+?N>v)>!{KC4=4df1mpXvK{>I7{WhxYW^=6DCDn) z6kpG^T;GtS&XR_&Z(?4fj~wB8N?ZBlLJ#^*n=xRvVKsFW{ZMuujNmKd8t=j{e=yhY zLzpVQ{_a=6B{yP!I=A5_Yl9ouwEF9maFbDhoI_Qp0~8R185MBv*K)i(top)`#S;e7 z&9}%4Ty~qnLcC_7XB%V$85r3f>X=WD!fZ1coxq#i>@jav!;W|yCx}WjQW28 zxE>_y-9rgpV@bFpop2!O0)4{y@(bf2MFz&W;xA7*QQ<=55O5TRN33g%6FJx%8!?mB zrREQmdn5;+ZPGo5NP-C}^XS%v&u{i$0Hgg+YZhCK6!jX}D~9}r(A5FRZ{@s3aadH3 zf9tVE#bE3Bhnp!SeTy!(GM|s$)q~uNtr?=(ft=ETn2%o`EsqQ5$CQ3ik@d*|o?dEF zP7BSHmK#5-7p&Y!?tcHimF;QJoq*rkM;w4Npy?~g`6)y-FN38Q0!8x4M!~6U^8#fwP)gAgC2HI*OOK68atO z!>eArx2kM?WTGZ0Xjw& zdh(?z{G9z_D#k3>=dFyQ=|RzdLKydOne3o;X|pSX!9sf1rhQMb8M$_=*SHxm@!lqe zS?{6bOyluHKLyweeb=R!x!;=*`^k)}y~uehKfMuGe+iJDU@Lq{%5YfyN?C-9xEjlW z-XreS*i+&@eJ516KD|r(zx%)6+yDKod-~V;dcRHnZ!*>2u*v^T6ZRX5G8 z`wKt+O)#qDXPfso2FkeKfKvXSV{OqCf%0mwIR^08!0DHTJ3Duq_c+IoQ4R%G#&g-$ z$B5pwn~wRTBjNJe1^P@&D-)_c*|=)wDgr9(dauz0RlOT)~=0=YB`OJp$R;nCxvguM6Khu_CZm05+JU)mUY%C#HY6i`o zPR7DVEjYf8uO9`cYJF4;;CEEr!;oMiv`Z-+!%yC5RZ?8v)*0i`JJ%wTxE0Uo7U`P& z(ZsgE=~MP}p8;fl2El)eGn1P&zy)qu@fT;yOHprdjoL{LLdl=DLD+>C<{+o|a{rn? zpXSzyGOd5rJ#vzM?BsvJDeb>tEAU@)ocu=*bblH47kh-ydps!U4Km}}af*cDu$*U9 zu@Cw^SioE!f%R-YQ z;bLdUYM}U4@Wtt4Cy&3#fIt$hnMs(Z+i@MxkhueU(tt#pw-K<}_I&9k5^o)m|8_*_ zqMV~m==PYdjmY9-8A-aN$a7~~7d|r9gU2oE>p^u9(nbAtU!4$jD+()o=zc88xSH($ zA_YEKcq}>k`d2;S4Lgx%PG;S0Q<30K5lnkI<8ON&0EicBBmnDO# zgj~%!W{FeL+T`x?=*sx^v>#yp5u*)Reocg;Z$iO5+dH+A#t|i7x@Ev)2Dtkbs9)if zc{DY1$>CVFYY9fWF-e+sMNn;yM}uh~XRj}S#cdBtQ=?pr7Gnp(Y)I*GOmNF5Rc2|k z(y1TnKa@8*m|bnL{;Eyn_`sCKQM84LGS_%Yap-_@xXNx=m{Zt8KII_P-Lva-*P^V624puP@j@q3R=bc`?JqhI z`PAwLj_Uj8Jeoy7Hy}0{EUOx>v1eNX9(Ur*M&)P@Co=Q(ZNwXzc$C`e&R#X~`0=dJ zAZxvQ>SZM4+nNZ-e$cKVaj+xKE{UD08B{m)+0D#GwQuU3`GSAd&#arBl>R}D`YPIn z2{>*Vi*zG;uYtb2Ija%Hda$AN9VeULUbQUXFFbf~Y^>DZ9puHBhIiFH`A5=@&=->(*6!xeu23HP!o$#f zBo`CS#GC2Y4F%hBPYtFyrY2n1wcSM5Jht6bf0rJrVhjz(xXiIQrftMj`^hr`By8Ot zTeF{wyW+*8a{NQbBP4h9JWdxzhu!0ap80VLDo-!fjaEWJocw87?dBBQ z*Ax^fM#b)u_o48kmyWgAkNb|d9*m^2o+IR@+fw6pPT5l@j3CTV9ESlMQzJ)Sq=`63Qw$QwNvM2 zx_3!w#w5)Dy#_t`^D}jMq8b>80bJ?K;0iMxHTY0W(r>UIk$>MQyqlM7W{YZT(=5Bf zC3Y=3^1JZAAk6-s5@Y|4H&Xuv0{It-zvXv-9o_r)2;YDH^A}~{U&i_V605qup#r+P zz=Pmlu`Kk9aZ@Q>__|;R;6C3*c+J2en%qcDL@5nU3^-h+CxDz>!piGP+9n05g7aWy@oTptT63pUe^+XEMl?-h+S!k0`5lghv zJMusq48Pf#276i~9}1oYXnI+$ADd;1+NgS02l2Xct|9q`lgZlm4v6N42;GISK(G!I+l#C+#IbTL=o;{YBE zLJc0ey`G)d20rm!EoWVn`7&=dk;lSM)YjZeC)*|Kj%l-op5muMqN87$^!uNps6=6Y z3YF(rS_GFctmxV@pcM-6Wyaof=S`=x48lt+yWa~SdJ3A2cJ2V)t#B3@S^#l_ z9Vl-1wZ%89s*kDGrd7=1dn8|-A&G_^ z1L0LjUkl4VH_!P#&fD*ai>}o#^a!t7R+&>kab@1)Y+*lGJb4`jMAECiVv96^!S#!BD8_0mO zHrmixR<61-{zqOOU8>iMy@&5VFl|_Z30AVj)_Zt3v(k#oiLXz@x;lIp1bkn5^^cL& zYU+{`bQwnNJ6vu(dN}a~`2l^KtltUeQrF*c{Ne>Ndtc1TR}YB~%5NM+$-3nl9OZiU zD86R=gP289|B$Xam1->J_|A=P1i=NayIY7sh(6fSdsjKM<<|#U`u?4N{rPN(xw&Mhlmz!d zbRqtRi1?gK$oa6G#!38Adazgwy1SO&1Mu2o*OqZ?utYq?x_-3O)9Rd~-Qdi( zo?~|!*m8P51$Do z@X{q`T@o9vKHAfJ*pYr@{bw)@o%!Ct_e?=aD>HTZ``)6V*+|)}$ZecgbL=1~P09{G z*ds2d0{w%#sh;swI(40_omysrP#q6x_9pDSyD>2h_+QlN7-FO_O&3?bm$Z-1{qb=% z-sYYlH>CU}*vEfntyZ@i+#(Nnk=kcvGqGtYSfvpcXQe0)kK&nDe9f~KbiO#)D=XWO z^tpU@LiBaZOJIgzWnsEo1hb#9@6~O7H~iQS!>OEIaLIXqJ)t+RQRh=PgT&#TJFXJ$ ztwM@)gJ9ZkKJ5ZUtP2MWqOTB2z1!j=Jj)LwsR*|Mi=3-NSc0)mO!8Ij(|5bif97j5 z3ux2agU+J-G{HlT2d>ut;Aq;c1WBY+pm(SwKi!dQ;8fy6{Mur5c)8$1O^@hN1Dy`x zcX1%?UK^RXq*A-B1friFe{u0VCHu-{T{2dB;4Jq)xkbAV#>Z#8ZVC8EvmtIo!{4er z^Jj5{vosr{4a&Z#dZjW{c;0WitbZLh=Zc(1zdeX->V-9Pgy0`CLv{>_DQi5h(dQ^y zVIlWE(yox;0<-2d+o1fkR^P)@w7@0QN59z}mtL9G6pZD}iZ@k(*GdJhYA~&2@~jia zoWI4;8%13kt8OYjdpIv|<|6it;OCHuLnj?#rr7+iB+ayf{5aBlNz0Ml{J0qKBF%+c zpCro_5~2)_%KM91TeD7y^m@A``}ygZSxaem->;W;5O+8RlAxX%C+y*1Jf;3nnkuC~ z-H*t@g)o6n&Pw`4ty$duy0OYSBbcUVr-e_j)evz${(>$NvOPsm=?rg?L#X(^stak> zClsGtFmm3Le9Is6ghy^6gKxI)ZEQbRmnYxM;QvN9|8LR8J_f;0O!8kl5c_3PVyAYr zS5z{fU}&h?4m;~jiqf=(Lb`oQUXN=E&u7gs-c=RuPEI_tO`{g!#<_=w>-LM0p+c~Q z*EDAEVATKlPl(Z)JqU+XFWx62{*?viZ>f5JMYDl(+P|cy{Vmb&uL!k&=tm;^z-}0b zUwKOwE9U(PUn$4|Lx{enmX<4u7Y&rnHEE;!3~qdxjCR&MZ6;W(x@NQWi$rI|eN?Lb z?gpz&tUUA!oK>Bt1gOJ~_r7sd)vB_xnog3fV0;~@e^wF#>5-%xt9J{9R!g9-kIxUs zb-=>K_-Y&Kkf2QnYku{i*@wUb8n&r;W$|GCyO(`!#3Lc;zjcSc_37WL9{jdayt7l_ z?CkQuXI-w$maCJ^iB+MA`#=FC!4SgYnY7lD=Wu8ymttjZsa@Hjepu`RSLofOFwjYT z(6bNX6ZeaUW}i*q9|t@$@rR%vKt(m6DiOH&-H5u|m|=rAcz^Ilh>hR6gz@j(nYCWE zi6%)2og%@bZQABUG=$L_s+YiEs%QOk#xI>PGj$ z!0D43Y$%eEHpMMsQNhC6@zUK)D~wn4kF>N`gH?hPfp;p;8hhfqmRa_ZlpP`amdgEh z%>Ry{(O-}9M*uY)G>*pTP+fp>g!@nHs8#bG_vq_{?e)#ejxI?hiwrtk%dU%ejywIrtci~pa&Dw(ZB8<_6Vxwbd)NWRFK%laiQ2OnUTXS5qs5s*|t>Nl9 zj!V4bJeG}W1=vbl)_tZO5JvBN8!+0rj`AjEM%Ta?dUH@=ZPrS|YsPzqhf!rcF0KnT z_7if)Cca9>um8}~0ikC%52^}a2Y3L#E5p^rZb1Q@csy=a%`^@Ca)*;oM)KOm-0=uh zySwoV6Z7xxpo%jf08ZV50uCw&Q^_7rzKBa_oZ1`y^rUXh3+eGHoiU}#YueSBr2e=p z%9Jur)rmu2Bm@9DHB)nI;c^aplU0?QiYrjbQ4X(Q*U<2lpa!AD}eBkV0A4a zcRAOAG5RT3S7cMy0jnf{Hvz+dfYR?tP9uETpQ(CQ*EPn4i8;h7vE;p9j%4M$&>plZ zJ@=dJ#4`VWj3Ahk^h{MHR{QzmqXh$g924vVcy&zGOrJ}p!UG5I#HRIV*RJzD-_rj7 zfZO}O)VY5MbuKb*Slwjj0a}&(A(5s}(Ta=IIGSHr?4;_FUqW`wI6~fS9=@{Jix3-m z(Y?YelyW@kny)r;teJ<>)j6&Vul(G(X1=#R(2;SbT7#1!mnc&0CGD-@--$|||KXmT z!QDhYlTfs9SUQ`WLgVSxt_5d5E0bFk>UWD)0ZPsU6zQM{7h15d!h}E*ps6KQoNc@fK+=9&N-i26K#F7JhQAi$nip*xR7wV zX!@7jPrOZbQ`AL^_xccISpUc>O|0>;Dx$tN?W}LFNJ;4BH6erbm4?_4+h|*sV2|#{@HMh`_}+Q{ z5qPygn38th!)nQ(2TK#AsuYGmpeDCYfTeIeT+79*)C(D&ufGUdA zt=+`=>bNcw3aaT6P|or6DCM!#_qw-Qg)(|FMY%HX?*=}G$pq;-FN|k{z(50#4}<~L zk9c})o$7dOi`Z^H>1vq4c(aPvm~^2V*M47@C(n=;?y4#Ps}Fi1l- zw0aHYO*p8d91sBfcWx?MpBjPQY8;j;wT8{+VN(;|dnUT#BwZJLO{&n201s%>H@8n@ zsL^Z}9B^WMBZ{vK zvEGfcW$^{97gam6n(H4qL}<%hX*}z3N?h9IW_{1Miy~cVVV%%ucm*t~#&PK4Z3}Wf zCcsO=s=zMMu)^WA+NlS+qCtF99DvkDu=t>-=;2s;1zxesj-cgLxBBC7wj6exDNpH)hV9omqy`(_jIl@-U6l3d>+zGWUCG$F(3=dMstSlh^RGfU)!4M{`{+&rIjyW7*b@7|^d8 zO#gW5e(wxwSBDx4q#}2Y(iEz~ZjWwd3IR{Mcu=QTEQX8^j+Dt}H8x)UnCi|wt#^be zXnLNz@8u>O3BU;_;t2AQV&^G~uR2%Lx}u1~1Wc$8XPfY3m!!MTHQqDbNp-IFJ-D-$ zmv)~wAA+@w1MVn%>3VDU(U{N}xnl9*p-H**2h8ebFvokQl}#_Rbdw(PWFi10nI9I`a#VF@ zBTn6g6mv-yKgK}OE~(OT6XBDs6tsyv*X2Z8Edd1CgOMHt#&#>{eEHM3&~Iu{Q^h<_ zdX&$A`?h>O!Ed%%)c z(@(wSewW-&*BoOK%46?FCK0+Dksm6T`C6BEsg(# za5*p34b5kqw{3JkI1yv5edm_1UAS0&_2bO20DcWgn%$Vctkd3+O2DOX$)BT%yb)6E zR}6TvhBc>t$aHE#d2q&<-ITeMS<@^0vjI%VcvNt!nQnNc zrFLvl<+}F!`#nd!UIq=6n-MSaq4fxBxAl;{GZ);}>}pifoIkO?pwEV%JH>eF*yqz7 z&owU=&=UuOl?8-LKm{oW&4vVznq>n9N&)-zSqm5s@=>piyL-jelx^Dz9?q|p>qe~F zZF|z_Uuw^VrrF?*kTe?5Y$B+eua>YP4y(PB3apk-g+p19b zO@+wKfXUDEZzcnf194E^eDW4G#KyyiKQ1SacJ8ViyeFiFwL8A`(23-en(>cBdYzBB zYl=yb{)9xNZG?br$$^*_wqYe9nm|6NQL#QUxIy!;pUOEkm?O;_FkPR?aDKu0^pRS< z11(XMnNM%#-S7caBsny-9BGhkiSU<*q|R>KO7kf2;jax9XmEJo;CcLo+CuOL?Q_VQ zF^nD9QU}sDiOr2O@5U-zD5spq%`2PY+0O2!O}Y@3ckU=UACO*`!Ja?J6?oc8g6cK+ zZOxnDRpUd1a;~J+bxg6Y!3>&5h)> zB0H#5&WQpw?JBh&w+@Xy?i0W^wp*H+&y=AH-&RN_DB49_k!U$ht=l<)62NAN07==) zIX7FXD4&XVYy5|<2kWa<9MMfMugp68$5*32UUhjr(mkKWk+F9cTt%&=cXK`GLd}gc zDGGPUVNVrBFND+udUjXuOs-2A-@iDzu$emqiR3-$k!<47v$Bq<_y$HOb#=UZ&_T3* zRcbapfi&TCtO8>Fe72-t$vY{sKO!qgyw7{Z>i#P5>!a(lr*;#o;oQr3Xt*rRfdu0~ zjT;Q*4CYf@qY641vJ0oAj=Ir>WWQMNwZ$I3p?&7;mpS%5F>|ycd1uKBUshG7r?}zi zUa&I0;p6Qt4PjNNgWSJ!=w=aQo(1wl9-DbUM*Tkca&u4)<<81e`jhM69O9#CRub6n zUJ1Ch!akv36`ez}tyb+^Um1=E_LQtRdde~q1lAe|`k6eaC~Tuc*tgy(mkTt#;(>yJ zgKpWWW>*sxI9Z#Huxy(UVXJemX;*;M9MrZv7l?qgJ~>=+loTz%a& zp=toW1Gh&0Ja3&9)|CQfacLHD+pTdS5ACcrR-0tn2X-i?3)v?_g0FWm_pfq`gq(*8 z)1(OSsONj{w?W*^F<{vGV~rtaSKidhsdCFp?lMR>6wagiL~o6qBi^d`1aILN!4#+FBC_g_`uXl4kv9_be6&kD#{dyi zK%c-7wvEPjg)06DVTNlJIi_Vq`AUq)tbgpjPBi1|P)N0tZ_s_PK+1=x7gK}B)Q``{ z_;qN|HBmm}tQ_uE4nF$`F2$?gO?*qS);97}uImrr7Y0PMmo$F}t~rk<$Hi)>jbP?8 z0=PWG(FQ~{um|sea|hd|H6_v(NLDwoD*O1TPOIGO5`T1^=IIwQeVMlHjfGcg#Fwq4 z8HUR?KOyxob{hNMa;)W3rxmH!J1&W zn;qtHW81-pjC&I9^6p!OA~afosv z$K8+b`_qm55gCcvc>Yti$&5kIvI>u1ZV>-@#*m2I+~D2o`nj8kX}&}hG2{k1I{5dF zdnRI41;T2cBHk>o^BzU~an#fPCSSCn(EafX7a%_vTcNyYyLrP2k9nz3b=ec;a-}2= zey2vO#m`{}nG4jJ3+8%H5$-7foMw)mi%-=g(U|Zc+3$Z?$nnJ_-`8+>Wn08 z_KZ}o)Yc~x9D-4!UaE@yyg}a|9`=!X1K5z|U}3_m_`bPVG=dakRBHbILi6pSlBI*! zmshz3b0WpDxYS1>?%C)5#FGP`8e}xI4xYZZ>tkuy7WXU-);bWT>K0th8Z}jVy4@o6b&65Em=|LG zc>R-3K9jK2!1h?kvd_huUxW$#2l~>0{QyqvBp{Uw?<=stTcY}1z9M{+aG4L4zX*4* zCr@nC`SZl4NP@4{{#aUru^h`JI@ShH>if@>xs<5~J*BaBm zAZMNJrwYqpiqQw@h{ zjKnXp>WF!_7!5@rSfh7wS=hgcsMD;K)G9gPAbtX``RH<%ra~Z7C&X9kcZ}#Lfz=rb z<|+UqW6bJWsz++p{H%c#B0Ef%OpV|+2zYW7^St4zx0Wf%vZ;HuAg8bgvSXY{GN9iR z?zR4SxQ19WUfL|`R$!PnJ);8}fN9FOr4fT8KGSkl9T!BrAPSujFx>EWu7wGAW}Ql~ znTw|l0VAX{&zhcB9Ys8tcHW9DIkDG_E!0r)s$~fGi(uQ`RS(O77_<#X$J|sp&iX_{ zMa#&VV!%@)Cmu6IL8aw~c&EA>?Mn7H!5#-I+egN-{W!#5*sF|)Zg~B64H4iHAv3(Y z4&M?*G*kTYINeHB5n0^eX2s7mDmr=v{o|hLJ!ww~zFq`|kESqhD7ZJ+SlyTzz2!~5 z!{1n2^Tvs%>*A{to9jEear)73Cxp-F7bksqMFF`Wu-~ybjp9JG29azS?pe;|o@aS-aFw&YnSfGapL z*tlZ)!I3QsIO9^qOn`&tPIHxlo{Wvhvj+uvFM?h^_$7>EG~JD?LKywjNDIiL-?};lHfTC?M;y9N2%#oH&+d> zo0wJAnoai)iZ|Yg^k(23T6h`SUduU8{|Jun>ezM*8pfuLKcm?ZJ~fXdUK{*orLQ|x zxN=+7Ep9dW%c|+Q1=!7WHkVFgya(9`=_qe*&fM9I+(@dmhm@jv>-pUaH{sOm^WMKYJE zs}%xIb(O))$Ez8(p%ck+Ooo}M0n^o6?@Y{S(KKXZtLeEChFi&Q792AlxmSka>7x=x+|?;=1R>-~0O zat=|8Gd4;5AcX2UtXzGgq=+?Cki`JhA+yl}q_A=9udLy$VDE4JgkwNevw>ss_*F=* z1~wiyBogcK{1PPiBt7UR`3(c_zdFrl{hZ}fs0oy@419U)p=L2|@>aVluw!KwrRP&B z&G3iyhUbCf_~_0%DW~bYWq<0A!e9$aKUvQcsf6-fx$&P3~|Lae@ayS{T1=o z1N{-8xtpmjFTZx2RC=)neuNdJew?uK%#%WGtm04DG&g2H`EGXkpni=|WTD)h1M3z) zLwWzovmV)B$oX#wpZ$+ss^3i5`Hxd_|FHud{r6_?z;5oZyJ<51&bH-$6fynlpO7_` z9Ssy*>t}-XGXHjYtYm#PIl0tb*b1C(8bVT?7w?Ikk~fpIj5Qi5W(#JLGy%K#`!`Ly zB>@X#AZ30c6+G`Ov4Jr7-vwVSV(R4MYTOPEklUr_xR4pFfK?%q#{$4$_eAYu*ZX0T zyGiOJw?1}Bc5xh=FED!AcMGT^7_fHCz1_e`53qqpL@OX9YdJ&YT|*6KtcFx_TK;)! zxT}cFoh|XId*8aQLAL&c{8o-ZFJMRMxLQ93t_R~csz$c@{N>s4@Z~ylv@X?G(dEF8 z%j=+C=j(GX?d<8e7X|RN224nRm^vdtJ_O38ZsSRW^Ur)y1=}LhA`LXNlTD2l6{>G0 zorh$xZSO{p#)-V05WmUjzJI&F-_UP1$MGk`NmK-vp0;whDa|TB zuV@*;$pAk}O4gE#yrSrQxAn6dquALUHMHHJKgZG>rwEo4o(|)rd5l*x$-Cr$0o+8t z#6`u0x2HtTOw}{A-G5Hk2l4CroyXZ3cuK^@yrG$VY!MQyVQ#)sw&d;my4SXFanjx#45v9Tt z0o9G^<+2ga6J5Wkzg^XfK6F76;_LQ1L%9Ro-Z5~5^EP`H0CH}JQJHNTGF5M_?mmv= zM=T+f`qIxER%=!2umy$RP7ve?rt4SV>4cMSLYYxsc$XVptuRisA;E4GQ*n%<9hYbE z>Kt*S|EqGB%=p=a7Poa;dp7Gs!H!@;JwzQvH(%l#0c6zp7$aU5agm55#~86Km4g~Wd4x`DMD^OtSgN6V_7 zRifGJ9oH(ZdLO7i$9?Tp!-^)@<@l}BLyRAo4bEx^@D$NZUU@oJvy1IrlsB$O`>0ib zs59{7tLjjf>#fM~iGN{BYc5+2^qIuCZX86UE!HNMqAa@np-m%eF#}5v(+RWBh)eL7lPjzew_ z&UJ}YKy)dmzg}qLr316v_fL-dw_?WLU@Uxk2ZlvM0Q8a z@VSSVvN)9Y|5yLmh4&YcYQ>|D|G|QdB^a3RM!z%*+0AW{L~PsjS9rRCKq!@m1Enk8 zjU{a{pXzg&T^Ex^ALcBu@g8}84x8!uTb_x#l*GMj@~xRWN7e(j#KyqZUnk6Q#(uM7 z53E)N+|PCrJJA$|^Kc&e)*w4XM1K)(e-%nJeJyfH##^`f6z&Gy*glEe-(m!R$Kmj| z7{h{|C-RIl9F1E z{n-jgq3wf`m6~wICiD%8YsGv3qt%MJREQfI;p0S6__FOh*ySm6yfx|d?B%8+{(H}2 zro4ig%aat{*r8Fdn(rMO;VlOM8=_kn|Mpdt&p6>vn4H?E-I9cMZdSMB;m8zjG|nJT z(`YjR0@eI0I$&_0AW;)426At8NOM7AM@L#Ne3|7Q+bZs)+-Lv;P1|pq>3$zqmBAwQT0X zW4YICZGu_F&fx+z9swR?g^ogUlMdhxHVvNzh$zAM@fKbA@TJ8m3-Hu5LLHR2d~z4$aLu7mo~F;6DfZS4YMSlY4V3HaQZ=g-<5KK<~e zSg-86L%#yu`7q+-=}}>Kc9U9|9I0sxdEUiKja|=dn=68cbkaueCvaTI)jSt`M#NqG zP+PzBdw(e~;6pic#~kelq3!M!o5ZfWbZKNE$qG8kf*w?^5Q!e@js$@#oeoH z&T-!vAKT9ts3G{D0IZ6aTP}>#?h-Z*pnZWSPl(LiPpqffTO`OIl-N`xyB@W{(Ab^QppuwC1 z*l|j+)tH95f6w+~Usxd8CVx4(aW9A$uThoV=jOdr+-r8iGd!k`n|(4-#9#YDYoD|K z42;<`?#MJ+mU1^XrW{DoB_~%YZsXzz7UMOek~JChTxpZ>gQ=vWH#+Zq5DL4D9Nnkc z{pr#Em*%i64w>E57BS$s|0!!Q$Yb^(@G5t%EvMxr`V!^v@(*wAO^I~Jtmf1__580> z2cjS9IeoPUEQmi~^UrhI3#5@Jx*#~8OwSaox2i}uV;FrgwksPBo{zVH33 z=jsurT0T_ii5n?%b)x{WZLqeRoJ5pfDqk-x&Cp#Xxv1KjB>ll9oP0W~0+PUJz6pEQ za)tt3EiOP`C&yyQO}Lg5F8ZBmDdCR|;O*uL@F}O~R`v1xW_K$NzW3MOycSIttl8)H zE9>1p7gaUg=JC2#LlKk;)g9o=URFK03558|{6Flyc{tQ>-#0!|*^(u@ELl>PWG~AI z*^)@vW0Kv3Bn*bJWG5no7=@5!!XQf{J4v#K7&D4&nMw31WBPsE_jUb_=Z^b%x}M{? zkLUhg&-I7HF^=Y z*U`;8+Kc~(&y&3rC4WP8+q>r@t;pJ;L-wjout>o(sYDn9B1odjwx8*3l*PJ@l<1Mt zyON*YpRkm9h`wEN;u`G|12JhowQ(Z7_ z#bRB1{jquTSbR^%k^^IdKO<+Ki^PX#jNIS$viSPTDL#Df@E>+U0X!$+#D3&j=&P#d4 zP`Z0fENKL1O?$oMKo=k4Pl6D9w=*!S~AnJJJdrTa-TIfNSHrGuvAQMiQhOU{n423Ezsea!yPanj- z7!j^-f+?SH?wLA1)M+66MJqXnbCV?jDvIdqgz}FlKE#2p$M2k*Vmlf$(m;>YQx$R4 zGZPysrtQ-Po0X{950jaoL^Z7~06PZ=kd>DvB=WulPn(#NR>my@ju<#)xL@-KQ>c-X zfUul9K^p;pilVPn*E-i2mm6X2=tTdXW&Gt>3OI03Y-?{2CQlu^sc=oZw z8(e)-zR-jn0Ih|JXK<(d;!}CFw9LQxX-y2#T(%dr{8giHq)#P+|MpG{~6^AOx|1Y)@rL!ehHz!PjqPP@gAA0z3Ps z%9jq0PdvQSNpTJopVUL$DL(2_K^^C^8M{Bn5|O7ij8rNI$}Wu?RmMq1ZNQ+kf|Nv2Dm z9Iu*%US(tudz1%%wmTs_eB@g7XtV2<6_SmdULT`WX2*<_DzAMrKE}dU6^MK77(bV& zdy*!)OPErw#`hI<4^7XnwOxiZnnQB{u0&9ngq!He*TrPJ7Q>y13yB(i?u77?S@~#f zEnwh`l#ejESS4h*>w>n|Em4W02dH?mtmu$XVj|X$-7m9bZU0KRi4$NN#FttgG6(8rt93pK(7h`03~Gp~9XzrV$f){NkBL zcar;44(SPOmVD5g3zLU~rS#uY;@$MhFm+oZU26+FMHhIvWxVJg6f$~OP>OUow{S7L zqQ9xAsB<6_QMCWXQYr4(g+wEx&CcA><2zwSdyftPRc(?447BJHmlahY2_pZW5Ky}zhyI+CjG#FkBN z;$2ll&FUT4GWpLJaprjWhFy|_>HX83R3IAsk4@wDkQm$jQo$m@-I?PfNb@a2q(RdN zMWP&`N&tJ9FEYAqGhQ1OUJk5e6IRYV@^r{5k()XFtm$b3y2e3Wj{gx<4)$Mm>vuGl z%}G!mz``{*&wls?S<)yUfA;QovzLGSya&QOs3OpEW%w6FY}pc&1R3Z=|4dm@q?w>- zlc`apnpV|;1f(&t(Lb`#R%vv)*KCS4=*0dS_H&R!spkaX(SXC2wn|5TDDxSL0uWBH zh3EJ;)Quu_3-u2?>Vb&P8|D_=pg-n(RpO~UePzO2K${FdXpeDJLrh{L}vcrJAE-> z{rZhC=;RX|I~bSO;&7@!$d(>Lp;fgwAq_@apGsyhB#Vf0)w_9l?#Er6cgW+l>iU}Y zwNdU&C3-eF{!XrxArSQh)n-V(auG;!B?QW1nq|rSS5ueV_7$+yO&Z)ze5zBAJj{V? zIDdwNW>bmtN4uXpS)vVJE!2id9Mj}QI{M5d3_tFaU*bl)4GYdJ8B|ajq^CZnj~J9Y z-*)mp)EPZXSGPDR8%w1P9n)l@oaOESQ7YZ%$@6Jo?D4Px3NCNi6pg0pNM1YFq}|%o z?=08FDMwKU#oM~#DU&s1(A_jSX>RR^^&*<*_{;inB>|Q8YJ`+s^)NO`L*}DgN2+bF zDu48c{MXJFbYiCt1fi1GLQeqSyJ6J>cPTo=5MRRE8e#~GEmXGt-Ko3mM$%lHW~!xn zPWsYEr6Xl{(l=QzxzVn8v%xo^oFr;-#Zp>DW!BTlzCb^P_E35Onaf^j_L_FWgZ=or-`#CzFmbqj5<*Fn33U?u#o#8j2&r2KG-me2P7~_ zp<-adc4Py_1)yzf>&H<9F)S|ogz)_@4hQ*9M4}3`BkzRT5bp7##KI?$CM0Uw7L+0( zGbfuQ#D<$7GG7|wPnhD*Xd3Zjs;=g$8z!)|OjwxRHsj>CI8AdULs;m_AdG|Bqj{tj zENr-g-9mN->TwnZm1vpTDO;9!^2Ns7ih;>IhC?z?XM})%iV-XC(L>kAliUL|*%i@% z1TJ|?OSVgh&mOU6SRcJPIk{}+I_wlKtJ|dI<8}L#(eZit3)X#X5gZVR=B3Y=`+lIf z8fKPzm6>Gg+JWanbg}Tw;N77j)#L-S8AAa^XC>|h!*4xN)2@v96brG0ETm4%KmZic zI~m0us%{N3^tjah9=kOPB{)|NNvms=DP>_@u=Tg8Zhh7J^xn&h?(ex!fp=#^N%wq` zE&oxV?g`rEMyZdQ;Jb=y)+gd4a0h_`&;dM_Dhn2WOWqsPKgW$ac|y-vSS0Ca-xkmO z9{lF5QEG>)+df=#{=U5^K6^y^oyvXu3CJElw7WP)J1n2yt?M>y{(}VOi6`;@>1Xg> z?SlRxVbijGFH{=D$;MpX(T&>9Mt#f$XMgi704gY$3Fz%8hM(A_aLFRMtDj%{2?T^v zvb(!XwvH&Fw~uA-h(XoQ4Xn}?P#{&Lj>)_z3?g;CBM2LGDz_LBMDGGZn+K=$#50t- zSd(8qy5DW47|MmTehFlqD$GQ&s5{PHcBx87aoS92*Q?b#>3;lRl-d;d7E0<0M#xe) z4s4WcBu^|hpJk5fYKDqT=;zg?iy^yp@?QK$xB90JT3O!GpI_&Y>6VxH{IJ%UZ9u&)?nc_>6M;Yscx5#p7cLdq$MPE^!ojNq%+B=yFL?-t;h_+zBHOsDvm^2 z5<(27b;;7xTDR-j9&Xw#jvoC`XSOLF!;V_=oC^ zWmpZ&))hFOAmMm#?s$FK`W6gmEtvu(Myku9r+_#N!nPfH^7#=&Sw~~Yx5%pxbRFjP z8)v<;MBOj^sF4+wYIvaR4&}jBIg;R;rDRNuI*Lr&F~f-+tmOfdVHVcq`kI<2?oX|c z*RenU1+l!v*nKOEi?*~A5*mIP#!t~De~&9~nMLF2DTbaz0SkPG%Gk`|;0g<=UaqCt zewl}ldQYh3ygA(Z_0nqh+1^SxxMw;{_$e2+OQ@mpKZGfg@E3ld=tl?5jGoRYD%&FvmI_1G_%!hfc+87 zw}VVpZD&`#HxqGyf~$L3KT++3ScaW}ZTEKWygr9nFC_EL2dArfBIhnLzkiFs>?3{e zm{!=72O`NXeO6G*D5Mr)1W0<^*6q<7%67e_R%gc0WlJr5>J4k-LqN^(pcJtt>x9Q6R2}lv(u)GH3p8khoq_unnkl=Tm|_LDJZ61BLE3 z`(y@Uq(3^x%lK1I6dWiJlhliif5~Zn?iIvzr$-CG3n(@ukPx>~_cHozK)h4KFerS} zSf8!Jt}AW!_|Uz3&t4^8x_zdS=@qPcEQ-J)ut=33Q#U7qB8#F!vl)29W^!m@rp`sf zbJoba_s$Gjk3fdxYwmZgSY+;c$g8M!2_(pyeWC&?27m!FScs~0PDq8qw4HRM3rwuT zW{!`A3L``WP@R(#qlyBWrosHiE`u1cuQOJKNwL-<#{xR8yt%l~>IN=?ytYzB(Bzo{ zWVfVD$JJ>|5Xz$~ilC^zWddBIsO*X86!H9hLHVlu_QzWd`;U&U0ZwZXLf`bLLSVH- z))8bPm4N7qO8^M6J?{;|sHyCmniP*PIixtqDhzJrgWa1QLfXz5C~5NM7%IsG);^g` z?e}_N?fB@ac@7Z%dhV0?)gK-M5g_yYC0$!1I@T}AsDmm=E{;>G5XYYM!?WY{HAY`1 zu=nrZccvhTqiQBp+X!;WU0Tx>v=cTTtu>bHBgC{z^_yI98#b-3Cs7}*TVrFz5-&z* z3}$Ha>d>TU9o=gVX<(+?S?V&SNG8%iTb6gN4`BdY1+F34gyXSxy_+W;Gi2qOUl#kG zZ+adn{K#`oKqVf^_L(XJ6wG=H+F!%#mm{Du+Whpw_YX8b`Fdt9v)?Q#ZlCy6ZRY+* z3w11i_R@~d6l@8(F%c`k_12w)^dbF}30+;=@RVq4Y@4#Sw>#63wt~oga-XE4c=7J6 zV7{fR=BwnxeRHzWI5FF#OKO;yP3~;3G@8bB$5g3@4pDDbh26!jKR?coI4f=Ik9Z8C z>i*X|_@Gi|domj$ZL?tn8GvyoPPI{aNh?8`(E`Ou)M207RL_kb-5Z1HR)m-ZT48qi zvz2q5cm_ojA5xFRo#b69>o|(!mRXs+V``AFKgrL_^W(afS^wP|mhe+7*X~KtQhC*8 zW475^VnD#5(feNz@-t0B8jc<{$Pb{vEB(vlUl6|h!#nwxJV|$QkV?(cOxASf0XV^-#=^@e%S9sL|*t^gad6UQ%LT2|X)G9Na%1U;VrcNw$ zZhl3(t*^Jdp2+=xDqEaVAM5_J1;I}}3m6tq&XJSDk%lE7@H!#0TR&>~=~oMN;+|Qrk(B)3n z8;%znw1I10U0R@R&mXJ_=Cz0xaGix~GGSS0K67)|+dvbTbi9=dL^Rr???1|PGB>-u z@Z{d;)Oh+H5pj2Lze=;T$Mplmng0GP>&CR3PJo8W4pd&=BubDjM0pBqH#S7{H=lKJ zh_{wiDoWKgk!5`Qyn{Eamo5M73ZnVn)?|iYNvoFiCl>(rFptzH0a)N1=HJ{8AE6SEo2-dY&4jh!}64?7mVpOqeCv{w#x7B#6X zOOHo1wWS|K;1TRDW## zQo?z08`;7!a3e$N0HeDJbH9|wk4fVStgXam`WNb(e1v`&MJ6ACBI-qvxtMjjXVk}$ zDo&eF;Sr=sxmZ$xuD_`|vsc|xB`NUYmt$-MyWGUP`RoWsT@tE&8`XuAtjCe><&ws` zS|%+mGO9c-_dkW<-?koilQ}QwWOgw?k-x|Z^)L#S30?S;XTG|nieFzRQCkQ^WFLBHETWZ$&`rNVzpneV-2U<#+1G2LnB-fd{6ca^ei?Q;2~ z+z5_7uJovyM%R9~8#fIP4@b3z;x|#`wK!L@Nr$ael1jIrD4@hyk%uk?`vom3eD|^x zpXfGAHQ2a|Ty>u2e}4Tj8p6rE28uRFZOH*TRzu%%gI}Q-u*R0=K3r(WlFvV#o4?Vnn=!_Z*ldf#Wu%J^m=>V6y{-HImwV!D9d{*TK+0p2S}UU z@;-{xRef1hACD72dN;;wsoNk-I@qQv%N+Q49kYq?SgO^|+g&g!Pp>h68I zM*{Y@ryZcudDXL2I&Ysw|4?sPom%|`@t*vEcb!;43oeWZo zJC+jSOJvsif{~d#G$4>ZY@lavl%9Aq(ZNDk`>yc#AdC;UV|Ofo z!q3p$QJkkt3i4izHHZ&n$nCoN)JLS+uQ#c`(Y>G~5ybj289u$eX`f)6`f_@zf}F5v zOH%1pOO9DbJYj0cX;qEz;JX!Z{<89PR`ji&fb(5v5>8ASCI!+8Z}8zknI?OnhL9X< z$<19>fe30_zl4oA%WB&ka9rV-pQP3EubDj84_?xmw-jG<@|r$HBN zu23;RPxHufW~fNZFxFGM(-SvwtF_39-MWdUEsRN!!xwhW?PsvNs&RV4%(W#J&wbkC z0f`lgpRO{0<%DqEbV`Brp4rz7ax{KVpY}-a!4mI|zv;h5{!cGK|Hv%uhVJiP1(uqm z9Ku>uC?9nQ#;!O(k8sr|Rp#uF0(`~u;v6_1$)0Q;=jbt0GPQapJe^25w{n7Z+U>Xc z`BzLL`s?M;{UFeG!S@%WWV2?c2>&}Lz-_PkJ!FsC`i}C~CMYqG>Ib51-!BjcwhjFF zAaAy@4~tjQ$jDMj6oI>im#!+R#-3qIU{R<#6a%uRRuHQAHcKH+Pi#VP<`$24UD4|) z*-8F9m3=VHq!6jCOMt8ukg%mj(I>UUtm07jGddPyt}r z5b)j7rM|a6Iqt>$G^s#2JS5<>S?7&pUA>z$y=RWnjLd=u_U5~>>&>KlMZ|$<*LJ~! zWaEw6sOaZ7k-FxWb*Uf2Z+flV*NVHAzP~*6X3zA!bQo+qTV0<_*MY8$MwfJDE8i#c z;f+AyDgAUYYd!(FV*zf13C{{&(;VVRVc_La>O_if=eZ75Hj5X*g{oa66mwx0^9Gez zcz!|L-uJq+9fv6|O)6TvkUwqKlPcoy&EMw?D(p5~j59g*-k`mdE>G=!6iqwmT9k*a-q!vX|Qz z{on_y4x za>W`HS*9I+g=0D~+29rAS8fu6rfYT}Nf1@yDWU{BVGq~=q%qvD)SX;3av6PS=^{hM zgrol<&!;!6_g{~FpQ0UM6(&Tlc~i!gsM2l-l~~3fmLS2}>F=ENbN5^Bw>$o*mpxM2 zXEL_EIgnlQ!iCIsiRI+H;(c`CuW``d4pSWRIx(A09yy5UJQ?Fw~g>RMY|Qj4WaIa>%0)VyEF|| z*=t}~p(PQ0WCImBBQi>HB~%3$EY`s5ecx=zvOx}VN#X#T*jS{w=TD~Ig-Q_ng>782L51-z1l zP>e`)VNemI>=@;+$nc@;)tURmhe~kQ7&DbC%_--Fr{~XiT>NorU$XS=fLk|(JQ~4Rmk?*DlpGVja7AoPj)q? z(gsLqEt~U>1_{he0FKHmYczU;EKs}sMnxgQv!JQ={6PU=Dm`#t6;0JxuIHA@a-QOL znBqXBO>go!vSJ>4?XWm|Pj$CvAiJn!lb)4)9P2*QdfqO06e!)uTfTv3)G4L*+B1?W zOP_wQH4GuPtTOR>-hU#D-MrsXp>|f1*Fx90FtMszSRm%r_Ki8Pxx)>H)&2{^7n;UT zRj6w@E82KQ4?q{YGHKYJZkiwJ4zmg$5VO?Hrw&2ohe6Vx3AiwzoM>9GTXgM|pN?Qi`%JvdN?BvGp#GaV%Lw1H88_wGdqu0ZI_xv6$|o=H@k*-YDO!;>O`_Q zrLV`mmuG*MYIgoms}(zsPo({2Qs3rfvT_c2m>`i@jysG8_yp)KXKid7T>};Rr$3Et zolJYf_G3VB;B?7{$4=tiUq-crY2Rr&dncf|LCunQJXb}tIYG^jw1J5)x<~!8(Aj@m zUA@eiDIpk<{ei*p?bz#wujH$yQhXo#Yz59>qWFp8E$!AWfOhI9Q0a2J(L-;<@Ka95 zu>Tjgnsta1JLkgn3iLjt26-(qR1sTR*xHHrg#lZ);w5vx#ve!{25dsd^4jjDW-64AJmfLbexl;@5C#SfWa?{%KpzVCOl|DyKb#haDKX>zN_Znu{l41?a^ z1H$ni&Yl0=vxaOksl0Fv3%YilMXD6L|E$E~6mnKJgNnA^PxXSblFZkYf28teod$v1 zo~e*ofp%LeyJpfa$Tt({PMaz)>62TiaSPzSpvcO${4lmJ)BQ`2+>!a1Zy`s^(kzt~1Kh8^TP$?q zBwT{geD>OHS1R#Yrjm=N7|WwZZH23!Rb7?79GbsJ-X6vR7*JJyK?c=#x;9atzW;)p z1Y3W1ljl&|M+SDTHTE#n*X%~wL{Lj<926P$<_4x$4nM;Q4Si9PeO`{cjPBE(QX$kW z@Vq^&!R*sgjae1)+%iTgWp=pgq_s`H%w5Ug%ZO3xc>%ZHSN53wfbkO9kUx5o=7Y~8 zmoRxy8F4Lc=HN)PA?gWI8bCP*5M|CSWf!7J&udRY2X8wX^bx*AfZh-XN88AcoU#`+ z38DZV>`JchbS1en@sy{PB5Rv%VWH!EuvQ}>#+MuEeSNOJ#PCqAGqR4)Q-7?E2}%FR zxnWhW@=!VJT=&6LmdW5Q>RGZxf-vAfN~0cuu^?P6a&(%ip+OYaMG$KvO4FVi?MW)T|pvnuuc?U*aj!GKSQl zciPA9u6hbT^Gwnv>{}@9oo_VR{a*e~Cjb5AB>!vZpU*(^@VRm7>EubHZZrK^7;RnQ z3_I!TfY*#-Gi#yty3N;VCu*;F*2CAl7fzVQ>Oj99*>Nm7jOrbx=zvIIg?89ayUKSo zd%gTU7K!DvK~R?ZpM0>8>}OCHql<0J5V2%HVVdn0 zupLyRF_0vC%;Ds?_nQ*VJDCS8w3jMUtj(>Sah+({TZ`(S>^w)dY#A^Ag7CQPC{cBn zf~WUp5F9YFuq{h4;j=eUyv%<#piyt~0^Rk7V@CO65NqH2i>N)$pgkH*Zs2Ws*AZE; zN8*$)SKJ*3WnT(COqx$1lr}qqK!3Xd_a~q4&xmImemw7-XYG3HyieCdu_(u$w(QS1 zE<|zHjKuI-PPgEJm{;FP7uk6{YfCl^yi60`kZZ00xG=P-7BRqAX_`uKj|$yW>dcBJV38!qjC1){&w z3@lKO*aINVZZj3QFOl%gQ%Gkd=5Dic)zs(g=Eesy+*3+#&ZZi{Z}a>3)H^^R0Y_6b z#&#p!u{2BA%m2~2IM8yJMl(io$GA_Nd)8$8UV!G$WVq6Q;(@VScW-aM3uo#i`YT9v zXj!pp0dsX3*y+!BHZ1=AustcWgZZkWJrfW`8hUF~bZu32KI?ii zVgA5yYolg|CIeiMhkO9N868tL+3Oq(pH~mPd8)`R;Mk#t{a*{&-jB=8v4lY(`=wvhrB3*32OK=~>eSU}vD0Fw&*rnFsxy-o%zyy0(WV}X zHEc$XELcXwumkaSFJwyW-OY?7?^9o$WZjIlv?XT}GD=BT48d>j#)NCKdVXv2x5cml zk!|BevRD}ptMqKbyVB_c?JH-Uyt7_isn7n2h5>$rwIe`F+suiPZv?+ez~PJ2&?(9y z_e#GHL$qV9mDHES^dGI=piEw1C1#70!a0sK^sATw*vD*hnlSZtHZs$%t*#9;`J~z^ zrP%g#Hi#FTRnLZeOO6(l_l|90Ru?DMSB1#cPKyj*RW^I{vLTNntxtkB9iQCR=yB7h zP_EpkCdhL>;D^mDj@2Am6l}L)*{gITrpvdZ5n`eHJ-KdH$V{8jK>aK#@)raP3v1RPG8wye;#pR) zcO$!1l}hVUjf}OeMn7e6o{1-(u*RS8>C(T5t`3!?(32#(da$3!nK8uCr^9xIRn7MT zJ-sT7ApEcMxDAi^AJl$MN2_tb#T{Q$A4w4)6?EFukt~vn0skp`Y(sS5mx?LVb=U0U z$!{Cjaa-k1P6j`&%e`<31C{s3+hrLLq8+qzbZsU;8kzyfyg+J+mX%rK3r^-~$bPhhJDOTGj!0VgN-B(*?U%Sn4U!IY~!3P8FyXmFq2kY-^O@EMPsK zzIrr#;-13L%bZ#KiZLl?7EKYY57LZb{?hQoR?OmOUQwWr@29?+n`xbgsufMuQr~om z+gptXl4WOM;i0FOaGWE}j)c#CeRw83vynlDwUbHBCC0iHQOMFow+m;S)%3JFAxOUp z>Hrs&e^k?PEh%@hRE-y`H=_0V0 zh?ZJ>$3V;sOVqdI{R4ztS^ESXL+jOwQ#0_`LO1icukCjagw3M!F;BocT#UUSSu=qm zLrgNc#BH+{EjVv1viA0V=$moYhc0U75xCF2ut!Jzc+>~oNo(z6nygAJ{H?_+WWC1@ zhckUq3kJwOx7?XCn_TZt51s8Xy%Z?1FHH5qi6?*FLf9F*>n^reUt%}WhlOLi04ebp zSm+em|ILKmZ4wo$Xp7v*okxk+nWg_ z32L_*dRxCX8zd-!in4!#oBo@i@Lzdo*^W^>i2U2E1+9MPOo7X@!CQBC6!|ki2Q2HJ zJ`S5z%4Iz!J%g)BY@9)o&%(nXn3CPRto%QM4VMp0>FFhGUI3bVI(ZN`enHaDXfD|_ zU!gKgmtI3ESB-|Uc=$Hi+Ai`1BsQN}?@gWbq|gs{HJqJd9?x$61sTv9P^4MI{|Rgp z=`%akK$W0=(4@yH8cEfmiT$XKApMv$pNZ`RhawXW`4bvXAAKnc~N#tNptn& zmNxocal1@8s_in*@I9PW??)!L)`?`o^f@8Vy|9kEA*<#y2o?Q7B&f#4Z%mrTa)k=j zV&i3?Ob)RH^^EGzaZ^6=6aTIo_&WqYdDnvbdsS!`WaVE&|A83*%R<{(P!?mbh_QSz z4aDZ*jq6C6F_qVAyboJHypdtl@9uQ}N?%(|x!l3)^5@+S`zMBI?WXrYc7tU003!cQ zVfuHp{9k`~y_l|NW6r z*!I(35EqlkNxGFOGVIDQ2&oskG*aFyUUqGA#s+cw?aBOf=}%7g1so4pTkYdv)q=!> zB2T+AiCq-tf0HENwYPTTNS#B6P&N4W^mVa5pL&N6v7XwjtBif#- zt{V@I8yqmWd8>nL1J=}A+-iX$(mIhP-m-lGG{e1XWHX9IRr3$1tir&YAtQ%UJJGWB z!V_06m?9NQb>PI07}AjfQLq{Rw)r@=BK`wmz0B=tgB5RsydA?<6|#oYNns7DG9z$cN0P zewdyJJart0D6pC{m%JqEm|;qLqyx&fU0IMiK-6fthm-&(NO#tg2Z-J>9#%S0i>Umz zoq9TB^3K%{zDG(euL{pq^*~loy9i`^9EnAs(K`scqe>+h8`%Nw-UJxql8xI4cG_jC zqwZ&BHqXs+jzGSB+`cHP+{)PXe9i#YmJR?Qv-z2T`SV8C& z!A=>J&Gec#(qM0sI%9t&u<~R|p+|nzRjnr8w($3sjl02TdtCB%m)&ZKXsqYk26tj| z#BIR)((s0zJJMBUVr9eVdsTfJRgCYI=en4Jyh8w6?35VIE4AqQ-KFXgu;#ZT-}D=P zV2`5qUuYyKaZzJJNvnWSL3>!#l1|CsUR}z-;*}p5ibKMypl6HJ10;>n2Jp%^k+;y5 znezO>a{c^O#zv!vvSWT0J<`w0&6zk%SuSrEH}jSwb+>bIqJU%jCfa*kDdganx39NvTf=s;+QZ$myYhR+@CNX1W zi*n$%uReE`2I$-zQw_Uqh|MgH=6sH;&T0jVWeTD+th+Va%)WUTEI zRi}vGt&C?#OUsJk#z|pK_OkJ%Q=Fxb*@nDh9K0}|P0d-%EvioWL>dyCL z)twFLswysk+3lY|Fm~4azlQ#o%)lOX{$1N0)cJ*j9XoxHJX$JBk`13S19^{uuJzu0 z_Vi}Q0xJT&s!>jd$UQIQFHX$h0T6q zp$AB69>xS&7U|8^Iips_^Rh}9nK6@#f znx{0DIdPd=NJhn^<) zNjHK_2!HYdtMGKg!uft(k9>YIG8rs<{{9O0fTfkt_B)W!9r$DvKlCUFC$K*Ni?-(? ziH+N&THAYU{*2lz4wgR1)3%+JB@%!7O-BuvV>tFOJdrfsj!8n(E4CyGu}~C9TbIaO z>BRnE^D!)n>)LWkE8LrNO@_0x0qScgBz%+q+WiczGrQIl zyf`F2sO=$maO7sCx(@f`tmX}aZ$F;+rT}T|s+cc*em!&9wObaUZ@FjAfGmxHIDa(D z9q$BxK9@|NCmwmMqYKe=h&(N6OXUHTFU=jEvoTUB@97>T+y3F~goB7gU0Xs+N3L?; z>{?7HV;|8@=39>pb}RPOsi)J2N^zem#`{bwWM4m9qny8=BK3AdC<@JuJ4S6&!P9RD z#S9|gouNmEu*RAf;Yl822&Jdb^B8yw+}{5H}v$< z@j9ivA`Ce^mkRm6B^djT;s)G>B^H^?Ucp&2*x{hKUGqmDX0K1A6{q{6wq6i&KY# zU0-h3YJMDo%A(#^fxzu2HaOGd)=*KBPH11=F(79y7#|B`#JCJqRD4S)Gq`!V4>x$_1nPyjveUuY}u8FRUz(9Xo}p7b4W9DyJ8rr$>1t~_RWl8E8A0zAI2#;!Ql+#h>9N&g zDF%xld)bm795Yyeq@jJc3qtt-7(qE}>nsr5`coVe^UVNv%KdgxQub<+-RhbVtA=4d zOXUg7TQG+22WmDS0N=^=TegI?Xq;#};U&VYF$5FWZ0=VqAUNT0h2K`|&?(lwjI_5s zHzsJmj6d;csj2ToaZ~$YOm~EiTyqy1FMQx*sYw@DJKw zZyZ<96?t%6{_4J$=Qcp@?V3611_IWZ$4A11eWCI$@g2mD{alFp;uSh5P%)>&HoZUo zOZ4$XJ-zM%LuPEkw0Qd=p=Fn02Pt6v^=>f8 zudO{WpG?+&MHK}wkKLh+&z;^;WE_1;w2GD#27KlX#n?EHeX-`?z zX(3b& znf?a>>D~Rm4Vzs6h28Rge^;)i`DDL`!j2?qfszZtwYH9^gQeD@$yJci!topC>_7Vq zULpTuRc8ks5!$c$^-?Wr>nH_O*(^O=a1K6*UeOI>m6*JjQHFlhn*pAB{ zpr-WOmz@*zA&<}HC6M^r{IlzdU4zR#RCB-CTuOet=o5EpLv6y4t(8^m&?9!MM-Y}P zVLnJ&vJSBlL(EmUM9yqYBiKn&G%3bdP#xIT!`-EiU$x?mgQ)X#{dKt?2`|Df9frSY zfd`jR&_nTlUI&V=4%Wg}PmX?z^E~BM6l){- z+)4{k4;{=rH6eDL#RMoKe1@u1%(jznHrs0ScV@<_%T?IJS#92q5h?rvssYj3cZE() z>wVmR5K=mu4cSVK2P#o_?GFKQTQ+vcV`P~WR7@xn$vJl|2FW_ylc9jEXO|wA5nP-3 zVQZ$uoPLc&Q)$L8PLcp2QeG_4GlESGFMt37hDmW!qi|f-M=(p{?fu)|E$*vTsnJTF zK6fi8cFB!)?dMk^dZaa(E@4L-SpcCt^tug33)o($u}v}-O}WNwbHfQ9vQ;Nveo$HX z)YZn1>)~I~aZo1kn`K+q!cd%)Gm}Xz9kxl{?M5gff0DL)r60Zbq01j^2O8qB;;?aBj483*8OCDF9M)7$yYc(s*m0F!|8!i%LxAmD_AHoaGfOSediT)$3E7H|v7J z&j}XmBFnbKrVyI1gxHXmXX$Yq;3-}VL>^A}EM4NtP)&m^PNo+>BzOBBYHCnxKR6R7 zan8tdZt2;7D*F3(rt;r^OZ}0mFnIs{4RWNuTPA)yK6DUwHqEE@+_1ecJRrJ zC(du_TjO9!|X7Q^kS^zHILRmptU4rySt0>w~O{4bRGUeBlo(w@4}tzT-|rD z6mWamQ7g$WmsH{sks`t&HVO1Bc<$#EU)6lE~TX8Gh<2@ix3vdMB!6}Gt+ zcIsPM3rkBp@@z?(Gsaz+>N@E<{3&V3M7W@U?oiJM_6ucE{PFicQsstN5^$Ww(ariK z+_E(Q^MwmkCK37+n-VN*Qzy@Jq1JD@H{(1a{Cn~Ji`2FLD;)JJUz`r!h^NAlq!r^;bdyF* z8$6d=m(<;k2ec}lj^1Gorm}0$*`$VCSTLx$FOpL6X4vr7u%RTjTKib)MdeSo_9e;| z{~6TjYB29Fh#Iw?+6dBKk7{0&MhR^NU@n156tyE@{XbTS9*a+$IcdTTDn&Bb<86lW z>*~pzudl(}zc)U7D;_;$)^at=o;;tUNH>j&vXQLo^+raK*2`4w+o_Lw#q%1 zWg5$7zT-;2WHvoh4>kp8-F;_66bNE?=5Nb^H#c~dWE3oh3P&oiWqxuQ@GP$zxn6v? z-wblN>lmi|f&?53k(i~6DW}jm!wJbuNN8GX_MKy2nzfWZKg_~RXx~5dH6ytCLaM8a zL#?T+&oTc$0uPl8r3NgxDEW+dXmu}l4sPNCDqdMLtBSWL7t*R~hP5CZSBf-c;DOFL220 za!2ej_6X$4rw3e^qCc8W4UpKH`wIeQ_jal*Tly@+OhVn%>E&UJ;dX_e92J5H8hGVz zf#V_7w=b&m7HbPGcO0>gi_6}AaFTW4q-&E{>2ZG-e)EF??A%kJpv9jAnHe@83$KN& z*s@F5AEm>lcIo&9AkZ4#^zYVde-Nc=9{lmpf9P=8mAisX!QYkO0-uI&$s+}GHdD!C zSrTo@w748kuxfv;)n(>r&FN0*%boKSF0O`UOC0SJG#mP`5CcOE!YKG*#q|Q zwu`I9kMaIe zS1GaBWgf}buUKD2(C@b_+AB#p$BMjj-;ZBFr+r2gK!Um-&HQEV1d-=;RVre5sXF#h zlZ>Q?@fSGgU#ltHe(_Z^23@mJ+-AZ#p_NZjtxoP9TRSm?H1YK*T~bxfb$Q3yY24Y7 z#PJ9#XeQ5fh{u76W@Qgp>+VSE`}#pni(35#YWeYsS+{Aiu`Yo)xwKYhtL9m3j%~~f zE<|`O2}K8i8BTJv$x}eOQ$18_(A#FEzod5Ez>oghBJ$N+NUA>j!DIE$jt@btxn74T zTp_^{KLU;ceoq1TrRHIEen)qK_oH_PMY{JDjojSQHaU87-QaE;hu2vbQBbmASMt7l z**psYPsoKiiY8`h9zS^oJSZExW~!&2y<7`k%3BO>Ea- z*bKd)X1nXMtJ2adZ-R6D`kM#e@`v6y{Uf0{W%hs=9U`DL@&W)W1&*}i83^y1IXADs ziPL;mmF#ooTNijR7O!s+7Mzo17HZ_uB%kT*vm8S03VeG&!~S-b!^Q_nT6Sl}t?*6X zB`V{)3cuuN%OG^vO~Dy&W;d?;(@#sC1Dr*+!z;T;7Ao)g=RqfG@#zE!P&(v3^pqNBy|_;LcRS3 zsrUt{%%%N3;ZPqY=tqbHR|G3ivn){y=W!8I{^Vn0Ma@kuqn}IzrY7vJUFa7%pI@z} zAj)k{V|b(GlGf=L5ofg<=}f1b?8@a8B3N`*?d^82HlbaQX7T)PL35?gjVi^mi7SPV zy~e-JY%TjYF2k|uAmsQD5A0g?^}kS5`71@hf9P4^yNVxskWL0D$AMr1EV>1o*^#8s zCdfNTk$T!kkY)bR>-xk>*OlqDw^FA(N77X;$ygP~Gp1^cknev|ElJ;l8TI$7%>Vd% zHyvninbD2D?ffqE5`t1tBcHoXrb&j5}D?};WWK*h)L3FZ1&t;}Jj z9HGN_uQYRPDkprSIov9ey>h|T`3L=y0?d;-JacFaDnfmWXQRjwwoK}mvvH9DuFmlJ z!qA%oNA}yj)vh$8l|Hv2QU(fF??XzF5?c9YT>_LI;teRFM)80Ra&~=|WUQzyJ|J2oeZVr8j|F5F$-f zdhdje3W)Sx5)`B-AQ&aY=km-w&suZqd6#G2nR#Z;nh$)CwU@crx%U3IUzx_b!Xh0- zh=cJ#^lN;QnEe?j3$o?DsfC&L8Oor$oV?iXsSQT*uy99+|7tKik5q-nL;i2EW+!XBpC&#SGf|kFXaiL90Ed$$DAnW}0CR0x7`C|= z1LgR{Z83Avb9~5I8)-Eo>)94*b){4Fl&O&dfM%!e)&?IIqO84efGiI(0q^@LjSm*G zv5iYj!qp}nP3I_`M6G6@yF_ofwIV(~S8@0ZWl2ylAz400oivM_Fw4<>=16LCBr<1p zStZeN@!k$$G)(%C;(GI8G{`vl!F$?f$^g(wmZvD9Xb6xv1kNN-&u&<_u`&L17zbxp zxS_Kw&%;SJ$E0i6j_t^4zYcVy5HI0&qC@o@qgkj~gwg3%UA|-UlS|&LHU}vV|CZJL z*A6@9@Ac{d7}wt+2@Czg;OwV*>+d;K{-R$`^$S7vU%OWR#906FxBW^$5y(-C(I3VE zMXkvv#os}zOk-<5XaqIfT{GA)>=E*n(p6(;B2%J#W^NlM$id)a7uTyi?Dj1Ku_3cd zHF#)6dZ;|qc_CUzob0E*4 zxRs}_?$SZvp+?p$rp7vstdAdjwk5emB&9%)mJm1*kYp)`*3;=bRa?Evpe6`|OOf5ChWpf})_|fF!zM+7B>0(eN+l3} zmAFw3TeAu=Le2H<-%hf3l{tOljCsgeu+L#;HJX+bU_OTO_8@q-LuklQ4;P8d_4jbT z!0!HJ{})24$)nY$dsMv}ExK#t@@Sf8+Oug%p*YNBXBP&ff@Pevy|alsG&3gj08+s8 z%n7M@H)nrG&e}(>1uwm!a*}+1Iy-Fh8gc7N=lG>};4;Gz>o0OJCnx-1*We=x2dVc! z(G3DdiI(6p2egUBpReE>e+WSa-QntUe`x3=#Oy|j^h~%Dmv6seiFJ2xUx351W&qyJ2bfLglJ5>TYZSoeSx1{W zXd_f!3KO+r%|CIw1&zGDonc5XDwXm2qJHK*A$499aZBP{)ik)!Z~}oX42qn%de!#} zn}eM2Qbd-23o>IhKR!+!$E8vZ1M@izwRZ=k~d zmBIQydFellS5z4NX;}LY$cjx2I#L~$D}M(GP(~ajNEbELy>2)c9=>8$>KeYb6=~U2 z%^FxcB{r#AEs5f2sj6rclBO>IEf8AKQ_|qUc~V{*nujb!SZK$BH&O6X__V|LE1@qi zzH65asb$Isr#{YJ+Sp&6FD5G-=5IBd5M^Ky6itHZm(B#COvzFAjg{v3Z@m_^R@2+? z`#k0%j*McW<+NwkgPDI1?4G_T)vH2U`VL~`_l)*Iko3sTFG%N?*9Q-5tAReiur_{U zVL5OxljopUr4KXx(i(^Eh4NsS1W>2P_Ozrn(12QBVp4Tow8sG%JG-s8*#q&M{jdU} z2BsFj^P0WI>|=qu3UR~@&5H6MXa}m{K8`&-8~&~WH^{DEbj`-zIC@>V_BkEwIuqk@ z*{d|-UV|fz@>NcFIiX(55&7KK5yZ3jwedBs*_88Zyn<$TuZDnIK>pZY&`W+gN&nN8 zDgQIHHpiATXt2bvpkc?e$zrqjabz*jaUI#0nqkWMuK}m<#{4G!X zP4WVeAp=R}|1SPhG4#LpZu~HG$^gV2d75co0Z#2O>N$H17b)w>7Rt?^k^WLskh4xv ze!Wa3x21c?+gII}EA+pG{K^R8XE^V#=ox?NBK#Gv{@-@##~+?ffV!a?Q0+QunYFdj zR*k?q>?-H3*&&B_{Bs{o^|cJE4qw(d_J+ZMO87|M(*%=W#Gju~RuFa4cThW&TU&Ux z*V}7xfnk*!>H+v?n|(lhM^tf8wyIwA%+f{na}^(MnEJpNHLoloI99(5EF~Q2Tnr#d(le<}k3Ps( zlQ!@xj!vpvBa#yF&FkWy6?)i|Sk_uN-MD$Sqv^T;h2Jy&2n?nK`2|58w^# zcNVZ$mU~Ga#1qZtG^H38O-APYdx1IC(#-+B%2S@2WfGo3kPYoyHiW#R3ZO)rBhr&( z5mJgX98HY`cc|UGS{L18f_ao4Cz*7d$&qej=75!FTumdwL?HZVA~1AuE!;SPKEbHk zE8%Rrk#?9hG5a0V=k&3tEOddRw3u;;#rURAhk4frJlYcH6XLxk zeCwD)lR?KHoG*c5YXyH3S-M~siJN%1S%OR7lsX^TTL&*Rx+l70h0CFI0_A1}&VWwf zi0*Z|ZwAqh9mxmKVcJZm{EYjKb>Bg6egG>f@Iq|0q|U`GPM<6#-1fsOX3<7MbP~kF zUB>&j`sI{}jy`>_S&nQz;T^{*FJ;D8K zOUuS4zKnH-T0Oogczsr<23*0K`1V~kH2sxn4-qv>Q z+gNqVHQhq7g2u`LakQ}SZE8BOY`}yG(FH%AK=3{{yytOeet&tvd~BoI#-c;nk7Mp) zg+V{>o%HK-tpN)W1cs_|Fm2eSvm?0Wj|F8HGpp*15*525}4ga3Q{$1BSCv zawU@V9IealuXVpZYLm*1PhI!ZbRg>b4-dC~VK@4-a|!j^)}N&5f1wrm>`1iq&p*G2p+BI- zQ-u_xaiCk`go%OfiHy2Z!gpv7E7D*?_il~yzqf8-HPjHul20T^S&$QlU{MF?XSY>zovTvIzj!} z1P|^+Fq5yoUmPM^K4-SS7_l>d=;7!lrl+h(FM4~jub%d@Z|&8kMEyIYgwAQdm}ae4 zu68Z27TnHe71vs)m0qyTNn*GV7D9K-CZ5Ir8Tbz}?8Wptgm4)eYQ2A@U?6Ma;hx)K zwo+=cD)Na9m5EO^8y}zfVRjcv-e^` zREBk^aw@3_Fa5E+mGELr$SAbqV(yjuT<@>uZcKZXKP6A{Q1~myd=@5G_D5?bR4&w% z+=Or<)tubLI9-(@kp6#UWVKgF!+mR#ZT`Bs3F74pDQMzdh6MNU8ThC;7Y_;`j)b}gQ=*PJPqAt1Ddl8U(Wu2f^`4Az}$be6w)mE zx!(B22`sbx`567`X#M!z?;fvT+9Ul8iw9cqHb5vY{xJuuPy$f)!@NMmq3#7tuOK0< zoTSaehxssM{B{RLWmqB**7>b8?m_vQ)ukp2Bd04_M8VgkbTapzCEkUv9H6Hmb_BIB ziWUjHlwAak-VB1+x#hw*NaxhbTgPr-J36T@OrbI(Zl9OnH4xVfR)f4~{cTZ9^Y`f6 z*a$~Hl3y{Bud{vn0SRU+JDru<^L6^`J0G8=u8yFRWkL|ri1=0n`2FCVsrlMMw8L$NLiG-P*T z`ljxE{DFOoZE>@;w@?=Kym6x2F4|?LqA^0{I@i5(;8P#)D%8~K-!$5=mE0X>5frH* zvf(qN$;LNI;*M5)q4$fqxmg_{?uUt*!wn}szFssiGH(*54s{re4B{cVbfgQ(V2nq! z`xK%T?9In!22&|x8s{sN$o;;kM|t$sUQchO=s>c$v0z!B?MaPx2n2I^Tm>AnkI04f z;+qaH`Ioi@o?~=EB$HVEEjUjCPJLAWLj#Pjc(Tx)gxlFITsqD)BBzqTJ;6+`~pvt<C|`H z6-`-p&u6>Mh`Y{W&$Pb=^gdB%2|Fl*^xl|4D*PLt$L|*|@8&PRx$Tywpy2yX+}C5q z&pUPzaK)uV$s9gG2`*tGFp!OAgKw=h9*bri>kqiYZZwT~@LH{UA26K!U_PIdqC<9IxBY_9j+ z4iDjcTx=}E!JrO6FfwDDL{|1)91bt3i{4|*x?*cqZM<-&AzLNhO|jqD^Qw8+G|ibK z5!7628)q+8R#v1mcMwVM*wz*~}Zs|oZw!8KUWh>nWEZwkR z^mTM3gs?VzZ`VZ?Do`r}+*__v(>(mqQS1n=b4yfkvp= zv8K0;-<`H^F9>{fmrKJl^9I4!HArF|c3jhWQJQj^ ztWy0x&w6OWDgeIC;?F;iUmj-fJ6QfYnE+h*;D)3tcyQcw z)=C(TDE|bvJl5L&e8%lwWxll<)HT(~%_cYx>C0~>y!R#H5wsG~fsGE5X(Dn*kyRuM zUe3$H{o<^4_ycnI!gW=ey=5(epMkT$)SP~J!;L;*$TTpXa362R*sC?4gxJ^M&(dBC z)OM8v@H)W(ZemW{hf3mQj_S|AgIb7lp#ZaraH%Z8w^fX=J8ilM;fL9g0*pshs9y9v zGvMn#%+?6MDPSNksneEJ{bk*;@8D|CYxGgFm>=QHCm2{+PFoOx*G?~3;77i;FEaAj zdXnpuZ5b^>J{AbWVW;|Vbzz#cc!gttMpQ)w0rTi~a-i7-(`Cj;WM25Y;a*P*o*r)M zliB$x@z_ekjwHfsls1~l$O~tQHMP)y$64*$<}~VC8r^Jgiyf+b70xek{T2)TYuf&W zYDnmPL9_iQ1nzby6G=gDoFe4rNSkS0MTjUVG0R^~SA)3k*!!glMEFLZDy}#s>>o?^ zSeg2fC4~p6kqn^;)fhHA*G6!7se+s*8H$U8*k@if73MLXH4t(gN>=l+hc+=C|Khn3ligmS3N}Y?`Cjr(8UIp$(+Cap@Qc)qY@xVj=}B4bH$8Wk`T4 zj^`^)Lnl1X-f5pF2X3`Bb@0379j7@FSWk`iF|rIHp?!NM2G13~*m7jBGeZL@X3_xH zIDV2hwRDSGTWK^L_7({D_`x>pQPkb45xHiU+^oxPDVdqPxaRD4_~~<}1_a)pz0e@Q z%1_(k>I!2(oy1|d-{9lajJX;=WSF)_Oq}z#SG}vGeA->s`lI}Us+z#gkLOe)pcf|| zQ4}ccP!LUwlQTY0%^)LS)4u&dcAi{#X$x)Ey%4F4Q+Lg$Zdu;Foci^lfR$M{mXRz< zN;x=#H2qu_$&51~)OGbineXs%mG)Q<-%i_~h0TaX2{Oq)ht|)WLNeStxdHzUnu6f0 zau#8XBrURvCLe9Y(V~1kmtvT`sjGx~BK^`6=j**MT+~af4l}iR>pDy@5mFsoFhb~T z@~)e1zR<1Au57qTQ@WhS!XD zyq6Q6_y*H;2Wpg}gb0yQnj(OU664xgo%;9Hyc?xHGr*;vOE1Te>C|vd$z8hnwD8h0 zO~ZFk6t)roQi5Y0CF%fX8R{fgL2)NyU&)_&uDfV}#{0v-hu0ylyJU7xM>By85J`Tp z+pg>(+6nz=yp;j)W!_YQ#c^kdXN#m;oqnSgR_9f8@yjcEn98}LONw46PYne4wPU76 zda+E}+DMHqKEn_cKLEF9O83ncDSzL5#Se8q-<7B1qGDV0aIa|Ou2Ox-*E0iwCv$@a zp)8sji(2S*DXD1ONg?VYG?vD%Zd`Gl<~~vt#2?fLW71}a zzh8IcA-t&>^T4~xm6qM-FIuUIi{KSLIA7^6qeIQM$+J`dLaJ>95==T;Wr!2q2}0{> zDR(HML#-!}(ab{jnNOG=+?1P9@@EU-G^s9iC^tbpBRsR7+8Y480w*F{1-eW0adT(f z-W0D**nK4J=BK=CsSn&W*{$-Jo!z`9y#Xps{uj~fU*JD}OXuu=#jJl5o%rW?=C5>u z|5`C??99ca1938}y_bB28!!x$C|Vhun#9aVLh1BgTq2N9lAPS0PaEYJ`J0a&4oBEPs%fre6I$)=m8;bpI(47Tv0X!~*9!Jcw(c#1N-tH{EA7AvK;? zQyV|+dNa}ZVXmZ6YS)xc>BoR-HWeo>A<~eBnk*0M6{FTdNYmv%yQXCEtGSTkdpeq1Qh54S}I*MY@a92c218Z(1|P zW~VH!bS=c@?N<{cBV0)L3s)OCYg2Q2y>KMW8?Al1wQf?(_dR%O=*23xBvowQ>^$aD zKMD$@{T+C$H3WyAMsx>hlCXHpF(d-#J{=wzjyjiNP=#lVyQ2|+^q9JFL)m!fwyjRG zl`GAuikG`eqAyld7G|8R0uUU?$PNfI8h3&~8?jaDQC8Cc?55Lwul<|){b^~Q`TdV9 z+hmE`GQOcYLZMy<>Oq654>q%-pq=1|%W$;{BdyXbsmRYC>$A`7M+u6Z-g0*6OQxc} zJ7{hP`w7Wwody?@9YOgYTn`!yk{BvfJ8Mv}SOULX^~XyK!rNNUu+aCZH+t_(kn#@9 zk-Iqk_$quBY_Vhqr8cw`>z6SD-vmRelv+TNmkrrYBh}bn$VJF6}J$T}&hg~~jeRcs^b z2&Vs*o~$Dp51v6>7@-_Rs^M>^;7qSvi|OJcYYU{Di`KVahu0?C4RPb zwrw4$2T!AyxO)yy0?RagsCuYKjJej=`Ki*Z9llIq>$&;$e+NmK5y6zML1y%-Z<7w~?|pUuV#@hDs=u-N zMPZ)>^RoYC83cEF*6ITXogvHD>r_tUZZIntE@ z?V^y!zzAA(9DQVo7+29s$V5^m4lE`%hG(O$A7~!*rm|OIkCI=}t1ntfZDdeb8xNmr z+Lxff5xaUMkwPSD3O+s(RpOp$ZyQ>q57!ot8fS|1cyyLv^ak|p%5Ob`K>cC!wsl7w zk$nMIT!j)bx*PP3%FQ^@`bRwo@pZ(WUs|0X?((nu(K!$4`go%xWK`e{{23LWWaN@!O-o15qZ?@1(?=2K zbgAM%zUbfCDC9y{!c0Ing_lqlhl1k}p(S{9B;athGF-YhGsspDR@uz{RjE&~ye>84 zc#4>>pJ4vx;>2h+*Qko1eW#tnR#{Hsgy^uHcjtvR9!cBgUQU_Ar;!{WdQJ=$;b_l?{D`3E)eY*re z2}jYC+oMh>%YJoeyQ$wUyhAer+=6r~z~teZG#U)_y+eQ4a}WF}vK)^B(80Np0LKeh zq_Iu82FM)z(=7f)et_;!Ct@klkRQp6@HY0Vx1-yEwkw3knIQCP8XeyZhI?w-U zAUJ&Jcjnt9rFO~}2cNtkn0nW^NG9!G!6fx4+HIQ#4q-#PARbY82#19;djl}trmD)C zT??qHOH_#biioxN!!+RsNsbEKZ3zM>;n5%-vLPujr(`8sY{+L2jNI+0nAc-i+po|` ziW-_57xQ-4^SIghz*)};bihp(!|;Cxeaaz2fr!g;08DC>e|l^kUI=xN04cJ4fk#_? zJ)0WD|H!E#LdxS+*Kp1iyltaN9tjaG! zTiJHaZf?0KpY(E%k>AZJ#7|MK1wTt6@VpU2>9#{U=vLM+BtvaAz++R71js6e34Zww zk_SeAVctvV!{g9M;C|6vK<_LEYtHnbsZmDWM2>w}>kvxex!VJ1$n%y!&k@6H<*E_Q z87dwd&V9|KuML*dPkQL7Gq7HO438uAVR;Rf$Cbh;Bt!6v^~pMUv1#<#nA|4DFu=cn zT{Fp8&$#tkL2nwp#JNQmvBsZ2IN=wMM=iGhfaHybP$QR?Zs(P(eh1yGCPHFnt`2|L z%}d$jTDVmgYZP|VdfAZQp1JoT8|F!~$bsk_N-D*H@GkE_8EK6tBVIYoxoInAnpe~* z+7E~s3HZg_)f{vE;vuP$$Vx-YiztTT1V{_tLHb~zwM1d{TOc>&QP>9KzJoqrra%B; z3fe#b0ha+Ym?&;P?kZd4w}akIA&jhn6_S0vci?hdmHW*T zPHZ8H*H~!hV1(a1$Ns(D3P;KMg!G<;2s9g6WU*qY-UrL>g5*Ga(|6EAKH6Sp+8#BoZ*k2jj<)USylb-O)N{Oi zEgdCg1e9IG60fd^eFEN%-+OiPdZ0%%bzh()Nox6k?%Gz=;z1lgUOok{W!5=;Y!>D` zvVm*z7xxmQ>natKz9#yi!6PSv*$-0lr4z#mm~FN>ayJofKjCV?gBeIw#>De{=j%>* z?Bm>2_rr`o$S57TYxA%hxZ?hL>b7j&J%~|Kfl6`IrLwg8xrf{w&M*^SfK7{9YLxD+Q?7jCzsQ z+tyzygf(l9%&LWKGbyk&k2hBXfR37nR#xn3H#d0Bf?k%V|EXg0TVJu(-}v+YbW4A! zVng$g7)AkT8Szj-q~LuCfR>RF5J7Ojh2zx#T1E_Hzg*^Rhef|bD6I~sDmw+J(Ee#+ z?GML>-@JtW#opncdhvfw=CQ^A$Oimg==m2>tlx@K|Ie2~;gGK?39*=cNjUVIp2~v~ z6!yUM6NKl+k6y={m%x?uCF2g##0p*%V0LU?SGj^w-7ojTbXC~R2CC>YM?)+tLILx{ zpWdhUv?2#)Bx-w7>Jm1j2=`ie)R|BiCyUZ8?%c0;N_*GYmv!``U?`_-@iS@hRCns? zr3@l8G^ge;&$CsW^x!+l2!lh%X(|E6+X8n8chV|mCg9_tq7@GNir6+X$8+t-jWY=>bOf~)pUggtb>u-u35hfkB0>o_N4gugVhWxOHDAdGKu;#4%2G)e3~sc@Uyrjnq8e!pA{XWW zdIV_{@hQ87wgq;Sn6HEhviL`WykwNGPt6^op-P#cQHgtpOYRlX6_-AuQ8oqpznq0p zLNj-?lu65NFpWdOevZJF5MCpSrX<3aj+e^XbEy3JF*6nPM;Ll<&0|BcX=bLc=4+5& z%|49LeqsL7v_N6>h9+WhrtBe>)4kLuAx06Yq|*u%E798?dj}>G0Z}*Wtm^G!A}_>C zhKJHzpAC&orgg$&BkP1@4qw!0x!9%kT_8-vYIBu^0g8|2b&95_FMjNOOsBWOCu|D9 z4c2b7p%dJY{kx>c^U|T#W)Kn=|Ah|+damY3_6@hnS${|4Sxx9P`SlOpfg_c0`BC$K zWG_I=W#po5N*(#wMrB=D4W>|Ly`XMhqpmtFx}SgzhgB78bB)MSc-J9S(9SY$WaqgE z4LFudwd%S@VdNQ;zDIOwuKjru7h$JqnUr?EK{jF6u^h#F_H&Fl&-CKwPh35GATeiQ zak4%Yd4sVW;vMHRBqFZ#!<$v<+Gh3d*TE{WUF#(@3ueFs^yR;@M}(M~Og7J{&uVq~ zu`}B-QtzKcbxrP@L4PkkYe^OHfiKX;$b28PaeE!9SV4LN9b5{KxV@!kQ>9= zTC+3*r=_J1h{~GY5-}fbGP=@b(bmEIzUYL?yeigyJJ)!%mbM4j<|FXwr*u`vMCVIAIj64Bj z>7CvJkS<}4oa1>TE03S11*lAPH{IINjSY4D2*)YJsj8OG*dxE-KDIPVi$(J^Q$KhS zO>^W0-#ZZKI+c!4&HvkU_@D37e<#5QOa@ibql=+HbBc|GwH?|UxIi-L^bqWc$~Sr5 zQ4v^mt%K)7L%l>Dtwvq2F12gBIQ5)sZuGxFvhS3|Vs^}fjsmLsE8gEhFZQb(iySS9 zDHLOcHq3#*7J5%;96sg>%8i!(>E{=Me=SzOz@3BETP4ZohbZi1Z6Y|f=Bu3`$5}o^6Tu9~iTw;>Z-jfZvkPFU@<2ZG1z^$e!*ZsTFR|`AFBiP) zaQ0p*)bF*35h&3+4l^@|+o~X%?4Kv4;^vN=D827iEY=t@Kg%J$;F5hZB2MRHjO@i6 zLyO66d+lR~#o8QzqOsMJCG#Z=%c|YQG&i{}KfBmdHIFl?km3e_97T}BAA=WN#DtG) z$`P$?(9;88ZUOAZmj%R9b3@nR!~EF`!;7lJVitZC4BWBajxW7{Ymvzg zX$(F-h&L65FkMP~!&M{k*~D4&?b`~)e)}6N@1pY|e^fqv8vPaCWd|4&9h?suoeq2~ z=jHE5STPNuyX>4b&A4YN^da$NkETBn-L3{Dm_VpV_rS+j{mve4CPZ%Jj0iW_$}^3B z*^fJ0DQ~>NR%-&HYI|p^3p%7CV!9DW$!9X&LAXf0I)vuBNUouEyQf@n>hH95#pJg; zn)~qJ&B#Sa#CH%sS)K63hDaMJdlSH_6s>RC9l+{p9Zo0RbQMkI&w1i3Tkzx_x9}-V zf2mFNyj3(ykR)jVKc4l9tWNZp`w+7Uae3%?l`Dn4hc;Cl+Jt<2!8bdf z4H8=eJGu_3p4gbfmw2BaCadQn6WTNKhi2fugszH)kasqlA7)jz@3| zdP6jiIXn5|5xhurXPRFdze$|^)sS(GU<1Rn;WOZN+St7kjX|DId_hkN*R1W9Gd&9L zDCr@b{ZwY%IQy$u%kw=i2|i6cenKLOX8^_cYPGTM5!M41n>dRs!_7ZDQ$B317uoxO zXOwHnNOelGtC}bsGqA9HY%X1M>G*;G>eTRO$YfPVD?8AP!Wse7fJlV4|L;Bf|)YwO)sY|#t*TW@|OE)WJjX9%au&QUCfs6Ob zI9w@w2i*IuMNS2Qjf-}6hqWI?4$gP;cA0O9d2hzexW4H){fXH-4Z zBHi588(!$cj&AN{`qfq=jGV!>N*i6)k(BvXff3CcE(Edjk6~QvND4L`IpQd9a&%8ufi`J0kFT%_dZe4ySo$zJuhXvbny4uAaL0 z7TFCO2Tl*XEr@e?56wra>TDGZS(EOa*}l(H;=cU&h1A<*E2_skhUz^h@ligRW=uiv zV0A1H3+#JuJHQCwd(wL}-}6+w!|h(<2-eD*flSA5P$Y+SEae+lZACFa2 z?$xR)aEScSP9^rH$C@kaFIX6HzAe(Id=;X5Q-@cw`ZGGpk&VclR_0%TEIL2BsqAmZ zY>Xc?kFeReWu9jA#OBc?%LR8f7&USoH&+%8UCa>DnvxIZ?h=xy1r)AuCX-vmpFer3 ztXs#wJNc+w;CxxIAt)vO6#P9Ffu>r;fP+}bszc2Rg`b322)e}VR77c?*Yn5`(Q5s~ zbBMfi+0OOpZ|53EUg4`tg==He|5f)(K=&wzSy`5_1 zhlR=t$IXa(xZ0ee(ojFR{KG{DUiaIhvQv4Ywzacw8k`a($HgG0smp|5i_p+)x^d_t z1|m>%u+6xdp7F7b=)AsmWkxn#$fNj+ho_anvBzQt`NxE*Q(`N`sXqhqa0>5H%y}k7 zq!jy+W@vtwPV#qI~4cFh)QxK@zm1N&T-oBon*|P zG?jzWIJW>DJ8)+z!7QOwW{r)kONfkKut_(|{-RH?%9h>m=}V2*SL7LYv%K}>T$%t! zImhT_T0pAjx13u3`PAPQu{C}@2wt)@P)xZ!M{)_$*Oc*)o`b=Md0nczW(dzpLovkE z@rnxJ-0vXni^SC{xWb-=M`vNZDTEaK^K{&ov9fCG2_FP2@~SCk)~NYgu{3&-thr&! z*^6OIm9e>?^0;Dfbd z&H==Dh2zK!G>hxJ8ezEv&!gtwXc}LFP?-(z_ZT{v&a<7=jm!c>E?_)*M96;OaEcY9 z(;|jxH6#8ZWGd%7NG}`C_~sUBqyGug$=#@)={ks>b4R{tDPRt5b(nEK6UqYM)eRB? zmf~0f#f%A#xg+cQwIdhVZ3@`BD!w|4pOhY4n5G*v%eim%RTff53)tx>P%`!yKzoRA z>~WL>9zshQttVa2}r2y?BBQ0~)tagVYEgvQNxfA28pCdj}?s`tyHTA(SbOW8Hzgz>(+h*`7kg zgN3MOr96ALZ|rxx*Bc`rc|42P=)6a$2{j-w%H&4TDKs%@U-X7ilWj@4D6a#pRc#r< zLMVlWMBS;hKCbpaE-pUTndolKw#JqsQ|xtg_X5)}jYqp?$2~9DHDq#MyPX;NxW#I- zxkrwj-5n^?jb!ez+;GwQ22(45SJ*; z!|zN-eqe>(*d&S`?6;8W2mrLy(&z|Eo-i|y456nwhBDE3eqWrBRp&wQ$B0#zF1Xp$_Kj8{!$o{3IA(~CAb!R{xHk%X7?1_?9 zg(S3o4e{xM>*#%xd;q}f`>;nzf_Ro|o zD=waAH@IF56Y~TQB*ng`&9Dy|!c+~UH3gQ;kj+TWG*yAe@6N5AMuuLpk9o8-_c1@2 zUQMxdd756>^UNCjiICP|(s-bi7akhY;bEJ)$9rr)sc|n&Kj~tx?=4Y%>tj_BmmdVf zKTS(huOzUcj1N=DFuXKMx0F=0I9^kxSNC>IMbOZwzR?ux=U&dsPr>#VqIZz}U zmPhntvJrAPTu@_d~?=7P4&2+XrnQR0Omp29i|0|w7bwoH@gr*yWUU5+8Y+%$*`Pm zrz|GDb_^|mHIjA@ROdhK^O^Q`nT7lDSz%y#Yo>wG6@lQOUOLKcASB#ro1IQ7E9@y|eDt!=e)0vPC zaENX&Gf5Fli-ME%JQTuf{pLI@fu1r|+KbBg+ug zf<;JQoQZ}#XwFt@q+OtrA?8BOFhI5Bzb8*#F>sSFl{n4Cz`^kFjO?YYQ$gFg!J1CC zfSDrz7;Am{tqy3D0f@2H2{-huiEQDK=c;uwyjHGt7kn>Jm$TFhpI%AP{joR&FF~Xt zVF<6+`&`{=0AU(>nymdC_iO5r1G{Se&TSq~dUVbV1ZW+n!repNJ$$lUIZ^xpCqJx7`X-&L|Ks(iUyao zJXDH)G#W~Rhh#HUV$Uab%SQS$v%kLOYymqeeKKX+E`3vrz+qcnUoi?G6V+QQ>-7Z2 zC$z=Olhv>8Sy?59fOE##_`)Ym-LW?q z545uZ(k^$T3g!`nK?MOmA0_a>bieAkscUrT9qFj2<{73$PqB#hE2wt0IFxKOQD4 z5g|B4q)(SdTA$H`@{G;ZZ(;E|*n)uje^W>shaQD~szgD7P0sE84vL=ukoeUL?VkX= zmEfIwC~Lx5w>oVAiC@hfhu1jGRN3oaqMTIp^^e>78KQ4lbduvqm3@bKEdVc zVS}>e8&9}gW2DuOoR{K{2vnf(^)5ypa+&>r09^&Z0mSLQgT!ZcBIr?Kq&k6ywu~&A zvHYo*iLY%{81!K|+9a>YW9sDw&h)#_{nL$@ueYL|U!`CIAoGQWnur@X`kVW8t>Pa=pRno`KeS_ErC^ub72HbjGUF zWWkdFnL7;Os>5?Vo2_x{@Y3;*=`$AE=ZAtsP~w#hXX7GT2nwCt)B4?6ABZ+~LrNY3jsvTnZ;dr))I_hW!>%XZQDmt}j&ye$l$Au+R!ODzK& zc@wBfo?r0s78z>x7J8YJKh0TW|7f73rgX#L!$TgKCe4(HK7|2OiV9hKyxGZZDWHsx z%s0~PgqwU8eqUiTiwllrz0O%r?{lpW&SBui^S0bYgrd6}Sf(%3d9V#U!@yqSd)V|~ zsSr?Gw@(ypz8ZdGi#W!62PGlZg$+wf&nSx-xl9s#vDPXPeZiBgC13c=P$Ki|tMQ#d zUx=Ep2eV>2;*S%tf>_mw810iNRbpvD;in)8QUM{Q8+N-9KBFMCmJt!I)$=%$nhsx^ z^oYa1&Esytc~pfwR&CnHd;^MAz-}LW2eG7qH$5jGph>h8>ZSv2zhwYj`gDV|ZgiNh zDThF#i>6T~fC5U(CED6_3wtP=8!r*{DMvEd=zKUHcEa+eLZlV0RiFO}4mz#W=1A2% z+H78c?8IF&>`F27eu2DVOyr7mmTT#QZh78rwAHEiz4o=ge?^w*Mr|U1@qdt78uNT^ zjeDe|CN*C{a~C=nuVT^PI|(xN#?Vv5ZOGS22;4T`s;}BN&nKmJa+@WsFZm4biX!U! zUu@;w!$t5AI&<&|Hx9pi`3{18+#MCVlZ~+|L=aj4Z^Caah#=?6JKC!qNcjFsk`X+| zR=r3en;ake8j&5`ir6ruHZnt6oW%-Y;R^cc3z+i zH78uEJP3TNyI=HD>0>(=UhVayhWWi-TI%RkgsO>N)B9GO>$Nieu{2GKOcO6 zuJ{@t-TV|mp}4;mKz}OG{RgislNiO`0aLqLe+RK$v950!{yccZVRf9Zwo2}0@>nTC zl`bddt%6wPlN;d2R2PfhP(=p=Xp^6=ub=+ZiGLuFPpG{_ohR%kEwymB*FA_#!JFP5 z$M5&_y-ED~zU{K{Ovi>p>&?6U^n;+qMe2AUY5$L{rib?&toqIYY!f--9cJjIs_-p& z&#eNRoDgw~L9r%QPD@?!lwc~!xRaKZ6Fz-fCZ^4ymq*G(Ok&_owpKPSQKO0%;`1Y{ zEa-$6L+GA?0p;=kKMx2PRxCZsYEBmL$2 z9z|jmsNI2Oc7+M-<+%Ry)E6)}{0%eT|7d#}#qS^wv#-htF$?>$KvV2fT3HtKRxs2p zfo=6cdi0b#8h6#r&Lc9inJtL^w1Zac#m2F>)KN!+lW6D}auS$y%K&c;SF^~*$ZpKT zRt>`K6s?-tmu0RKX9KGziu)Lh#GS7;Sl(t#Ry>!o0e`D9IF;V@4MLWIag)H8hn2UZ zg22NYp9O8^jbwfKw*IKdHG`kbcVB{^NS2cJtur44@p7SSg&GhC63EQnv(FO>rMj7E zuhbK2dLuW}^xVJUXAiUKQcboeKjKha@5Z5O{6$5iDk39(CCsi}b`Kji&;HPdlwrTX zGe0Y}AHLP!CvaLe>O&WQ@TPbP<;|LZAbekE;yz^hoq~X2v0D+LG4Rqzx8F4N6YbII zy^`wM_iv*)t|x$x7n|H_cKWz&i{XOaQs6*h_CtuUgkm4Fh-{5=qC`RJD}AC+PeAW` z)T8FA{R<(Q_r#vQzWT?Tn?dgPK`TLGsN29h7IK)4y^VpWW@lXeR@bcnmg|0c@9WFs zgf;edX+w&{0>|PvwuzDl235qAC8?NJZL$doLD;=WaIV3I%lY(Gl#m`foGqJv=E7Qi z>NTIiZNtuxhny^WX`F+|EBjhR>j^nJ0WOJocXwC)=qTvc+7E65l!>I~V)J z+H>4J*c-6e*%{eyCgJdq;0#QUAhc~BJWN)@<(ysTQ_TtRlG}eaKFqVtH#I`<`KnKH z;nW3tx7XCinqUbFweJ6iy*H1B`fvRHM?`j6v&&l6>{%ko7E&tvQb~+$l5J!nWZwxP zB>SFaDEl&~gph5lGq!A*k>y>+bicc=>pJJY<9klm?{{DK_xt(Y*B^6m&g)>_^Il%B z*K>KO9mB^36S!YG^PI%>7gl}=z$Nrn09#ACW#Sv`L6?KhPgp?jxdPYL0y()}+^zW1 zTEiA8H#@%B(@G`ySuPaM+IsMI*Eu=ewpwJ;O*lnjV{!A8xv4k9+%jiFQV(y9ZL|x) zW6mhN<#+?Gc_3QOh+5<+(on4HgKyGzuWp1x+NeK|1zbG-A3$@!wCitMn$9DK zQCCL;?MeP8)c*Gh_+K83!*znSkn38^fAlg<_U}{Qx{3_g=OUPcSSq^QUzU)4@P7DS zc?2v(_rN<4^OR$bR)Tnr>Inp)vA=skA&A0#du=s7f(1Z=3ouT+g-eY_mhNx3F~`5M z=`6IQep(wJTP*PU!ya1cRG;5SSbH{PMY%twbQ~_$`NO~TRVat+Mphb)tc95NpiK9N zmnF}09$PC}Aly8$C{U>mBN8$YhqsMP50A z05DvRU^qxY@D@3yq_8D92e5o?Qh(48q#|lLwYsM-Alzeho^(-!kLTssa5h7Wq!W?x zAcx2RPz|9!SPOKsqNm1&KgPQ8JD3ibUqM>xYT9Zl!_vzI`tEtF_%bQEjYV6KzWal!F%E=Juc3Kg_zdv26!$9L=1vb_pmkG@EH(GF@LoseU#t&m(ALg2$Vx~%8 z;&da9(FUz^+PZzD=}kex&1%$L{}O5sn-x6gZZHu17$4APLj~C81CMrRyNIkAwsAM` z49|sv%3fnl&GN`EZ!L%|N}g)WnJFpH^1xJr;zrV3TnH0p?`ee^$10JbI>mknp@HR8 zNh(2Gz8BDCw1kiKzVV#72vfK)&Q6;DXeI|2U2&ObsykkCcc5eJ;fiR-soVsgRS#5! z{)rSYO|Tx%?U7{aFOIl|@9B(-Ql|y0W@JC9UT~*-`^r|%!`VnwtDrom{-(!bosBf- zo2}1o_s@QNN#j%>_L*RFP`7hn|4lL&SE*yo(fcqn%(V4Z%F5>-Jua`i1J;U{8Y@`| zf+IVi8}J5Z4|PV;B}p5%8&d+^yQce9QZR9$&F)Ojm1Le9_fjYlp7^#=!~yE_aU1mW zv&^6)a5n=p8wL`!aPlABS0C-H*M}K2n`6v37^!c;%Eu5Ymz98+8-X-M4wTl=U* z=A_!x!`XOfK2=Dm>d$Y8=w=&@ZnTUySif&dA99W|5p+pcjMe0Nu|d(|JProz1V#uf z__2BQ7?_(&{;(?4Bd@Qp)9vg12v--z8Kd(oRFqyq-YN6!?bxQc&VXw5sO`9ky}8Xm zhtIXzBTd}%fU0SLs>jFMDI@aw8Py3)40a-^GBh$JUn!QlDIst1BJ;Cd8%C&Xw%dS% z^PH=?F5pZ>J)vqNX`gZJ1)92k{B(+ZsJu26`<|Q97m{xOVzB7$#;_VSfee2rTSC=xro*lAZ3}RH<-#im{qMUg}91Q3~M+Y+xyOWz*~N1;-roD6*oJe?MpkyxPYh!(WF;5C zwYjNnT<`8(afsL1h1)gM+Exehf>>O^a8AeZ&ZNM2s@YTOPOWSNre+-M3BjsCNmKwV2Ab~B`v`>X#jhL-`} zh$)Crs3b4NMC4~*9$}v7Q>7^xSdttINxVGcKJk72Q;Q0M9IqbXFADZP#yyd2QbU-& z8n<%XQ#OsvNhp)&JZo+XO*}V16TbG=OziPjZ4z3^99$z-Cx&D#m~4M^|1CC? zd{b}Og`h&SV(++x?qz^}5;6(M@0&qw8CvgW+F|RexbvU+^B8K#dkwoG z_DvE8ym#y4pI8gtGBJoI;^-b_zi2rFD4O6L2uu{H^zIrbdwg7!m$gdQ50uggo2@DwAuqp4wA$J?bdcw+PMn7EO=<6E!?3f>Q zI}k>`EZ`fD???Z-&lt({qg*hvzAlmg-(WlKYbfw zlSdl(4uS#qsq03Dyi<`Rqq|dsrae#Sf}PPyR>EBtD2^N z2{^7MPhcKvg4yHhO>o-z7YPt!vqwh@D>4i#6|*ynYpx3^v&ybs85>kB_WafW8DRF;S9~9OyZ6(A32pK$ zDtF%takdIbu*VGh!Z77tWjipM+V`%$oSd#7Za=R>-6l5wQzh7)qo< zC=Vjov3^iB@X2NcW3pINUVOVRS@>A&%9#Fxs>Q^!s!OEz%`X)i%UTfG01146)j=Nk z#L&l*BQf&TgWEBh2G*pV9dqTy*&jq#9%ACpJq+#_*`9Dte=(2ZD6ggIZDv0uD07A3`8>#gG{{bGuJ7Tk&5rSs;voor z@@IE^#8V8zQ+N7UEGSwKhA!2KmbwZ)d>ftkMIfy`!qh|BKpD~vu3^K}YvQ^F0y$`i zWH@kxYJ@;fJN+50R*1E<%qfO`8j$T<)T41UUbfS1V-ob`esJ!%I+|V|-{C*{6LJiT zQ!CEZz(%RlthuPyxmuaclw@cKUKJ3+(7p&Y?9$~r_l}RV0oD`8-fM^NY2#&TQo%$G zFatWB#?I$jGRdkPe~di+WN=dtCR-EOAj=hQ7Wy7CpLA({Hv-?EJXbjprH|u%+9ZxH zL}ikx@7|lSPsuKnfyPh8iQExB&wu0eR!1XC%ynH6`9@6TL{E=J5%3;6z_rG~JfntR zdWukYu**$rt&uCe8FVvJT0C6n@xWQ1yTREF%_TE|`wBpkUh6^1Qp!)rm3x3`p3$AM z^%R4tcRwyokh<=-rXkwQHpjhp2bdvQqzA7E=9mCx!gXAI*S;Z@gigCMv&|Wf){vol zwN1lm_azaLBu?X=N`1)kQs?xATsk0AQLN`<8w^JJTRjlBR;N&fiVNFq?62r>|@bgmYxst`~zV?~& z{itD>bLHx>Ow_UxDHpz#8hk{7yJVOFIyieFaK{f*PIpEQKwRBr)47@Qfx9HITp_$^ zo?~Nn`DE6WdL_t@tfQ6F)q1#+DgfICWJ0v(3+Y(TBkf$aC zGEDv1;lo(TjJa};HhNp~nTQv3J50qgAbQ z;KrOmChYRfS2*RL#pW24y(OF>P586F*VKS73@byZu(oEXqADRjSK5u-c67PVZI{-GRb<~U(|Ac| zdqhpZ;Xro9WP6J`t_Ni;fs~?xC+XtVUR2mArps@eJ_zMDMYwdTO_bQ20_x{roX$S! zieU%`%!Z#?HQ6-u$NkddeJBVQH$FGT2EITAS^TrSC=%C;y}Ufv2SVOY!wcJ%Jiqnl zRKV@7sgLW|VRgrPv+fU&+_H7YUYtjI^Dy9h!qoV_%$wlq!@<^x6|Ik#_H~PF_VBUoj=IjgBR~F`R~8~NE_%&uw}$(LukHe9zPa1W^79d_bq$_J3e#D zM!>h+*Aes{I3Fu36B6$lKj%qua z%dNoWuZ&Y()yGKD%k9z5HFi>?VDgm`tm+%LZzVs?f8Iz=_e9i1=s@a-EABsVD;&<^ z^BztW|3l~a_h1#UE$F}e(fH+Nc!{`^+V-dv3hwV+D1U>8MT{gaxBDbXKXb0fn$k2> zL(2KQZ?%h-m6(4>g@G<1aF_kNh(+r`tiL#D5e~cllJtmk=~4L)B~# z3byH^&k_4tSr$GMyypD+m~!qT}t`tw&79 zj^v~tzHUG%^zbF4i3cm%uwTO*yvh(4J|mc1^PoRG>rK6h!ox60H^Br_=`A#8_{hy7 zQZl9&->i7S4Ix`Dq5wg1$e#}gGX`9txz1`lt|mjHlUG~n{Gc=3xbIudy_L@jH!&bO zBoeYMb;N&s_$FFMkiyeV8UZ>vKu!0IFfPCPeW8X&k#o8=06O*KSrcb`EuZTtnb;*t zTRZ}xXyi`BlNnv!YLcHS5mMv^4bv_8G%45T*{9Fn4F&}iz`FoGszhLP1;V$(Whe(7+ zxo{O$PYsN*nHadVj;OKddnnHr2tGD@-A&;?GSP{#jq(1}L!+h+_%UBEx*Vf={1MAd z8VF<*eysU!+1{&8Er0Ew%1{U{b5aq=TH{d8C>kmvO4;c<8|6Ez)? zF_5I5dwoPQ5k13=CVw5(qI23*{6nrtVw;yd*i-kr&*1MZb-%j?kMLFeg+?A#4s$qJ z@T-{amo>B2mSnZ=M;K@`8@E!ALKr=)vI1iJ6&&-&V2hC#IWAsla*Hh=Onw#}L<{l$ z38^b2r0aBT?z2jPZDjhUDFlv#4Atv+&bDj{dE4+=#sG{kt|HK(z&YJC#B-YNf--Nd zj!VJRwEoh&Z{hXFAme47;`CQG)WrOU)hXo%sG}aMU{gD#7%bDCeD$}W2S4W4@$v!c-W43XBfCaj5_QjuP2>aP{GeVsvKWJ%UeFMSTB0402{j~eq()3%3 zi*D(u1JK$1fd7-`f=&D>t4o6R1)}?CL$*@>`I^=-n9aO z6q!pdXSWs?}zoGfoP`SZ2*E>t~tPx+>Vd$sznSYBPc>EYE!M2{R(j$X>QAUKCUve=` z&^Uj);Plovhb~(#1pT~(asUZDZl1nlmf4Z*8)pRKdhse+aEzjw>AdiZh*};jR;E#*G2z;?>_w?k}KC!O0-08Q+VO^m%$l1U3p?GnC%cU#h$;-1MN)^kyPNS}BCka+K(~h(2YP|4w z?=fpBgH5oxBL2`HoR;nkcLJz3Czc3>eR>M-*7iIS#T*0Jh@30C_MV$;1Xf(_qpR7l zyn#Y9ryqR5sL}T63ch!U$;p!f&*x9O3s#u9_J0BSh8dX3j;GCd`e1o5c=to1`z>>P zFUDHL{8R1b`tmF>M!cTkT??E#N%X6m?pAyI)MGpFeYRG9TdT_@zVoRcJ!=b#fi+jw zp=SuC7+3virMRcIbhX(L>aSBfoGmxm9MzacDLlX3 z%zfLD`Qhfd6J9Q=r!sA?E-iU_v zK4?u31FH&0K`&PTX+eeuxB+0P0iO}5Vdxe2NgvkZXiW>fXZ}k3EB|Ewkk@N{4Z zmRP^!$YqqbdyST4V}Q6ZWa!wfc~395=(4vS01Qj1HzC!rg*d(3l-irMYXQ9`L>qmbv(qC_bOQ z#~Z^-M`R%A0RcV*aLukPa@^yQ`Y3UvNQP@!y8Timjm=$4>ke+lhq&lk-{}xqg8cX_ z0ebL!$CjcKqcY1)5Ng8JN()Lm`fzkV-<9qTJ`qLoIPfOP6LJctzErHpdYbyvq>gHM z#vCe(P4DvBD|up~OUlI)bf>3lyeZkceP2?l-?NQ~2hc|0kGQhfaCH&oa0k=KUgHr} z#$Ms1(kr81ux2mLxUM!{ABQ1n50YVhK&H zgpPg^ezXxINF}>2W_kEr|I3_?f0fJTuk(K%;^ZB%76$vdC|gd0Ro12(LU@52Al$Gv zfCX9w5_Y_YY#dYZHkT5k`rM=K=kJpQHE_S}Kg9!fGh_6jKw+ zuC;SS*ECj<+=S=}&QUEQ*zv8H0n}r?ZSai&ps++d(|Y+E&zSb8YsKO%B3^eooCm0o z-TnL%lB5eXgPq?X-<25Q^qt%~00ZJqP7wQ*={rui?AS*BkOb>2ZJe@rsvIYE>Oxue zJ#4J_Ap)Z81}+ocd=N*{?X1Y}KA@|48Gi$Fc}8et-HSd%`D#?2<$E9d9C*}??0sAF zP`Ro7Q>swvx>NicsUqzBc|hF05&VNaK%PzONy|@M!y=!JUDK-6O||rZrhSiuksj0$Y)qaO>#;JYc6Y&Xo$h6tGvHQbe}wammp>4PPtmUQN80^M3DMWR-Waw)&jeJk7$fk0?m9-gy>$c8^h%1Wsx< z43NeSMAkRBe|BjS!=Cu66Xv>j(#A@zu9U`PQ1|2h?3rUJ=LHw*qQ^jcE>VdL#v`2mu&Qdgq6rq*2@C?Tli47<4A97L(_VHN{;Sb4*hpYHOof<=D>{m0~p zNmpKz`o=_6uc@lH0z5l&0d+U+u=HJ(Pk1SI&I*BgYOh6W%P2;VN@!i#>-8Iby%Vd6 zDm0aka}%P+n#~aGIJ%^=FX-m5AP^R_+HmGh!OX-;e5d@YT304p=!@xCF;?pRuOSVuYd_8G|YNDfv(ES*+1hfA(?9 zS$JocvQ&t8h0xZWx1&2JT;>xEn5ryHu317}&^@5_H-l!K$L$oZgV%kB1<3I2Gg(8a ziH^!e8F4##D-^$48B=6~aWVD5&GVz)dz+ATlh2W3UW^U$A`LifJE(0Zcm}Y-HBi4o zxSvVnfceM{%PiRjYvy88|0%9e_r`1s$i8g*%mvUhU?>fG27ov{yuyph#f)a2A7XDb z1AGuJ+K+3@m3_Kf!_r%$I6FppF5tR0BN8GNqF`l~?;oA=B4=3Kx*%;Ugiyf|6Y!~^ zqcRgK734O$uRRFD8> zuY*3ymU5lQ11uYD)gCaRVhS}q3Y>kMsLDq7O5W;6_};BV*6T$t27RKKdUjn4!u(IX z{y!H_9lbUE|J#T3_od+N3zgd$k*~Zhle+g9iz&;9E{A{pX+D19j&`4On_G^zIC2H1o_y1*6?%FNhoH+QftI>vd~?%&-1o)?QKc&VM^Ei z$+{DY zl5>DDiW~K#^-t8tiwvE(IMcY@>L%c&n@j8K`#1w04$Iq{yOp*1gnF7q?~Scp-Iv@G z{r=aKR0l%UP9n4c7--B-y@^B3ur!UST4NK+q250}rV4+uJSBmJf2DC`=L*m3{xoN= zH^AR8@JF)c6IFekg9tC!DX2PoSWHGI4`V7;IFDR~<#;>Ur_GW~MsA|>@ zzK(c3af@2y<`b}-lqd(c)B+ykjjVB3;Ebb7L#`J4ogH5d^{w=w#=5!i#appcD%#PD z7FTsXK(NiQKhp4Do~Si?n%{BOlJH9$|?1H-hBvFr|M2m-24}NdW!-Q#`YOim`H(%KW>}@}GyF{To5@ zPa#Oakb~x&)@-+{Sf_Ga7!rkRjcpPt5w3c<#@N1$N(>Rj_3>yp+TTDvQJUjcLQJt=jy*wVx+z<_cj>-pWCO?!uecF5Z#mFB%UeD8qs#k}M zCWC0RJ&b9zW807p7ivG0cyl*;Ujyq=-V0OW84*cxm$Fd7uL!%I4UHE{4o?PT&=eU5wDq%b(;n0~pzMT~7y{^RLb{fr>X2Of=ZG6scc#*62c*It_Pl2)q6=_ ztE!IYL@Bn`u|=!WUm$|3hH<#&)e(s@#Pgn14~f1G-TjVDrJEW-D4GZ4SN-0!$iR;U zuz?q|2rpQdFB0jqPVBU{nVNOm-csBgs1sYN46j~$4eD6D3%EDWfHXCROXzD)?i(Q^ zq?$5Y_IKxJntV`{IG%YTWqE;c6u2xT%t&NtAUPhPPi0#LoIIx)GO<7Zz)kiIo%b>T z?(%YWXP+d9;AZ-%TUmizEgUkx^ZT`dawmp~ytsoAD7%JQM-v6uTUYxH@VIu6E8oft z1YdoN>j{>pcFz&&>uS!s8duPzY?%jeeymntuG`XoB6ChGs76_xpio|dfV%Qc6?W>M zdKfa0KwUjh5$9Tr=wi4I{{wUnId+OX7{*kqM#mjeo**r z%$3Qh7E?P4iBmI0=JC;_ZL6+o;3549xuNV@AFHb9UIZSK^;{@xrQ1-{N9lcqw(s8_ zlp&hjI(F zAPHNpOzVRZbxj9#hQygJm}ENEY(9dSOjCdi!cX(!fmr0hbA&T=|0V*CXY1}2^2W79 zvssSW0=A}u3$Fp6;y06a zxvSdPfZE9qVSLtCA<`dvlC7hH6E5;PAmjjK$t=R}Ag30_=zL8RqfXwJD<6h7Im7=t z)KyyKjYBFVS?X=CZV&7{pSw*=Il&%B5sFYMfQOmk2ST^YNpD`;1Syt<0@9=ARGV_&LtY4k->L##~F$o2!5m!j*$15Z>1m4ef(lpl&&zRvP&)6=bjJA4COQWQWZ2Dw4Z#Aq_xu;cSy*Jbzz(f$?&0V7|)Ci zx*Z)&K6I|&iCWrNix8mM(ZUgovKWi3HRSEwBQa1$5_4%-6W!RYs~gFbxT1L+2Y-zM z2`Bb-;6Z1)`F2FYX19Y=LYqD7>olixAA^a|pk+{RJU!Xid*vx*`kw4CUJ{}(+<&b- zfX-`L)}XOzkZ^L|@zrBVKi>p_WY%-n6K?cgN}~g>04`M5Z|c`vZYdY%%%sf z_O!3zmQi~q=$4EemXr_HGT6m(c_oQ-`CBOp-fSdwJ0@;#?~-i$Y&hUUZ9~CuC{btz zegoyLpr-Q4Q?^9YEsktVp=1Cl?8v3~PWLwTS!0duO8sGkdv4hb&yYMV>}oLTQFAJ~ z-1EI#u6{=TOzix|e1ZL%J$l)6Wc4xZO~H#2iVkvi|)w06wBpOE`C z-H#|H#hYuENC$3wMo_&S0bSX%Q6M(qnw9@2< zLQnj= z2k7(X*2mFrM}6+k)y>Yrrk7yT-TkeSVzbC%1lUSn2Rgg%0$HB;T#?SA><<0PQ(b}0 ziexsY2m{ZieEn@(20EUoy&Y=u!ZiDJY+$WrQOYK{n30HOSDT^Tv#w-LGX3{W&elTo zl-iEf)c%A-&5(@{w8#VP=56U_)`lk~7A&k=O36}>fU3syMT8&DsO|ke6|vv+ z8gRb@y$fF7xEFh=b@=Z-rnHavEt|hd3i4l<%Lv^xuybsqn6+UBk}$m7(@v~29AGsY zmNQe?NOYH5?0V?RhHb$FnadR(dfM3J!Lbh(m4V>)_5AKSV35V~2^0(IG>hOW=G6^h z`bd5FQYgEGg`oXK5-KxnOZm%VhizNP)gz`0hf}Qo;2V*CXj1wK5i!Ek6Hx=S0W02( zzxr=51K*Vc!UJ}N;b5jwABo=7_=Xsgi!J_h7c<2mtV`Efz!F8WMMM03+ z7Q2#lL1~(L-l*$99b1r(i|VSgp$qFqhXx8aVzL=m;;p%b=XB1*nz>12*(zE4kbl3& z7yQ|?j2<{cn^Icr%v&>35muu0YK;k@RikgH?PrA4ft?O=t@!lS=o~3QCG@e@qqvTN zi8W(fD+=VHMDQr%%VyN^AAdLwmb;~1jk{Viyxue*of|aGj_U`+*VlU>G<0W3d*ucq zvTM5w@dH-C{f2DN!#Px|V(q%wA5#4Nq2SPahG?nDhbN?&vLAgx(#PtL z@|F|B$N-8JWv`j$5+HHrt69ZYw_Hiq{+YAapX%2Op|#s@=Q*S!F-G5YMNstn4072A z;tgd1aXbtFFCNy7?#@+2Ir?)F%y6EUW?+oa^w-1koF_hre-Jhmt(lCUBeWGCe|Ao# zh}3d75E#H4VN63?PC^@8Tc5J^*hu4rTEi*}8bVi>4eDid#MmNCbn^wyw8FRFwa+4+3X$Htka=xlN(c3TSU;nRX z=%0Kq_D7e+5q)(xc4I(b%N&du!8A(HD_a36N3IA5MYKG(@rpz_X8NV`iN=M8EDt}H z$oPs=+^{&JZ}AY1jP%c3TVQ$KUwLGu+(EWFv^5wFsxg+2HLyo@(Eh2BtDiAsj zoN~r%^;=zhw0uG~iaI7=K77#DAa8kj)Scz*ntE+d8~sVBV!BN!-V#$+SYQK&woOd4 z_=lH5;m_|R4CbAF7NkMOpi!aHktKT&kDx3qD8-cf%%z5T>9$k)<=Z&!))Za12!D6y z``9ORKS)*Z(Q6u!w_J0THK-1$kgS9Wo81W#Vt4Sld#nhOs0Sgj$_{Q(A}9h8CET(d z*$fB??BmO)JsfhKO~yQqb6Y3B9n~iWI+JXB z^9WbKN~m7{cY84VO6VtKui#xd8J2jMXk?M>3(+U%S-$*8MH$gUc~k}woIXXqYJ#J# zZc;8TO=uCjFe)K0nu>rxX4JNf~lErr9 zIeB?(UpXH@KPgP;ss^=v>+=K!rVTq>)IRlfVmHu(8(-tSpR|7ITbGG5MRx6X|2yWV zo=!){Q+7X~zp_mZq5&3w7~UuSuPCAfhb*nE)!!#&2&LVDBKjK7CyaQ1o$hy!b=r$k zy^#-ab~Fq`$TwD2IW}B)h7Q>oNEz}y2kP;>PRIH}j32yAiY1XF`KGg8g=dPfWE(di@fT8)FD&#A^}kQOQRA0vRrLK9oLj6aAey&&J?kVAR|-sG zm;jr>gpFQzQJdeiezHltYMQlr`m=BAvS-9o8a!;3G%n|SM zu6-H5ed0s>gNyS1PgIR(cS8;`C8TyTzNiTiq(b*BCJqWcc$y2vQzr$sh6nBl-$Os) zn|^Vo4g1zmvn!x#soXi=($<-mbW@_Xs3}v8Gpd~Da!s83L=i>CyLooa;Y4pO}F&({&yz1~?Y~^}6 zo)z6a+vR@_xPbNZW6;X8=r7E-&VR#qOn_1L_#8>MvZ>VmMZ{geXufjdTbDlsC(_OP z6fM70S&+#;ZVONOAg1E%dm`3F+-00!KzM{YX4025VcRDLVV_G-!Npc#0~lrk9KJl# zDod@ex4F@~cq!OJ0Y%gIMEQ&ey4JJr3P>1mm8VuhtmzjS!|fq4U)p3|@MvprJCe3< ztAi`O8k-ngr#=uMg4zsCFAOP@8~4m9bmBQZTo~#opmniYK=)QPGgHF*a!arl4ICa@ zTJq&b{w69eq&__>+G-`Wp5tr!H?vghxP`Y#(qC<#Z3qYiclo(8lYGkq%`WQqGBS0{ zKMUhU+I?X=MQHH;yty4L@k2pTeBDweI4~X+965sb>7JcP#gZrRBxB=v5h8fuR3>tL z30w1F$(&2d42eqDbcUMIkq|ts%KY;BY%XvQa07c1I(m8OPgzW@u%eeTxN{-`X?dRs zQq~4(oN9kxFol30WJqpbkk!h@igdiKeJt_Pk5P9Xd z`3ptREg9h0I)UA@sUDM56CucCTU15rN_ep&Gz#VWnjYGH)LoEqyX9IMe}cks;0n01 zJ>&>)Hu;~q#ory|&V6$9XxQAgdTnYfQVH}LbIVO;Q^Fsisk`yq&qK}annu%gM+hHf z`TI`VQ}F3NoqsTJ6gUe^7XKfv_XU{_f0W1g*OUwYGk;yp_S3IN)+geSjq>LOpmNR= zEV&ZGtT{??qP*|2+sA&hfC`v?JNGe4PU{(0AU{(~r&{Xagdh(WX!x=2WHvPAB2U#zfr-hST6ikFv>K}1yi$nJi4ejPdKmywUF}}~H^dgT$ zx&I(B=ryiXL<&3hJf*=a~72zBg%(%cV|t=IP8By!>8%oEl7 zQfR4NcrZ$lW80RA$gWdiWtpFcP6w$=Y%(3u=KSESrHi?SA#aXRcg-wI0w~-U1x>)l z$j_?Ru|FZfErPAco{6u>$3|BgQnUGL_kScGX>Zj;Q-NCSQQ=LnaFBx);JKvbnjL~Wxv*(b9# zj+Rs(va8HR_w=|*;>+3?WP@}b868L1A3Rs%wA6=Tc)19IIAl|gjMl5wAJ*wgJN$~* z0yy?cmUg6m?EtCzyaE(9uWcdp%Ft6b;}gCzyvnDjC@taEQS~3MvIi>7adAQ1k66qc zzS;e~zUudI#t{~9Z*@9X!sirm$GGMu9oc9dE^(b=v z%U^kM_^-I%fkbgdloS==%C8y$Cw~UKLL9bSL5dRYhSu+6B#ON=zV2Hg9o^*8cFt6@ zUa6CG%CuoD`S$|q!y8%uH$n$At&=y1h632VgD6mO`XN+0@2X-v>@Ts}T0;>i7Z6(C zN`o-JBbkOhfw+UE7W1Ruptd}JvLdG{k1|@Fq8c>5%?D3}= za;U2tk>B80HmXbCNxP#b7+sPoTGswhTi5t;j4ue?p6EoioCRocy;``X-24dwXkAlF zD1w^qJ^Ya3>fsc@{O)V`z@i>+y7cR1vE*&Y98uhVGBw=?Ofs;+c{{;5CUov8t~ivs z^d}_TC&}%zTbA_c$eC03E`PL`nVkvu>t(;?rM5+Fdt9B;IZ0zRx023+#m5a~|R@GEvC z%IabKINxAT%GH4-r6D7qj}10NpN#K(v4XgMklo}lzZvF#ths(nRnZ=A+TJir5M)(k zSlQCZH9RXrj)Zs0MV*Yi7}73jaOX8;8{}KBSZjpN?kaG@4$t4)S+F(RX|ZO$I>Qc4 zL~ki5Og?Luc8K^?G|=B39CTuVzNU03j+(#T?VJM1Kn&)A z$>)JZ7SHsXv`PZJXWKOs)2 zJ{29d0qLotAo+Xm;~76N533sD3%mSP0Mh-Npc+S>nhzx^;S@uquua(-G6zAs=rw~Z zXDHTO&r|4D=jr?HHqBvvc-y%F)LJE4)&Qu)ZJOZvnnropVD#_vfd~ibS&GJQne15O zJEzPh?pgOdyq#n0%&843TTnmT=I)b5ymrkiYlHz%mEU(qWY;&%v-tvRx4z~1Thj*7 z5lhkz{K8#D#O%zJ@+RT+?Jvo(~U8 z&eAziQr5J?XHpRYa^;dRo8c{j@Eh~2X}KB|aLrDN?sKa)Y%)=XHw=%DL~2PpL~11{ zxQe$WwfC5;W!D76H7OPo&fqIM59~Tu=Ce-#)~aWV$DLaOcHK&$b^ITMVhj>k5@l8= z=^no2x;>ER-}~q%1a-j(s}n(#Ty3~HBZN;4wQR>v0Cxlx9%(-}h&E9YCRu#;UgWuT zvi8k8?iYC|_pibC=Hp`3?N$(m*lE)C*KkGDmSbwML+-%ChS(V9^q9O)>{*xW-cD}` zkeTh)EVx0&K7p0CL|MW$-r7cjFc6Rn+`ScWViJf!W-~Nl#M3Gz`5q6VCJQNg!^NE! z=Te0YZks-bkL}(AE7$oD$A^hbPX3}e+PaWjTICb44gSXct5vl5C<%r)G$F3xy205} zAE)`xd^qd!1)*ODfT|Sk+FMC~F6%FprIrM#TIVQw#=KWUTTG=^L0K*rnF4Io+DO}ajg3`uJJw&s=eDhRS|D~tM!d=}S zn+F$+P+8LW%@BWf00NjAcmm23A-#*nBNzCAnJb}J|icahkosTB3xI4Lf z6Cay{vzsrkYprk`n`LSd)sb$<8rNq{yXXHAWatb=*2Zu-NjFu@XE*jJwSqUjd+JO; zO-~Cc-aa;CPMupg1Y<@}R1a+m;6|l;%9MsF)?ozV**Tw{o@c*lqw$4g0aOP}dyGyY z5MWV40OD4wEugg_rK(ichnZ!3U#ME|o!Uz?x?Tg_3gf&*_+rMcNN5bR$=blj?MC7& z*GF&z+NnKbS(Kkuov{*Lp5>BDlN%g1F;L1lKO^s9J+X~Am!})*3ST}$9y&kA)vs$* zO!)WCvJ+XIEDFQKrBvN3tkzg%fJg5)Joirvnq=^^0taaEl#dFXDWKAvh^) zTsI5?*SUsQ%b7c1!e$5Wd>-{ImK*;n<>{Af)>I$5Xn#4$r7^F+jS7*W$CpTwyszRv zHkQpmlw^rmn9ozAKh!M#;Pv5X?UBb^4tsJ!G_XJsadL zgIjSVuU7nJN4Hx~IA&3#I8Q1>PPkcKYf5C#j~WP1qtfDi9;l$Uq{3Z)Mie=N5CVCz zU8hvF6msSp)gfQdk1XWQtq>U^vA*}xGU?Ozm<0W9-7-5ds;0kC|KT`qb#})E+d0#= zOwx9XjlSfi;ydm|hT>?C#i#a88^^$IVz^l#TzWho%&svkp~Ez?Y_o zM;vB(gSU*JauA7J9>G7xE4G<30?ZS0jW$k$@9IVckCC{aNu0Ul7qqO(v8#^eoU23P zVW{jANLt~q9izM_;4PCVw%$iy%O#rJ-<4IlYWFUVk<>*yWZO`qva1$}_4{{LenOaX zM_qGp)bbVe#qb9;-&2)0@?<8_Qz7VUqFrb1YLd3dzjIlD_!_NuV%XK~H(7|oj~)kW z6*SVg@C|Q=;VY&|`xdFB=)1w{O-spNx8%ibq0+)uzA`%aW3_>3W=N_9Y)-B9ex&;|zS zqbM!WT#jN&Be|BV2A@P`hB(_+hxKd(?0UQgB;2uakWNfF!+582k!6>+BvRkc z@{N6j2zdL8%=3$g`zZb{S2Q1FdFXW6qM3TUTWi6CPfZZ;ol~c>(#W?2>*>`l_+_Hk z6KjHL6H#B(eQN0RynAU*L()OcMrBlkdON7N&+SDKpfZzPP|O9ddqHjN7T6VZp9!_s zdCC4|r)8c(2&2jX+5^MeMISS&y!TW>&NkE{JIG7LmLI*3itIKXNaiZk1ltQqUv%EN6|IRSWLJ z{*{F-h_t^TafC-15Ww|znA$RkH}PU-dEjHFiIZ2Wn;H{oWiKHqmsnfgNOn6!JUE47 zkbPJ3($2kRU*3Pr6kMR5b84kUHv6>^rCQ^3h*MQ#1QOMPKCF4lS=XgV(}dhK{ahLq z@*7#w{f5iyx%f-_?KX6EP597|GN2Vx@m6BsseJQ&cDEZhhIypK*3o%)Zk9FD4U20< zj2CV)I-}JX9n~2(yc(M|drVr$2RHot7A99_7$SW$^CT$~_0tk%qb13lPc0;x&0VAD z4X6q0F89G?ubb~H!yVciyfaJSYu#gP95&C=QL!oBACj!}FMOO-^EMmNd6&oZ=JuGT zy)WLvXwpxk8t;`F%8%Eo@9eYN7rQkWy?nL#{@eO9_v#ax#_P_Lq<&NhJZ|McdIPjU zRSm=tME2DQj6>TouudG|I$-T9zw=^`AL?1!F8$2V?dwVVo1O{&57LhNugt~vv}GS} zk+2~Sp^ds=;TE$YS?ICO)O1lt8y@prbGf8We&)oRv}zd6RPTx4*P?b37f)&KqQ<=F zCqz24&JWjSDiT>!>PsepE8NEx1zC$Lkc0Ip!q@gu&ei7bO_`BuZadD`4sz54fwW;C#Qlv^a) zO!>MOiN~BRwQh@ChQVbO34~^mr8t@N7rjU&hg})^qOYw`+b6cnt&VXUQq(r)2n8fA zul{;V1~!5fzq27K?{yc~Q*-whx4-@Ydds!E0g;_QKpo2r^mBBV~x| z5*_CPCHp$2IzHvX;@KWtuM5t~Em|S|GgOQxs$-Xd34Hzhy%w=Ce-_6Xs%o5fM2R(2 zfwW6|RloV6rNddV?oSQ*P4*)R`Vo}fy4+%20nne2XyTcJmjU-T18tOXB~WF$v~u{E zLFhOAk(_kjxzF=W@Ih*UmyV2P_ok>q-Cq}9CH7(Bg4DVEPxNA2=?K!Jgp+=A%?>6F zBis9N%+$!1L7v6lUJf0`TAvdY=1Cr>->XD0X9*lce_dC17zp8|RXtled3A;XZ<2|n z-q101h^ZtqWi;}f<8STX6idF*bI~&T6Ilx#-Uwx_vRjV>XHtSIvvf$mwE-&IRaOho zP$Q?G;kSP?7E9(xHau|lWYxnf6*3nul&)HA8Nx8aRmJ|FZP1#u(m3m)1Zp^1CFqEku(}j(+)v6Xej>!;N{5$`7S{k4DlfOjG1+qColv@tr7j2miWJadS9Wn*~*BmLolwGqF2-?O-R?7>4wYJ^5 zc~As5(a%0UW6*uQVm87`X7$~%+Q11@vXbgz2T|*zMR58*3a%m59gV^*!a86exDKC{ zbR79V+WYc&sMo&#(GXcHWGl)N*<~waEM-Ze1zCqgB(xk`CR56mtrVhTDWojPI?33# zifmc3jv0~NOr*gW&*hwYe$Q>@{EqXSyXQXL_xZ~!)%SIMukUqzuFv)Uyx;Fn)6?Y9 zE|q`+<&3vXueUqg+h=MjaeFTmIxWEmCl+Tq!}B~-2s#p$ySrS`?4lvZJ6hl7zOaN| z*!;wGz=ja!)};C|9uiCCds51!GG4-J%Gq7wy(+Es6$R+WVg@Ag4H6t1P9~mmmo}fg z*}#AQL9nM;!`|ZaI-ADjtz$#Vq`kQ+Ert_AaRR*FzM7pfvaSWoMkf9}IKr&16>!sf+t4*Kk1X0|>O%kd5^kUrjGUU2NmEu6uFn^8vcZl4(IQs{#D zE0+^32>VlByl+?8hugSn+;KFx znLuqD-$Tz`jS;FPOD8PprJu(kiOUs*|0qY)`p5ZydYFCXIeZ86=&@?`pV>YGDVqWJIhf?Y6td_%3NKtXIxFbSSDx;O$lhGB~$ zh7Pugyt6x1*8R+m`I1%N*4`Tly%jsJ7uepNUKj5j`lgKHX5pPa#fNi&(Gyb!6LXNP z4=*~q5A8?Qr;VX_11bSymr+U6eS1{7q5P&9p=PJ%=0}?V8DXhREEka`jQhgC8K-L7cP|GUV90Tz> z_&-B6Fw%`x0217e6i_#jqgx12@L%eKkqa9m|KvCU_5L5h&(#|Jn!)_S+I504jj2OB zY?BTXs!NEdnlF%EZ+hzl&)3f|uaXNqk3i`z@NDV}F9zS#=tMO=ik? z5xcW}1(yIz;hDm=N3fC`zM(tv4-KC&=-ijd_dKgU+ za0K^{Oq+Gz&o7{tlU{8ao*J4tU4+5i%%lL*z+Ve=6 zSExc2&-U2;;pQiEqH5$M)z7;k>y==e3nyf@5+kvWY0ANBN=2i0F$m%I8Ii6y{n^IL zuhSJ`a--{G_Gayfn2Gjt0#cMdq}OM%QCfHF^1Z}N_M;fw=$wVcVyR@u5W3y|X{BF> zg)%TJ>5;Ez!|J(tz&G`H3uzS-U_o=Sa`5p*-v0ipj|O_IhV_pgW>yI1(cW-jAOW=F zhFyO)Nv0cvv#Rk8vauh+N${0KGLDzY#!1du^E227?=yMdC^CGaL1TyKzI`7|o{(YZ z7LVq73}wP0-WfCS&aB>}t{f!Aj)zG{4&HvCErNSLov6q>CF%QqBeI{Bby9WetQNW@ zvf8(t#)UU2z|B1kSm9xJ#SXq*2z+;G+JV>Cxy;gvCqINy_I*vRw7NYITU>&B^)LT4 zVM~5pM7)J0a=C{(WTSJMS0K_0tzP6!Gf(@iNk^9-PK_WpNxEb^-z`vw#tpY_!%n_w z?3^4=jcUCvDloxWG03=NQFfeYPCyy96gr)D53&))yQZb3diF#&#p0{Y;ZwyaM$+4Y z582-z4ADQ(pb-t16fO2DK#wv%vBJ!YnSxB zCyZSs>NgG`0r$6m3j+GApfUyB85ep`67}eg_>`w{mUe(}N&vX3{b!tdKgK8h)eT~O zo0PI*sY{V7{K8dDCds4%=V|||67{SzzzMAn>N>c?)1!BH2~yC%wOf{%v*L{CCD}8! zSy{8*rBQ=4M?b-77k$~x)`g0F@ z^`-^kX#8shv8X4s+f(=%4zR$NQ~g+FrfBf00NiJ5N?lZ)@bu@NxxMXEs+sxb=d@c( z?r1ZAN{#qDA^?>CpCuRxsOJ<7U7gQ09~oUi~Nf(3^Oc}e%)AI5l!sMArICqEhgT5)sag(yk)-A0MY zdAE;Uav4L0mq`(mo|4=7S%@x!NN!7_u3o2_obS_fTv5)?2Mpcpif?YRHRrgohh_NM zhq`ULr?cJ^&`cg9S+;&4c3i|)SPn#P*2a#K^tv`GEbS@sjYTo?dCtfq&fGz93ym~s zOikb-w-OC-{7;uW&7I=uBW+tfoXWPI(#<43vKHJk{Y>ec7fmA5<)z>OeTaRr`N^#t z5*egnE;4+iEyP1hTIu1_=SdE@<^Zpln4&9H7E&4KoDp~UloPq}8I_N%u}Wdg%pS>X zg%cq}UxJG+G5VQz@8Ne+Gq%O}nCCxPj+BIRp1H5Rz2uSj+k3s@Vb4$8_8v8QH9))k zhzx3?>}VQy;Ha$}S|)VLr6)_pu_WyrjKxjC#aep5Nl?$!G~%Yj8`!G!sQiMhhf^2Bz7CZe$)CxKH?387CLPq zF)SrIAKp&#TH+%@ai-}6CJmydPgWMZCw?U5OsqKLLhh@W+pn-kB8BblDJ?%OA3iO? zG;g|`oE$1%`Gb33=vpT_da!n69IA~U1zS{zw z%#fJHy&F=lpJJNV!he}!&mif(D-_F?%F4+>@7i|5eLHVJT->gErFFES7qDS*k!Q~N z8Q(;7fE)E@1n6&$J3A%sgHNd#*lQFNe>MnxfEAT7v3cwQyuaT_E$engh)RJAZ^n#c z9q#Bxm20dsX3ObnQjf;qT<#;e9Ro6fqGVBt?Q+|amO0&!t+P8>KJ63OZ*-r(uj`mS zA+!nwdI~lN!3y|UkTq9MxL9~5iJ%{(78(bTaSuoK+DOJV|Er>sKO6 zmFBjiwYT1%&iUy*FM~8gn-J5^@K6rP>ju(#%%@o8;98@|Eoki&k^_-$umQ+BB&x4; z`MbNzWTEf(zKv(dR(m{Pc4cZ-Ai$Q@haL(M&~Jrr8C91gE&;X#h8J-tg>)hp-;wT* zFvGFP>%Qx%p6_D05_7pkm$N;hT+&WShxwd9rhG20h-3!R+?={H_T>b2LxN&ZRShvN z-SEkHqDW$o#B~Q@(>sTYo-3y^W4FTI$xD2_DUy6VUE5zIisuf^Q zCB{A)RatV1H%;3XXYb;ol6vgbbhtZjjK^MX%!tFA5BBkk{{PQPo+9?Ha>v$Y;*|99 zZ=MKj;*^CDimMTjR8iFJAKen8`a3FG=~7d4<~(3OM0o&4_WO^x=4Cw(UP@K_sw=)) zCKaF=WR`0=ZtFIRpeDorU(4<(kD9JqeyuMRKL)EE!ym1xwr*FG_fifU>CSMz*jrk| z-J%$%N>_8d#tU+CI{bxw*!C@;aUY|5EoRQTY$tM%EvS6KbVNGT~p^@ zfef1n;2)E$S0IOa0sIFc`mR8tPk!}gdqD77=5hy69~3)7HaYfJdm=SFZ_PWenkfRA z>ml&6pUrKF%|qe)xd8njxZ3sXLrzCS&t+ci5$7;3y*FoU8H}4MO}NfoWAh{?3^uGl z_=zerdTr=q8Q#h#&faoybYE!S4dV`~YR#%%U^~pr!QH z7*a+GnFAAAK3cMhiB<@(AwOkYQ`>aju zdzaAts*Xj5c*0K_w2PTqMOGn*11pd>88ECNv4k9o0!S|n{tIZ5_XK*Mn6RWsj0An> zf@!)~&6FRW46w{h_{2lMGa-cM^nSJYF?Dvt4gn^# z0YS)&+(mw;E=Pd6BpP+2bMhP+9)8L%MXf+G`b(I;;cf_+lh0$X2FiFDKAhlrp{iQvQlpcS{>G?xqjVP8*1%d9od}^2mUEZoZcU6 z1-6I~B1&*FY}F6@wzUc71!5Xv%vczO5^`~eXt?vw$n)@da)Ddc?=OmdQ%3W8*1Gd@ zk%L?$5gkQq@g1_n8%r?Zh0BrwG|f;Ko<5Y% zfLz-i@481()ljR|>NU5M#lc=dRk^JjM=xk{f(E2(HV(DV;L{Ye#MPV%Tp_x#q2<9> zB1(M;issK0OHE(f_?q*!YfZn2$lTe-6Ma%ABh8pu+9+8U&tgwZ!FSaOSqXc~SAV&( zId4gnbakO&!$Qdy(gQ?fNnw7;lY04ee1**j72*apn!%Zn_|090Ur4(XcXoQbyEtzo zGl_IRjmR!(jvM|sz98zl8v zN@>x4-l;aT*GgASw!}xv`qNp6EA8Do^D>mnk6L{EfXSr~{~YdqjF1zgFlEtIC%~k@ znIBnQCZ31?U?Hiz_hpHd=JpF2+Jbdj2tr+o3`Vf**=ozK-~Y(JnhmdOi~iaNZ9R{q z^i?WYJLhHqg4{$h2C9PCh-|JQ7(fQVwTVA^CZ<_y_OU6t)4#4_EMUV!9dQ$=qgh|$ z23p9X|1D5T{wELhM|dPvmuLDaBnNCtWGM3xIA?;V1@W;#X}-hxE$Ff69L40^=PGs@ zPmbM+*65D@A`iKKK!!5tf0s}HBh2TI^5RsoONx^-^DSV+-UQu{@cfyQ0z9OP>4Kny zNZ@wOniI?d6~q)h#9O(DF`gq~G>km&#UD)>(|o2|MZPJru(dnX_-g@m9ijS4_P^?h zG)sUL^*Rdyy!&$H%|R17p3DxH;Z=P+7IsTv2K2it?XRyxZa)`;_ckz%G2kmXu*t62 zB>&$1zWT>P0k*P-Rf;xML;e5WAO9m8{89GDzgw(vp|DM(k{4YDa1C1i3DIoTso41` zG5-`HyqaiGeJOh$#d+_t&f{6D4YE>FgNDgZ_lsFdUaGN$uz9Sx)Ka5y_?XohEr^wG zKu%r;`B}TKIdD<=cA5T%pH!mKsy3@Tovh!P0~qH?p|H=p+5xlO1#~!p7hoa*53%Rc zp3j-@9f&eRS9MK+6z;~5!AYatGe_Suzm?T!MD3P%d#lmss9cy?A-OAwJ%`NU*F3PN z<0lgzHACO6PK(0Fm`gDI`}|qT#@pz@<;tuviE{h0-jkQBqK02 zSJdyg4ia2cjcgwumG-eosHv=C5s`PSD>q(h=unC>m#C}&*thocfCW0 zZ1O#LTc^$EfhY5RsIzN-MZIDb$zu62@CKf(g0oM%da!%s5P5qP%kp?#`zGi*YEcPJ zk;CbY5sX`3c|H-nEX}IMRhPt#md9dx?hbybXYnKyAcNHR5U(BxC_*Vn&*QBc6wKsm z5zV1?3R@tG#H=$dUIHbaNh%dNrBhzl^ zZVeG@edxYq7S){I{HnwQ%ZYP5psa6i1KQV&WIrCuw|2QrWItY>`@H1tYk6JX2AY5& z$Fm`)URAR)I1VNylf}qw7#1>%i|I?)Et1ap&%VLx?eSL=0^WYEs*F%Ev7&*S5~2Xi>GP|xdjN!p7CN&2<2wl7Uv(V6at zM#E5Cl{DDqsfR-^ENCuErI_zd^6a^#&%IHjQ%j~m%ve*>9s-TJXmb{~!{|6+W{PKN z`$VDye$i?1^S}+<4xQP<@dq$=FJ1U{JJ1B0+_@j&XV)@oEl{z%t&Xkt!F*h~f!Oh> zEQF+bn-Cw_*C2dQ*_f{(bf?Gr)Hx2C$ytOeen)vV16jxbSGpGlZP?Ja`^CHKZm%qz zAfF{Ihr7dj%dF1cY9yL3=^|8#&6(h;b`!1T?%~1^gBv=E&Mkia@|1qXJ?)Fz-Cjp+ z{7iRAqgk+QV+sCQw$~CjNu{(ct>e6!GS=wUm!80E>FbUtGhUCdE8*i;AMaz_=Mj)# z=~f4waaDC0@Pk-*v*QHnr?_h4l|kEYPLg%kPlmfc(MDZWp?hA0x>v`)KRvKhg!Pn= zqyq|Za|jrAbf5f<_FA0l6MF(?7PWSD;CK8~Y)+|QcGPPY-)a~C^XIzj7~=(0-pR*o z%61dbd~!cz3zTs8Xo-D+>?uLfr8Db0N~LHhk_?|*wy{eD&Yo6Xq&dYnG# zlMAawWPOm~(t;B54h(?QUTo~GP??-4GV~-LqD#rM<(9bi>gWgCSC!`GxA#)C9dq^Z6kVj~peUE3g}vBNpTI z<^-6$1AUi|I@#c8lk`gqB5)#0&CGYTLd36WzL6We(b7VjL|IU$LV6l6tRcd21Ccn) zE&hG@9SNnASL$y9v(55&?-otL0bSucK1aB7D?(6iCY5#a8r)RM^i-bOh0r2KW6J}s zh?M2v!gZHqjwa4yj3V3x^-)G@{`>B3$=p&L%p(LX-th7Y1l+6Fw>}yP%E5Cp^xp2K zU7tgv^V$?L_1$x%t+qa|-pX~SX@7-@C_b4DV0>%Ym{ba<*=+tvysl(rqMzZphAKZ% zeACYj9G#blQEyb;QI&!*5l)_Z3tAg5^qxB7pmXSo)T)AQ9URTCG~RU(dlWkXQqzd< zB1z5=&B}Y=gi}ZmLO?mpabfEUq&_m?gHM?wMrQeJ1IlxnSg+V_42a~9M>vyXOR<3+C ze9`(DDCz&eOX@c!YE=dIms?epj0;P_d4j+;meN! z4+F+D0nc}@y{e8mOsMhV^4r>xJ>**snJ8+>RQx%EsX-(v)#YwO3Ei1a7S;Cd%0 z@#2xEmFz-QwCK+5Poe#kzz(J94Sn<~h#3`%7bVxLCN1k0#;>9(VM(8k`O&Vj3jpr( zWIi8wbkb3~kWuoz6hSA8wP`S2d5`WOj@%*uMZ@u=aif$nl+&(=1sZqpLmqdSAes`z z9J0;gdNVe5_>}ojLQ6T0zJ=?u(4(B_HC!zWvs~!7e5FaD4jmJ0)i6 zeI+a}C#;M!P7OBb9{NRn2hqu6kIW#xyJctM_-m2-Z>0*jfOCiNkw)Ui-41;hx<^VS zD&h3>H_8-A2E-f7&)k~B2HWh&O-oA6xy!fq*f+sr3nDJh_(?3sqfdaY8|s4I5;$YL zSA_Ij=v5(jq9LQ|6ztUI52@Mb+fokgl)PYil#A(AlcnpDkYzpI1s4<`qh{%o>0N?T z0OUY7V%1_Rb5s+4L9D?oz(g?o!nU2&P$4e`nhzF1A%5Zrj^%rPi~_7gf(K@ccak-J z`mTd?VOmdGX?Ax1%etblT%EK>ragdYl`RB2;EK3PtRKR3zp2NTU&}#U^~K4s6T6O= zIjdO<1Z*82uY1!&8)f2O)#3Si_ebN@OgdAMYP#K}$Xc-Uqlh_JOqDw$xP552npIdd zg=B{2pGgwe@ni@?wX)omi}$#%98F2SD-M~nD~Ob6kZ_H7+{ zwYTnc;+|c|7`;^OK&z*Nm&5#Nut~IKFmKRHr%PRs2t4;r5(GkjvR18Xn|NsyhR_`B zR^WN~QtQ=xl#te)!y0mWS)0$e(JHa-7xR-w_~6qgUk}0}doVTDFtfZnKRJ6CF=!|E z*3Ayx7a~;n2XH4d3WK!OmO>O1U+TadzX`Q^*qd?}fd$3Lu%!9jF0e&y zMPLcQu?C>}BY*y1Lx=o(mUKqD5_bY`8&xJ2FJt`MKHzQR_%yBF?aO9+jZW@Kt}O;z z`e;tPRKiBcUeG~NVMkC$!PXL*BB{^>zUI7ZnMV{PiLd$gU+R&6xXOF%GaY40pa5B0 zF+20|LKo^b{>KK3O=cp4RCbFTm9sTIMraZ2zJb7 z;ryJ8ii68rC&}}y_l?ClPNx|wIb3b5*lF~Hk|(M`Pi3o7Pz3($NdIbU2vMF4*qYj8 z0ErdA!^rz0aKOI$idmWE0j8!ni&+aMKImf(#sKc8Ct2d)mt`5)R~;nQ#*eia*{^;p zfA62)Ap8FH*3fEw0c;>HGPJ|t1|Xs-e1LBwCJM0>Cf+oOQ|z5{W{Z0)*Dti^&b3|I zs&prb&%aMztbaQ!3DP*5R2ZGJ7R8q@mi%8 zWmr~Xr7X-P-6rQm0*6hTj@w`6zaPPQtx|0Ky(lv)13+@9445MK066~N+vA7X9)Go< z{byE>8NhC;RU!kB0J_;0pA@PX$=wH(@5#tC!S) zd;u8D8ql87K>4@ydykU?jq)!zjJTzyr*)i3<2>E#jyg#DYORl@!ZAnbQW60H(fN%icj zq}5{ST(~$xtTAAh{hZg+H-7w8Bdk!CBYRR)PdF;)w(KUzqWCId@IUawQ{j&{ zy)***%Z`vzYa?@a&?|!VK?V`2*OnaO!N#`GAeG&eCK*<}bb{vaKn;h#zW4$ZlGye4 zR{9oxzt6h=4y%(2SCb;lx!fXZ1KA3{H?%5t(eWW(wVvI|2*+~S#I&egP5q4^y2C9; z@VMnk`U??QD6_4s?Ivzv=x7G$R80{uDdPAKa(qFli8GtZ`AG1g<`6g?3Al61gH5ut zy%6Z!$9YY%P*;M2Iyqu|odtC+y-eBs@aL@>qC6D`B*5RVIW2yW8DKMcgwCYc;6HSl z@$a-i|Ip{5$XEfXfaxv}=W6)@ajq8-=en4vbESuPtU$u~l?i_Ng9-MPS6pX;<_yK# zq})cT%+q6fKAwzm+|V|1fkWzpkmSjzqx3w -
-

Pasientene som faller mellom alle stoler

-
- - - - -
-
-

Hjelp oss å spre kunnskap og åpne dører! Vi har laget enkle brosjyrer som kan deles med pasienter, fagpersoner, pasientforeninger og politikere. Last ned, skriv ut og del!

- Vis brosjyrer -
-
- -
-

Hva ønsker vi å oppnå?

-

Målet er å finne en løsning på den utfordrende situasjonen som norske pasienter, leger og forskere står overfor når det gjelder bruk av medisinsk cannabis (MC) i behandling. Dette søker vi å gjøre ved å opprette en registerstudie og prøveordning i Norge, sammen med flere gjennomføringskriterier som må være oppfylt for at studien skal kunne realiseres:

- -

1. Registerstudie i samarbeid med utlandet

-

Vi jobber for at Norge skal implementere Europas største registerstudie på medisinsk cannabis, utviklet ved Imperial College i London. Studien følger opp alle som bruker medisinsk cannabis - uansett hvilken sykdom de har eller hvilken type cannabis de bruker. Slik kan vi få oversikt over hvilke varianter av medikamentgruppen som virker best for ulike tilstander, sammen med bivirkninger som oppstår. Vi er allerede i dialog med flere Norske forskere som ønsker å bidra til dette.

- -

2. Bred indikasjon for vurdering

-

For at studien skal kunne gi oss utvidet kunnskap, er det behov for å endre dagens situasjon der det er nesten umulig for pasienter å få resept på medisinsk cannabis i Norge. Dette til tross for at medikamentgruppen allerede ansees som lite risikabel i medisinsk sammenheng. Vi ønsker at det skal bli anerkjent at cannabis påvirker kroppens endocannabinoide system, som betyr at det kan hjelpe ved mange forskjellige sykdommer og plager. Vi mener derfor at leger bør kunne prøve ut medisinsk cannabis for alle tilstander der pasienten ikke har fått god nok hjelp av andre medisiner - så lenge det ikke er noen medisinske grunner til å unngå det.

- -

3. Generell forskrivningsrett for alle leger

-

Vi ønsker at leger som allerede kan skrive ut sterke medisiner (A- og B-preparater), også skal kunne skrive ut medisinsk cannabis til sine pasienter. Vi jobber for at legen som kjenner pasienten best - og som følger dem opp til vanlig - også skal være den som tar avgjørelsen om medisinsk cannabis. Vi mener dette vil gi bedre oppfølging og mer helhetlig behandling for pasientene. Dette vil også være en viktig avlastning for en spesialisthelsetjeneste som allerede er overarbeidet og har lange helsekøer.

- -

4. Dekning av medisinutgifter

-

Et medikament er ikke reelt tilgjengelig hvis pasienten ikke har råd til det. Alle som får resept på medisinsk cannabis bør få dekket kostnadene gjennom det offentlige, slik som med andre medisiner. I dag må pasientene stort sett betale alt selv, noe som skaper et todelt system der bare de med god økonomi får tilgang til behandlingen. Dette fører til at mange pasienter kjøper cannabis illegalt, der det er billigere, men uten kvalitetskontroll og trygghet.

- -

5. Etterutdanning av leger og helsepersonell

-

Det er viktig at foreskrivningen av medisinsk cannabis foregår på en trygg og forsvarlig måte. Det er derfor behov for at leger får tilbud om kurs og opplæring om hvordan medisinsk cannabis brukes for å behandle ulike sykdommer. Legene sier selv at de mangler kunnskap på dette området, noe som også bekreftes i studier. Uten tilstrekkelig kunnskap kan ikke legene gi pasienter den beste behandlingen eller føle seg trygge på å forskrive medisinsk cannabis.

- -

6. Gjennomgang av helsekrav til førerkort

-

For at pasienter skal kunne delta i studien er det behov for en grundig gjennomgang av regelverket rundt førerkort og medisinsk cannabis. Som det eneste landet i Europa, har Norge et regelverk som fører til at de fleste pasienter mister førerretten når de får resept på medisinsk cannabis. Dette selv om de bruker varianter og doser som ikke påvirker kjøreevnen. For andre medikamenter som kan ha en midlertidig påvirkning av kjøreevne operer Norge med et tillitssystem. Dagens regelverk diskriminerende derfor pasienter som bruker medisinsk cannabis.

- -
diff --git a/content/kontakt/00-some.en.md b/content/kontakt/00-some.en.md new file mode 100644 index 0000000..34ca8b0 --- /dev/null +++ b/content/kontakt/00-some.en.md @@ -0,0 +1,7 @@ +## Follow us on social media + +- [Facebook](https://www.facebook.com/StoppLidelsen/) +- [Instagram](https://www.instagram.com/stopplidelsen/) +- [Mastodon](https://oslo.town/@stopplidelsen) + +Learn more about us diff --git a/content/kontakt/01-kontaktskjema.en.php b/content/kontakt/01-kontaktskjema.en.php new file mode 100644 index 0000000..4a6ca8d --- /dev/null +++ b/content/kontakt/01-kontaktskjema.en.php @@ -0,0 +1,277 @@ + '', 'email' => '', 'message' => '']; + +// Start session for CSRF token and rate limiting +if (session_status() === PHP_SESSION_NONE) { + session_start(); +} + +// Generate CSRF token if not exists +if (empty($_SESSION['csrf_token'])) { + $_SESSION['csrf_token'] = bin2hex(random_bytes(32)); +} + +// Process form submission +if ($_SERVER['REQUEST_METHOD'] === 'POST' && isset($_POST['contact_form_submit'])) { + $formSubmitted = true; + + // Security: CSRF Token Validation + if (!isset($_POST['csrf_token']) || !hash_equals($_SESSION['csrf_token'], $_POST['csrf_token'])) { + $formErrors[] = 'Invalid security code. Please try again.'; + } + + // Spam Prevention 1: Honeypot field (should be empty) + if (!empty($_POST['website'])) { + $formErrors[] = 'Spam detected.'; + } + + // Spam Prevention 2: Time-based check (form must be visible for at least 3 seconds) + $formStartTime = isset($_POST['form_start_time']) ? (int)$_POST['form_start_time'] : 0; + $timeDiff = time() - $formStartTime; + if ($timeDiff < 3) { + $formErrors[] = 'Form submitted too quickly.'; + } + + // Spam Prevention 3: Referrer check (only if referrer is present and clearly from different domain) + if (!empty($_SERVER['HTTP_REFERER'])) { + $referrer = parse_url($_SERVER['HTTP_REFERER'], PHP_URL_HOST); + $currentHost = $_SERVER['HTTP_HOST']; + // Only block if referrer exists and doesn't match (allows empty referrer for privacy browsers) + if ($referrer && $referrer !== $currentHost && $referrer !== 'localhost') { + $formErrors[] = 'Invalid form submission.'; + } + } + + // Spam Prevention 4: Rate limiting (session-based) + $lastSubmitTime = isset($_SESSION['last_contact_submit']) ? $_SESSION['last_contact_submit'] : 0; + if (time() - $lastSubmitTime < 60) { + $formErrors[] = 'Please wait a bit before submitting again.'; + } + + // Get and sanitize form data + $formData['name'] = trim($_POST['name'] ?? ''); + $formData['email'] = trim($_POST['email'] ?? ''); + // Normalize line endings in message (convert \r\n to \n) + $formData['message'] = trim(str_replace("\r\n", "\n", $_POST['message'] ?? '')); + + // Validation + if (empty($formData['name'])) { + $formErrors[] = 'Please provide your name.'; + } elseif (strlen($formData['name']) > 100) { + $formErrors[] = 'The name is too long.'; + } + + if (empty($formData['email'])) { + $formErrors[] = 'Please provide your email address.'; + } elseif (!filter_var($formData['email'], FILTER_VALIDATE_EMAIL)) { + $formErrors[] = 'Invalid email address.'; + } elseif (strlen($formData['email']) > 100) { + $formErrors[] = 'The email address is too long.'; + } + + if (empty($formData['message'])) { + $formErrors[] = 'Please write a message.'; + } elseif (strlen($formData['message']) < 10) { + $formErrors[] = 'The message is too short (minimum 10 characters).'; + } elseif (strlen($formData['message']) > 5000) { + $formErrors[] = 'The message is too long (maximum 5000 characters).'; + } + + // Spam Prevention 5: Check for suspicious patterns + $spamPatterns = [ + '/\[url=/i', + '/\[link=/i', + '/debug = 1; // Uncomment to see SMTP debug output + + $mail->SetSMTPhost($smtpConfig['host']); + $mail->SetSMTPport($smtpConfig['port']); + $mail->SetSMTPuser($smtpConfig['username']); + $mail->SetSMTPpass($smtpConfig['password']); + + $mail->SetSender([$smtpConfig['from_email'] => $smtpConfig['from_name']]); + $mail->AddRecipient([$smtpConfig['to_email'] => $smtpConfig['to_name']]); + $mail->AddReplyTo([$formData['email'] => $formData['name']]); + $mail->SetSubject('New inquiry from contact form'); + $mail->SetBodyText($emailBody); + + // Capture any output from PHPMailer.Lite (it might exit() on error) + ob_start(); + $mailSent = @$mail->Send('smtp'); + $smtpOutput = ob_get_clean(); + + // Check if there was an error in the output + if (!$mailSent || stripos($smtpOutput, 'error') !== false || stripos($smtpOutput, '✗') !== false) { + $mailSent = false; + error_log("SMTP Send failed. Output: " . strip_tags($smtpOutput)); + $formErrors[] = 'An error occurred while sending the message. Please try again later.'; + } + } catch (\Exception $e) { + $mailSent = false; + error_log("PHPMailer Exception: " . $e->getMessage()); + $formErrors[] = 'An error occurred while sending the message. Please try again later.'; + } + } + } else { + // Fallback to native mail() function + $headers = "From: kontaktskjema@stopplidelsen.no\r\n"; + $headers .= "Reply-To: " . $formData['email'] . "\r\n"; + $headers .= "X-Mailer: PHP/" . phpversion() . "\r\n"; + $headers .= "Content-Type: text/plain; charset=UTF-8\r\n"; + + $mailSent = mail('ruben@stopplidelsen.no', 'New inquiry from contact form', $emailBody, $headers); + } + + if ($mailSent) { + $formSuccess = true; + $_SESSION['last_contact_submit'] = time(); + + // Clear form data on success + $formData = ['name' => '', 'email' => '', 'message' => '']; + } else { + if (empty($formErrors)) { + $formErrors[] = 'An error occurred while sending the message. Please try again later.'; + } + } + } +} + +// Generate form start time token +$currentTime = time(); +?> + +
+

Contact Form

+ +

Do you have questions, suggestions or want to participate in our work? Fill out the form below! But remember that it may take time before you get a response, we are not many and run everything on a voluntary basis.

+ +
+ +
+

Thank you for your inquiry!

+

We have received your message and will respond as soon as possible.

+
+ + + +
+

Please correct the following:

+
    + +
    • + +
+
+ + + +
+ + + + + + + + + +
+ + +
+ +
+ + +
+ +
+ + + Minimum 10 characters, maximum 5000 characters. +
+ +
+ +
+
+ +
+ +
diff --git a/content/nyheter/2025-09-26-banebrytende-studie/article.en.md b/content/nyheter/2025-09-26-banebrytende-studie/article.en.md new file mode 100644 index 0000000..e58a4f6 --- /dev/null +++ b/content/nyheter/2025-09-26-banebrytende-studie/article.en.md @@ -0,0 +1,17 @@ +# Groundbreaking cannabis study reshapes chronic pain treatment + +![](./cover.png) + +A whole-plant medical cannabis extract has, for the first time, successfully completed a Phase 3 trial demonstrating both efficacy and safety in treating chronic lower back pain. Published in *[Nature Medicine](https://www.nature.com/articles/s41591-025-03977-0)*, the findings represent a turning point for patients, healthcare providers, and policymakers—paving the way for regulatory approval and widespread clinical training in cannabis-based pain management. + +The trial involved 820 adults suffering from chronic lower back pain, a condition affecting over 500 million people worldwide. In Norway alone, nearly one million individuals live with persistent back pain of varying severity, according to national health authorities. This patient group places immense demand on healthcare systems, with lower back pain ranking as the single most costly condition in terms of disability benefits and lost productivity. Any meaningful reduction in symptoms could yield substantial benefits—for individuals and society alike. + +The investigational drug VER-01, derived from a full-spectrum cannabis extract, was evaluated against a placebo in a randomized, controlled Phase 3 study. Within just 12 weeks, participants receiving VER-01 reported significant pain reduction, with further improvements observed during the open-label extension phase. The therapeutic effect remained consistent throughout the entire study duration. + +Notably, patients with neuropathic pain components also experienced clear symptom relief. Pain levels spiked upon discontinuation of VER-01—a finding that reinforces its sustained efficacy. + +While side effects were more common with VER-01 than placebo (83.3% vs. 67.3%), they were predominantly mild and temporary. No signs of dependence or withdrawal were detected. + +*"This isn’t just another study—it’s a regulatory milestone,"* the researchers emphasized. + +With these results, VER-01 is now positioned to seek formal drug approval, enabling healthcare professionals to receive evidence-based training in the safe and effective use of medical cannabis for pain relief. diff --git a/content/nyheter/2025-09-26-banebrytende-studie/article.md b/content/nyheter/2025-09-26-banebrytende-studie/article.md index 052c4fc..0313c10 100644 --- a/content/nyheter/2025-09-26-banebrytende-studie/article.md +++ b/content/nyheter/2025-09-26-banebrytende-studie/article.md @@ -1,8 +1,8 @@ -# Banebrytende ny studie - forandrer alt! +# Banebrytende ny studie forandrer alt -![](./cover.jpg) +![](./cover.png) -For aller første gang har en helplanteekstrakt av medisinsk cannabis bestått en fase 3–studie med dokumentert effekt og sikkerhet mot kroniske korsryggsmerter. Resultatene, publisert i Nature Medicine, markerer et vendepunkt for pasienter, helsepersonell og beslutningstakere: veien ligger nå åpen for markedsføringstillatelse og bred klinisk opplæring i bruk av cannabisbasert smertelindring. +For aller første gang har en helplanteekstrakt av medisinsk cannabis bestått en fase 3–studie med dokumentert effekt og sikkerhet mot kroniske korsryggsmerter. Resultatene, publisert i [Nature Medicine](https://www.nature.com/articles/s41591-025-03977-0), markerer et vendepunkt for pasienter, helsepersonell og beslutningstakere: veien ligger nå åpen for markedsføringstillatelse og bred klinisk opplæring i bruk av cannabisbasert smertelindring. Studien inkluderte 820 voksne med kroniske korsryggsmerter – en tilstand som rammer over 500 millioner mennesker globalt. Ifølge Helsedirektoratet lever rundt 1 million nordmenn til enhver tid med langvarige ryggsmerter av ulik intensitet. Etterspørselen etter helsetjenester er enorm i denne pasientgruppen, og korsryggsmerter er den enkeltlidelsen som koster samfunnet mest i form av trygdeutgifter og tapt arbeidsevne. Enhver lindring av plagene vil derfor kunne gi betydelige gevinster – både for enkeltmennesket og for samfunnet som helhet. @@ -12,4 +12,6 @@ Blant pasienter med nevropatisk smertekomponent viste VER-01 også tydelig sympt Bivirkninger var vanligere enn ved placebo (83,3 % vs. 67,3 %), men hovedsakelig milde og forbigående. Ingen tegn til avhengighet eller abstinens ble observert. -– *Dette er ikke bare en studie. Det er et regulatorisk gjennombrudd*, sier forskerne. Med disse resultatene kan VER-01 søke godkjenning som legemiddel – og helsepersonell kan endelig få opplæring i trygg og faglig forankret bruk av medisinsk cannabis mot smerter. +– *Dette er ikke bare en studie. Det er et regulatorisk gjennombrudd*, sier forskerne. + +Med disse resultatene kan VER-01 søke godkjenning som legemiddel – og helsepersonell kan endelig få opplæring i trygg og faglig forankret bruk av medisinsk cannabis mot smerter. diff --git a/content/nyheter/2025-09-26-banebrytende-studie/cover.jpg b/content/nyheter/2025-09-26-banebrytende-studie/cover-old.jpg similarity index 100% rename from content/nyheter/2025-09-26-banebrytende-studie/cover.jpg rename to content/nyheter/2025-09-26-banebrytende-studie/cover-old.jpg diff --git a/content/nyheter/2025-09-26-banebrytende-studie/cover.png b/content/nyheter/2025-09-26-banebrytende-studie/cover.png new file mode 100644 index 0000000000000000000000000000000000000000..93ec8786102ebece6c9f05384dbc38cf96ed9ae2 GIT binary patch literal 85465 zcmY(r2RxPi|37~0Jt7=gDHNGWR>&xOWJI=P@0HETEGa74qLP^r*_)zLhwMF)J+rs} z>*~Jm&+q$xJnlz#N5{FY>pfnt=X#$q;Sv%P!cUa1 zFO9+f@GX_)wQwj824^wl zeR+3IdEF$wbA8#C0GH=jf|Q-C;JJUtUO-Ur$ibfL%2#!F+Cg6#-x0+xQU`SxW>a@; ze1j9?v_q)nh}pxCKeF{49eH=F#z_AA!SA~q?=mw|{(FNstua3X!RX)j!XICfu8aJ? z7mNzBqW^qM7_~d0miqsBajR4P-z$WrvY+;({qN&#P?pgl&i}pot@b)2CDrnm@ha-y z&q+O{+YP^2$2ocN3XSeVg})zyyUF8U6-T4}4Rb=|-%%BvM$N*e#@D@2TyMU(z*olF z{_$)WvCp$o&4rk>Z-HM3qLfiI+J?pEII+dNF;T4~$Y+1K!P_IIM~tJdsgFgI?KZ?| zH(Urq&9a1EJh-f_;)-PtLs_a7g)%Wm3mqLNm8{kUiUl3|H2N>#c{uAYXD446*nH(m zxGTk{RoPh)Y%k8B)*bd(Sg<9$i0?Wk^uU3H0Pid}`oio5ejGs@LID&`5$B{kBk>e- zv6_}R>)$*0+)=`7?7v+0@bTkCcj*>EKUU96Po6xv$j5iX$cPDbR!HbnQc}|O3pjax zCu@@}10_~u^}D~w!XhKjOG~r9xS)AcK_RTj+DJ)oYLjR*T4-sgjBIDjUm!U-88^%8 z_HY3yezl>EW@@3~0h!mq_L2E_%)Q18cDKsynN!8+9fDyL$JA-h7aKG$@|+?XxW#Fy z>CKfMG^`Y~F{HCboHor{=0fJV>S3;!5EmCA+?vVln=0J?44yVNHs=KdG>a6RJb!cp8%KSY|k|8?%7&E-M)x3Ov>eC}y zF~3dQgr@AeqyTT(Y0(1i<1E>Y@bbWL56Yr`TyI8O>G>vxV3){*aM^utMXeVe?yOT? z3<0YAXA@CsjeMNH_RXGN8lCl9{kt5#Byqh{(9@&q>guX?IvSqJFd}|XG#2#YQ7);Bhuy?hxyG&F>n7MuO@<;!(-bqZ~5Z9$i@Ytd{ntVC3- zpIm|uj84gM>9gJ=~ zer3CU_wvK%Kwn zO63%#uAZL7uTPIAQZ45?Uw`@fRTiFpqUg_9LvX{`${;1r*TJ{;Wm~xmR3G*D&aux* zHl;R@N%;O<_ez-9(gfiZRiF5j6f)HA(P}W&Zm63Sm8C(gk5D}Cosie^k%YWP#>V8R zi`?8K1C@Dt8cIry&pA~)dwRmgk5;_>0>$u-V!!UmH!?VqZT;fH7iCW>rf5(Q@Jn+M zVB;6Bl-a@D!+oAo-}rCUNa?h%<|BjUlT%crsIC1R+i6`Ht+SCx|NQy$*o1`050-5U zJ7z(9Rv$lpJj>3G^Wnn>6m{%tI*Y*8KgN(VW6U!dd3|`T1DwyQ^b$$fn_K4;fx=RTmu#%iYl= zKqY479%!z@UO{&@wfB3LB)(ILA^vA5;J44Q_95uadGdiC6y@ zf`>#Dfu5r~cgES|{94@zRW*KG`Mb!KwAl4|sz;sC5f4gAF4rDy5ASxI9BL|Y{|qW& zVGG3EP{jr0n>aace%;>M>(|0cro0@TyqBRyne2JweAi z^wN93X>0cv@+(h{4+2|UtH_PLN4*BhotU(BbbfYrW;itc3{|k@k*^+J-hQXI(;rKg ze_*JoQhxK_V*WeewDyKOwuH9mD^yI^Vl~nD0B_B&4lU+-mbW`(^0HjvGQFJVV4O)=P4@B7EEQ#js9EG(d2D!A z_olFD+FrKmiAYy57Dd4wQ%{5BK1-{UJQ(Mct zGvYy|*1c35ygjrgA4y4|MpZU0E-rOAdx1l2NR5n-D>9+x>>-7Kk7!`^yQQqH(50D! zC1-;RhOgpRLna#>_amxkCj=X7FHB0z->fV)FJ9@e_}kOmC$(_Of8DRyI;qL;5m6W3 z%!Mf@!HzUFliIf=}D)=--zY`Jp|%Hv-dU zWtsSbEd)A_wg$V{JmuXhZ-^1zG<$G~f|B_0KkYX5@k3$yGTwYek`{T&>b7V`y!Mi{ zE>!`G-aI{)+xV!1?d4DlbmiVm$`+RM!iDpEd=#)sp(HeYPZAC-Jb9O38bXab)%v8H zh%*dx`tonCnLz%<&|7bB5~Ojx>meYVoSb~kdQ}`x_ePmHrr-5^?I><`MoN6c^>`}c z>LgU-Bt2ns%LuV3ig4-*xxeDy1%=h;8E2H6oB1wIwLI9lxOI-7pVDI%`x*A;vy_x! zi&sNKhQFt$n@V`Ur^}cT-83y?AYO4aN*?m&%{g+`Yv?<7?o^A5 zS-w}C@?_#apRroL@mYLTOGUP9#D;C^m|^4SV;H6wKWwdm*K_ZAh}Y42x=dQVt*_y6 z3h%1Vop=F~%na3kumY#N-rRltDZVh`f~?_b_Xk1|wYArJdV0=EN;0|BZP6n&`P1jm zuglBnIXO9Pot;~MeSR!t-*a)a3R(s-c8h%lEr)v>e@0h>7?93wY@E6hIojEY`SL|6 zE1ogQX=$XhyJ3jWr)XdL(=6)~VJQrXoCN ztT=2SPF|P~A~!d;ix)3mx3l9OaTX1uhBaSm{iB&y^V;i!kaRwt%2oa;=KqjcmrlG@ z_*nMvWj@!?^E^DHi~U7y)n1F8a5HZeW6p_-Gd?@@ta`QVo5YHPJ2z}6LX?uGrlOyp z#5Go`G2dAhW4F(AXra3b*I!=ib^i~^RiQU8K1&u(VzeZG^yrZZwjE8TlwBAW9zOqm zMq~C(Ym$A{f6tdnVsqu|${zFg2#M2-|GO(DZIv^F5&sn_aauXn%S(6V%SMpOio6MX zh1+T_uv*~iX;)e~KlvEHi4&sEvVZ;+U-3u#f1e&J{7EocRd_DT@PDwpXSMgWYuX|UvWhbZd$f6~}Vr`;nc3-givv|L#TPr$@ z+ApU~)#;0(*CE_9f51Y0R*vMn7Q={(=5}Q5DzIc zKfnE|v8`BQ)karFG0!<_QZlk8aYbk6m8!7f3EN;EY%UdvB)lSfzL|KyO+T~VGJ(XPR(b1fr%HW!oYWdB%{z#b{Km%oFR+hF- z-9{M7wHcpMG!66BnELyU;&*{Z!q1I!5;w;k6EWtv+LyzW$%KCDXQY#v+lb$ZsCzWj z^-lF!dU}kIWoyQpH*e&XKUR+ns}AU?=TYNo?`ARaPw7(RTiy|~f5q30J4GIE)wFz{ zXjD;;$9cTIZobkZy(d8O{!-(>2g@ygthI02@{2&z?kkf}<^Q;aF3z}ZcW8=y_Fh;D zoc)j+5@PPx72Roy_r{)KENIp#no*cA!Xo47o+Np~&*dO)?5fa!v~QiM>&ceB($9In zqjzuLD^RL^kE}MCt|r zB;aM)HD6Ibk~$Od00)l{a2NaBckb85$Z^j9Uc+ zTWklcX>kIdDa*0maWH^{%kG1m0bcR24^9q$cuiY>5qA#w8Ly@i3ES^oksVF_QtO- zE^L+e$Om7<@zy`El3_hKM$Z{c;0CW*j%V#l_x|y@_6ma`Kvgzv9c;@zTG_|Vn+{#B zITF@6uuP&i=GTvOCNUv!*xnE_kbPQe{|U@Ru4HqeEO8qPpZr;)ZX46VM73?&t1K`&9q82 zFU}rT_`P)Y+^xHJ@2>4m#aQ;ezhgp=`}{GRh`@!gSk+iRF$5v&=+H(`vPA9f`Utjm z4h%f3^WXV3lj3so`vm$ZHX~%Sy!`6YU@4K8mls?MVC`s_k#iNNZNWPhOY*X^GFw~Q z#x}O#=$h4fCLtjqAeVTDq8w!fv==lo3JWRycUF4a^>uaUwm3LB*)LzFi59wY7^?`p$|^qBvuR2pCTn>TWr4b$;PokeC1tbsdn#I=AuataD=Kp}H$=c_Q^ zRd2DVBxe?P$4B7qo40S>HhzdMN(V#>1*|1dxgPGi9i_Qp-6k4w;DOEpcae`EpI^Hp z)Cv`r-nAB?f(%U`e?4V5MfD!iBA?yIUw=*Hz)>&Fwki z3)!BxOUDNfcskXgYa%xfR~kQ*^EC7k_FB*djx%v`ydAt>2WU@tu6BE|uf(byx7y`! zvEldA?NQY4@$1^1b|``sTMW(orxYl>JzkVP;L4qboDt zlW08$VPT&>efq473>$v}S&a1l#oGmjbXpS%SW17ga9Ftp@zbh_)9$a~SqKOS5~cjF zo?&7V806Rf6iJhNO707%(Rlf&$~vn)=Ik8r5Is>bumnwqkr z5O8(l#tmCLI})GHWuC98ezAcIx!G&&X2&$Jl=cI;Ibkdi0;&9h%gf+?QwYI8mB$5o zKEp8hfyK8tZs;=jjt@p*6+Y%ODmULAb<|o5LL%6sPH#a?h|Nfov@#E>ey*(v$^(`;WiEP$i4DiV?n7l^iBA>{g{^9g56>0hb#2t|jn6LQ=PL!UOGhZ30LKwP&f@##4`k#tG&BTKHVLT&ZcwEp z5@CZS&g2pqDQfQIRkV9a1$%m4;nGNb=rmkz(VeA^us+G7rNxB>*R=`RYlmwsvf25~ zl9Ii5r{Gp7s?|VN2%`qFCP;4fG+gFzl4_vR?L6%DTcA&^KWjem4nA0}u!J=ZgYa$Ds;>J`J?tNV_x*gW|O6%l>W_|4KFw!5oK z%gE^Q!-vGt%;J|bxJq(!Nr3c2{Uov^hf>!=MFk8-{>~l7EVZN%D4~QsrvWrL4PRx6 zz5sMaM1(HO?hX7>!@=mPmVv=TfrecgqY9^9^_=tP&I#UMGB{jz32q@`3qb9%+3K3# z@72@ys>}^u|9YWvtIy~Z9bNeQ_q+->ZdkNEWf>^7p?c-N0pv$LTHYpBI!jiq{A5fwczCB=epEW6}H!64kix)noU_EP@afJktG zAhZHT`QSeN4P(8@Q*#Jl$MZ?~(Dt9Hwhw^^_m{>S*tog5eOBvs1Z_LdqOKblpwFE@ z|13E<3U;Uk%m)eszp`IVfR1pMV2Xmjzp1W1gA#Q6rC@?L0zIXxOB*V(BEy-vnMqmP z6u96y7!eT>5wxH=%DHlqkQ^;|y+T`S4>faQD}B{@gt)yVHZ~UX@#B@z)a@stV~zV; ziywS9tf4}l7Z(>dud%SO@I%*Pb5O&B#^~c@hlKXU1i$XW!~ z25r(Ofz3)qMMV|cbg=5`>o3Z&0UWkLIEIrGA2eGb5L#WaNZCBiz+ee{6zB|;E%xAJ zXLlVj(4Y!rVFeQ#TMWpXATA=TN%Ptt z{FT}b4U^qLpiw5kDC}S&F-CMVtPF6Ttg9jIK{TL z#i0x0p5`)Zz|mGeTFUREskcp1i=IQy$?@vRO_C0>_tdJ0&W% z(r^-V@7}$MUYUj{5J?bT;#xBb?Vba`qSl=|xeoWoeU2zl7|!>YtW;PJ)NF525dc#neR>CUS5K|M6l~1knTIfcx~_Z3xhIyIzUwsK}Y)! zYBaXY%-}Tw(u&MvbZ_4#WNwI~fk*lB?VDUskTkG;PrlmXfTl1DG*lc}AgSe!gEZ6= zFz)OyCm=fd?9XT4($&q}kpey4rS_OGFE8J<-^5#%_<^Wt@cE3SfQ#|`CQ)gU-sgY} z3)JtPgAb)Ufz zj=n;Z{7??Pnlac}+&Wnq_4UYjwiTMx;9^CA+rfX`S0p*4%ZL=@h*>;`5ANkBx0@aQ zVtDxQVIv?Vw{CUO`T9oGS_|7THM04k>|kI59LH+!5b+}yfsFy65mAHd0}mD~Q?ELm zX?@D_xHn(l5;W@U0)c{$1lh-mo%}P~KbX*W!}p8N@Dk6+mS2!aa;EwwIn1?c@ubS* z_&QKaoh&uk`}eP!`pt8`H>oL?-@fN%dbrmSd=u#n>dBrrBScCV_JU{eD zt8#N&a6wCnT1v`{VUu|ZFae*Ul8K4w&r)dzE(+QEfCMn_r%;04E5`S%teOPL-vd4c zexB-43ylDgTG5uEz0Ac<@Bpp>#4V^!J6z$i!|72fr65WBQV1)tnWlTEd+OJ(04fIk z?JcRpeZD&-`1+>4oKIOK{}KdIQHEQ$Zb75xVV)!F#!INSFhect#2tmwbn4KrcQMw@0Ae}i$@p?>v6JCnN%58 zi$%gyssB4*;9rF`E2PAg;*5Fipg!=?PN#9al4oQHJQKK33}AJEv$t47dIkb% z7Y@&W{5(PBqpSUG1?0CkK!46FK3yv5+h`(U!$%#?YX)~6yn==|-mvQrxL!`_rAsQKucw|M1p`EW5n4p=u9 zfKCkn)z$CRty(}ug)-g(ZF$q3HHHY#64dZUWYf2?`jaDCre%y&L_2>C`QYGSqNs~$ z_D<68-}e9|nFHQ8sP^PW3gq$8fhCCTXi;ZoFtaqgC`$2>O?^1raKxmdsw(8r$6Hqb zy!O3O1tnN2Ik~x2bD_?yXvDpB=cbi2@5#AU{Yb#^0f{9!%rF580cKNePx?0u;_22V zQj(HL+DnkzZ)E#E?$*Xq-P)BDphBSd=g%K%xs0+hy@XExI@3lo`S;tOUkRCrJl^rE zt3N8{RZA4adG_p?pz+Pf$Z@zns3vY2zcjslT}Ne} zX`lC#;mY!GMT;Og$h~5&CoF?CwBSQxA7G1yzcjEjJQmZn*L{5Q>5~E|ON5SQWgkJE2ZHiiTA;tc zC_6!K_Df%Zk=IG!ZlsQ7^yJ=bx}vYIuYj-t5t+bp({66DK8m{Q1UC}XPEV7cwl303 zFX36iM|R-e)Mshd5O`#583>6{vMhfU?HswB%VR8>_&+vATjJpaoA zOg9_3)V+&5?q&<6_L+XEZ+?e9X!9+bm#saE%5$OFD!S;lsh_hmi$x8Tt>~N4=u_+C zmVtp%sEMbND|7BL&b5DTHjeWs9I?RKUEtcV|AgZnG+gGu0PBMNT@PPIwYITwG*Xve zU1Nk+iBxe?Qqp1obcjnF(e=j}S~@P~psiyv@Fsr*?bD0TBU_ z3I_UguP-bh&m)W0gif3!C;kLgs=e+(YQqJbWDi!s z7>}Sb)7b+G3JUY@2?I+PWcEn*H|O8({17AuAF-mS{9Q>y{uwdU!>Fh(k?+_eS8I#= z+xp&wxKfPwv);c4@o*BD0f|AjFlsW@a&zt{Sh(H^i>hjB8PS6|Y|m3$?B_;!#Zi zp1xsedH(r}7j7L=I}-=vC(^JU9t;c^91Vs`I2!45aAbaN6f-AnL`_^qsiFvXj_!>x zBpA|A$FBwoVuY^?Hag%qD<0b4L0MwjYzaL+bUY~_B_PZ!U7VQ<}Y-4SG7kVyq zCSlMGI$z)T3JwD`14A}hcTj0IKnJul*E7 zOnoK^0DyiuACtN-&0^V0w0Ww6PCL(|ZO=Przg~q~2oeN`;DA!yUm3|I^I6&;BHIk5 zyBa_Xs>r6D$@rcICs7%%Dg*ib&p|Fcmo9;swSTM!sJ%w_Xfs=eLSo^;#z9m}3_{5N zgt8rG$eYc=#z#sLxVIl(HNaxKppn{$l=Yy)UCMA(pg9IL_xY~6j77tGBxcvr)eQsT z<=Xz-Tfg5#2jbP%KhA)9bQg#<&evPL^@YY&+OxE`g4url{OR-OGlP)loYrYNy2&J) zS2&jBFj+|1F829zcO+or2g}o7Y^t~qG%kcN0)_mZDlQ!6GT(dyp}esgEHXjN+A4?R zCr506HXmmM0m zc0IH|>G>l(EH<@Z@RU_*!C&igKzgM8T~>RUrNXBL*=+^5zoFmo+TOh5AClAk)41&2 zJA!DTPi<{Pqp$YUnCioP7d+nQ=XVEA>sdrucuLdPOYj^>>laagA0>QZ{Dd zh1(_XZWl}MuC-WKK54gzx<4XV%O<^-$>?+}Q!p@akr)+8b;1&F1&oUP=aGQo)C1aB z?Q=_)1@2D0adSP=+N%l$?2vj1-=m z5<3DMNT9Hq)YkD(a;V{IBgIn}Dl$dOsqsm>oxtO9*1oo@ENGfxBK0=SH&yc-3UyC?p)d-mSZoXu;P1}V3vzaRP+^k|I>GP><^ zed6(*=TS;0u@A8;)GSz{;KqW&Cs}q2g@R3_-BG_}^GIqv>KHt_u6nT|9x$n0 z5IBMDr0Ba?L2`rm@WsL!O5hBQ5VMg#lP$@~NnqI;{ga@)`fS(7kaC5*_wU2nrev+H zt+T^1PEJlZ4GAw_&fm7?smeMU(34$Haj74)Fo7yw{iufDV4Xqfb6cAwqOM95 zXN?O5zX#r99$68*cJRK4WNzSNaMP3iU?PX$Et<@G7&m5t+G2VtwLn5=eX&fp)4(yW zvDO9?poPy4$_V;zdqQVY^w}9bi3nrxn7N1Z{B3bDadg$6y4BH;K@Z_SEs^m!w}S=I z7lS61L8QCf$c$=52kn??{)&_dXckRV{{AYM?RY(*!CZ0g0EHRWseiIMvc}?QymPs- z*tKohZTDx4jpafd^GAQRN&%PV>~w|}R~%Cp$>z}nuf03(va*n<6vFmE(wvZqMD$F- zR!_4zEU!uRl?iW~OEmN7{L#fNLVT`N4=C4c2uT4ai<*s%P4EPOncG|^dmxBT09y27 zNXAVj-&h$6^3g&Bpqk(bkC=z{tg|K=uRQ0wPao~Nt9h^07=+WDUG(KsrAnK-U*m=Q z1rgpyQmJDDI(+K~jpTEE5nN%D9!L*%#SQTBBk5`H1FD`#JujYnP$;{W-jHYYGbZ@Z zGBDV+a2V`4&w^X^pya(;h+q#OP##&^8l53*qtiFWX)i&P{>E|bXpg5%&XupbJ!bY7 zi-=~gWe}d+{kOPoEe|7(D`=F6)wub?OhiEcL_d&x`GFB|Fl3c7Ffa(NR5;(|4b!-Z ze_h5_BCVaM78Hv4DgBoCroLL^UQF(p-~&7{W~$~iDX}!=ygknwH^Max`WSo1H&e8d z2B{#BuxYUTqg`*tD5fnm_;@y$&@ue<_h*7Xl=~BhXI3dhPN&qBYX_zSBLD&O6Kr2E zhj1itWl-+Oh>Qnh4je}+Kj;tl4zKUb)i0M{`m^`UOORkf1V>+NZT^Bo6JKzJ6GN=T zeO6w9v+9_d0QHXGeOp{(eluYY{s-YQ>X_5@(>N0+lF!LnQ0BYIL2UNMIM@ItE9QwM zKZCot#>ZPEWM53T$qcewswK(A*5`{X$`AT%!f?_9*Bz8Zv{P`Hr8iTL(<1R2T`N&O zb(m8t2Yb73PEDZpH~)x;pKPwF5TjP4>#a9X)fAOD<|CDE52K?$0gQ|GTI}01v?V4B z-fdwM^jS0K;NZZ&SM1$a=(Qs{@qYgH9;vQ=B6waO%gQF9o-B5DLCQkhW5yixRUpRu zhP$myF6Q7{PNXjOF>T8U9(X-qV&*@2y9dRfb8L*2x_H>3H1z0NT7QCh*}4r+ql{UO z<+3sZ>#j`9=H@2lta0&Ah9$nt)Ztt(m2Tc7gqWlta3o%XVwCro?*+B)PyVZQ*$38_ z7V2pi9@6I(kCgE88h*TJ>y7W9UuNEx+o9K=>z^(`De`0L59;{L$x3zbpwSPL@Bdit z#PcH$Pn}01G?Sy=<6EO=k2r@?(^T$dvYuTQwa1DBP9Xs=Y_QaZD0<4y<=AeuVkRKR zbNlm_&ovf%j+(d53!|LM3yyy7?w8A*h9kgNCvxmQrnYdoOEnzYJ0BpZN2RiTL@|vc z2|`w?2Q-c;XsOLC-Xo{9JnkmZqiql!8qxQbDmEl7WG_b!=l+Sy&&%uV>Uwh^H01Cm zoSIr2(U(&_qR)t^%o1rmc;v}p>p}1ADZ(7L|4NtQo&8MySVd7bQD zns?F4YuMIN4JC@E_I z6T#fn=y-c9y;8F(4c6v-Fg!D`S> zjh_s*Y{P;LYlHPDtT~8_qhXCv6cDxgcKV8l$ZL?y!IJ0;uZb3d1ZZ}P)D4kYP=I6H zmdpC@=e$nP{sqKV9_(5W3@3ouf?NQU>U*LP9>}8-3X}<{{ z$V5JZ-m9%mv%NC<7~afr;liQ~v43pP?wW-`yqBRNMOp_31tY}kGB1HV3OF%6aGNpc z&ttPW>8L#Ml4{0;`1o_zt}){gl6Q)ZK_|flNe^I#Rbxv?|6=%Qn)HBm5?E^UWXFd; z`j%76TAOfJRzl`o?4diGM^AQZ%6#_dkYb2cA2p?gktGG49)tvMrqkPDR)&5?*a^|N z`gVvNOXLp1L*LTTd7Gdw!hzfctMBh;-Rq119De2H7s@#}FngTU{#jZI-BY6~*-GcXcmLkZ`}_wzKX76cZV3sA=ns*uGa2lBWv zC~ow?vtKhcRVFje*2RUY@@ZsbY4HxZoab`v|g9n>g<&s>aVeCkH<8>drbG1y#>-mo}3_+g2aw@s4jd0q-LH- ziEad9Y3AVOf(qH4tx1IXSW&T9|08(6JKb|!WWIyzXx=9M?)vYqplq-tm*z6U|^|!)XjbM&EdZ(HI2_*10YC(eWW79jE{nSh)H`LSrL6ayqTF{t~ zkm5{cLJ@>@+^ko(7W>bG-J$rDS=Qd32gwnG0(cjME~pdDAOs@DSU4HOw$Di_h;*@# zJ!Z#WUtfp6Flk*92)pj(B?2xw%o@xcC|B<>a$(WYB?y4(noucf8`XT5#as99@_>c%~3A!PzbM-t|+M_+SVQ@RoojbRd zZ+1jVM@P3GxV5wVo;|FAum_@v5LAYVZ-!d{`w+e9lH~CeY*ks6M_|$|`YwgvUaJWD zU>13CPWlA$JyKEOr4v}!z2}N~h2q+&62Z`Yw2X~MECK=DAifL;OWBb%AJcU}Q4({V zKxJvB7e=NSLF;dBY5CwdczJ2GroVsa>;0AAGc#|1oPuV)S}euQ3ET42$MW)pja$8O zHda9A7~(N2_vCx6jub%=D$3k zlA2mi5=L+ReQ~j%5;x$bNHEdC9JGXvtpw^;9F4NFG7|Q>6xdj6D)7p8pAk$@0J_vr zYtZ18*B>prfI|xY(>$i<>-sS<8COpzl7Gy-7Y7K;HrZT38>*PgvbgSdYW0p1H|J* zWD{_dG1Kh{-UDNB4#Ogu3yC=0DYb5zc85HMImBak!EuRAO^tqeNgwz4tT3E#K_=?> zX#9kwV)Q-};^~0*h4j7}?^Q6rB&mTqLXmm(BK3mJi+{t3v4bw!+mjW#Pl`9VvRFHH zoxE}$ObnGdAX!`_M*;aLG56mOSqU#evUq1aSOz&9vbor=x!MmI#%LJPzaDRHZd0;| z!{)yAkK}N=OScg(1jC2--XpleW&A1ZZzz|BJ2&Nxq5d}Xd=Q@bIdHMNnn{&4+jrkF!9VUP! z-a{HS=#VEruhZZ@tug{3E`twu3E+J&mAMWFNZf29l4=Fv6V4MPB-`euQ2?Fj;k zVCf-caaLJXwFO2A57&7HeePTRtBNr{GRXJ9!Jazju68t}y~wSxskugOVkx;N;1#x( zc1S;d!X)|zDlS6uwr8NpHbN7{dtS74Tl29+{k*)LcYFFuhPIKvO#h|Qmn#WQ`|taAo7!ATe=Ke*Znnh{9GP4J2_85Q zRm6V{3&(umAwax_vIW7@F`p@l#_=J02_tvHD%o(U8wpul^LE%ug>g zr5Uv*{E?R*+E`lvbQSEVFOTC00B1?^h!n$a#| z;E)*i$U7Au(KRQ`SHFIZ1KB_6mjt8fOE>l-pDsAsvJBXVODu{~8if>KbB?Z!1sGF> z(?F*HTuXFxt@kjGEuc8igDZYM>dbkcj#pC12*LgyS`PgNZ$T1y5GOf%R;i-DHGfJ2 zavp%H5C_ZVRS@CG1kNJWJFey+%Dg?j<*OSp9#X&#GhS?{OSE2dvA36#m&co6YrP~P zAz_{#`W5C8GCg3}pII}{A-%M}vs%Bj$d+=%AWd+Yo4Vg0B)e0; zRp2rSm;(CKQtVu(vPjFy%Cr9C09yguk{uI0d5*N*0}?>tZ$ErEl_KhL6VUCK@G}rT zL=M;tb_7L0E?~iqM|u3sjmOlI99QSOWYZ3i^cM&N2+Dy(4}XO!mf4>yQfr{d1VWi` zuqC6OD{mf@|1|G0oWrl&%flsRDH8%;CYN*x|3H8Y5xnJJzu(v|C@cez3>nAp_G!|A z+xl(!*k1T|@NDja;D$5W5)w$i;AeLGcEsG=9OkG-tLR-`dxCvn-^nnT-S_e!FY`_GcqsI;QAOm^s(mn>O=~YU$NE*;=z<&x zPiUP>M;=R*d6_A8E4QPuD)pPQ!+88RiLudbQJ0};BGv$u95J($-)U%ktHse)hPDI4 z83z|#21^Jaoj^HXDe<=6NMyTODt0C6qm`aM)iZ!qIW4<6&7q$kGn^L{t!TL)n${m> zmt2kFG~kn9rb=U2X!#ZX-S_DLS!`-G8Gc9sldQc!Xj;Q|gY3ap&L!S2)Q{ze0WVA; z)B*}tMfgMPMp1VEIro*E4F$Tf##^2JEVH(h*hBV(Y@XP1hT`E07T(qC#ZKb=0=zh? z2Ch}c`vIj?Y$uinMBR!>o5M(Zx?JmNK0wL1ocS zU7$rfs@)oJe%_?=b<(GJ+1|)rdW+he$~Hvm%CJMil5$w4Q-F>IiIloXQbnogAf-sg zs-sNL{+4`0FmX|#b2-+!-9*YU$9fJMd9=2+Mk%r$k#DJUXr85(76LeGGz`l2tzas9 zNxfdZ>OrTQH(NzXD|@}!!+X>hEy##N0u}EsBrf4x6|D@q?&X{>nG4Fng-4N+Mk6Yij(_Y)6TRC^x(4F zF_jvS=I#hdNts*-(diE50yiz2s^x)<1RQq`LS< zsy)T;CBqD?o>$#RhO>DdJ>r>(XV_bOO>`D3(p@6jAzWqf|xj5zZQQbGba(RY)~bmCf7O zEG?35`|B?*t&}c1vNT<$-Qh6$P>he*Fu)K%tDOWruMHw;4hzH&aFVV+A=)`Rtxr`Y|P^i!{&r)Fh^HqFE+b=KwLxc9{!y&R9+6rCc` z{wnjuvX~zQo7>VJ?3c;kddpVC(ZD&01pWsuz!nn=`HA)P^eW+`-PUD50}m|FvM&a6 zp2zi@1)ESYAO~Dx$ApauA)mYkAc_t+0CEaAFz_gMKEh=mP8xgwp9ne4Rz0&O=On$% z-1QXBuZSnyb16;8pCLn%RG=41UQvdmrc4MZvP3=n#O$CgJ4Q2!@|y?wUq%9H+s6;# zO4KwMp@=UJmHu^9*DlcEVT9hc;V&}^?*p8S@D4;oCEpQlb>P4=`{~=mQFSA zrsonl^(Nr#LsE|_u_6Ea-@`ZaEZm&6rbQaoS=H{jnQxks$4uvN94^WypMs~d(J5L{ zfh3ri@A|#YrKdb!!@tcC8+E&NU-4>{lJsv3WFMacs~~pcNnon02$yg1Z=Y}BL2OwV zI63-dFRR}>%ba^f?;Og;CfLhTKgnLNT=BCjWA&#r`~RKEG3NE_tu>}dn%wfcWn%K= z-`ojYkOM4HNa~Y=hqY+!xGhA&Xz2sdHY7g@*<5OE6{z}ClaXw#5a`f6IYsl&DI;R` zS&Y@4x}y23Ii~M_OV?o`Dc`YSwe@0K?2n5YS`$9Uj*z80qWPJ$8=*=PM7OVY>p<(yN z^*8Z|%sf_$90z~{tnqem*bWIRLw*Hfn1Eas{v3{xG<^G2BaMfuqAUki+TZ&6srmY!PMxH

dJyiBtpeuoms~aZ$ z<(WXa>i$u_G2f!)l`++V&&ZZAJFJ0l6Todxf0t-Dj&E{KWLEtS1zr~JDnKW}R@bEg zA%iRe=Uq1KBl%Dg_OqFA($us_e>IvK7d*7OK~BL|B#-RBQbhzMh$U;V?flVtyMTWg zg?qAC$V%URICeR7Oi&tV)A?fpcjwh7x^;(-!q*MC2u6R`{xsX%bA+KD&nqQQ}?bJMPd5-`uN)@ zC~m;1lZ3JX5GyJ-u#!SPYZImg>8Yl;jU=?x>KDu}GvG_A%X(MfbR@0#stz|KR&*T7 zR@}o4Awj_)Jr0hlr#Tv_FVh)!cCVka`{(-`31Jil0b7gK* ztsw7@j2Iha(RBvYKp3<=-GCA+&KkIRYxJWNoNWiKa#rS~%2~TGWD{I=Sb}({nU3_} z{im`2JGrNr8CU0E`YJ8$33MXIfnpqpdjil4i-XM!VJReI3L03O)XvD;{1FBSErQVp z(YYyLph_AVeRsx@BC6ZaWeVZN*V8-I6y1~(*DI^rVKHdJu>}1Ofey6W&3VJ`htqIVm#>uJYs-0CU zxBLq$f(z3Yr)2tvFZ@1~4J=2hpT}dNz8dzHiH>G2;Ed#uHL-PYXo0fi_Cur}bsyo2G29Y9K56#!m6Cwk^w`sxh4x( zuXCl3jcgwE+`ahh3^M#*I1!l-l7MAAFK96+aKv25K`lJ#WwhExXUSZh;1-kCdTZAOrwr@2S*yh%(KTN%Zf3ZL_@|y zGdja}$9b7*dB|h^(n4^3{wd^g3h>1wsa7FretY8&;^@WH1iM3BDUDlE6`T_xpR7__ z`0&ZwEJB0K$#gX2K54!z-;UuyvB#(l0!dN^V~T1_pyF=$^N}+UZ25k8;7Vm?a9H<$S)o3 zI0?92&s{eJeXenlJ2zq&P>my#Yhbdm$YE-l*M9Y>+lp%bV!JRT=(LVMv3P$;W|KSU zRSK0g+OM~Qag`%bVo`Ydnb^G3SBpJOWo#)N2LYI;`64*d&T z+s4fm6kj>6nFT*_r3@2hP$PD=iDl`;9~D)HCk-hx% z(!q^innm>w5D9{oZ5Kz(5(D4LLc8M1upPXHO# zjjk(^U@uPm^FhMUJTjgI)=;fEHvr_>nlMshdehmw)ES_PtF7)%8d zBbY*}*eBP$$tS6`<&+5Rgp5Tl(hJW@kyes_OrdY4U=XvRj)$)qv1>IO^J7X7Vi*}A zP{oZWAhu`{G{&IBY>@s)rma%h(tNg-3v~Y-Ka0vaclf#;m~15gNPh=j@}>HruC~x< zhmpG(mq)Al;mOjdcYv{e+Q~`3`0Us%x789WFY(^{G?Ax??KDizT78wngbVNuqG}pO zr^y^kYKphWxN97J19pgTXm*$R>p0@VIW+EO>&q?a>fiYsZ_Jr6(Dl7;Hg%kB2WzYQ z{ukHa@ijK`coAW5>&$0wca8$Evpz<$eHuxe!t1m@CSmm+U>5#0Shf`_ZqeohSuuXj)+mqd}c@M`iLm6TI5T` zb~K>4_cQp2;l$(QsCIp+^u4_uf#t*6o0j)XD*h?Q=g%%r%SAsp)LuCrwqejDT`jG+ z|Fg|>>sTt-|B0MkN4~&G{7ZrQFJB)syooz^|CNdV&e}SyCT5xN+QH89WYUG(7|KTO zI88&-)H39L-UqCRYe-rOneC3)+}S>2!)Tj7$2g_o@mU!Co!p1d*2h%m=zo1#WYay+ zuRky?lCoX>IhL*G8o5pRq{X*?*wj>MRoTC)O|CpejT+-+`_8vba{Oz%6W_Iyf%5?i z@}le8j|FC4u^q-K5%|1w!)!%F6FOb-X{S2bkRefN-|fskVdJk{OVhor_hKt*K%7hM zBKx;i#T8Y~zvKSNO+l`LdMbMRtAblCk)wtGho*{l*7r`MTYCZZETh~M5_V)2Dzpx1 z*EC*rXnJ{62Kw)^-sNO>(qHwk@=1t-(PM)eK#yldwsZ+x{YaCmX5&X z9bwE;=s08HK_ijaUXRZFBlk+r9HY~U%A6xxE>ZvdiX8Jp4-L47Hqp`S%gc(?$=TS% z2z_eF$gNiclDL+x&sa<_|Ge`Tes)=WC*LQbmK}=DuS2VN&Q?CefX4g17MpYVk=l`SWs-vn}v$zNX3Id8Wf+!Lq-7O#@ zEn(3q;H5)AN;(Cflt@b%bazTONJ@8i=j@}-S~Gvldh@vFp8I{fez8k2M}CY|)FqBT zGyM0Dul=`YP1A5Ua-~x^Y%-IzauHj-HeBY6-|~v-5vymUx%J)p?Mine_wcq>r$wk^LL(wHR;n9U98vgV>i0#y z8BcH09S$;K$t1EHXYKZ3hoTWk( zy*B6G7`+Dn*=$GF20is50g0w16~#ctqh4MIoWFngI!A?u-{x22ib54~%&Q|eMlppT z2s|OrvZYC9%J9pW^}u0$^~mlfU*qm`&4xzv;^2^~^S5y>TS{E)48EM-Ee7`_b;}mu z+PR$zm$=L;XgL`Yy)K?K{rhras%dR;*n?-%yy#cQ$bB)1be<}^h;$L_Dwt5B5j+v1 z?nY}dRwdYSt2$%usNA{o#pU?L?r)M8yEFO@6lq1W>scR)M+C&e#LjWlgt>X647w4cUOgZZbx7t^plu<$a>#yp|pj?Nd#kF{dMk57ZC) zk2##ud_ptZ6+~p;_-3;4zuljwQI6ASq@ZR)Bb>2}FH$IR z>fa8Pcv%9LBI4Lqw_j8`^8@$!FncJsvQi5u+X*{^~1 zY`LoDxFVbtK724!ofra-3H%j>4Kb4;FO(xPJ5vKn8yFJvtUg}Mn z)f4c&PdfV<%jgu-=n~UpHHuP)XkkY`UMubC)_!sTRYHYC(k9ErRi#f{4?R1w&_%0z zo1YIJ+um+^YyR&BH1X4Geh?2*JS3hQTdi_dBH#0*)z9KmSacuwHl>s9udgVbifj9h zgXV%l8I5njF24qO_0z;YjXzNio1HYHK(*AHZx}D1xU|Sa<3@4dnL=rB@&5El0lMgO zXVKN(iPhfS2KU<(chP^Db`KWJY;rdqeti4)(}T%V!jNl>A)T-`ekJo*ll5=T;EPGF z`1c7kUVP&D{qSx7#&L1KJ2h&8xqDk0EK+o#HBO=nXBD2KS}1t}42C}YU&@;<$J+FN z{|JFNC2J7-ogcQox-Sj}8{Q0dX(}s=llpi+xhbhMDUhN{Q;h#62Hi#L?^l5jiU@M} zpe7>ZwC*_7Oz$`C(Da-2WiFyCPPF^D=y}VLltP`yZ0x6^>lPts#9#n_87ghWe+^)* zyiR?n#Q#2IW9c<-^La`&RG2dG-)skUP5?Zy1`@tFdA__3%wn*#k9s1D0a);#E>`4r z0%7jSwCLHL__Lifkf0_4&Qbd>Z;AWq5Bm++&i}627CQh9|C|qnIYWNHJkzkFQLG*D zn9~=Ad#WW_0M{Y%(Xs8g{f+Jr*D&CzxnHH=*~qYP2?S13WT*2SrdoU^Y3*ukY()Fto91K9NDs{za^t%!z!1* zA!)!tb^#%nBcGO8Jaq*$K-!Zr5{w9g9N|Fmjyc=`)*TN5xB&#n2rmfh{QJ-1Nc<6U z2Bxb|oQPzYZb(~FeQyYsG7)6=kdz!P1roxbX_{=#WOmQwu- zAB$@7zXPLJp4(3~EHbKwf;W{PMM4)UsBJ8Dz8T`y))6cC613yoecay9c9Qi>(AeB3 zE7o0D$DCZZLgRNFaia`ePyD~k9Gf$*jFg0Cb|`=i!QzS>i>9W8HlSXzJkj;3H~(*6 z!%jt}|A@Dud=N02YQSElV1g*a*defdACV;hB?I)fj3aB|&$VitI?Kj(GtpKT4yy#` z`L=^NyVdfbpRL{HDKxfuJb&pY-whv3BO0!aonFP>%A)AUSj9V(AC#Ie$MTK7R)}_O zB`r^_tPBQGux+W=-(nJ*rh#I9q)FUQS@q(f^4h_>~^m395;mqJ;T{Pbnneww2FJNcwcW5?YEk@M&q0Cpe~so#ZW z(}3gZ0Xpk^*s9&&)X7{lQVVQ84PzYqI?KW7&(#S9k5KPzf;CutZSV+5FOM|RnB6)z z+hw`jHM~&kRPE%;j@I$gx@6>?-KZL4x((m@UCV#TtD()ZHPQ1Hspi5nnav`%<01sh zPD)Hn?0lnJbXK1+^5(bM1q93VKHeEuF#SqT-e@)X>F}6eFxUNM?%wg>7h8_U?HIIZ zrN$pV?^Dg+A3LnYIH}y<G&1DaRk55YuTu=~6d`{)0BN0ORlBI4cyDQMY&xAHyHL>W1fb5T3L`|&FsOHt zbEeSXRJ#q#Zb~2qV3i**Xi|)T)5m@sFcE?lK21IDZoVa)H8?LcdK}6?GrD?o+-bi4A?$K+1uGo#x`R3ka4~ukh}(j z5iv$?1HTS@CG~P+b~-li3E`NNz%gJtR{_HU%WKVf)*0rRr1}eMYgDVP#J-`561)Lx zwmlX5R8p1GG~b-nBTcXMpC2!7@_oFOdF=ZpyKygk!C5c1-6tO0tVYCZ*9YT4TSb;;{YmEBon>KNct@lTV4xf9Xc%5gY!D)!9{+7sgX=Zi!7{3<>^6NTe)ca zy$7{ao1PV{m>8QiRL4&O-n$l4N7r2|rnL>xZr*QT@>Ri`zjgoWw@=*vHDe|R{|RPR zC+g6c1Z6J?Pff4%&=FByLE0cR9hE*9)2iIwxW_ z@woqOW5w|!7m#GkMUS7*0VTqDNhN;C#ab=ILEe6In{vgQDFyOp*RfyDr0~z~Y93S) zH(l&2bIhT%QO8Ry?>HQ6<8j_eO#eb-S$sQkwokDsd6!5b3*SLI!*`c?4b=zisX85Qi5_0N-!iYf-v^ z0PdB01zDR>oz6Zm#|#0(fK!C;T46MlYnZN4^6{HW+7^hVH=4?ot!g)ne|?z$$mL4w z+2Og_X{K8E~zx58;Zu-zfYFIZX3`kEjN@cNHWrkNB;+`0tB7XxhYLVc_<9&uD1}0lIO8`pa&a+zINChm5ZaJqveN3C^%o&)LX$k zM;x?=@89EG>06iMEA`*|`yvJJ_JjNhz`)Btl>P$NbkSd{Q<#PAcDjtsT|UxWYrWSjlbSnj_E*01xE zC{j(YzaVhAGa|X=bpL$AB|N``yPvu9O{2 ziH`j=Ca?)nlB<=k!)4xv2?^?H- zY>GOi!14r6{4oQs%Y74WDSA{n_eR6(gC5cHYB$$;jh2g_KDftWdl2LjE2v={-x;jb zryo7uv+0&3xe-j^MKf&N(n@bRM`pCu@*^wPxLdsZ{=mORnGzjpddismO|i6NVqcmV zn`gtknboiT%#<;C$-2&-vQ*4yq$=k61y3tHnUD3qF|pAX7JYiIE0V71i1Yu% z6Q8Gff)PcVa7-1_{ZhkpXngd2K?FnaC#l>Q{Keq=XB&dB3%aG$_QQ8FgK87Lf%DNzS)=FlQF1<8 zxf~aO*ioDQGSBY|_B)a|w>T2FV|B2V5JSDUtEiZhW*fjrqzTAlSXCOv-%I!AGcDg= zOtF{x*A#u&v$k5$;P5XeFgT8@Q_^`yFoSh8`AYL{01Z}$r%~%0iqEoD;+G!3oSqmD66PTf*x#kmhg#8 zqG2mQgnz0R(*L@c8)9sTQ*b*3J*uB*YPKg!6FRPy%$H1f*iUF$6sS>nZeLlZ6eCrB zuB`|yiPPSSE>Ic)jf}EG4dl3k9*SKpDeQK1JBO|~KYgq-M_SC=dtg=brJx`jv>dDR)!J`xb%>1^WxL3rNB3x#tyxw4--O9Rx>2XG{4#k zuID(E7Y)|xZXHvVi7c1+>e+6sl41?m$ea_4nW_booBn9FJ$`_xrbO%HI~>kI)mD6Y`ye^&9A8qj#lJ zuF7n($gjF?RDaI@G@nJG+3xgpapo{vj=U{g`Mz552NgyB@KwRWJd<9!Li3?oFcLC( zJ=_FWz~7GlhHIN+JW60rOi)`((ljE?u1VQlA*NG zfCA9}dDU4M!di~)%@ASajxX9I~9F= zg0U8Egqbd^ZQtKXht~88J~qqNzsbU4Hv48wzh@#gKjFvBj=QY*jz_~IVlJLs)V?{7 z=?f{K^n(TzNY-p-!(6~ekusbW0$Iz4HOqhZ;<0f?$djIHjqI_{iqJR6*SAn%p=XN~M2WQNKq#~Bn)>YZgYN;k(hlMcyjoy4`4(oSq13iCq_(4vSZ$mRELuRKkt3B?}#!MzWJpZP#ci>hp)W4eImwGnkat=@{;exKC7M*g-1L zA+#-5z7LVFYpfD((wpriRMsYNhE$Z;BLhl^RNJD^7x5!7EdE_4Q!+X{<;v4CdpnPw ziMJD#@xskRMsf9bBOefmuhf)Kj?wQQ)!}P5VVzH0>d$aj>GVkF^wvKVX`~|KejIo} zQ^B!bQ(F5>w?p9Zj{!B*Yt-`BER=zpJuhf-6Ot-of#(elh*3h09N^~E7Rwuw+oODW z>~HjnnMm$o#uGnZoIUiPmbP~^Zu!J!a=pWI_rv82uS+)3VIow0@;X~C(G2I;E8W(P zSkv{lfsc)P9Os%#fv^5%Iu=|(J7^Dxm0CdCBlFUc-<_ROL7J&ly8nAxmf{ch@KZ=9 z#LOB^U%YV^2Xnn6=3c#7TQL|dwF57{*QxUHk2E!JZZpl(Yg4WJWyoU|JE|KyK3BV% zOHvY~_V+eUIowKAr^FDR(1#frefSc;jnPJ1Z%9v{9ohE1#5Am_n5o&w{_VY@tjW3P zF?o9-f13{3waTd+`oZp-go_ul9yt11HyWD!FCO# zaC3Ebo)w|xD|i$!c59qE*`1t@KestPcNbif%j|tc&05~oBs$*LT%xyv9GeFWA|4)I zBumdl5Pw!z10D3ezNb&Yk{aL4cG6W$2k*(||I4OU1E_sp@R1}H(7pK_AXB^?FVaNq zcBF1P^oBf;I9^JJ<7D5h?sUJZX=UiH(0Q3QuylJ5Bi+hAeh#H!yUP%ox%B3mmZyCj zU*QW16=h|P3HJB>6~EoyTP+lJTq9L^p-olK4pwt|Kum@q12_sGI}Xa;tm-xHt(I># zpx~+Ehf4)Os31-$Wm)~q=3mgsX>no=l&Uu_u0)mg7IesvRqLo;Cv`h_+1MT*3A&

yP0bf&B=^f zeLld0Ejg_W%Z%$0Dm~D|#3VJP#Jgy(B0T0X8zMIa7wqc%Z@oDCc4Hxddyd_*hcl=1 z;dP9@%0AVPR2Ac^XV@I=snpk>{CQAz@(%t8R_zWD8oS$=H;KR0)QmkbXLyuk%)I|@ zo47(r0*%Kf7uP^M+m(Cxfg@uWhRzMS`@W@@ESI%M+veJx;Fo^sW0QdUV!*!7Q|Yyr zlS4>V@pL(B`fr7cMRla|&<4t~s<+&Y)IfO97hs4t3-%F{?pV|YAcmQKRq-!HPE9n4 zj80|uzN@?DL%v$w?RohPI)OTyK*@WoiThqwH4r#xq1>ne4x0u! zK+6p16yt>YStbAdTm-bXf!!3T2j9EV^>Q(L?v6V|daZv-?sIOi<+CrHO3c{U2}KPR z=Y;N$9w>aD^X$IM7cYC%Q6b+S;`G#Sze0*NV!X_0Bil7UlEh&hCnQQWlgPdMU}w?9 z(31EyYUyjnH!ztzMM5|{(M>^n(6FdC8E^no5sKW_pZH!{m}eN+@OC(A^gKdh?j?g!sbW4%w) zWbow5RB?1quJYSbn?~DRCq7VOPrw}4sC%kDzc4@Br1w>!#kc~n)7qJtLFxJ4(Pmy* zQ$_wpJ&e{brdW1dmt=ngW!|4~t|#Cq9=d$Q9Et(_)t-SBX>sumLQa4=J6^n39U7yrzq=F6njBJMRB*Ypb75tk4$-&)>kn%erm*iKd0IL(q-Whlj`Gd1A567XQu*YsY{%^eH2DdD{H|t~V(H5ETR$ebHFEKE&vYrSL;oAmg zFt5;S3H_g{WOZ<}uq&fr4ptN(D?s?>5yz|@oL{hvqbZ?gm=t7Y3;}$w^TAMg`*Q1D z^xg|*dKZ(TL^utOY{9J%vz5yA<9lXq=LrcTc3p8yqnlnlQEfg<_ynC23;^5|aX03f9dk$KxHt=_K<%^5po5JG~b|yU?uw%mdS45p?B} z@D)VUgc)YL#&$1nT=9L*?{NXUg>QSMxqQ{Es?)-?G7bbE!Q11NUdyiMTrr&!E|@>8 z87S$fsqDss18A28Pb{6{ZW3b&T(dGpb!sZH@dymAr}Es+1lwSmzk-a zz6v378Nk*viJLy&`U;WF9KkCNFEKxxJwDtqsk!BU0l@gC^}?Hu&D|`wSYWv#-XsKm2Yxn*|UOY+sOV1E`tJAAbAL8AoiMl15 zKog)Bv+H%&kk3d--vzRK@Lu)f6Ao8Uk34AKJa`_mLDfh>1mf>ogj-_LYgoAqf>;zi}uoin7D=VrFFE7X8yXqb*;9K^@09* zmdBCQGy7vM?1AIYd;(>Z&`75@I<6V!VTjQQ%cx23m!4-DO8qA?^ZEzXY_`}kCD7P) zq56ZMla`Va1(^q8Z3i^Hj7+SF)>?P_xclT{*sf)L+#O@dNEKX{I{h>qF9MBvp$SXW8aH2jheeU$$b*R{8$HBPtCl`uLY(Uh(m_w{pNv~0$70y9AV6)$kWKm2M(a}*{CbxI(c2(PAqhmB=-9$nPCNg{u zj*e`#s%t_+J^p4C1H8BL_99QJ4yFP}Ac{Dz*~BBv?7>0e?-N*8#{O0#if%_L@YZ|_ zBJ9hjZ#skF#@q}j(tZul24iYJW^uSwLVC8CslCzgqijR&mQfx?l(n_+XESwuNC(G* z0?zrtJ#FeQg!=80`qWP*>Bn0cjXIeq)tq9V5n$m<4hvq)@HY+G{Vc7*b-p}pv{9S) zUg&%)(00}1Iyz_SB{>EhY&&J$eUqm>jP^}t)xKkooOk+(<_F%X&u0&rUXKZHz(9lh ziii`^-ywbM{Qv%9 zO5K(ni6=C23IZ^01qJC<;9DEi;sVlDFx)>ZVm5VnTBazlh?ugr{`#i!GS}cTLRyAd z5=~_5pGctSvZUg>yu0gYnsOsVc#jm2?nNuE`>$8{Z=oioM4jFH=RTc|ez=U=@iPBj zoq&WKre`XxpQROX+It|V<)Nz6Q z>zC^c5{6-jY;0zdqTfm!lSfKO;6p>g2WZ1Uu$pb3#kl`_G+t ze=?NsEQ_kLy;<Jk!E=h`(pZ#`ERX5e6M*bMBSDrSwT|j^SazERtnjpnNq3G@n1W z-$0dC9ra~xoosh*LueE>AzK$^EM0Kl&X|#5gq>||z;}k}<2{U>-xgJ|RcFgpbBbp( zihN+9j0_v`=1i_KMYmH$OviL3j?%mLGCg=HBTbCy>-56?V@0tY8Oi>%S<%BUH~u5xfxQfJ)gxLY^$N-n-8Xp!>; zsg&v1hyqw~AQS(smU~)G?N46vhb%3Tr^?5w6}$07OQPPhlbiL}ok?vN8GL;lkK0P| zs*Bt=JGE@1V)>XEcr;Lg_?SeI<`kxbj=R%$yv8BRi%pj5AA z^Q@n$Fmww`VT!!_Ou+20uNbYFE%sIB+uteMeGMna%uCH*?A{d_GSKB(8w%?3d5#Mm zU=L{7LtZqs{O((AOX4x!K2d>^JxZT6Mh zH>n&Z&{)b=a>WNbiau~YUSJu+;-e1R3T>&_2cb*%;9wIF=Yeh0_*FaKCO9I37zV|0 zXzCI5R&vl(e*5Mhe=IRvMsjOmP`ArH5j_;nT54A6iFXEzULm$ zq*ktoxo9XOJD4ZhxOaLj=SmM7*NX)OYMI^BVW#-t<^2hbm~`Gfv^d<3$h>vtgE9N~ zL>H9cd|ciKRF?4F%jK0=s?P5wxSd~E=iGcVx`9@uA>}B&qm%f1e;Kv`j#bB4;1~5L zhTm>87%W<6&R2*CwzbXg9UH3|t8fZ6q_t`T=ldvj8#-{brwwf;knFzZBHwc8d3Hoi z)f{1?KtD?M2O83oeG*&8dVxfF(9N)lQZk$^0Ndf>zCUBXOgzf-$iaacN-D z=G&E=M#LHQ&{OmPy>fqa{pu%y%&=Ng3ChO7!7usb9ET(pq7iP_un1pEDG$5N{3lgB z6~IKx6~g{}$H;!hWHiV3F_!mfr0=jq+4)<8jGo;-$#DBDu401u(7nAzY70YICz7;y zYs~PcY$!aPk9!WNJdDNTJjD;&NAJ*vjy>^Re5p$Dr9M%VDvzC`Mzl%2z?41&NK4>j z@F?ai##gL5Cg2Kkap*#6a6QJD(RxEsIR(CkDlhe4Uea^ z{+T9E9n4l3!CC|a>_jh3Kc=ut`R&x{aS6v5Ohvp_&WO7{)5D_&Qpz} zbF>2jA%?5x8@yGwAu&`^L|QK`_F|*64ZB-2OpSRSCB`=nR=MFhMlMQ}7TMvg3q{F2 zHf4sg6D+FWSO(|+u4gkl;(Go4N0gw2)})aTbz$S#vb}LwWY=FJ!EFlp1#?qV%EMa) zC#)TC6NJS+j4%gJ*Iu+nF$2^D!S&`lR_95a8EbwRfL%b=F_^r5Jr#0(5Mp9%Olo<8 z*a4^9Kq!dD+If66SIL9J(ZkW#{q!UrSI4_dl2aY*;y9oCR?YPmIe%I@Byg0cOX^+J zSbV0eU&YkV*1*$4mf^2yo!f4V6putU^B-Gh5rY$uEUk=HM8hAB0_HZD$V&lS!}+Qs z*~yJptouIJ-x*P`k#D)-i^^4@fZHCo81nrPRzR_$`XLhZDv|sl<+dZ`JWVmq;5_D} zXkVEHcr*$2%WHGJLE#Hv!U$0<(E44Jm;fiO&dilx0swQ_B1*({vH;bIJ@1Imxt z)ZBC6nfXlk)2i7y#mW%J@Mc>(3%vY}vMj>WQx&0TF-FN7jV=*B5Ig${0%3Rxv*RmI z*Zf22z}!Gu-fs6rm6ycr@PD!UxADDEtO~;yS|Y0Z3W9H3GMTiDPE%N2{ORMJKY}>R z7i`F^z_WzNe7oJkH54c)o6P|E`&}|;uPm{}$)4;N!l%mZ)t^ZUZgGn-T~Dr%oE8%d zy7KM2M>FBli@Z|*^8+`xnzHe2Jm{;5ACZLxJP}|>7v1ZSH7txjk@h{w{aF18Z2(pt zz6Z-FD=;+Z8SZZY^V5Z;6+Q5#O?TY}q#dVreC2EsTvau4xPPw_-&!T!BZq; zQ!klb7mv$cFPkRxPsulRpcBNO-xV9#I*VPGO;EedJl|1Td#eCeoNNLmW)t~xh?AAj z-k`ph?qilnP_qA5wpJPl?s(H%f%BJFKKKTu)ctx}^m8eLm+tpt{wFWR^*^ax+emYB zC967nO4v_9rBV1fMOHB}KOc9sI#m8%$)m|~YL1oo1s|N)?YWL50A&Ech1sI9#k!8o z@hhGpi&p@CBmEdu2|@jQ>p+g9iEh8%C}B~>rUje^=}$2ZetL=~mJ>R{pHAk(mC*~8 zZ~XZ_jfE2CtevgrUp}4N(AFIO>(Rlq=!xc27gg8pu)VEK-R!-s$5;{y%+%dhy>>$i zyO<8Mp)Sz{1K#ea9Gg$s80)tpJu@{o*3Zv`O}PRUU8iKo$sb?|H-9M1zsUc|9erf0 zQ@b$m-mBOdNri>mZf>C0K? z-E-$l<&q?3eG%F|q2rHo&a2*!If-oj7lJFW{O9q-gG7@|ShF%Rgv%3;ALy2C$j+mE z=R52aoX_sxi!yiRlU|^r4%S#$(_X|RB`xii{*d<~|K8nTZi|Xbp{amll?5|C?ANMuN!Od|enRPGVzY5tj#WyW0_tQwC|Yv~LK~*8gOm z`kJ}e!8DfS#CE8ikFVO^;iiRhk;@MaxYPK}ndxA`MD)Okeq2opyJ2zjDrWgzY%UeL z8l&@lelA{h*UeU56N~W%dQmHOPNN3|k8wPXjW z2~vnet`7A*-Nw9`+~3n94iaNnKqU1Kl=I868|()zdR!1ozF=7A7p^c;Nqq^-48>V2 z(ZPnQ(`CiOF03s5?k@x>&@;pYcef-851wT6L_KxsD&K!-71aG18huU}URo;!_eT&T zWAaKDCk|(`UGneWe?YB!JM^;Uv&8q#qko8}KM&?AAc{YX+o#G9+O-Q1J?;&3v^`|{ z#5OZfHP)UIDMzD%c~?xiFW>vwo2%YeoX$m4wuEDx?St$qCoUHSqQ?(EQNtdTIS9n|q4~Z>DKPzfn#^ab$$; zmm9HD^w+2;3bp2S8k?8SUYUDNCjQh%S&96+rta&v;@`89!pE)e7e<)!$im=m@RQt2 zMtJ>lFgaU`qZ;P5NQENFl&2LWvmIdW0vbmuu&0n?V5MG;{2SnZCeYIOC7C-{EpmM& zKnXvplg61S{GIu#6kzNqYXD_r{iK<+YT;Fzzt2Si$7ccF_=SGc~+p!W~R&tYrBYKBv!79 zVSg@WFb-Moz0z0;HoJKm5vNf0!(t8qJSf^ebNl)nVWuiXf3EC& zJ8rDTczO75B>no)_SVmYkE;pkIWMkuRIik5OyXAs#tPn9JJ_-?Hu0%`XP;WcttB0P z{8&Zink0KliXkXIt--o^v%_8staol+fb1^>D`Y{F>j4KEhP^zaEr|}=|B&2ZE>s5a z=@))5urc}8UMulq<8ny*`t9mrEy-BjmK0BK@71c4+2!)%(X=E6>3h>NJ)AF=r1I!{$4jQQ_MSQ!z0&Nvf!b1>Apo4tNT$c3;nRL`#{;UsXwyr`VikNI6n% z{!5W2Wgg;?3&I&jpVswLlbJ`i`CKHEe=*+t>Z=4(fs?T^CdcXaB8R;pUI#-%`uO5S z@mHPPFXn;FU0qK~I1$rG(lWu(ccSz4jIgERUMY*HUFH4~1ohXb*MkL4yy^l1#%5+I z09)?0M_;b}aCD>w2N&@sVDj#%2)WisoP_>`fiCoN&Z62sWC_m)5Y&dN;XdnD>@`B% zmQ@y5_r#Y!^jPyv2l=;sJ`_1yK6mmk#Lt@lZqLhM)Q@4QGo5_>M}cBpp=x;u=De^B zW0zR(A;L<-Y(Y0dDkk4|8i!zqB9kV*K^L zl<}W5T?oxWk1K5Jr$~b%o7e-xyUufpthWOuJAR-09(`65IhphhlV?b@y~wvWT_O8@ zZqaq@dQ}LeX8t!*GuR2i3spYiRHnVum)9H*XiF47Op>rNgBL%Q^XmqfYTL4mo%iHx{G$$9w*T zvYcDkfCjNog|t`8R|b3*v0r!Q7?1_!L4--KY{`-^j>E}+?LudRHtFhup`s@T^=+S3 z9?@aUGk27Y>6+=a@f$^f?HR1kna`+j8p_taqh4rk2v{bp83_mM8tPcp%P~Y zidnkHJO>>W9zmXX$P*_{|T&Fi-F6YUM$jp!D zjvLoVE!Z1AMB%EWRo9cm*Xc89>8=i&Iq&r|u_cNh6Rf}8U@>{#fxjlRydW9!*)=_2 zA79kf)818n@4w#T0;aL?-+~vwzag@fNJJEzJBV2{nxF?8%(0uy%}Cc7n<3YuNa*EcQ$xX`l}^r1A!Pf5{}(^73;zKBD-=A9niTVXHLmX~BZt=a z`3*_0#kSAgAIA9`f|X@JWtcRJZ~5`T;gsl224A{rruw_GBu})<-o?hUR~^->(J5Sg z@m5;6C0tnqZO^`ukK!5zIh$lnw)OFS3T?Xz zGCX;;9X#rB$X{B|k;%miL_zhxiL4KV6>)TO)oQXp%|T4&5UC4^mP6u6;~xO}&Rm7) z*J}CF=lP_9AYI~<+tSszdsn5rXX56VV?N&3Oz-c*@A|c0#J$)PSbkS?Nd9xc0<+5&uAwbMRyT4SB zovHdTUQ;_? z^iyuoJr+r`!?-sSbT{Q!{Emp0i=Ck8!I}l|Wo=5wD+n+$OK=dwEz!x;rKy;gIc zI6oV53fVr4IG-tH<6aZucRHxXc zH+tJJ4fffgu~r=s3)+WoK6kTYamVkceN4;2oh(0SbT5=>tVfATdIv3Fq+0x?37LLC zWA?#befjZN85qmO#Klo*xgHv74BQQu(GAiC{yg*r&^kARg(qe{q5U0BcQHXVjG|lE z9=BqC8cS_Qx*bM3HlhP%O$glk|LA@&FdOYKGYGHPSUnZZeca3@#^*KjN|*Ou`eFuW zb6;3|^N2a&yFevkjr#EC;p|Rp;)V7#MOE9kBQ>4bIXj+)_3sl*Fz$0_;vhf9CF^hEVVb=CQC*2~khMUCTcoQ&klhTGpwf_jFw49KpDsuJ5x zF4(}9nQf5lfgZgx7d#0)ZaqM?1LwXDY=!HAj#Lb*Y9G^uBF73Q#IV_HacRk8rOpyo z76ER`3A{5{Hb@*!Mu;IsfH65!w_T1l`Kp93Sb_jUq5&ls?74pI5J&HEjD07j+Cv%P+#-gE9 z>})A$7n8DStCOXTyS_5i3f`%d@9(J;T@%zdBnjq{5wo&lN2X3tbFv~p31k@P3^y#! z_bk8_nA7ddSwVPLHB1@s{zu%r>gwu?D=RRW_5}ZkXIWb95W`=B{cN)V!gPhDA~1u~ z17j8mDhWPxs)oSUx~By2-GbeGT37Wl>aAjErV9!pUaTeg`ypQlD?l}zD5HdBm>$!L ziPw?vi-~jo7CUW}-PntcSf`t^XX~%WUY2}hI*Sjn>TX=Nx_)Iq{+&gh;ZN&jd)Y4q z`e@Oy4_D?#Ea)kU8(=#T&x>fizFFTZ?obHl#h4kdUB7kWC=; z=t6`-I1AwI3RMiDFc$?mIqa@L*!n;=eAq}J5?1H(A(TJ?d3p>nJ`RSIhqgGi|LLi& zP279mP{00s#G%)Ow%j#Bc%Qt&>E;~k=Z6yy#0}F&o_SMU#7z2G>yn;W0K0vHe!w1) z&TVKU1$jp-C1%J|3+Oh`!^Wtch+c8h{}y}x^eNmkvWg-gE+A!8t|1N>8z%y(4Tjlp zAF(}}E{edyD{=}7Mg|7H?*kA1Jkg{9J@&X1}b7+mtz2-$;m9sDPM6m*G`Fn0YzV2hSWmrX1 zyI(f|rlp*)o$R9ML<>_Ek|&Xai(E4h7UsTLRf9S;yZ@scT@;({Mab?DBf1B>KJn%R zAU6!#!}8$6!`B{`xE~pn4BcHR2WH#ya26KbbEmASPDDdEkIPkxHyc!>DY`Oc33jF( z@pv}sy$?tqd^^n?30_Xf2!8m6p;)5!e$uAF&Sodujpj*Ix#l~toqg5u=`z$Pnz+@z zC=ml7dm#jM@EHcT$1i+Y;DZb24z>()fbAfaYN{#U6!BZ+Mx@W9`lSu>hBpmb81j)`*xEpAcrO=+=E3jeCs_#HvWZF5+o`|Hfh_?vCOt?-8Jj|UC)OqMTBv@<6L z&U1nrU3Y2wqgqFBnAp({8tx_%T{$<7_pl6Wq7M#NHn!LC+1WS+bz`piXz79-tXhS| zy8%!Nq2+$50NoReFjdr5n5-uMd@eRtHO-ISSecZ^wAUqA@Ix=uGt+Gj=jciEH~YD? zJ@OyKBh#1{%k^cdIejO00oBL_ym*pC}J z*=mVa9E`(ZWV&v(|4kV0*pwUxoolPB%fftm=Ny78;*ti&@g%5$OhZ^U35R0~7Fg*hjzZiWK_+ZUUDH&W5mA6dvJ4E$j(dbX{Ol5W4)tJm%KR(6U?D z5_#j2BMIqZsK8~iC32y?m0!h~bs<#FL8z>#&XJeXPt0i+E{v~BI#C(O`p;gm5Nk?- zdk)sK7qgAKZv)#OamhsrV0fSuh?LNfCKWW0O2G5d)&e-gc<-Kv(CJ&gp@3hwB!2=w z?bL^Q+Yp14jsgRG`YyvKbl7#%SY!iMs|-Sh3{eRs+tehR2U+8U0$It7y_r&JgO%aE{YsBzg$`MIp1whbC_am)pmX>k`}{*sn1FD zEvy~eLOPu;=;6YZI6<-RVc<>v4$h4YwC>_Ob(jLfg0yp!LB~ z8Bx7~f(|Wnp`jcr4jo2P#N{`vuf++)bK z`El?A5a30GtZ1EqNdh9>cqe)|g2@YnwhnIxKmG3CAA8((Xev73R%8rp7 zh-r1Sk?Cr=^oX^zZU(hEJn8Wv#NqwM!9*dT6ma|(&Vj6mtTcrb0;4OWhk>Oz{~_xO z8B)L+R0m2Jxpn0yBr|qx%@kipjla1*E)uMfZx+Cm={Hp@+}WyLx0@z<%D8CzdEM>&_&)~xQH*fq z7{HqlTlGIOQ{+bl3exd{5j{4&P-3|HI?2>9H|Dbe+b)^tcJlJke(rOB+(%D=W|KsX zry`cx3b+!EvE|6eS(EeSHto+>I}bM%wPxo;?K7r0&{}*N7Jjv+EuPDs&VNsU_e|9 zO3lN9Y#{i;V4DMKPdbGdz6TnOvPz|y(e_&sq>r7P1d+YtaRWz@(JL(WvB;jPj&#C^ zKh-iGzZxpPAL%L)9x{8j;pYHj>r>sl67AD;%NGDgi13R{kAqaaYVT@8}i9JtzJ9 z-j@Q-M81CYay#+G87d)kJs2gCCJvsoi5Ddq=)FPLsAER1>bxZ(Wp?k{ZwaIU;n==L z*EnpJQBNx2=H{mLLw4j;$!mW?8XLvz|Ih;jipatz_Zq94zzjnsKY*4YkpT!h=((L= z4LGFX`hyr=seR+&?Q5$N82eqx%8Za4U<^17>Ux0tpQy_)vty8aXY6UH~ zkW#u!QMy68y9A_LM5Mc0TDrSAAks*9i08WJ`};pH&dj{fIp=f7zV=>g?X`%5k)QV~ z+9KWN;vO>b;>2!o`etqt__<-=ie6wF-z}PZgIpJrk3m?A(q6=W?kAb$j_p+k8kbXPaGNsy=28(d-3mJYNhQ1}RlKnJuPv z0m%b&+~+*p!c4;_+48Jn=MJex>z>t~fwWkhgag32qzSjby-zz)CXL1 zVGTaE)mIh#I+mPr2{fGtYa`I2N1ugaqvaqhn;fhQPp++v0dik#(lJY68`IvO2K_9u z=~@VEc0nM3^R9ApOA7!7@@r}mM@LlvN&xhZu_Bnj+LoD(&2sYVEASp}HnW3+!-6~F z7~WV;{+hIyBeMz~AD4^)O)5xc6=gUVSe`3!|YJ4mL^!x>i#2 zM>}4E(^r+~Ip#TUS&}0lRSx}6O=B^L4<&k}PZ8q~u)NSiLRg!egKb%nM2$A` z#ogNcLV zJ;-+g$*zx^IM&9zsa4)a*|m2`-wK5#;(_!9>e?~@hbBW&*gi^jFH>cmUSm!Y&GUjQl% zX?=DL8BdUny!U0H-FOfbB$oi?WL_-B)gs3DKd;VB)})IG7ejR?!-U%J7DnV< zy``OOjMoe%vXnm>Y`uBQ8~Qm|N_QMPvzV&Bjo@vg58>JCdaCdP9}y~%{IcH!u+CTqmFf_vE>e?oUzzPZJhV2Pwf;`P$iwzkjO$7*Sexad|npyc`Ylytulm z0e50@--Z6G`_VF)Zkcq-$+d-L<632D7FQ^^Sl(-3euw&Q@H~4w++FEbnjiu@W?(@9 zod)2CRLxFKOmKD9C<)dE6R?@OR&1Q5MlZIBoFIdCKbk8Pc->T541PxB5q5M(opW_G zOo9ALz}iTr=lQNA|F~ZxvL5hy>Pxk{3nDXlT<6=$-{^oHe@9xnc>Kf`v4rP&ic}l- zHjHl)CaBT1|0M2M=EIt#euk&SdVVrua?_{@?de_yVI)c-L)Y5vUD4hO8VH%JC@x`x z&FXWQ*+j^d&@0}g9fpdCB%cdSenM;UrpK{|FSHPr5y~+qOKE-J)hM3E5KmyBAl-Kns%C8|9|n{d@C=h-mNhn} z2I~O@6&1LJgwU2F7!N0WzSfOyS4Hana&D^!WkdRunF=IHp$MvG?e*nx#zM)6#ENbMqwpOa zTnz&*J@=Q}OA8)yV};k{WA#$!iH@3DCs-651Rt`;@AUNb!LXJG4k6GP1NB?hK#V;= z6sBjVH3XUa(eK7M6|Q!g1jrMwX61{}l0fQ~Y*&i1LUhdLL(HAcl(`KY}S~(2-(jc(`Dh223@eV+WJUD|-Bd z{^Fr1^kOM@UJj(v7i6C%YZP+5J~jG4Bsk z@}2{7h>H+qviYk*jiBnB_R3pSVm7^>fcLmQwD%hZ0BF7pGJ^PZ7cOM{1&xLyVb(ZH zF;(6-PGEwi*@TlmtE?38zbqHMUXb}nvrvUAaI>7Rd_69;#eo0yU!L`g)=F>Wq8uan z;l+lgqh?)FFI%B7Zb334GN4L#tazI)3_}$ArVg+cL;DUeC%Pj+gu348Wb`DEv2s{u&==) zW))!U zq{42j*{}q~LMZR~t06e@6g(onr^}`8u}<^dFwo&>=h&AOwzOmv<@l!W?(Xh2IfE@} z$j)8Hdj@d8VdZEV3fUx70e=?+O-+ZDzpkxkPK+R|y1V%j#Dy-&CPmND zC$jgUz!UYEDRmqF%8wkeqxT~?y0@P+y#-oP0E*SNmXt&RVgT$Bz6Sm2amRyL?A8fr zTBRA!i?19I57k?ZFrG#*_6nDzK)oBP?$293N$AKSblGh~7SnxR=ekVViBuBC%v z3JrQb1$iIoY=trPhbRxr2rxM4mPY9MQTBuIP$8!Yc6Ro6;BZZ7%m%mBf)A=pa^K&V zZ8h~P&*tt~F$%%1&!34DoivtKky@YB3NSTY?UMw}U{stF zUfkQXFK5Z>ygXY~+!bz*!O?xhfd8$}7!)7K#0w_8W;*!!IWj&P1SvtzdBD`?*H;23Q8}WcQ62WM+m~-rb@tckDN0|xzi^w~6n4Vr zkrb@QU?Y5Xdi|1sG)XI=t{^|(%)ezFm@a}2_8rLN1%4Le0J;XP5yZ||D5dl9@~Rmd zt4d4vn@7`+lqUzw?1M_L4#0T`EazfBM}=^WLnR#CiS~9e5bpR$C!)tm zFAvLubo93;6=aY3(fN!GQ1)=oyq5ic3n!2_Hm~LS7yXZf8XM#O&ao-GFb5+|t!8kOK61ehUuDRxtql%$zjbo9-i&k;zxBngwE?SPR z=-fvi@OV0c58??}g5mMK^#HmKwybm-is$*Gy2VWOMqxG8f@#hBT3m&QM>j>PmF0yg zes{A|zp{i=hRa!tEL!Ckbt=WaAk4kCAc#Da??w&YipXm%>rO56xYKgV4uL>UFcl*} z@xuOm*0bZlc?3e>fGiKxVL;1KTC)M01Hb~v&z^X^99~BBv$OGNcLgIQr_*DFyr>hk z=a{&?_uVkN*1nqAPyQwR1$Z`&+J_$SQx9_|Y||dk#L#|=Xj4F%s1N=C>tquvE25nt zOO6!({`~{~YCiOeJ)gCk%mf6!))W^rD{^XSYVw)rf+Kla%iMe`e9o!yAfrXa&W|j{ zFH_k!a=`2uoA7s2j(ls(@&TFA0o`*uX8@68Wo_|B@5}T!W==#L^>kUL7=F28h?fke zp?Lkv_tdsa9Z{vbzb3u&O{SaPvpJx|&4wRF@irXo*dMi~%V;Fvh?HvRB!1pj?8X>T z7%MV3`1_$KtFO2ybLcsVG1C8|eIVi&Fv9)-yOXv3l9Dn7I6WXqFUoYn1Q~=umnE4& z9EA+%jKWQxPnAt*Uob2LI4^(l-f1w)V*CZUFq2D5QCos8?(XsnP1359#&svp^MBL_%W za<_ad-B^y|tBX0m-tw~c-0xMX#Mm974s$ecu&Jk5m=Gb56m%Qc!yPDfhpHp^$d9!G zrWMo0Yf%lK49PG#O|eFKv=7|1n%pMbzt1r2%uosrN9NP9N3J=Y7QSs!G~ z`3g{Juvin_-QA6NK*e&VTe|5=zdgRw;r2ke|6#cU?Mq zTNs0()r*+jr$g#bR!(*0ZfG&OtAgsW@m3MqbNXD{lneQjyI<3P5Cp6zPxAX5y%ym|Ac)(8}1(6d9_D9}7t zew<+uyIu$5#;I)WEX0BV_Ht@^TIO#1(_?=fP|4flYaiLu)c1j?{>)6VS4_7(#5QU$8&;vOo3!g zr!?^E0X|CTy~Gv+q4vYV+uz@&Pqw!>#;bQ(hx)8P9(1}=u;P@X&EiTVuvMU1)MOm{ zC8cL-dk$bSQk?=^!wD@LkQIQ)b^y4FM1ANVfcS#QPjmY2x>+cv*QyL`j+g+h8x)o| z#>V2`+q|&-rUd^ncdVY=d-3X#ffT$2LNiw_v8oZ)$>ej{#y41@i%3eBG zt^bVSO!^5W=Gw{e{r&yGNK1YF7ZBpBQA`L*BA8iZXhA0IAObioLHo|c${MYRy(>J| zSSUOv>+{{(S;Q$nGmOTec6k_8QqXr|)}LE<*cEe5iL;zywBvh{t?=mjjP`0#n#@sZm-1~dgs?RL)p)JBe96 zaTV>cCTcK&F?3_t*-oa#ngH?pYBqWdlBbV#%w-o))k`*Tw7l%Mk z_2y+#G7rw2V4cm$N5L-d5mmS8UyVJ}L&J4&{ zYkK-8km{s?mK{7(kb4VQ>C!MV8U@SG0Q8_qQwCQJOu5M2+@a1PxFOA44EW2Zhut0L z7^hYmQYDCAF0NfM&5NWPE)s?UFajN1UjBIA1KN=G`Qv{TgV>J^)WlGj4H(Hwj)~Qb z(PjuXX2h>qb>@M*e9$0C5;PE^+yHt60cgr&3?_P%_qVI$>H*IWtaN3o zO1!R)c5YxfFd&P7H6N6l1M+U7YCDQirGEiu;!{o}! z2x!pJ4#gE&EZG20KXTAc*@tv>aRE53QPZob+1W2wcX=odM|H1@rqrc4)~?XP&l*!H z%5AHgu+G@90{y{D2F4zsDga^&NjL}ica{pSf&?l4mq8X*Rtvy|28jrl)_H^QD2xC3 zvjBM{m_|7OtNRsDypXJBQi-DqNCrlM=-sqp#!3`%(={iI;J2eB)xG$%m{b6z?{Qqx zI?RHY#Xg`0A8BBl-{@_o&fj31ely07umOK9D5!CMoKt4C!+`;kz5ikZI zA_D8XI5$l{QTNnbQ^OYBYKd3!%)sep;IR>M3(Py9L~)=(7j{}ZIy~G-kf+KkFOLN( zW9QDQ$azAPjRKQ0A|R&hM$E59TKfHKZFYoSr{-xX10@O}apPC`Mn0ASyT}89$jybG zk#AuLYKm|4&3TlgDB9RenzA*^0H&Mx(zh4g`gk~qH=lKwq5SR$*2P&p$f*JJ27pn7 zSR-7qTYtV0>-;krpd(6GX{?*MvY-qzgor$8m)M4h+(=@PL8K zu6h64lZq%B^zMN5=5l~sGvz&!JJO?fzBvu7W=Nbd2#EYla!{%^doB5GJEDX)b}KNX zq&!>E-tWm6yH~)9*YE2Z@r;lH!ieCY-h3M!mFPWJhg}z-5(xIjDA}ZCVO9FyF#a5t z<0lqCJ>FK70W=Zc4Rp1&NhI+A^obAZe@I9OKul!=1z1gI7Z)S91R>xRpcbI+pEoP@ zn>#tP^_UW0dTW`7R*B#|kChVG%>#W!L1UvJ%S_UX$RHYs_D06n-k}-;fDbT-C7Yxa zq#7oV9E$fSwHHGYm-s+5!%8*!NhHZtVAM*{vzLrrghu32kbyISX7s%$ZXB0!OHZ#L zZk-BylPB&OhW*$%6yI446wYmJlx2L7Y83=90=I$%2>M@W2Uo0%2GVlkdF_%vH-jti zOy=4!y>;U$c&kOB&uUWhTkzc2Kf@va?)s~GdDIzE&b7>AShoA~fYZhYzdOd9=3R~S zr#uHSWCc}n35qxL_&9hbWqmAai|-h%&QerfZYn4=IZ!y#4E`t`L2s$9<_78Hz2Fo9 z%rZ!UbOP@FNaJAP3YxP)3PnqcaN;y`#LscafvyJd;qpjKB1dX(LmtBH&ilC?hwa3=1PyYC%ftiE$MSxR2ru$?Zw(oW`}*E| zw1C<1q@M%?nexIRGl>7(XF;weFd9-%O1M>X%7r;h=h%aKhL_hcW#!}-zDJC*ftQ#t zkWjez&9S!E8JS^*FySn(GB-ZV_mU7cDiU%~krP@+)o#zM5Lo4->+XzR&NtODH-c~&%8L4`p*J7Pk;1%; z^25lVw9aKfz6?RU3%W8ii}p;cyQI)heONI+4>`91n7=(5JLS9$g) zonbN!1>5du*0At#YY%W09@k4$EIjd{wq~<0^N5O##R1zPf4(O@(Vd`h_r&p|ZE%{4 zD6Kiosl?Vi0u2Q?HM5^60WEb{@^`l%8dm+EFOa;~Oz&G2+1su$eXk3MZ05&DXS9vG zJxP)ZT%R#f>bBIV6l!$n=;DS0y1dD|v7hTw4p;H2 zF8881+EbxV7}ck6fS-Z5M{3L4QEee5=)$@PmP@ar*&Hu|0P(S076iaj0zr?pH61vl zX`5SHGr=2?q~TeDg&s!o-+B6MGfbh0v{taZ2jp3ff!?-&g7leb$1T{o z-Z|_L2Zg=Lq$|)=2@x|4t;z)}(BUl?=HwmRK{QOJJMYKPmi_&%8HktsTU%RN;4KA` zR4^j@Kh~<4xPFuvELRH-OPh=ls@%5oR5u+txy3CE_}jD7^*nR_Kgq#Q1Z_uaU=$$p zYC;Cmd{U4_b1i$Hk60C=HKhYToqd<5^1_~m6Fsg!hkPs&gjTvIx{fMlC@nj`aDGno z4?sTq1+!CNs9sSsaj2DzQ(tx%wg|kiID-E+Pi=QJa0iibVz_}4TTDTZy%CaT(i-Ut zF=_|rCzFLdHp;N&9@h@Q^!C^umC6+q+wGCiYEYoQIs_l1usfguKras3LG+aU8 z=A+5aqqQ8JoY@LWQeJjVl2GeLbD4d65{v(mR`yx`j)jHVK3B5T%P$CORJV6obLyIg zgFO#dWO{RfQCRex_2||V24h_ohGScYl)PHU4}(ft{_n4f{`hv4eQgA=CHRKG_@FI8 zZZUAK&v#ld8XA^$emfOmVh!ZDT}fL$+mF&+YYwZpk1MP#59#zTNYp{qf|DK=oK9R8 zFzQXs%Ias`bXgel3@%?Flr-S7)TpL$0MQ1dAU-qwUz<=Rd)!XN8%nbxU)^bfp2}5{ zTKpPf3`9I!z|$HvFEcFrONH_r?IHM$QYLv#O|BJsD7o`tfxa zO6GG4m#>*9b17sc)jwz0rAxaDEI$B|eBB(y{TTWEr1YizhwqmAH2dB!nW>ZFzk2NBX9!y1;+>gFi{WQLY9QV*SzPj4`H>b4!g`(N(KB=6y&!=NJ z@?@fyq344JT?&V`Iiw)ysZ~^Mm5g5ZU<@WtSif<>;=+eg#m~y!KUo?N%2g*9kvjaE zLjE44gJs-u8r@up=MyNox8GOp%$EE$s<3xXr-{Yl`<(H=DpL=3E0=n#Grppic-i8R zDe8gYK#BgAqkJoOQml`7<2$0|Pt^b2Vo8|>2g2|O>jD`YEXNDqi64*JsoRTe(mUUs zMKFr?ekcma|Dt(ZcV6e^H$2kt3zqbTpmDKl;!zpz>?0j>u37n}g-UyCM3Q7%VS6io@n{x?GY&@37M zWOBbwgATX|&|Rv7$myA{xW#2OVm3rXfqtIiLYskWY=px(v$dz@0*QV#aWruMDwu2sV!9WILGz&gBL2f8Zt7`;dLGVk6! zz=teStdlTS`h1eAJr>RQG6k?0W`4nni~PcJ0t;1bH_nDj#zS6Z2KT1Y>>6eJQE33x znF@ZAhDUZkfb%>+)Cn4!J4INQusgudhaoBoAEnEGXI2lQNUJLTE77vnJ{B_Wg68Zs ztARA$Z);f=rg=%PoqwwlWqB+lPU)kzQD z4Tn^T_vt^;ZIkXQv)O&$p_x^xFjmU=WTQI*TJ$;>0f-mC37*z2yBY$zh_kN}XfmP` zgpHvx9%??FFMPy6e2o};U{YoYh$WGmZD=d&(b`oS@MQ*(X#@Z+^T;N#wFksBZwGwk zI6pnY5eyQb^R+5V1MXIU=?wd45MmyoV_B%sIp7`5iR2h{B{7lF_50WQniPgX)S;EE0*B3w3~&r2OEsV&S9OV?mX-bf-XAxDJp8(P(#PFT=n#li`Ps$ z?^)LpT5j&|m|Daq($#4z|5w_AH`Em=8@-yiLZMW<+bQuo0%*ljcG+69^<6Rt^97q8JrM9vF~OP|3vDxxOVNYv3Tsrb%G!dH9!@-%Y39&ieiR z?V}_%q!qLw>giBTA@dzAxZz5#G}zty?=1_P{p7NmusD%G;|r!PfPL?RFo~}q49aPF zO#E-LYF^SN5MD&!mj+h=p-aA=wWx$i*p6H@m-H8wCn%EFR#usvy_)Rphtf@mucy|( zk*8Z(>-SH-U)$*yzozqYm&7AnXNcV2S2E?hepLI$f08O-NT)4X1y2X9jN%m`^Z%~J z_Kv?K)(=Hu!vJI$Lj($j&4f|RCqi+vl&Q}KYN5&R6P*?daO zkJaqE(2M5*e8?bqdhC`1FmpRw81wxCR&u4?-N5U>B}H;lDUv$+g`8(7AH7p3QyA@A zw(sKu{)_WNc+SS{%M_>HCt}F7raED z!le3B_R5|f?ipweTlv#hG%gMH;=Y#(~PoQHpI3u)*vtn zPh^?$i1Xk35hou;v2k%x?jpZkXy|6WgT^f|>mopI>D9yRQ5Q#QV5yU;u`t7CfwLN8 zmLF`jfKW1Oj0JE@&VXeUhFQeKW;YaF2`zIcXfBcVG_?O^yFaCVNZ{~2je=-yV1hyY z%T)GoC%YB{JN5uOoS7t+ik}}Hn-xVTx-RYCkbl*Ul6Z*K4t9(8_eu3CVhebp1H3iy z<(iLta|5xPVkgB&hLhfD>98U`LQ~88K}IB9Oew4;DeI>{_|;b;Pa}dg9kKfj>icIxm7JsS(Fb2fC{T@j z?fQ}N!@oJtiwSw$Yn>zwNYCfAGbH)NW^N>N7X)`j)qPoAT@4bo-N4Ir-91Myr6nRo zT4NkHp*>hT$+xC|^@WTSr$-?hr}{3U?G6tmAWn`zhg$mcs!+ugw{ zCRR6$OtD(5~wst7ej?l}eXLgnM!(ptR z%L}2)|_Yyn1eTt4<6LEnoYOXc#k?%wlnXZK;1x4maf7IeE4bcu9laeA+6;dIvwY&mfwtf*Z>EWgx=v z7ujQmY)E>G^qo-RBa&YZhhKaz_l#{M*>Ev4A1Bq9>HlYx?fZ{tavx=uUfsiFm~$WV z3x`+oStQuZ<0INR{P{U8-Yt`G--Xfrb}nP0nLLb&SIk5$mhmbUno$q{5YMVtYZZU_ zs}OR*WLwGe|9kffVeDL_v<_N)H~6$)2<=rs*N)RVX%K2?aRc0SOc$ zwGwRt!aATuAVMTg`R-Y4;sPwgzI_lJ!_u0XGhNyB4(OZOVmw= zVKjs*<*-WooFFaEchO2YYtjpXjo0`f`b&tM|ERF|1MN~nXQ(SBeInJv{Q$YmwF#d- zf9n{`z5`#Gda2>Bnz8ol!)<&qw+%9z1(f$$>JcP;KCpK`s&zSxC=+>E%qO&TyUdBw zmeG0)k#}&dMDSOF+O=sjRV<>Blo2(PIh}W3TcHKgYzZCd?5!Z{^Si2RiwF4qd-%3a zu0ZI2%2U2G8|c=RhfwyfCSQ0fkN&?a=1^@OZ3;Hk)SC`A41VDbwcUbUtM$^F(M=E= zOKj20&o%5y+Rz3nF{srASI~yL^lYz)j5Q_OTAlS=IGPAP#9U?wa2!YAJHJ;2)a~q( zSdoAcY^1hTUd3L5V#*AzF7PT=`}nrn;92{Dkv0zv@mK1?&l+IZ0%K>&L65D${lj10 z_Kv%)Wy5c^BWS;f_>83CSJ!cNPdlZka`B5z_u;ko@Y#1-?Q`9iM;eQ>S7)8>eo?f8 zts(Ev=lt5j3&-r<0k$HOuO_t#7F3kih|((ahZkFLu~(^ChdQaAG-IF6b#!^^{+?$_ zV(}ukwy)6N1#kT&PFt}Ner(X}%`i_k_A8LJP@Tl^k70gK+wB!XHrkypV~BabnpzS@ zkVB?O#56(-nngSHf17w5U(v`&y5hI82pjukQPY*+vvDLLoWt&owY zEuHxNAf{cjCqG6*YUi5N9M1JA?!7|#hyi?1R**_L`_a~CSt~5RyELBb1J#@W#7Ta- zY!0D^<%gWM^Vphvp@#=}W?GZ`2PKZkq{1M7URjiVo&2gNUg>fjv)k~fKBG4_>Th@h z`6hmnR{3;1HE(}PRKW05w%IJH`mMQidgaw>nzOH8W|QsJQMG?1mdNoO*5#Kb=l8p# zZO&pa&+M@vzRKTp!+jhZJ~ly~iSoBm|xl=o*-Xhjqm(TsP+2ZDRdg zrK!J?;~mA#9SEU7RwVc^S47peV5$AR^@E=8;!yZc2wn=N{7L#oe4?ywlqfvMb2kkN zD}^9k$fL38(}ywV!!F3>CEM@b6A0G(1;EDLvXBb!tcJKFyT*-2N3G|h28x26B*xxd zd~-&~ox1O{>Ub{s`d0~dz&Y=w=JB;4-Xe{`cKsJ{V?Grh+00vO$El^UL;~r~YCaL?ICIj3R2(C3|n~P->zGyay~(#R*M|(Jng6Yoj>#2Vb=GNs+ccE@{8F@ zm)@3IYpf`7onEvkZO+5hwet+&Z_Z1v<7zBUo%*7w2h`;$1F9>1eSUUIQrRwcubY;~ zE+bDepCqn(MY1s~Fm&ZRhmbM2y^+_uIP6NYQX=s}_`VFYGssh|uYIPq^fJX+Q~v`r zFVdj@m9;i}xNsV~0^CI}k+vGJBY`qg!NL)gr2`x%07DFzsWHG9LrIrFaLvK}x@9jv z3i1nqm{!OQ0*%r|?WhTj%EKSL@lIfi%()wb@lUHLxC8T;vwEK;C4`jo?)+yDMMlNm zqdfTH-k&Wy@!JkMEKeI(x5 zI#x{CmP^i0%Ac#6k!~?*kwJj206JZfS0I8Ozi@&(Nq3R8_IUGS*35=4#t)yKMtn7! zekM)kBB6bMT%kJE;)UDnVm+n{Q{F9WSSzxIm193$PU5$HM!DbWJ9ICWA$XGYSAUo) zy!+-=vhDBIzhBe~WxZ|l%j#VFcU6eXAc#E=7|vO=)^c39Ci7hq~^0 z#QNfI!Y}fHlwRfE<>4^&e%m&zXl*O|0=t55ha1`c-q3ZHzm-sGi;ndlqbWJtdc zGMxw$OCFx%wuL^07QUH zQN1RP&W*&SQXl4!^==#ytDG1de#lgurepkK$EnzYS$k*mi{8ciU{tjb4({aKhgf?h6R5*PZaa1Z1+Z_&8Ei@+DXj6QR=A&9pVlefCb*-I|+Jtnasf*jd zyY(H5k+)#{rK-7^_V0N{Hf8Df;L(*lX932*iq?9@p};y(3CW$aoby$w`Npb9M0g6< zR+Vn4!8cE@(J-3`Y%CJ*0c#EpS>`ypSfTJBT(aK$kQ_)W1G5wBr<}@keO7COT0H+` zY09KDDyc{c-8-bOhxme=Lx$*%PnLP>+a8yAgURVrOw^`Y*(J|`Dnh8>9-6l3g%ai0 z5=1XG5NNnhGDexV>Gm>5h*v96>B~O3X`R zl46egGiFWNWc4@v30@jE_Xoj;tUyKCD# zueJ)RiW2CG;KGp2R$RMfn!js%66!_Qp#+5SnMAWK0?z~JLWfF)(t{u9#j5@%T&^lW z>!>{n+nQJIATvd4!sW*gVrQ)zK7Cvq;ZmZ$&bhcW8H;sX+??ntyxw;(KaV}y-LasU z;+a1UIlCi%zJ1hw5Aysrx6yA@?;qJN@ou=|uJl)KAd}Vl+4seX#}5@o?Jv{_zz<<> zCa{zV^(%Gblo^P(W(&tlY-XE^&`VQz9Hy8`nfE>cFCB2Mj3fMU_yn--z{-+{UgwzG zgUN{b^zRCCu$Arxj_1OWvW;O#9CjI@1Pf0YJ?OA7)XzmD;1 zWNlqoevh#jr4`%cN3H~1**pHa*PboC_%rb*`nVJTm-Wx`_2>T*VxL6gSF!!cX3~F? za`-f{uB>j1#alxYo;LS9G)td6e0L4(YvGY+?HEy#gn1d|_c5Rfshd;gqHjjK6I^j# zZN64OQK5iiDAWf=^Bq2=seTxSTC5V^j=_igcGW3U;BJ`aw%shM%by)}Yu0{T`s~vpuybH+-@O=@r=+dG8^9TCfk(}DSpNch zX{-75LMH)O7_1&RFLE8Zbt2Gab&gjf!m zKQztiG95}2I*(Ed8|X;X*`HsCXvY}&jAzwt|Cyx}I$oj>N7OdvK}~!lj=_w~=)L8# z`iU|>xV4hZ}`z*MH5s#PggE5s;JI`qz)3d3G88Oa1YwqM|Aj zH?Z=Kkfbj)->X+C=~FVeh2`=eA;>6rCA7P%Ub8$~{{`ox+i&rTEv0aV5tC($hSH*y zb9rA|+KAwmHd6u$?@l7```(ma`kW~YuTq7*xU9wgMH{a+`NQtLag8&aUi5Wt(>-!L z8z{_>2mZqHK<(DSCy@d1$>dbeE=GpUqy zmMR4wY3U3~gbh(k?^NVl2Kp0kwa{t_)9BvNFZ^txeK9Y3Qn_P=eeu;%9^l)|Zwn2Z zq8@L=`85XfS)25xEB?C-rGB{2`DI)gk4B}_(**NLxxw1y@jGG-#UcM0|E!Hn_#WX4 zo32dGYTLa18VVdlh&$?!rz|H7$X-R!PX9>f{mwVilJ5V#B+qlhOe^7FmP~k->ldsTvIB;ZYCa-w)f}6@+Df(HE!)t-kL6FvXk=J<`@v_;iCpU? z-p(&2t)fYhd5lBnjC3*TQS~*xx#hBBM zYq_Zpcv)mnC!l6knv*Z)vlH!fQai4d{`$x4y90G=N?>9%-c0nT8qU0ow_?h zlug3vk&ES3q`@v~goY>gwD9bk^G`Y3p}>fSwWkvDr*=Pp?Pv(9CCY6q{_MNA7rIIo4{X|&b_rE04#XJ z!>Glw)eA0b@pV3s)D`6tdBc|s1-DAsWu92jR*HFG{@|DDFd_#HYF;$iK{NhWo+Ga( za(3Jp7*1G$!iKQV8$QTy z#)M!RHf15E-D7d9Q|g!@aWG~PO2nreDwCr!&)SboE9nW2qR~b676?9FDu2e@m{elO zGwZSom^1DOY_jk9Hex6IrQ*BUMz^l_*(mInmpf$?39i{<#X~s8n~S}v=(XEjOe1e! z;)I*e0YS~2zGk?3wFoDM$F>KwN2K3>1kODm3anm$5DiDn2Uq^gbK}E(fm~GF93Fq3 zv0GeN_Bn4w`zKc0#pw-}HLHbsv7K(a@JAf`Vjl}>TM?3Ak#%JuO#hJPl@qJK<>tOZ zk}^m4MwTn6 z7zBpHw({LdeG?XHRlON8M1I{@1H^Ifsn3(TpEBa!%{Tr+@~ux@?CwJAhkunQ=Dt7p z#YK7`GWHtXT;BLs-(zMm{T58t*7M628y(}`i?!Q`2hV?Yv10$;<&Sgwnu&w>H;-(e zPju?jfsO66uU{nEH@WG}k?Sy{ zG7PN)SEbX$G|rgg=O2q1E9~ORe~20_r4&w|*BP?fbagC#Sqn%b&6_YW5919{nyF>V zN3X?w_N5cIQoTL1d+z4A9#jYEXKX#ep>!|m&EK+iHV|9l2WPz|>~?R5zpf47jP6yJ z{QM)vu%-r95o0i+NgN;z*%-zDv>uR=5*~n_PCscXH{#D%Xn4g>5ZjZP6 z1bXMcrGDodM4DV0hJ_rr4|m_>IF0$d{;pUgXfmJ| zilZ;rA%<3IHp8t~tLS)qC%SKlDC&i?+a}Abp~-H$$})$~Mj)B$1{@D?!?9%?hsyaP zJKf2s6Cz%ZcYJo(yfna8z7s<;ZRp)*`188F*XZqowi16Z4f^9i8R(3~9G77_oahh_ zCQAWWB{>WBd~ZXtD-s>XpDFzG=k&SNB@1uD#ux6YXR~bdm`QrCa#^-$y|jW(4dR@} zg0#exZ=PCA=I%+Z_iQ~lbDBQ2dDMK>7`CM<7&(r;HOyhUBR_m|751=k(=lQ?+()0a z=x(;dBHQod*I$VYA1}2Wcq|aJ6~U-A+1`rP_NnJ2h-QH>9p%VJ&4iZGwXUz}Cjrq{ z9@{m>w>kmTOI>EZOkX~)4$}L_hY^2>+n-hkw(M~sTL!fFTk}THJa|l^W}asJ+z=m&Fdain4DCXz z-4wT;bvSf|o3XJPs7W4+iF#b>&eu}Kig=5e_dVYIb5D0Y)=xH`q0@kKe}AQ|D|kf^ zJ$UlRImPLhBTQq}f;yC1FkFd4I6&axWkw7+_r>vC&=b1Fsip#0`=e9(fG)C5Q!J#3 z1>$!@vL`i3pZ5w`Pk!qe$$%#=a6C2s0*Ew&KU!g7j0G`K&aJRiN~*Y!+ivbuzm6jU z&od0oqdn3!7~S5q-|?>3R=vz+Ho~A}-qvv8`t&2rfYmMrLlQ0{mU(qooaxoqb1{G1 z;(g_nOQ$3yEa`n7qn2zm7$fkQK_T!MjcMg6;qBqgl=Jf`Yk|%js-}P|;!@L*!<_NmP@Ay8w zQClsp=$Hpz>iX(bgnl20tqFd>o-=~WufnfByk&=n#~9n0o_$r-={S1h>j@vEA2xWw zU09&AzL(Fv573L-#`cAhyRbMvkr?g+QR+NE!_=DDBUOx3KCM% z4JzH;-K{9yfhd`9u;!p1 zw6%QN7tc5vWX(($_T<7@^i7S)Q4z7;#=5!8Xo<4R$j5O1dv0RfxyrvNy%puKkm)>~ za;sM*)|bTi@+ORUIh~+DVfhN?o54e709tuID$t zM~{C@mcmXo`w#EA(i9RG^TaEEnA=0kWW2xXy34aw#)PFNezyFz|73-A!KBD^+KIv) z^RuS?p+9Rv$5l3#*BvS!`ebQ{1WG_}^`jEqws&ZmlRYgbpDN8PNIhS{Sv&4~7P35k zai%Fu6vvN(_Uw`OefQF~@xLe^(EUk|*&izvt+mDrK-OSq9nt!6rqn-5$4VOL`5aMO zVB&>FIpi;^^*K`;B;GZKj2-q`mho9J6M;hP_2{?hSv`s(=GL&tYHJP&=oh2$|7ihc zr?L+5(nOjhm#!S%=gayyt$l|=ZW+SG{PVdoo;rvt^^ zvV2=P%DsZ?$!KL9P^t`6I`PMO1qE@u7QSXG+yaLK%&g031m7KNim-FMcJ+U;>sC6^ z`op{4_eG%LEEc(3VaScEiwUhV=XkGEihW!jC}iPr`OWaI?M&6jedlFMJ!hJaIsH2K zONkR6Yw}oC@HE`@4UPvd?!;R;8~f>r0`2 zV>xP2^!a6S<<8fJ+SpMG?&XmYDb{2AgP`ML*i4@ln*N28=DMww z@}IMQIM*|7ig8#tU(4l|Z{(Q)1W8bA}U8NkBt*Ko!_O{By&v}fIwxG@EdXS?J%^VxE_*VI^xeDg&mCFa&o|z|uE7hICVlPMnJwHF(>S)UF>w*50Zd^9iW!t5PN>ZPHpe8j4(olgrz%A7}^ zXjxv=+V3#fOKml)%oe2>fg3r_u)l`b1F1|cOo2~LS5-Z$n;e-Rrs6?weMr#!mWax4 zjgDUEcb)n(w~&dvRO89auqA4XtO29;ZL)W_Ph?r_x8@&pNiOOR#Nhu(?|{iN{R#gA zfH)P7_x$>-(_ef$@q`U~PptzBRa!jUc4k6qMz;HWPZ*WE!g{hgwFyxrKFfM4_pp@< zP8C_qg;Q)ld2bOI-ThXn?bX{<&Xm*l=-h}6ntvHBL0DT#w=rzrV^w=eu}Mf>FHn|N zzW3un$Z9$p(^$E5)6zr7ym#sk1zta={Lvaj5PM95K~I!)$oMg$y$$1dPZRy=j^JK1 zaaQ0t!MouI?LF8Dx9M137soYBe0>C-6prKTe9bPLpVIvVp0y3plSr2EKtXdC!POZ_w9L$pDLEV4(Cl}A1gn1&8x!>VFDUvgwFxOS?p}9t zf8}j>Wv43fllC!+^3zi0v2pv*a8=2c5Yi#DzVD+Hd=&3GX2RJD^-k}6?esT5KYQTX zTIv#LBy@r5Em=&YQhw6XCVIz5b9>gawTLHV7j(QnR)(=VNBUmcj*Ci$iLl|t1Xp#% z$4u)1AH~f^`wU+6lGpY2zIRbpQ>S7-UgwMBla6Yn@wlkMR}_G-tMUngeh&uZ%RZSA zGFPw7UkjDJy_wr-A#Zl_*Wc(BfaI`OC!O%5+0psVzfvpQnn7vyw2eH6#SGy;!e&&6 zE4JbH+Z(V@xa>cil{C#AIh@@YYqiFi3^>99cAJ__a?bbu_ytyh?g)g_DkJwM6-gvLw2C?^jC6U?S57gJWqo z4z}zr*`BW`fPsST9>0IfC}y{DjK=KQRC$kotFxMs9eK?j?{y=Nv^qC$YC}%R$NHxS z4|2*1%g1Ta z1bxEowQiI?FFZRu4E^qObLVC|wZatl=1x`kFqHl##R2{x|LxEu&DB{b7BYQiu!B*4 z>myv+?O(r{QPj~>Fr4Sy-v@|Qn8wRBfq3dcs7?}%sM){_r)-(3%P2SK+_39c9Fg8E zm@^iO;e$qd?7`VAsuazbraD@kxOz?u4FoJ?YR?Z*(8y+ML#r%4x7tTm8S7=jQ-{5A9W^#4TUPXpilGD9yC2;T5u5fIbrJ#2xB9FgDnUU0oxfa( zwqJU*rfJ}^&hzi7@0$E`pf~Nj?P@giO3v}^)htoB%8guwF;`iu>Vb5*YU7FeYVRty zM{Z3-yh*n#zR|FOqkr&0pyJRc9?uaPGOn8>lclNjeqfhZC9S?_}e2}OBsrK zOr~4a_*N6eq!@`*y?1cgry*~Uk-768qp4%6qe{zYlE%8LZe^+A*T(cU^sMwH?_AS9 zChc#;NyT-eG^m$iK@-}RVp+3@;~$7+I;<_|Gy>qzeCdB)4F4t{X_3*j>uSXo*>(Ys z_HLiFC$;>DINES#llD3l=6k1ULZ{y3vhilYu*1KaA1XaG$}QnLfw{fg#ONA&O<5yw zH`uT+*rw|O)X}{_O4rRd*Jsq7{ug4H>Y{}&@HdW2`a$QgQsq_xF6FPRabj3(-B?@A zL~DTNfSj|Ezz$7#tDTLAP%f#Oe+TwiHIwk3Dda=MsAP!s#PT8rdD6>+Q7p~eciX@7 z4gFPge9k!>n(C*t)WNN=;(_{|75IYm0tm$kP`ff#Boh$h__oAH%1e21l|GWJ65`c|D%cyXCR-t5q@g-yv3u;3zkoRd`Ud2u~>kTL+-L|9eKF5v9meX zKsubkt|MPzzVtLx2dXapvi{3_{d2Nzf&u{=-(6fG$9?Dpw^*8Oxo;>Aw;0ezth=15 zb30$0@}~)mmraxC)MJ4NrU6c$zD!sXMa#8)itolO(lR{x%huXRZK0+(*k}Cjc=Yj+ zd*f>phmw`%88H{5MWf25j+_k?^id_qRlTYA#@WqAxtjNCBL^d@^j*2OsX&TgxSU<% zWJLwsbDD(byPy?-MK}@^8GXK;7=>+padyWMXGP(+v=lIIlnE=}1LR_; zerz3Cnftg)xH;ftBJ!-zy6|KNg7`LHO<5@&$7pR^Eia_+?-X=3?Q%YuuzEGQ+lKJb z6U#(C82e_y9~Um$9}hh-n>Atu^V~v{YO<8-XEna*D*9n&Fz?~`wjQ8XA>Y)6En7KU zZ;5;5u>92ou*+wSSCjITV~%2(!fq?0qXC_P_Z^zkm4q3>p7xXC_%bMxmj@%t6uIkt zX0q_neT_Pq`_>>LV$%&tbVaqB&udMswvSyV~hY`C7Q8 zem$Q7{K$N=t;}ToSJ$nGPkD-~?!h>Uk9O~diC=;LZQ7CUYL4S1$pcz%G%W+%*hLem z{&ThQB9wy;IMT=1DRVyBrkw=KrqwBI75Vx%*GHX>!Y9y76;U_b(=FlmXeU!A@vC#| z_{j*>0#(o+*}~3b*(&HSf4lbMBZbB0V%swWDG;azMURYVi7CaFEC9U`A>j7|I!ge4 z@;TofPN{3Z4j;bmIf48!b}lw<5%bXoU$4Ha*7MXcqK2xP&}CJ4l-A}=G0)wn?bfX7qaW%4GS>^ z)RA!izh6h=(xo!pPOz#iwoD$)2ZziQ&qNfel_@bf&L5WBWGT;A)6~1tZrkaHaSl- z{Y%b<`EJBNAnidyBi!04Z%IJ7wGzJ)$%pRnr{jXYOBh1y2Jq3N&s%D0?PlHsT0}Nz zaMwh=Sd?0ZseUAybH~HAnf(0cjV%g}Xn)vVQ9!7+v=xtw&5-Fh8`?KqFC<+QGju<+ zEfU>7WF@mrwJr>_&CNQJPTlhpuWD`62^Q?xZobCMC2oZ<=6+{hF)$+AzKPL_mv0CV zA68jptL4g`-M{Kfw46%Y!%uMk0AUf*RQl9)xI9+8N0sCMpuBmuj$3oFqv^6BIZnKm z_+k-%%IJinZ0>A*s>3^q+QD!L5Q=^@9>F!6#D>#kiD-CGe`H8oF-8dsR>RmsAGriO z@9+uOQ^>E{&p#1+CahIRoBqv1wf`j(*91c*BSRs9^mL1w;vZEv%Zcs-pvVPDhRch1 zs=hvQlb-tRn=K*04ljT0C2ZCW$sbSN5 zgh~iu{|ls+pl=BXyP+eqCT5A!TsmMTxvvJWrgDZx(p^i|a`m5N0PG_;nvkQ_YjvZf z7Oq(RA}J0j6NVT-LJxEZ(-WJ{w^ylrSi|f;@0VC~)y(lF|4RD6^<4zJ%x$-muJgI% zHI?Mm;HcHYy3NSbp*j{#bmKt00Pi{aM%c|n)42`a>Dzrj)Ts^d z?v((?;&ZnB9O%Bicgh;97McY~XQVh66%dP1Le!n{efY}-=8->+U68M=BTtL zo)7SSTW?muA zfZ$vN;fn>tmC7W~-LI3+fIG%r0UQCqKp2Uw#B#4Akc9E1j)3+6)IWgo`~pZy$6d?x z>&yY%4aj+;0A5NKtFRV1kt7 zF2vIl-+!r7V#k+F&9Gfz(U^SNQ^K=4qGP*iqP;g?6dK0g_{(@#pYw%{408`8vpww3 z6VS$DdcAND`&t<3y1n&QIRmpD9}Dj>gjhTOmd|cJavr+j_lJzN*d!e*w<7%NAYcSA zcoZ&?P%u2!>rMP((QwF}$D-~|zeZ^;T9D-3G`?v4eNpJ-#<@f-J8sE#u2Q26TV&3rK za?jRMha}EAx0G-5;)8Xd?ta6kS55E52xua20F5%tO!w4F9AEl@v-Z8sH1D_(IZKWi zmvr_!o)EP_8{!4i6BHh4D=Fp4Dn6mw>SEJf`i<6iJ54q3K0OvnuNFyuB~;E@J}Sff z`G*t>iW#ZffsdrBm@}CL6sFOG)GrMdZWsneG9t2v0diA^l{1BN21)YX$)DpG!69oYGZb`B&nyAJ8vBFN;2R?BpCXFSt7{}(icqiW?;s8(3gq9-YRXjR84gQ| z9(1W>?LX=^xWpd3eE?>jU|HuTf2+ZdY+uDrEOngD2&DJaD!?Zg-sQ)HflXc zLQM6()Hxkb(CT?N%KKLw@aRzm7N+-Di5WTe`^_e&PIiB(rf&=bwA~V^cRobV7Lq7u zU%M_|vX<(jINsotw_a0;&4tmC!Ve?mN7m}5*7^3w7Q4AZWwaD zYH350LMk!Tm!fNZ8gNS%pFR7iSOrl3h(-xO=RmZA0dD6yKqqb#XF7yjc9*(K=x4ig zG(bO*j4QGuNKlBTu#$?lA3%0oS$|qx#I}2DMwn70VZO98JGo*@mE4=`uJq`65uR%HIP2{n4@b*kOi4PDo8zt@YY zHk2EsdyIYq5Xa;}3xlz`lGq^D_s--HTFYDotoIDNglPjJ_O|xP4>-dooA375nuK{G z-tY~s^u+?%5VdO}J|$lm{oP?C1fWzwn(e?GH5c)RrLhJ;yTnH4xYSGP-U0e+>)E7% zpvSB}Q23hyNHSZI&F9oev$V`_UnRQKZY7Ae7M;z6+8`Gzo7wZ{CB^oeY!u!Uyc_*OlQK@h6HA8_fd@;~* z>8`s=sWoon>Z>v-{ac}N0jC^PzDhzW9B9PmG&ggMjqzwTrS+tKs(DV!`E#@>>5upR zpN!9BP|WLGK0H?s)5sX;ULVd@&rxNuxcpli+eib_P*tf!i4)#b$v3e9^A zdF9Bne2{)3EOvf#)96$f&x2ihG(CV$@{$9K=PfSnIf6i1WkkR5OOx2*5PqCc3jI2pkG_%?!`cQM zZ>F9B^BKM^<+AZp(0>Nd`hN>%-3S-(q{QCwlL@^bC|^)`0YAb$oqXOfWApi~{G-u? z2ak6qe%Z+zcL=_Ld)nQe`L=QKXef}>Sf(xQO zKtxQA=}H0$RTQ6d3m>@aL+m(~mV50e0 z%N4!8wQW{;VhSqt7hSeI_01w!u;FP46v0xG=uCN^$m=aPl@lU^bU7s~C(~~@r^FwcM4$rkMQd%T5t#A=~#rl?$^-dT1~P-2ec7E3>bZQLqTfDd-S*nX=WI=} zts&~5g5cwQ;aVkji|D>*PhAw&tq;{(%xNR!Zf1 z3&2)QQzQi`=Ae61*H(0|cB0-p5(mxmyubR;q@HZyq_sfE@=rtIVZhmjt#3ToRu|UW zP%KLM?Sd0ewMEFWyPsw=xRO&bmQymtB0xcG#?+8Bs8ujyj@C@-ar#U{;IMw=Xh{>+ z_iH-Qwiacy?#a$?q*r2u4(<7(h4S5{feQmYfvxWgI|2x{;@07kjj^{F^COqhfvfpT zmb%R(61VuD>!pgZyI=dM*_~5R%21n^+S1WI=kp*9%a*R^C#$Rd%+;IbbA1a|K}4NW zJDKGTO{cIpylEZsB6*Im9Bw`A#sPV31YqE<|C%n~SpiMva_oKJ&@`2JJ=}T`bcAex z3i%6YV{r7}0gI;sVj~B9dpxn3IGC}jt+%otm$0HQ<#n^em#3Y{C@H7v8JBN>0e}Hh zz*PyLshM%)3mWN%~W=T%*d69bM8^#`57Di+Rr{+%{Y*M&X76 zxGPT=XY3>BM4&&<^RaXx_fQ#MVoczp{%mqaSUEqy#diX!5K=9FJW5Ua#59UOmYab1TOkBTw zgi=`sOg`NDq~I2$sfuFzUJg4!a^LMv;)H+wCtP?^$!XX&(eE}4MRaAL zzV=BZ8E4kB=3l0=hyGetEi3|34X;=z)rYdpuX5SrxXouD@atDMy(nr}$;o<~Z zSxoQ#B=~A0&Zk2v8!Ab$zS($kF1e>=!HTV7OR)CS*y0ZTxXCs~9^-w0o}koDe&%$u zL+PiPN+?Wlh^%s&W%n1kJ}gX=yvLD%pYrctpE2e59N%wFHBf7|3k98UQK&q{TjK<# zI_R4*Sw&5A#bwy_d(U#>mo=?YbfZ>$unJ@7xt~7!?s*oya~W%MWq$B9@e?)8*R%Eo|c=`?56pV?6dF~v$=J>40$4R^{L@^xF zQyJ$zF2A=IdR_5%KG}W%Yg#vL#*Py-gsOIbq3;LHV|09E8A2G;@-O+d2nYE_%Otib@7LL%D?^bg^3Qpf4f3UyU)Fdr8-)4ua++LIaPYZBT z=D3$wfz9fC9KVd%^85sxAio*UR?8>S%~{q0^eEt7P96C8%IyL$q+-n8?DfB%UvP6} z@LYPJP?nwTEnUNdy1q9T4Gbm=`ZzDf+fir&UWx_v94WCp_r zV77&&`w!?s;^Ub(?De#UrXD9ud zu$tZBNGI!ooz-g}Tkl3?MGkf|DS4bk3j5EO=a%+HB=!s+H^(p#N?CPI)xC_+=Y$vQRKi%UwRxA!=H+xi1e-C{_NZ_d zBHEXJOl%%kq*W5Mns6{MmADh7Re8>z<}pPIRLjv{a{ZH%3%TC>94Mi5kurg*?vH%? zLZ_IxPw?XLLGvqTTCc4_!^^LYex&ck`Jfa;(q_Yf3O2Ec6-YH?l8_}F9J?u!Xc5;u z{f0}U=G*Ri%>#)AcXe%T?Lux3|AClu4gWfX4g-AW6U0B_v*t4c4rN-Inj_hBGH+x` z-uO@(vbyh z(x9UshVt}i!_s6W6hBY1-#~P~G0?*l+4%J_cMdO z?bPNafyQLd!!~4DkY5w1a(d6~?~8`Ewb?$l9_`d`@lXCIR0E%LT1&TtN0E55ShOfr z`Qb~gx8#Q}zcBo0#H=8XG-oDJd~|pollIE~+v0u|lV**~nzkDC;&+;M_#U>5rnHtw z_^<)&n%<Opjt+W=aK%?( z$_LyG82cD{9GXQI1*&I9Kv|WCr_Cq(45HE36$zsr3DGiY5)Z{Ze`eH1)Qq4PJ^jGD zQE81b?*qqA=fCj3yO`;49_xzab2u%d5iutTjr3SMb#yP93ve)!Mt;o!ty`RXf4fsK z?aL6Ty4u&Y`WT-6`w4%C8_v`GBbawi6u4qxw0&x2qs1U>AAU6F@N4`Wqbf10{O6sO z_GHX=PR38DTez=_%+BXW6&}tJzDQEkS%$}q`Mrd{!tyz@d-b8%H}|llqM|MuF6}FQ zS5+P6>;CsSn;344hdl|9K5iMg0Q_BWu{R!yjXzx!!W1 zGAGOHSlVrCoo3uWJNI%xC205K)QEXkc3~drx8d{jRF_L}bi#%1@-Hw9xj8Qu)d01y zg|OYuUb38;qlYJpJDE?wlH*!M2Dqzzj{Dd2-`kaw4u^QH@nw-;6Sp!9ss@}Bd?hGL z*@-A6+1iw(dD_IED0yB;#0wLT&j|fy-^}vIs|lTh>&2G=pMa~`q61cB&s+G2=kl|q z1^m;QX-o}+1oO#VeDB@p4%nlX!;LTZFXx2dJYNI36GW;}FyiC*@kzWSyo{smzeT7# z|JoTF?vtNS_s9G)-difYMy=#X!K1}qY-HfBq)@pd2--S|tTDkUz$TRY1NBOPDw+(t z1x4>aI)bMGZd()qhf5Ywd{r=7A>Kdmd+P!-)u zIY~H!@waeMe-!0DIXanr*~_FWT9l>Gyt>D(@Tp65LyBdB^6dyJPT-v@v9WJk%*Nd{ z_KxsF@5^K|4!!1><(^3Xw~EhR;9^kAq#rOX7cm_QqFI~$ZjpPOG1r-0c`z5Mu+>J0 zfHfl2A2Q4@3f+wP(s{aZ6gM9FqB*OD65B(Y2O1T!v*Vw2gBaExyRT=VW+i5?p3^<$ zH1C`(a(-DjcFk6A7i@WtJLx3`|Ec+!YiIPtNWaEv-0lVL-q7DcW>Kq$Vd;&fN=P|7 z-dWkE<6mu7nt8G9%^Y7K(CCPfhb>_5O=+X<_I?_v8{jLq|2VLhtz4JpT2C+&LccU= zJQ-t9=Fk&DjxHPpK+(-c7)5dWCL%C;+DeN zuwHVLQ$5hS3AF`{Z~rd0qI#~w#P{N_yc)me#_W`mX2MvwXnFD&v1P?1gS81~PcS)8 z_tC^3XYhGNd zTJ87js^X;$yLi$>)sWZLhN9S~l0TlKKG9*seMhU&x^-STJ9CSrqNmibJKBJ0s}$Pd zEbp;ecCUKMhJ~9ByZNLQ)kLGd(2l@pMif@wcO1ABxH$%b(y+fykFyJ2GC4*%;(ea@ zBqt+E++kPl`ArY?qe@nV_FQ{>fI~3@FqLf^^ zy?3K>%StF0c=#b^AV{b;!tYUi2`oUJxke_twMTGmMw}ygm~od(;a|7pzlX1dGn`Lg zxrxlVcl}5IIMZ!(dLU^vHks||K8X(*EPu4 z#Twc8oqh&RLZPOT%;&PgPoH0QQU>Y|xz8S5XgMJNaaOeGe!j87_IaY<^Y3xW zxd>E!_iN510n$SU<7<|m2ZwT_ z1RA1-WfKV5`_Nd@i-cALuGWaSoI;Mvhr2K&FO5?^qChpB>=NCXxU;g!bFwPA%?JkJ zBw2E^$G>%MPWNSR(Z(^4#1f^22@zlMTI3NXwtEjXa{Ez!CtuJ%l2q-t1ZEUe$;*4f=u{;!9w1 z2KF1huB&N`Xwy643x_J6e;S~e$KURVSNI3@Eo)pAtt@lgLPA@$6Hb0SLov4El0#Rh?#mE>6Ck+(&>9=dn zB*=vLqN-8W_kf$8^F345e{{DeUXuRnDD`9eSgd%BQ2X43Y9L86&tVV!EmD&x@nO89 zU61S1Eu|PSG{pA~nf`K2pw%1wvJ)fNvqN~%f|E$KvslX`{j{$)RdB}}N39q#F1*?$ z#lh z%#BVsl;&o$|L9`Az>!toH-X6rW! zrr$7LmRbzBVj$)KUef;BecQ#&`NF2#%~>~!FB`*W$0QI_J^>PV#|XRL2`+*5C4QrUZ~@b@&M)Kv z_#J+I(%yaY%jrFrJ@nX>hZEFl{5u|EcbA+|eL>F2m&1@z*JY7!W`^5i?&p4qWIv5x zG54d-VLc`cqDEi(H$C2vSEy6w#@lnzsKaA@uT;Zm^Qvu-#ZdeXKe_x4Y^Q0tfLM+o zao?9x?@apRlwYt&IL*oVt>u1#b=;qbIJCI)-EC%f`adxVOTGZBQ88@5+4RDJJX7eN z(Ackv?#US{cs9k*p&D}9<{7C~0HY9sUn*eG>>I>m9; zfv7}y^~wDurQ|qOUVcjI=E6G>;aO)dQN#@(94BDMvm#_ei*m_dmSSabuqDJK`F_wy zmD5TNh16Kyi_gvlJ4!z2HNOuXR+&30b4-+dGv9*bPq)efsiK2btfOQKM;!H#`>5%O zKX8Ir%;UIrTmN>Yi447s{ufxT3-b9SxE@*(v%Q5hs*MG7(gsQ_qLd?rk@CDkA!dQp z33leTV|Z;m8_C=GYv<<)mp{6z_Uvxtl{4y$hD@zP%3HC5`)L#`Qg|c&8#%`NEPV8G zlp(zk($J7tEFC2NcM$o+y)MT94CM~A%iWD~nTLFIIn*XTyZ5`ODf?Y}{N=~})wZp^jY+0id?kw0jS zTrh7PSuxXl30O(Is`*yTJsPcIfDR$*BI`uxi&!-_fyO+8hwU$D#`C`YRbE4W$MvO3 z_T*F^%%ETb16J{grAY__W_ZxiYH&q)W+eYYM}MTm?_ky(h`D-K#ve!6{nciwy86+B z--60=9E9?*UWa0-=|lZV(id*j2i*(Aqh~kw@`dBZ7twv@w{%ku7NI`q7pdPmMZ4M1 z=LG7fgA4}4BkyOUKE{A69+A4eIzHv`twIz+BjS_?p+I_Ej3hbV1_^9~sgBKfW9BD? z=F(sD3W?PskNPzbp`l5!g?Z&RYeWk+yGLmKm~ccI+vI`mt}!9+S+Nx{Fx?>^GleKT z{IwIX?9@2A>Qf%6#)fKvdoWKho>njeM+BJmJD(Pmd(ESJLx0jkd_YIO?99FACHr|# z*M3h=-+y@T$ag4{D`%|ZEEwL#+teq(5tvq`W^p!j6YP8XKw5i;++_`jQC#Qs`L zvxzn60m|c>r>Ce4Vo1?-O`*Xaj^gtI8F)6?4i<6rG#y|Ibh^ovwRW;`J;PQ_Q!^C6 zPygYs_bY}@uMn@Yo839h6Sf^i*^5nK{*Shf&-U%tsu5etTwdqb8D1Q zxqSDqt}_auuXzTx@yzlGFyKqy)$R{}Z)^Z)jNlwUp3|V7L0DM0y{&MW4a0NZ8DmVo zqA@D3tPBtM@!h%7*u47p+Nu1^Tyio5C{j(Bkw_@P4CrN)`0;NQzjdK4KzJM%#b}lN6- zJOVtl{I6dz5eC%&rIh^P!|Lcv!i&Oz(NWdy!3WhyKHGlI{|Plin&!s!4=2abOvO5} zkREg^XA42ui_nF6^9l=5AY)@=FiA`PR1?=T!88Dy6&vkA?DeKRRAEOebFWYeVJ{+x z?W1t|_f(C4e7VAy@d6V)2y>-p#9Emsx$Dd=vd8TA@81Xv={KFHWU*b*U#3wYA_*u( zqy^(_Ov#vXy(UD;ayMt~d({>Y0&F~=-e>WoE{tYjpL#WvUS8-$_-Jn(7;6OfZ`{r2 zf(x4r5P?hu!LJvn(5jRsO4`&$GtLDmm z_Yh^jYS=le%YAFQu6eKLm;NenRq1MS-KYeP(SO(1naE<1q9F?up_aM+WPs=@$S_%E5Xr7tYzj0G{^cA0S%%%3Y8VN@E2_$&OD6n6?}t)Q5Yv}?15l3LbS09v zx3_Mc4QcJfNE5DeA8&V|o!IKeuDV^6mJ&50=J z_g-8>-Yw=h>%VW|!jz|3`>@Pu##PJF9E1_?(e+M+#mV|`nwWRBWZ;~`Jvb3wZinxm zY`7T!yEGBsa}FwM>LXy=4g8h7JJ+g$J2+KY{M&>GN>61Adnd6v4|QHz7;2a+utAV> zn7~_FF$j?4LCSumsw6Z#3F94LGhh8-SNy`Z41>;XPSWEL4;Z^U_tSd9fb7HT=BU5Q zX}SAz_w*jH6utXwftuI^%zsKvI_T`}?NK=2-y2u7ol|9GWWchF@B(SPx zQU3Nt9a0MYqTFii1zB`L19qk;I+3P%W+Zu$844=bO-%*Yq7oMycY3=O#B<>?j1e+cXQpn5SCkgxOu8amS(9=g5t z;9O%au;lx9r_C`&V624&oQlGD(e-V;$}#pfYjgHq>)V1^0)aF)H>2x6?BHNk&FKY} zU$|556UNU1?^*+Qfv=ve+5sU4H=Z%i=Dsr;6Z(s|4uO1J(an9w(7O<>{n1$9`HyzV|5;GJ_n(!RDhjikbTSx*vK6uUX%}FV`SPaT9{9ewGHl%0-?9OeR zhk6rJ%RMQo1g1G4qBE35&QYvl%tH>>xC1Gxba4@G@%$b=xxj&z=Q$FQbRC%8#VS2D zqY|0t&9~2M>*^3rfL{I27I`->WIpv^ehozLG~gO@-KHsciuz%IBtNp1VA;yVB?fNt z0RE(jr<4sD|HCm0gYf(6Yg$B#03m6|qX_)t)w;JQ#g>wK?o&xxNVv&iitGaq!D#N&AtBpMNMBn!()D9E;mvG z8${B6shGd1k20q)_|9`8avx4I(_HeI$bNL;FxYZ9 zd?PNHm5LXoH;#H*2{uE07wz%l=05uNhR&&8f=h62XdxHLl3Pcy%XRgnNT*ac7{qQ< za4~eN-$Zw)aF8icDRME5>09j2H$j4co8o17&0MyqE4uAuIT8eMAcewC^lud!r})5U zNaN9KSzjn2+V9IT*!*PU_5P{~oo?beAk|aReiTGa&NSvgP!oU$2O^&MKza_&B%Mde~|H2s^-nxq9 z**ax_bt9jJoVQE?d7QI6f63^>fW(1uZ0s_#ex;%KmfS5CGb;&Y^z0Bk!TI05VJUDB zpM!&55Q45SaNh}6eEkX`>KQsYIXME5Gx~e55C;JhO`zTDUvdO;v&;U#8~JmW|3vAu z)LSR>y~ueFN!CYQzM|#K`eg*HT&hg_F{X_b7yzMNVCd78I(uVKj3M!*u)OuWZF#q#JnAb2b=h z9`GNsAlAZyC(w&rIKJDyc)VmUE-Y;M8-W~jwM-Z=i2GN^i?yxfZj0P$MF?&U!k8MC zL+RV?KgX(~@DxZlOlIu7Gx_$nd!gg98uObcig$kkB0O`EKRuMhvx509-J_avJyfd^ zpY;%Hl2L@~u0)Q%5{ni!7_x}uefKxSp}Bj;^qKS{WTzfDH{zPQ&0wJ}Zp%Eiwfu`M zml~xJBmD9|@jfadbi*6B`9GHc{4i;#m;Il=SWWY6{u>6UGtrs4^D_VYYmvCk_hxS4 zn&h7pq|8ZC-*K`28|x63FQ~{+Lu?Bv?EZ5%)}sHLViS(@IMYP_-yfV{PybUe%gObG z^$h**t+66g|NTEu$PxeF!iA||Ij`;=C_DvTN9_DW{9T=!!fm36mHe*c(H#TT6FVo) z?e3mH`(DN8h;bH@hB{DDvUk-ZhdNR{n=bjcRL%ey^Zy;n14F*J|Bi&>|NWNb|6Ky4 z|L=1Yk;pI`VK&Qr`@8lrj57b&2eZx4cVc3fBs6l6L(LD~50b0B11dp_sd6JoPf`h~Xr zl9Z4rm~h7xUXIraR+hLg*|-(L*7CBXQuq^;s1SSuM~|L zv;}CIS3~2Zh|eh-aB7N`jeO8`(t0T^!|1oAWYTTqxez{_Da;JAS^In8B|l$d2&C135+yAP`6F)chwB5*lgfaZ?t99I9ypykaN@{t6Hm^d~dRo5msX zWGCQ)P*_(-3hXXN8w1_l1;I)Vn3d7MnzGy7=mxwxdHZ2FHv>^LY|;0i5BNrL-FXifYL3L7ew{auJJ?DFqDE*K~T15p9SR>wu&ZLXH5`&Quirt=0 zAiQ6JS|<*i9~&=O0OJwxYDGnFD{~|NJD-2^K;PuH8M3cgK9Oh2(^kA1^3Mi$9DZ>C zmPlaG@ZtU%Tx6Ix9q{>PWCEW!N{-389}(&yG{D1n#qTLofm!$4eZ$t#RJ|QF|IT=ftD;i<^zaYy4>F6@?iWy-@}0jzl~+sls4)&D&Ue?r8#lrF-+l z0|FOd+8GL#h`g#QLXg2W0xCSZAI-l#xL$MKz%qw9O}Yn>@cF3+t_}TCrsB>+UeLh! z7xccXFQj{vbG;^7d;R2Ina$_CE(z zy96gADA||rj(gw6^2}2oHj)rt^oowVr*XWOU|p7kRgd?re)X#3FF1^_Je>6YUryV* zcR?Y?JdD1OuqxFz!u;En%rOj&vFtzL$OtM1PT^_J<&7@LE8da1VT77wim2GeCkC7r zB8m+<-(6k~<5r3Ro?2hv0}2TOeI8xzMqx7fap6RSV5Z$M=OS`P9BhA~b?jZQ0dQ2 zM+E{s79{BW{9Gb*0r&?;VFD2)NT%=KNg+IODok?8+~%GU0=GviYwIqcWDh#BLu-b4qq)v0Ia zdT0y!JD(T#K{`jCD0wFW{60fe{kJt=&J}x9=)8WNS6xj6#Oqxk6jg%CB+e5B(G1e% zOoMRF-03#(Nbq(vf_r2;XSQWYpKQ9AVF!n3+`z}C^PKW?Y~-0qw4>NMLxZfD5zic# ziO{(K^z>Ql{7LI>$iC@H?I_3*5mnF8VGq8=a(B3tsX|kflx@6~Kt`>=GIUf+|-m?$?Ng3`%PPV|lP zErVhYrG{jFlWyO`A8gjT-YasCS=Oh-Fvy9J5dnLAZ4mnD)}7*A+nY4J##He17ZKp-qpeli{bc|iK)*}Kv0q9P*R*!PzOP(`eiPhKppm<*3OD;cRc zS9*R3iqV=h7>Gg)(LM|qbFt41c?Tet$L5>QEC>6;L7#AaH}fM8r!5kZAR}3#p}^~M zF>qMuvHh4o=+h~7ui-Xnrvb{NE?Io>Fu=MRBA;M^2M6`h(17 zWmTB3(n_Y}x6ne!$%2Uf@eiPByP*!$By&Lqa;9Rd_~Q5)idX4BvXfR>&16l#HV)RH+BZ-V2kI( z+7gCXNns#6KZ{>C&-K)B)jW+n7`+%h*Dc>UZ|Y?o*CmPV)2*=n8QW(rW&W0h${TD- z3~gW2VTYrWyII-_pfx0{GJrCoXDJk2e(_r1=DzRizOHl5`+eT$oU6B$YcH_bYj`j&y$u;tT;Sv|VmrrsN>D=Q zVhq#7i|^vC59ZZWd#RSqyVJ`%Esi{nY)tnzY@n3epXKs!bv6d!O~Rw0Tl{#%uU z;)d&oSOm`f<1^KsUsL0MVM$x@*-+ta z?4JUmN%f@=RwgDU-3EOf?cT3n?|=Sm0vuVq|CO>}L+L+%{!A?A?y9K`c0ZxYxMAuq zis+A53aP6xa&iU+)#TR(O2oUo%JW?F(NIb7t?gnkk$!c(^qnbo!ve-=i=m(SKAaAT z(LIAHeO+353EG4M#iNH@sVMa#26G;Q3B3j>ohaw{mc_BgD;5^5EN>NxaJcVXGqVhQ z4F!)~kGpv~0=KOD)Bhr}ORa9FYG-5}yRPZ6#ah#US5d8XCGB}*WPcPG^#Z@ z-{TEqG55YTlR}<3!QUt5!F!W74tD2`!fstL4u`NJ1ykw!`eN^-s~tH-1slG{E3k<| zRI~5%TO-90)%@VV(Hk-kmZ>C3Lc5Nn;<2{d3NUPI`Hbzcc!e0<0+`x^i@T^OrfgFi z^K(nB{icG^gPxh^sgW#hSZ3qrm2$`8wA^XsoyLmSV;L{zv+;MpND$j&?-}*J_Bcfc zgnIN?pP4B#0(O|R;yo5Hh!7*9w*1e9<8(x%PMk1oSpLXosCZqv5SlJ0@_D^+`1fie zdnLc;y?n{EzP|qNFL#qj9Uy3Z!}*(ARK)W0{~@Ccb8u$V|APhx3OWBbl>>+fBDnv4 z_zyfn)>TK5KVIR#IA-5}|N01vd~w`^lO)8}u(OLFVP_aq^v{`JX*5>ky|2)|`&8@P zzdx~E1Z;I_@*jSw!i`Z0j@S$FYb}A^7{2&3Z2t@LV$GTIQ{?_i2>X|5M@4}DbOlA&V$l6B5&G}_nY~-Q#4E!73sWZ0VZf`K zGlu{G%Jvv#a_&``2~!jM%(inH&f~9nTV;}c=i2#v4=3IP&btXKG3}3<=g#z){mOd6 zgO#6!=y<5lSUcm~)tl1yVQ88NCsWI^8fcqG+{+zcw;&kcbB=l(c&y`v8Cfq>a^@!& z>Z^x{Sj{p5-THE-GIPEerMP^1b9D;lra&50BO)t{pI_rHH%yX8B;Yxlnj|ONC7o}5 zA}m50@x-le;(KP5(TK#v#CWm;Tf%wAc+GQSyb0elcb7F0Vsx`Wo9WP@$8xs>@n=t(}^dGuLAY zYc-Ze$>ShP)?Frx6{bW8gc9ZM_p~(uSx#0$l*+|Fx`v>;B z-$jL55>&=x==8u{B@9hy?(7#o^`^TsPB8EXdUZj0=P>%rpRXm84RYbz^Y)G~)COUf zLqm}Y!F#}&UyR3vQKe0EP{Iu{C`R*_Y19xA5#NnJZk;3&7s_|8Uz(j=q5V(2d zTSyK--|MO7k8*S6ADIW8rde29pQx{|58vMWm4uZsl^0L#7j?6Y^8YD(!MTzQJ1`x;Q>kZ6iD!Nc6Tr5&dgPqt}NfKRf(jMAt|uidL?G{vhzhjJ+J3&4*XYA=&>RRg5ktiS%D_^`{|Cwdc63 ztSr10z^XMgSb*VSX=`_@rr^rmCO*Hy%E~LCLYMY&EZhC?!1J(@va+F{Up1D!in#$w zr8}cFw;YCv*xh7}c|ff&aYpm(zN%X-ku|4B4!x#^{Dzn>cEB3$s<6J^$|P4q7EV$X zOf2l|>`d`im63-^_THrjx;fkD-zZo@k6U@vcNi9D;O>1ODwTj)HB{wKFEq-K5SW7b zb*V5JT}!36py$P1n!EjD;2R_aVEDV%iIXRtkOA@=uK`4Jb@+U@T?)-WCBqmh%-fC^ zuV1Ia%h+=~acYfJt&zmCuY@!JxB6EE)GU9%eqL6ys`JYBfP~r?r`d9ipuoTlvNL9f z^_=%a1niF&FZAC{dJ|W8B48lVO|X`CfD?f|lKy9AW+oYmZDRiTK8}G_RWF3(KyVQ=r3%BOG+vNgc5Mlv_FFB@%H0X|z5V@Ss5{VlVqsFSO)z}TVRuPPn%aG9 z`_-#gM>>4AP@A{6jH3v%B>{x0D)V=f6-arCi1v)J6^UNa+7i5MC#qYwGgnRPL2d+)P^>UoKG=j`zg0bRL+y#5f3mtB5LMmyLA%VW zxo5)kP#>Ntxrc7=;KIEa#zaqAU>w(fPlweWmAj4+y}@vB6!oFT)XAw3l|0rM#5#B8 zVGP1~aiFTgHUr`C9VtvjN=Xft(De$IFiKJmb!X$xtU*ULS@uT71(ZIJ`ec3{I0|u} z89tY^e$deYyZhY}jmZRJ=nk+KZNi35@`#FbNla7I9=yh;T8U|n+F7?7H;S;d{hu^e zHz~VzfeS;z#iqH7evFoiyeq4f9RPGWV3`ixn!`9PuY)awS%_C5Tm7C}6bhD(qN)IW z?ZV*NUuvecUSlUvcVLIW;R}h?Eijg8^^t$VU=+yVl$L3~c$AM-Mk=A)q~MvfuMYK^MH|$;O~1lLm#y))_RvmJJIF3sLKNt^Lw1Q(RnJMqng# z3a(gH-7y$B)!x6Pe~L}h??*f*C#QZu0BHF#0v*$}I%oPU!&r6*598v*B_$;t^LSp9 zl=U-o##965QX#lpv*?cu7}(Lo+Zlc17vS&8_B7*@Ndnsdhok87QwR`YMhJUhs>g6u z8$~&7z#5pkttuSLSLSBcsKp*(Ji%e!7ad7sKG}En?25z`)T`l2OO0W*PcLT97U9B5 zi;CKbJWr+d7vsjtaJcv7-O#ij-J4o_c?Avp=ySZuvo6ji69LeuT`#wjh39qtlC5>+ z3VW1SgX#hoiAA15z|945mRcnzscXIIPOVyRXm}W$o~sdZ!zy=ukvUn^3fv>2f8osv1`|^nHjcmMX}yzOVG{7 z>)P51X!uYiw`f(LZW-Z#D$gq_Vxa8M>ndTjMu9tGjBYg`<7;d8qOQNbF*&H!NHk~4 zp{@rk7G~I8^z@YV_4PHgw@-3adkYHMd|td;njc zG+i%PM%)P<^=@U}dALXU{L3Q`<;klv1xXj(6COTf(iAO=`MIgw1x9!@e3J&A`^X5H ztbiVG!VTgFf`4~PI>dvVE3S`TM>QJ^*lrje9*!LuvA&$8$_}(WDgwFrc^k?*fuPZQ zjva~X!;hk-fgA>PM+dErvgpDufAXZZgM&lws)UVAofl{xgf@pdP$*yq+o&3=XFVv* z0zgZKmJhFFCr3f1VA6hP+8$XM06s19jxxvi%y?#cyNWc>t&uiY>+PVu1IDyQQlz<+OwMhfKB9X9PYieu1 zL01V>1XKkgNm@W^zq>u^3R7Ije6Tx)-uQ?@WOfQ912r^rG9Tleoq==V+pM)$kgFmQ z_}r^<-LNoqm=IX+hb**R=&U%xiNfuN^CYinKu9kV30J>*?b;-SO9*f7RX=?Uik9$i zQPod1f4x6~ib%q4O?h8rLDDKmPhQU}EZonh;`OJT74i|WGFyhycR^&xfbtIve2&L| zMO$nQ=Wg>rBLzXJLOJWemF`}By&eA$M!G-wELlK6ApBeMg9i+nEnNU)rs2@?VA!q1 zOElZL!BrXYeRi6rQjH7@4BBxb^s-8IWSsDn3l~0M2psa4FUL`LAVM)%a>sNHjTD+`Mny-3wy$UQ=l%khc%&f=#Pg=S$CgxCFby3M z<8#&O(ZBFV{7RrBC0a04%I&HJ1bL8Q zmM|86rr`Jhm2BG>7>mo&+}xBI$laOE-LMc}ScdM;9H`$wu)2&2MdWfxA8wXmi7^ zuCDK}oeVndW+S0EaMF{pVP;{h1xCL24-7m9lLXT#UA?^8H&*6jW>lrW=Pk_C~mij8XCMYTigQ-5L7k4J$QDK%)T?bYgmGRLA~Cfw~ed67d|j@_O&AUw*UR!VxO&cD)VEQ@o= z31N^l$$ATu7q|Q@fBGQtYlE~%@YE+26bfvH0ZBzs5fR-9fxPfc*}YOcJ(o{2{BG}j zi6|~~Tg`538I&%QX_j^^F!7C+bm!vp=p(3bIF!z#_R{xlyz2J@h--srqr#7BlBMdi z7c!R7F}Kr$V&aP#7?^}t z!|ixWEehO+%J|)V*6t7aT0!QL zcDyQYei*X+W1V6wHs@<<$_l?ag?1mzs0;8}T^vL7j7Y*ah7mMzpyIQ4fF(e3J3!XK z?nt|;+z_Fq!rV9!`yxMo59;TiKGS_XyuKc0SFn&9g2ZdQ!cetKlD$h-auh&Aslrq6 zASnGtHW458N-hvxoQ`1xNVUWoqSy}di!v?v6U0Fs*CsSQNf2gl0m0gyw?sx>$KxVU ztF7nbQz;a@^3_a6UcLjyiC4N0%8g=ow^bos1YuqzC~I!kRQ0yG@F@bBj*5U|x+hjQ zwUE~Y51mq05=7L2c;j*r!mA6{s-xWv8H#FwysLwheC32uf&~sVmow&n81DWF1InRCJj)&Dq z%k!9`%&L-_BdpHN5Y)e0RvQhWX8$6+NW&(|$;w`W!ztwP7r;su7*LCd=Y(Fkm%?0Q z!@HA*>`|z#<$b#!Ye`bqt*j0@9)@F?pM5AG5Z)sy0?zT83N7VDHQm`siu2*%c5;-N z)OXWWYZy@va?c;TW1!Kw0@*~(odQh;j(}iQNR$HRJlf8Uor^Bbs3rV@ms`--cwYK= z9i;%AJ96X>9h3P<8U_Q8#0JPBA_~%7I(nDk@I?E-Q72p@dG_>J z1Qho zYjfKP$^?0Nl>xr^09+aJ{Z%d`K{qry0|MM)CxyCPfVocJR84xT9ZEFloPVd{k z4EDtQ#tkXRH}3SG-F$M!B~dj|6nqjvP_(Zq3GBpC6oJLIs7F*%Qg0kW%S{U+EF@58 zzpJsuOeT8OYNW@2_VppY?X6gV{$|EN>xq^({WffO1oK}cPN_C}KpVlIbZf9t2B;`5 zFK-IVwtc6gmVlV=ICDc~^!S2MAGhc#1xrLFgK!R)*3%3cHC6Wkncd~y{h%{&ru#Oi zZa{j-uNZkz_IJ#wFDkSy4OcAxNtdw_v3A#d_2LuV*3we)(F;romoN%o!_(T2A9uDl zVUn`e-+%wTg|`$oE#U=UR{8wdV^nHQ61P@#M za<->)c;=Pb=4K5y@=l~z_rUzz+~1v_KCPS?S5{Gx-2b!X^;WIMux_^PZMWmyJrJwm zoK{$!NAOADBqWu@Ru_gvt=*rhpzW-a-{oNzW?pFk;D9^%3>_VODE)ahduee9jRQ~x zLM;P3yBuKTeE9X6m$R3|K2c0cN$uRbH-`oWlqX1z)r$u#i}g!Mh9$T(3G;5jo8@PN zKi78T_jKk&d)U^x`=G}fu0bdRlg4qh*W;01o7RAhK*Dkz3??Ag4&r!SP0bqlu-=!k zk&$Qp15ZvlMA~EV1JG+q$6XehJJeC03X7P-@)=6+TBkmWxvr+7p}2`QPj(`YXlwe?gRI`HE}@m z0z3lH`9D9NA*}^iOW%jSAKE%!Mn)cbiybai5=qhT9lhD;DaH9aI;eN1*FG%gj0+27 z=T-8iLdv37iM!i3h~erGwErYic8)=$^iz%1eXuMcch&qyWE}f0zb6TsZ+5pQ$AioP zI5@mM^Vu`RZL2{K4jA~Y*Sp?OQ^QHFLwA6|-&#exy1so0y#U_-k=#7HP%&0kR)$kM zuDCH&`|h<>b%ahClh|C`>8Qu~)U>q8llJRO$YX(@+3M5WK7zUh zr#76vJb_nVtDyZ|ssuMpMZ0v5WWa;}b5Yo1^bMj?2&NCa^z`)HLqab2xCX>}G!Vg4 z(Ao2Sy~<~3TLj4nwkO4&l)ms>5M0c?gqwS~=XKv~s(BMZ7g8WPqh;H5&^68qT0y}* z>Vi&34g$~T_;gVFcOy>~wjgi|QwL;-1Py8ESyECmtE4SuYvqxh3H%&H9WgQbaDuL0 zy(;F(wUA&!SoXkZB8YdFU(s_!k$6C)Z>NRo^66Pxe_Succ6?$Uh$8c=S5y5zUIjzH z_X1*pSc~OlWsjEPvoyj+uyT04UKYngWf?{VrWMg=Ra7j2HGeNw^@kEVU%C@mLKr1D z$-`bscj``ex{FxxD~5%o_CgChe}L2=RD$3fw@T6lM3IYE>(k~?m$Y^d0VTw?0if@MPC22a+U?vv{E}{WviSU*fQzUCZmK57ojnBx!FA?_N=p-_y*?Vxh180w zEcnMZ&zbyONvOX+yT80!zFB>z;he!^bFzS z0i~unQ>$IHKm-QYi?|K7H{}_ih{9!i#4GI72F@52P1d$Jr29jHY9>S0MgnyQ06=7_ zc=PE>ZM+OwY6K`6?B&fT@Lq{HU947Jc0mIKp2WK?hwc>pChKMhR5{hv?J}T`ZGD&2 zWG}^oQiZH(;^*7x(xE^ud1PNojRfB(tYT^`W8ViyO z9rL*`Y-=}-<5G5Zw!!AZm?oMhdYRfkvU*r~OP%x>C>XyVAA!09%f7a9nhz2Iz&(Po z!zs-~POr_HV&|}*b8>RRljhrR9*k}UZ)`s7<_|o%in21j9$S=09=|mT&E~ANvAsA0 zb9gx%jL^ZzpgS=nM-nCj7sKsBFl8mrC2=o*`jut*BL4I6aCUr!K|`=OS7h+B|G5KIy85F;i_b8YA>gn|Av}}qU}UF zjVuXY02!p3y1Hcsa|U?RkktOx`QvlCXVdTzt-1X*Dqw}0+;uf)PYi!Sq-7$th3bmD!`(Sc;+!AL-|!Y04uPrIc@YiY zzd@bt&;0e2qeLB^=U*mTq~z7B$FM2ZRBSe@f`8qHjj+S~x>*Aa7b zMX|}z4j&*v5d!$m*O%9z*V_qcDJixNpGSLrd9yv#@igYlFQmj<6`uB(DYC}tPqX8Y zyg(%bkwz>QiC zYPjAx7O#L@7#!9z(VkUfEzg5oYmBhZc&cY+toqpO6a55T9eaEK=l8lG;aHdo9>D3Y zy6XE=PZ&RG)WL}h8EhO+<7^_|632%Zjn}i-U0q=N>8(2IVy^U`;1UcjxZXb@K2St_I9}eDIHeC^FEnC0T^cRU5sPEKlB8RJtdwR83u>5v2`YDjk}cmKA9-Nu zeqwq_xtf&u`f+YiI6d@ve|thwZJC}3`<}P$quh^6G>qh_qUU)#=}!>KZv}JEQ=}Sr zE#jbDup0S1cTs^-3-|U5;e8&lb z?Qjw8%u}!4ytyF=LqOvG@D&-gF=QZbwe!^dPri;`<+1%p#sUzDL8tlh@84Sy=cQIQ zZ|yyJo5m@CN&MXZgWDA&s${dik5w(%|24$s-H;u%g8lLwPbZ&;05=^$SHJ5*ouuUC zj)~voPnN5^d@a#{Yvy)^fv!1^<0Fn|L%E(De1)7yK6whXbNk_NfHos%Wn?sGUR?YX zfCJVdlkA71qoW#w`NpyqXeSc=OfvwB;OR6=MB=eNKjLiI+qyI|mmz!+Mfn)0}xl(`Y6=0C$`lA{(22|lD0Z86b-aNnc^yLp+$xY?kt zk|d-lh*TG~PZfp>o&G9ole_u1-(eh~XVATcZUW)}NTMcyBZf*eU)#lSz`2oHDz?60 zzHT!q`zGhh4ae#HyvPB_mnFK7cd>*kvp>#7nX6=n_iw^}y&1`w8Cs;9rV)B6?I8tU zSx7YUpQD_)Ayh?3d3=I%$$T zmsQSU&PTK02<%&lE7!s?vL9*_bbjS!8a-g|dE%_rN4+HSCN+9{P|lGnt}T?t6HQC= zdz_JPkQUlgY1H~x#u{T4nb)y5GHF~xy9m`bC(HP}Qu@v4&5Fg9jzveli!%j+I62R$ zdco&CFLs}KZnfR6#1*!NHr5|$nmy{F>dfnuGJ>kfRj?pf8j642o~R1)7)@Y~Dj_{h zKY*uNHQvFMy5!6k%0|0p9MU!%i*LJamCF}J-k%{d?`cySFmn0@<6Y-XLREp%o2}U) z&L(FUrbkf)-WwchOT$wu*CkJf2`yB`K5dpP0nrI9p`YEfWV&K-FT?2YvRab*n2x^_ z&zv+mPyI|2TTh{Ka;VCe9Dk8HA<}kgLVo<#8%|x!dix{Df6zfo#LQ)v=PFh)&YmC> zejru~Y9;=ooqz7||4E7_R9TR+2a)GSv8_8XaucifVqEXU)0dZA3&L2A529$}ZlD F{2zGFR1W|E literal 0 HcmV?d00001 diff --git a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.en.md b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.en.md new file mode 100644 index 0000000..d4ae6f3 --- /dev/null +++ b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.en.md @@ -0,0 +1,19 @@ +# What happened in August and September + +Over the past two months, our efforts have largely taken place behind the scenes. This means fewer visible posts with photos of meetings or events on our social media channels. However, this less public work may be the most critical for driving meaningful change. Our focus has been on three key areas: + +- [Patient Organizations](#foreninger) +- [Academic and Research Communities](#fag) +- [Social Media and Outreach](#some) + +## Patient Organizations + +Building political momentum requires broad support, which is why we’re actively engaging with patient advocacy groups. In recent months, we’ve prioritized outreach to 10 key organizations to arrange meetings with their leadership and expert teams. Stigma and misconceptions remain significant barriers, so we encourage our followers to help us break down these walls. New endorsements will be shared on our social media as they come in. + +## Academic and Research Communities + +To launch the pilot study—a prerequisite for the trial program—we need researchers willing to contribute. We’ve been working to identify and connect with potential collaborators in the academic community. Prejudice persists here as well, but we’re pleased to share that two researchers from Norwegian universities have now agreed to join the effort. More details will follow in the coming weeks. + +## Social Media and Outreach + +Strength in numbers accelerates progress. Since May, we’ve concentrated on raising awareness about the trial program and medical cannabis across our social platforms. During this period, our follower count has grown from 1,700 to 2,400. We continue to ask for your help in sharing our posts and inviting others to follow our pages. Additionally, we’re finalizing our website, where a wealth of new information and resources will soon be available. diff --git a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.html b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.html deleted file mode 100644 index 05e7151..0000000 --- a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.html +++ /dev/null @@ -1,19 +0,0 @@ -

-

Dette skjedde i august og september

-

Disse månedene har vi hovedsakelig jobbet i kulissene. Det har derfor vært mindre poster med bilder av møter og lignende på våre SoMe-profiler. Men dette mindre synlige arbeidet er kanskje det viktigste vi gjør for å få til endringer. Vi har hatt tre fokusområder:

- - - -

Pasientforeninger

-

For å kunne legge mer press på politikerne er det viktig å være mange. Vi søker derfor støtte hos pasientforeninger. Disse månedene har vi fokusert på 10 sentrale foreninger for å avtale møter med styret og fagavdelingene. Stigma og fordommer gjør dette arbeidet utfordrende, og vi oppfordrer alle våre følgere til å hjelpe oss å åpne dører. Nye støtteerklæringer vil fortløpende bli offentliggjort på våre sosiale medier-profiler.

- -

Fagmiljø

-

For å få på plass studien - som er en forutsetning for prøveordningen - trenger vi forskere som ønsker å bidra til dette. Vi har derfor jobbet opp mot forskermiljøet for å finne aktuelle forskere. Også her slår fordommer inn, men vi har nå den glede å kunne fortelle at vi har fått ja fra to forskere ved norske universiteter, som ønsker å bidra i arbeidet. Det vil kommer mer informasjon om dette etter hvert.

- -

Sosiale medier

-

Dess flere vi er dess fortere lykkes vi. Siden mai har vi fokusert på å spre budskapet om prøveordningen og medisinsk cannabis på våre SoMe-plattformer. I perioden har vi vokst fra 1.700 til 2.400 følgere. Også her ber vi om hjelp til å dele poster og invitere venner og kjente til å følge sidene våre. Vi jobber også med å ferdigstille hjemmsiden og har utarbeidet en stor mengde tekst og informasjon som vil bli tilgjengelig der.

-
diff --git a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.md b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.md new file mode 100644 index 0000000..88b9bd5 --- /dev/null +++ b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/article.md @@ -0,0 +1,19 @@ +# Dette skjedde i august og september + +Disse månedene har vi hovedsakelig jobbet i kulissene. Det har derfor vært mindre poster med bilder av møter og lignende på våre SoMe-profiler. Men dette mindre synlige arbeidet er kanskje det viktigste vi gjør for å få til endringer. Vi har hatt tre fokusområder: + +- [Pasientforeninger](#foreninger) +- [Fagmiljø/forskere](#fag) +- [Sosiale medier](#some) + +## Pasientforeninger + +For å kunne legge mer press på politikerne er det viktig å være mange. Vi søker derfor støtte hos pasientforeninger. Disse månedene har vi fokusert på 10 sentrale foreninger for å avtale møter med styret og fagavdelingene. Stigma og fordommer gjør dette arbeidet utfordrende, og vi oppfordrer alle våre følgere til å hjelpe oss å åpne dører. Nye støtteerklæringer vil fortløpende bli offentliggjort på våre sosiale medier-profiler. + +## Fagmiljø + +For å få på plass studien - som er en forutsetning for prøveordningen - trenger vi forskere som ønsker å bidra til dette. Vi har derfor jobbet opp mot forskermiljøet for å finne aktuelle forskere. Også her slår fordommer inn, men vi har nå den glede å kunne fortelle at vi har fått ja fra to forskere ved norske universiteter, som ønsker å bidra i arbeidet. Det vil kommer mer informasjon om dette etter hvert. + +## Sosiale medier + +Dess flere vi er dess fortere lykkes vi. Siden mai har vi fokusert på å spre budskapet om prøveordningen og medisinsk cannabis på våre SoMe-plattformer. I perioden har vi vokst fra 1.700 til 2.400 følgere. Også her ber vi om hjelp til å dele poster og invitere venner og kjente til å følge sidene våre. Vi jobber også med å ferdigstille hjemmsiden og har utarbeidet en stor mengde tekst og informasjon som vil bli tilgjengelig der. diff --git a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/metadata.ini b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/metadata.ini index d5bb915..7ac9c98 100644 --- a/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/metadata.ini +++ b/content/nyheter/2025-09-26-hva-skjedde-i-aug-sept/metadata.ini @@ -2,5 +2,6 @@ tags = "nyhetsbrev, oppsummering" categories = "Nyhetsbrev" [en] +slug = "2025-09-26-august-and-september" tags = "newsletter, summary" categories = "Newsletters" diff --git a/content/om-oss/historie.en.md b/content/om-oss/historie.en.md new file mode 100644 index 0000000..abd771a --- /dev/null +++ b/content/om-oss/historie.en.md @@ -0,0 +1,35 @@ +# Our Story + +**End the Suffering / "Stopp lidensel"** is a national advocacy organization working to make medical cannabis accessible to patients in Norway. We were founded in early 2025 to address the challenges faced by Norwegian patients, doctors, and researchers in prescribing and studying medical cannabis for treatment. + +We build on the work of the member organization **"Association for Cannabis Medicine"**, established in 2016. While we achieved significant progress, we had to pause the organization in 2019 due to burnout—a hard lesson learned. After a long break, we regrouped, renewed our energy, and refined our strategy. + +In the winter of 2024, we cautiously restarted our efforts with an op-ed in [*Dagens Medisin*](https://www.dagensmedisin.no/realisme-rundt-medisinsk-cannabis/606186): *"Realism Around Medical Cannabis."* This was followed by the petition *"Medical Cannabis NOW!"*, which gathered over 3,000 signatures and inspired the creation of **End the Suffering**. + +Now we’re back—stronger and more focused than ever. As an advocacy group, our clear goal is political change that enables research, increases healthcare knowledge, and delivers real improvements for suffering patients. + +## Who We Are + +We’re a small but dedicated team—Sofie, Britt-Inger, Geir Roger, and Ruben—who have fought for meaningful change for years. Everyone in the organization volunteers, and while our capacity varies, our commitment never does. We appreciate your patience if responses take time. + +Over the years, we’ve built a broad network of national and international experts, healthcare professionals, academics, and researchers with deep expertise in the field. + +## Standing on the Shoulders of Giants + +We also extend our deepest gratitude to those who paved the way. The first patients and families in Norway who spoke out faced immense challenges, making today’s fight easier to bear. Without their courage and sacrifice, we wouldn’t be where we are now. + +They laid the foundation. Now we continue the fight—together—for them, for us, and for everyone who follows. + +## Meet the Board + +**Sofie Haughom** is a trained physiotherapist with a master’s in societal safety and is currently pursuing a master’s in health sciences. Passionate about the field, she has written professional summaries, op-eds, participated in debates, and given lectures. Sofie also brings personal experience from the fight for cannabis medicine access, having shared her patient story in [*NRK Ekko*](https://radio.nrk.no/podkast/ekko_-_et_aktuelt_samfunnsprogram/sesong/202004/l_d183ff97-c98d-4015-83ff-97c98d4015fc) / [*NRK Dokumentar*](https://www.nrk.no/dokumentar/xl/sofie-sprayer-cannabis-under-tungen-fire-ganger-om-dagen-1.13458156). + +**Britt-Inger Solheim** has extensive experience as a project manager in international companies and has long been active in advocacy work. With a strong network in patient organizations and politics, she plays a key role in meetings, webinars, and debates, bridging the gap between patients and policymakers. + +**Geir Roger Moen** is one of Norway’s most visible advocates for medical cannabis. A frequent participant in debates and media, his patient story has inspired many. He is a driving force in our push for legislative change. + +**Ruben Solvang** is a family member who has witnessed firsthand the difference cannabis medicine can make for patients who find no relief in conventional treatments. As our technical all-rounder, he manages the website and works as an IT consultant. + +In short, we put patients first and drive change through knowledge and collaboration. + +Read our bylaws diff --git a/content/om-oss/historie.md b/content/om-oss/historie.md index 2974051..6e72afd 100644 --- a/content/om-oss/historie.md +++ b/content/om-oss/historie.md @@ -1,17 +1,35 @@ # Vår historie -**Stopp lidelsen** er en interesseorganisasjon som ble stiftet vinteren 2024/25 for å løse den utfordrende situasjonen norske pasienter, leger og forskere står i når det gjelder bruk av medisinsk cannabis (MC) i behandling. Vi er en liten, men dedikert gruppe – Sofie, Britt-Inger, Geir Roger og Ruben – som har kjempet for reell endring i mange år. Alle i organisasjonen jobber frivillig, og selv om vi har begrenset kapasitet, har vi et stort hjerte for saken. Vår bakgrunn spenner fra fagpersoner, pasienter og pårørende til lang erfaring fra pasientforeninger. +Stopp lidelsen er en nasjonal interesseorganisasjon som jobber for å gjøre medisinsk cannabis reelt tilgjengelig for pasienter i Norge. Vi ble stiftet i starten av 2025 for å løse den utfordrende situasjonen norske pasienter, leger og forskere står i når det gjelder foreskrivning av, og forskning på medisinsk cannabis i behandling. -Vi bygger videre på arbeidet fra medlemsorganisasjonen "Foreningen for cannabismedisin", som ble opprettet i 2016. Der lærte vi mye, men vi opplevde også utfordringer. I 2019 måtte vi dessverre sette medlemsorganisasjonen på pause etter å ha brent oss ut. Det var en hard lærdom, men den viste oss at vi måtte gjøre ting annerledes for å lykkes. +Vi bygger videre på arbeidet fra medlemsorganisasjonen "Foreningen for cannabismedisin", som ble opprettet i 2016. Vi fikk utrettet mye, men i 2019 måtte vi dessverre sette medlemsorganisasjonen på pause etter å ha brent oss ut. Det var en hard lærdom, men etter en lengre pause har vi på nytt samlet krefter og endret strategi. -Nå har vi valgt å organisere oss som en interessegruppe, med et klart mål: å skape politisk og samfunnsmessig endring. Vi samarbeider tett med leger, helsepersonell og forskere både i Norge og internasjonalt. +Vinteren 2024 startet vi forsiktig opp igjen med en kronikk i [Dagens Medisin](https://www.dagensmedisin.no/realisme-rundt-medisinsk-cannabis/606186): «Realisme rundt medisinsk cannabis». Denne ble etterfulgt av underskriftskampanjen «Medisinsk Cannabis NÅ!» med over 3000 underskrifter, og motiverte opprettelsen av Stopp lidelsen. -Men vi klarer ikke dette alene. +Nå er vi altså tilbake – sterkere og mer målrettet enn noensinne. Vi har organisert oss som en interessegruppe, med et klart mål: politisk endring som åpner for forskning, økt kunnskap i helsevesenet og en reell forbedring for pasientene som lider! -Uansett om du er pasient, pårørende, helsepersonell eller bare en som bryr deg – alle kan bidra. Vi er avhengige av at du hjelper til med å spre budskapet, åpne dører til politikere, fagpersoner og pasientforeninger, eller bidra med din tid og kunnskap på andre måter. +## Hvem er vi? -"Stopp lidelsen" er en frivillig organisasjon som drives helt og fullt på frivillig basis. Vi ber om forståelse dersom du ikke får umiddelbart svar på henvendelser – vi gjør vårt beste for å svare alle så fort som mulig. +Vi er en liten, men dedikert gruppe – Sofie, Britt-Inger, Geir Roger og Ruben. Vi har kjempet for reell endring i mange år. Alle i organisasjonen jobber frivillig, og selv om vi har variabel kapasitet, har vi et stort hjerte for saken. Vi ber om forståelse dersom det tar tid før du får svar på henvendelser. -Men for å lykkes, er vi avhengige av at du blir med oss i kampen. Dette er ikke bare vår sak – det er vår felles sak. Bare sammen kan vi skape det presset som trengs for å endre regelverket og gi pasienter tilgang til den behandlingen de fortjener. +Vi har over tid knyttet til oss et stort nettverk av nasjonale og internasjonale eksperter, helsepersonell, akademikere og forskere med kompetanse og erfaring på området. -Last ned våre vedtekter (PDF) +## Vi står på skuldrene til kjemper + +Vi vil samtidig rette en stor takk til alle som har gått foran oss i denne kampen. De første pasientene og pårørende som stod frem i Norge, stod i utfordringer som gjør dagens kamp lettere å bære. Uten deres mot og offervilje hadde vi ikke vært der vi er i dag. + +De la grunnlaget. Nå fortsetter vi kampen, sammen – for dem, for oss, og for alle som kommer etter. + +## Møt styret + +**Sofie Haughom** er utdannet fysioterapeut med master i samfunnssikkerhet. Hun tar nå master i helsevitenskap. Sofie har stor interesse for fagfeltet og har skrevet fagsammendrag, kronikker, deltatt i debatter og holdt foredrag. Sofie har også personlig erfaring fra kampen for tilgang til cannabismedisin, og har stått frem med sin pasienthistorie i [NRK Ekko](https://radio.nrk.no/podkast/ekko_-_et_aktuelt_samfunnsprogram/sesong/202004/l_d183ff97-c98d-4015-83ff-97c98d4015fc) / [NRK Dokumentar](https://www.nrk.no/dokumentar/xl/sofie-sprayer-cannabis-under-tungen-fire-ganger-om-dagen-1.13458156). + +**Britt-Inger Solheim** har lang erfaring som prosjektleder i flere internasjonale selskaper. Hun har lenge vært aktiv innen foreningsarbeid og har et stort nettverk innen pasientorganisasjoner og politikk. Hun deltar aktivt i møter, webinarer og debatter, og er et viktig bindeledd mellom pasienter og beslutningstakere. + +**Geir Roger Moen** er en av Norges mest synlige stemmer for medisinsk cannabis. Han har deltatt i debatter og medieopptredener, og hans pasienthistorie har inspirert mange. Geir Roger er en viktig pådriver i vårt arbeid for å endre lovgivningen. + +**Ruben Solvang** er pårørende og har sett hvor stor forskjell cannabismedisin kan utgjøre for pasienter som ikke får lindring av regulære medisiner. Han er teknisk altmuligmann med ansvar for nettsiden og jobber til daglig som IT-konsulent. + +Kort oppsummert setter vi pasientene i fokus og skaper forandring gjennom kunnskap og samarbeid! + +Les våre vedtekter diff --git a/content/om-oss/metadata.ini b/content/om-oss/metadata.ini new file mode 100644 index 0000000..399ec9d --- /dev/null +++ b/content/om-oss/metadata.ini @@ -0,0 +1 @@ +hide_list = true diff --git a/content/om-oss/vedtekter/vedtekter.en.md b/content/om-oss/vedtekter/vedtekter.en.md new file mode 100644 index 0000000..cc3ee04 --- /dev/null +++ b/content/om-oss/vedtekter/vedtekter.en.md @@ -0,0 +1,68 @@ +# Bylaws for the advocacy organization Stopp lidelsen + +**28.02.25** + +## § 1 Organization name +The organization's name is Stopp lidelsen (Stop the suffering). + +## § 2 Purpose +Stopp lidelsen works to make medical cannabis genuinely accessible by prescription for all Norwegian patients who may benefit from it, and to break down stigma and prejudice associated with this group of medications. + +## § 3 Organizational structure +The organization is an independent legal entity with members and is self-owned. Self-ownership means that no one, neither members nor others, has claim to the organization's assets or property, or is liable for debt or other obligations. The organization is primarily financed through donations. + +## § 4 Members +The board members are the organization's only members. + +## § 5 Rights and obligations of membership +All members have the right to participate in the annual meeting, have voting rights, and are eligible for elected positions in the organization. Members are obligated to comply with the bylaws and decisions made at board meetings and annual meetings. + +## § 6 Annual meeting +The annual meeting, held every year, is the organization's highest authority. The annual meeting has quorum with the number of voting members present, and all members have one vote. The meeting chair is elected by the annual meeting. + +Unless otherwise determined, a decision must be made by simple majority of votes cast to be valid. Ties are decided by drawing lots. + +The annual meeting is convened by the board with at least two weeks' notice, directly to the members. Proposals to be considered at the annual meeting must be submitted to the board no later than one week before the annual meeting. Complete agenda and case documents must be available to members no later than 3 days before the annual meeting. + +The annual meeting cannot consider proposals not listed on the agenda, unless 3/4 of those present demand it. + +## § 7 Annual meeting responsibilities +The annual meeting shall be held by the end of April and shall: +- review the annual report +- review the accounts +- consider submitted proposals +- adopt the budget +- vote on any changes to the board composition + +The fiscal year follows the calendar year. + +## § 8 Extraordinary annual meetings +Extraordinary annual meetings are held when the board decides, or at least 1/3 of the board members demand it. + +Notice is given in the same manner as for ordinary annual meetings, with at least one week's notice. + +An extraordinary annual meeting can only consider and decide on matters announced in the notice. + +## § 9 Board +The board is the highest authority between annual meetings and consists of a minimum of 3 members. The organization shall, as far as possible, consist of the competence and experience required to achieve our goal. Board members may hold their positions until they resign or the annual meeting decides otherwise. The board may appoint committees or individuals who are not members of the organization and prepares instructions for these. These report to the board. + +The board shall hold meetings when the board chair or a majority of board members request it. + +The board shall: +- implement annual meeting decisions +- administer and maintain necessary control of the organization's finances in accordance with applicable instructions and regulations +- represent the organization externally +- propose board members as needed + +The board may make decisions when a majority of board members are present. Decisions are made by majority of votes cast. + +## § 10 Signatory authority +Two board members jointly have signatory authority. + +## § 11 Amendment of bylaws +Amendments to these bylaws can only be made at an ordinary or extraordinary annual meeting after being on the agenda, and require a 2/3 majority of votes cast. + +## § 12 Dissolution +Dissolution of the organization can only be considered at an annual meeting and requires a 2/3 majority. The organization's assets shall, after dissolution and debt settlement, be allocated to the purpose the organization works to promote, by the net assets being given to an organization determined by the annual meeting. + +No members have claim to the organization's funds or share thereof, or are liable for debt. diff --git a/content/om-oss/vedtekter/vedtekter.md b/content/om-oss/vedtekter/vedtekter.md new file mode 100644 index 0000000..37d50db --- /dev/null +++ b/content/om-oss/vedtekter/vedtekter.md @@ -0,0 +1,68 @@ +# Vedtekter for interesseorganisasjonen Stopp lidelsen + +**28.02.25** + +## § 1 Organisasjonens navn +Organisasjonens navn er Stopp lidelsen. + +## § 2 Formål +Stopp lidelsen jobber for å gjøre medisinsk cannabis reelt tilgjengelig på resept for alle norske pasienter som kan ha nytte av det, og for å bryte ned stigma og fordommer forbundet med denne medikamentgruppen. + +## § 3 Organisasjonsform +Organisasjonen er en frittstående juridisk person med medlemmer, og er selveiende. At den er selveiende innebærer at ingen, verken medlemmer eller andre, har krav på organisasjonens formue eller eiendeler, eller er ansvarlig for gjeld eller andre forpliktelser. Organisasjonen finansieres hovedsakelig gjennom donasjoner. + +## § 4 Medlemmer +Styremedlemmene er organisasjonens eneste medlemmer. + +## § 5 Rettigheter og plikter knyttet til medlemskapet +Alle medlemmer har rett til å delta på årsmøtet, har stemmerett og er valgbare til tillitsverv i organisasjonen. Medlemmene plikter å forholde seg til vedtektene og vedtak som er fattet i styremøter og på årsmøte. + +## § 6 Årsmøte +Årsmøtet, som holdes hvert år, er organisasjonens høyeste myndighet. Årsmøtet er vedtaksført med det antall stemmeberettigede medlemmer som møter, og alle medlemmer har én stemme. Møteleder velges av årsmøtet. + +Med mindre annet er bestemt, skal et vedtak, for å være gyldig, være truffet med alminnelig flertall av de avgitte stemmene. Stemmelikhet avgjøres ved loddtrekning. + +Årsmøtet innkalles av styret med minst to ukers varsel, direkte til medlemmene. Forslag som skal behandles på årsmøtet skal være sendt til styret senest en uke før årsmøtet. Fullstendig saksliste og saksdokumenter må være tilgjengelig for medlemmene senest 3 dager før årsmøtet. + +Årsmøtet kan ikke behandle forslag som ikke er oppført på sakslisten, med mindre 3/4 av de fremmøtte krever det. + +## § 7 Årsmøtets oppgaver +Årsmøtet skal avholdes innen utgangen av april og skal: +- behandle årsmelding +- behandle regnskap +- behandle innkomne forslag +- vedta budsjett +- stemme over eventuelle endringer i styrets sammensetning + +Regnskapsår følger kalenderår. + +## § 8 Ekstraordinære årsmøter +Ekstraordinære årsmøter blir avholdt når styret bestemmer det, eller minst 1/3 av styrets medlemmene krever det. + +Innkalling skjer på samme måte som for ordinære årsmøter, med minst en ukes varsel. + +Ekstraordinært årsmøte kan bare behandle og ta avgjørelse i de sakene som er kunngjort i innkallingen. + +## § 9 Styret +Styret er høyeste myndighet mellom årsmøtene og består av minimum 3 stykker. Organisasjonen skal så langt mulig bestå av den kompetansen og erfaring som kreves for å oppnå vårt mål. Styrets medlemmer kan inneha sine verv frem til de trekker seg eller årsmøtet vedtar noe annet. Styret kan nedsette utvalg eller personer, som ikke er medlemmer i organisasjonen, og utarbeider instruks for disse. Disse svarer til styret. + +Styret skal holde møte når styreleder eller et flertall av styremedlemmene forlanger det. + +Styret skal: +- iverksette årsmøtebestemmelser +- administrere og føre nødvendig kontroll med organisasjonens økonomi i henhold til gjeldende instrukser og bestemmelser +- representere organisasjonen utad +- foreslå styremedlemmer etter behov + +Styret kan fatte vedtak når et flertall av styrets medlemmer er til stede. Vedtak fattes med flertall av de avgitte stemmene. + +## § 10 Signaturrett +To styremedlemmer har i fellesskap signaturrett. + +## § 11 Vedtektsendring +Endringer av disse vedtektene kan bare gjøres på ordinært eller ekstraordinært årsmøte etter å ha vært på sakslisten, og det krever 2/3 flertall av de avgitte stemmene. + +## § 12 Oppløsning +Oppløsning av organisasjonen kan bare behandles på årsmøte, og krever 2/3 flertall. Organisasjonens formue skal etter oppløsning og gjeldsavleggelse tilfalle det formål foreningen arbeider for å fremme, ved at nettoformuen blir gitt til en organisasjon som årsmøte bestemmer. + +Ingen medlemmer har krav på organisasjonens midler eller andel av disse, eller hefter for gjeld. diff --git a/custom/languages/en.ini b/custom/languages/en.ini index 9255ee9..66042a8 100644 --- a/custom/languages/en.ini +++ b/custom/languages/en.ini @@ -1,6 +1,19 @@ ; English translations + +; Language names for switcher +language_name = "English" +language_name_no = "Norsk" + +; General categories = "Categories" tags = "Tags" + +; FAQ +faq_summary_label = "In short:" +faq_read_full_answer = "Read full answer" + +; Footer +footer_social = "Follow us on Mastodon" footer_copyright = "Copyright" footer_follow_mastodon = "Follow us on Mastodon" footer_handcoded = "This website was hand-coded by Ruben Solvang using HTML, CSS and minimal doses of PHP. It took" diff --git a/custom/languages/no.ini b/custom/languages/no.ini index 70f34be..b699fcc 100644 --- a/custom/languages/no.ini +++ b/custom/languages/no.ini @@ -1,6 +1,19 @@ ; Norwegian translations + +; Language names for switcher +language_name = "Norsk" +language_name_en = "English" + +; General categories = "Kategorier" tags = "Stikkord" + +; FAQ +faq_summary_label = "Kort oppsumert:" +faq_read_full_answer = "Les hele svaret" + +; Footer +footer_social = "Følg oss på Facebook, Instagram og Mastodon" footer_copyright = "Opphavsrett" footer_follow_mastodon = "Følg oss på Mastodon" footer_handcoded = "Nettsiden er håndkodet av Ruben Solvang ved hjelp av HTML, CSS og minimale doser PHP. Det tok" From 82aaff0008d82664a2b89b4b4902436661c70cd2 Mon Sep 17 00:00:00 2001 From: Ruben Date: Fri, 12 Dec 2025 21:59:21 +0100 Subject: [PATCH 04/50] Update organization name in history page Remove extra slash from organization name in history page --- content/om-oss/historie.en.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/om-oss/historie.en.md b/content/om-oss/historie.en.md index abd771a..52744ab 100644 --- a/content/om-oss/historie.en.md +++ b/content/om-oss/historie.en.md @@ -1,6 +1,6 @@ # Our Story -**End the Suffering / "Stopp lidensel"** is a national advocacy organization working to make medical cannabis accessible to patients in Norway. We were founded in early 2025 to address the challenges faced by Norwegian patients, doctors, and researchers in prescribing and studying medical cannabis for treatment. +**End the Suffering (Stopp lidelsen)** is a national advocacy organization working to make medical cannabis accessible to patients in Norway. We were founded in early 2025 to address the challenges faced by Norwegian patients, doctors, and researchers in prescribing and studying medical cannabis for treatment. We build on the work of the member organization **"Association for Cannabis Medicine"**, established in 2016. While we achieved significant progress, we had to pause the organization in 2019 due to burnout—a hard lesson learned. After a long break, we regrouped, renewed our energy, and refined our strategy. From 2238aac97b4f550a2dd85b5595e5c930b9297118 Mon Sep 17 00:00:00 2001 From: Ruben Date: Fri, 12 Dec 2025 22:03:33 +0100 Subject: [PATCH 05/50] Update Ruben Solvang's description for clarity --- content/om-oss/historie.en.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/om-oss/historie.en.md b/content/om-oss/historie.en.md index 52744ab..84df4c2 100644 --- a/content/om-oss/historie.en.md +++ b/content/om-oss/historie.en.md @@ -28,7 +28,7 @@ They laid the foundation. Now we continue the fight—together—for them, for u **Geir Roger Moen** is one of Norway’s most visible advocates for medical cannabis. A frequent participant in debates and media, his patient story has inspired many. He is a driving force in our push for legislative change. -**Ruben Solvang** is a family member who has witnessed firsthand the difference cannabis medicine can make for patients who find no relief in conventional treatments. As our technical all-rounder, he manages the website and works as an IT consultant. +**Ruben Solvang** has witnessed firsthand the difference cannabis medicine can make for a family member who did not get adequate relief from conventional treatments. As our technical all-rounder, he manages the website and works as an IT consultant. In short, we put patients first and drive change through knowledge and collaboration. From 7dbac63d66db1fdc0248a221d70a9c11404cfb9a Mon Sep 17 00:00:00 2001 From: Ruben Date: Sat, 13 Dec 2025 15:36:25 +0100 Subject: [PATCH 06/50] Update description of organization's mission --- content/om-oss/historie.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/om-oss/historie.md b/content/om-oss/historie.md index 6e72afd..482c71d 100644 --- a/content/om-oss/historie.md +++ b/content/om-oss/historie.md @@ -1,6 +1,6 @@ # Vår historie -Stopp lidelsen er en nasjonal interesseorganisasjon som jobber for å gjøre medisinsk cannabis reelt tilgjengelig for pasienter i Norge. Vi ble stiftet i starten av 2025 for å løse den utfordrende situasjonen norske pasienter, leger og forskere står i når det gjelder foreskrivning av, og forskning på medisinsk cannabis i behandling. +Stopp lidelsen er en nasjonal interesseorganisasjon som jobber for å gjøre medisinsk cannabis tilgjengelig for pasienter i Norge. Vi ble stiftet i starten av 2025 for å løse den utfordrende situasjonen norske pasienter, leger og forskere står i når det gjelder foreskrivning av, og forskning på medisinsk cannabis i behandling. Vi bygger videre på arbeidet fra medlemsorganisasjonen "Foreningen for cannabismedisin", som ble opprettet i 2016. Vi fikk utrettet mye, men i 2019 måtte vi dessverre sette medlemsorganisasjonen på pause etter å ha brent oss ut. Det var en hard lærdom, men etter en lengre pause har vi på nytt samlet krefter og endret strategi. From 789d40da9103ae5d808a3145d238dd8a9acff259 Mon Sep 17 00:00:00 2001 From: Ruben Date: Sat, 13 Dec 2025 16:29:07 +0100 Subject: [PATCH 07/50] Rename CLAUDE.md to AGENT.md --- CLAUDE.md => AGENT.md | 0 1 file changed, 0 insertions(+), 0 deletions(-) rename CLAUDE.md => AGENT.md (100%) diff --git a/CLAUDE.md b/AGENT.md similarity index 100% rename from CLAUDE.md rename to AGENT.md From c91971968ec4dcd016ee1b468b9f25dc02c9e001 Mon Sep 17 00:00:00 2001 From: Ruben Date: Sat, 13 Dec 2025 16:38:47 +0100 Subject: [PATCH 08/50] Remove trailing whitespace from CSS properties --- custom/styles/base.css | 158 +++++++++++------------------------------ 1 file changed, 41 insertions(+), 117 deletions(-) diff --git a/custom/styles/base.css b/custom/styles/base.css index 478a4f6..6bf7e4a 100644 --- a/custom/styles/base.css +++ b/custom/styles/base.css @@ -1,5 +1,5 @@ -/* MINIMAL CSS RESET*/ -* { margin-bottom: 0; } +/* MINIMAL CSS RESET */ +* { margin-bottom: 0 } /* VARIABLES */ :root { @@ -12,28 +12,27 @@ --color-green-light: #f2fbf8; --color-green-light: oklch(0.9811 0.01 173.93); --color-grey: #404040; - --color-grey: oklch(0.3715 0 0); + --color-grey: oklch(0.3715 0 0) } /* GLOBAL */ -html { font-family: var(--font-body); font-size: clamp(16px, 2.3vw, 20px); scroll-behavior: smooth; } +html { font-family: var(--font-body); font-size: clamp(16px, 2.3vw, 20px); scroll-behavior: smooth } body { margin: 0; color: var(--color-grey) } p, ul, ol, aside { line-height: 1.5em; hyphens: auto } -img { max-width: 100%; height: auto; } +img { max-width: 100%; height: auto } h1 { color: var(--color-green); font-size: 2.3rem } h1, h2, h3, h4, h5, h6 { font-family: var(--font-heading); font-weight: 400; line-height: 1.3em; margin-top: 1.3em; - text-wrap: pretty; + text-wrap: pretty } -h4 { font-weight: 700} - +h4 { font-weight: 700 } a { - color: var(--color-green); - text-decoration: none; - &:hover { color: var(--color-blue) } + color: var(--color-green); + text-decoration: none; + &:hover { color: var(--color-blue) } } .grid-container { @@ -45,20 +44,16 @@ a { width: 100%; justify-content: center; min-height: 100vh; - align-items: stretch; + align-items: stretch } .contain, :where(main>article, main>aside, main>section) { display: grid; grid-template-columns: minmax(.8rem, 1fr) minmax(0, 42rem) minmax(.3rem, 1fr); - > * { - grid-column: 2; - } + > * { grid-column: 2 } } -.escape { - grid-column: 1 / -1 !important; -} +.escape { grid-column: 1 / -1 !important } /* HEADER */ header { @@ -72,19 +67,14 @@ header { svg { width: 7rem; height: 100%; - #symbol { - fill: var(--color-blue); - } - #tekst { - fill: var(--color-green); - } + #symbol { fill: var(--color-blue) } + #tekst { fill: var(--color-green) } } } - nav { - display:flex; + display: flex; align-items: center; - justify-content:flex-end; + justify-content: flex-end; flex: 1; ul { display: flex; @@ -93,10 +83,7 @@ header { margin-top: .4rem; padding: 0; justify-content: flex-end; - a { - margin-left:0.4rem; - margin-top:0.4rem; - } + a { margin-left: .4rem; margin-top: .4rem } } } } @@ -107,57 +94,33 @@ main { grid-area: main; background-color: var(--color-green-light); padding-bottom: 2rem; - aside { margin-top: 1.3em } article { - .intro { - font-size: 1.2rem; - line-height: 1.35em; - } + .intro { font-size: 1.2rem; line-height: 1.35em } .footnotes { - margin-top:1rem; - hr {border: 1px var(--color-grey) dashed} + margin-top: 1rem; + hr { border: 1px var(--color-grey) dashed } } } - - .button { - margin-top: 1.3rem; - justify-self: start; - } + .button { margin-top: 1.3rem; justify-self: start } } table { margin-top: 1.3em; border-collapse: collapse; width: 100%; - thead { tr { background-color: var(--color-green); color: white; - - th { - padding: 0.6rem; - text-align: left; - font-weight: 600; - } + th { padding: .6rem; text-align: left; font-weight: 600 } } } - tbody { tr { - &:nth-child(odd) { - background-color: white; - } - - &:nth-child(even) { - background-color: oklch(0.96 0.005 173.93); - } - - td { - padding: 0.5rem 0.6rem; - border-bottom: 1px solid oklch(0.9 0.01 173.93); - } + &:nth-child(odd) { background-color: white } + &:nth-child(even) { background-color: oklch(0.96 0.005 173.93) } + td { padding: .5rem .6rem; border-bottom: 1px solid oklch(0.9 0.01 173.93) } } } } @@ -167,70 +130,31 @@ table { display: inline-block; text-decoration: none; border-radius: 2rem; - padding: 0.55rem 1rem; + padding: .55rem 1rem; background-color: transparent; color: var(--color-grey); - outline: 0.08rem var(--color-grey) solid; - - &:hover { - background-color: var(--color-grey); - color: white; - outline: none; - } - - &:active, &.active { - background-color: var(--color-green); - color: white; - outline: none; - } - - &:focus { - background-color: var(--color-green); - color: white; - outline: none; - } - + outline: .08rem var(--color-grey) solid; + &:hover { background-color: var(--color-grey); color: white; outline: none } + &:active, &.active { background-color: var(--color-green); color: white; outline: none } + &:focus { background-color: var(--color-green); color: white; outline: none } &.inverted { background-color: transparent; color: white; - outline: 0.08rem white solid; - - &:hover { - background-color: white; - color: var(--color-green); - outline: none; - } - - &:active, &.active { - background-color: var(--color-green-light); - color: var(--color-green); - outline: none; - } - - &:focus { - color: white; - background-color: var(--color-grey); - outline: none; - } + outline: .08rem white solid; + &:hover { background-color: white; color: var(--color-green); outline: none } + &:active, &.active { background-color: var(--color-green-light); color: var(--color-green); outline: none } + &:focus { color: white; background-color: var(--color-grey); outline: none } + } + &.bigger { font-size: 1.2em; border-radius: calc(1rem * 1.2) } + &.centered { justify-self: center } } - &.bigger { - font-size: 1.2em; - /*padding: calc(0.35rem * 1.2) calc(1rem * 1.2);*/ - border-radius: calc(1rem * 1.2); - } - &.centered { - justify-self: center; - } -} - -/* FOOTER */ - +/* FOOTER */ footer { color: var(--color-green-light); a { - color: var(--color-green-light); - &:hover { color: white; text-decoration: underline } + color: var(--color-green-light); + &:hover { color: white; text-decoration: underline } } background-color: var(--color-green); grid-area: footer; From 7d12fe56540c6b9995f577c6993452da56267c1e Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:23:49 +0100 Subject: [PATCH 09/50] Add custom SMTP config file to repository This file is now essential for production deployment and should be versioned --- .gitignore | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/.gitignore b/.gitignore index aa7577e..9b8a58d 100644 --- a/.gitignore +++ b/.gitignore @@ -1,4 +1,4 @@ app* content/robots.txt -custom/smtp-config.php* +custom/smtp-config.php content/.htaccess From 6cf9710ac1838e95a55dc0c9049ad8a339a3f310 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:24:41 +0100 Subject: [PATCH 10/50] Add Docker configuration for PHP 8.4 Apache container Enable Apache rewrite module and custom configuration Configure logging to container output streams Update compose file to use build context instead of direct image Remove redundant volume mount for apache.conf Remove unnecessary command override --- Dockerfile | 12 ++++++++++++ compose.yaml | 7 +------ 2 files changed, 13 insertions(+), 6 deletions(-) create mode 100644 Dockerfile diff --git a/Dockerfile b/Dockerfile new file mode 100644 index 0000000..a7b99d3 --- /dev/null +++ b/Dockerfile @@ -0,0 +1,12 @@ +FROM php:8.4.14-apache + +# Enable Apache modules and custom config as root during build +RUN a2enmod rewrite + +COPY apache.conf /etc/apache2/conf-available/custom.conf +RUN a2enconf custom + +# Log to /proc/self/fd for container output +RUN sed -i 's|ErrorLog.*|ErrorLog /proc/self/fd/2|' /etc/apache2/sites-available/000-default.conf \ + && sed -i 's|CustomLog.*|CustomLog /proc/self/fd/1 combined|' /etc/apache2/sites-available/000-default.conf \ + && sed -i 's|ErrorLog.*|ErrorLog /proc/self/fd/2|' /etc/apache2/apache2.conf diff --git a/compose.yaml b/compose.yaml index 085bf66..2a31ee8 100644 --- a/compose.yaml +++ b/compose.yaml @@ -1,16 +1,11 @@ -version: '3.8' - services: custom: - # image: php:8.3.12-apache - image: php:8.4.14-apache + build: . container_name: stopplidelsen.no working_dir: /var/www/html/ volumes: - ./app:/var/www/app:z - ./content:/var/www/html:z - ./custom:/var/www/custom:z - - ./apache.conf:/etc/apache2/conf-available/custom.conf:z ports: - "4040:80" - command: bash -c "a2enconf custom && a2enmod rewrite && apache2-foreground" From ee7bb7a7a638169a774d1904f21236a119411391 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:24:57 +0100 Subject: [PATCH 11/50] Add petition-specific SMTP configuration options Add optional petition-specific SMTP configuration overrides to the example configuration file, maintaining the existing defaults while allowing customization for petition emails --- custom/smtp-config.php.example | 13 ++++++++++--- 1 file changed, 10 insertions(+), 3 deletions(-) diff --git a/custom/smtp-config.php.example b/custom/smtp-config.php.example index 4a32b07..4506108 100644 --- a/custom/smtp-config.php.example +++ b/custom/smtp-config.php.example @@ -1,7 +1,7 @@ 587, // Common ports: 587 (TLS), 465 (SSL), 25 (unsecured) 'username' => 'your-email@example.com', // SMTP username 'password' => 'your-password', // SMTP password - 'from_email' => 'kontaktskjema@stopplidelsen.no', + 'from_email' => 'email@example.com', 'from_name' => 'Stopp Lidelsen Kontaktskjema', - 'to_email' => 'kontakt@stopplidelsen.no', + 'to_email' => 'email@example.com', 'to_name' => 'Stopp Lidelsen', + + // Petition-specific overrides (optional) + // If not set, the default values above will be used + 'petition' => [ + // 'from_email' => 'underskrifter@example.com', + // 'from_name' => 'Underskriftskampanje', + ], ]; From 21216f45641b0c71321fb2604985729719865431 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:25:25 +0100 Subject: [PATCH 12/50] Update AGENT.md to reflect current project rules Remove redundant documentation and reorganize content to match the project's current structure and constraints. The updated file now aligns with the minimalist philosophy and core constraints while maintaining all essential information in a more concise format. --- AGENT.md | 115 ++++++++----------------------------------------------- 1 file changed, 15 insertions(+), 100 deletions(-) diff --git a/AGENT.md b/AGENT.md index e637f37..34d2d78 100644 --- a/AGENT.md +++ b/AGENT.md @@ -1,107 +1,22 @@ -# PnP Development Guidelines - ## Philosophy +Minimal PHP for modern conveniences. Prioritize longevity (decade-scale maintainability) by avoiding volatile dependencies. Strictly add only what's essential—readable, simple, and future-proof. -**Just enough, nothing more.** This framework applies minimal PHP to enable modern conveniences while remaining maintainable for years or decades. Avoid rapidly changing components and dependencies. The code should be readable, simple, and only add what is strictly necessary. +## Core Constraints +**Minimalism:** Only essential tech (HTML, PHP 8.4+, CSS). No JS, frameworks, build tools, or package managers. Comments only for major sections. -## Core Principles +**Frontend:** +- Classless, semantic HTML5 +- Modern CSS: nesting, `oklch()`, grid, `clamp()`, logical props +- Responsive via fluid typography + flexible layouts -### Minimalism -- Use only what is strictly necessary to achieve the goal -- No frameworks, no build tools, no package managers for frontend code -- Avoid abstractions unless they provide clear, lasting value -- Sparse commenting—only mark main sections +**Security:** +- Path validation blocks traversal +- Files restricted to document root +- Strict MIME types + no direct user-input execution -### Technology Stack -- **Allowed:** HTML, PHP (8.4+), CSS -- **Not allowed:** JavaScript -- Use modern PHP features when they improve readability or performance -- Leverage modern CSS features for smart, efficient styling +## Code Style +**PHP:** Modern syntax (arrow functions, null coalescing, match). Type hints where practical. Ternary for simple conditionals. Single-purpose functions. -### File-Based Routing -- Folder hierarchy dictates URL structure -- Drop a file (`.md`, `.php`, `.html`) in a folder and it renders immediately -- Assets placed in content directories are automatically accessible -- Directories with subfolders trigger list views +**CSS:** Variables, native nesting, grid layouts. `clamp()` over `@media`. Relative units > pixels. -### Template System -- Custom templates override defaults (never modify defaults) -- Custom templates live in `/app/custom/` -- Default templates provide fallback behavior -- Docs get their own template variants for specialized presentation -- Templates use PHP includes—simple and straightforward - -### Content Conventions - -#### File Naming -- Cover images: `cover.jpg`, `cover.webp`, etc. - -#### Date Formatting -- Folder names can include dates: `YYYY-MM-DD-title` -- Dates are automatically extracted and formatted (Norwegian format: "23. oktober 2025") -- Metadata can override automatic date detection - -#### Metadata -- Use `metadata.ini` files for structured data -- Common fields: `title`, `date`, `summary` -- Metadata overrides automatic title/date extraction - -### HTML & CSS Standards -- Classless CSS where possible -- HTML should be highly compliant with best practices -- Use semantic HTML5 elements -- Modern CSS features: custom properties, nesting, `oklch()` colors, grid, clamp, logical properties -- Responsive by default using fluid typography and flexible layouts - -### Security -- Path validation prevents directory traversal -- Files must be within document root -- MIME types properly set for all served content -- No direct execution of arbitrary user input - -### Code Style - -#### PHP -- Modern syntax: arrow functions, null coalescing, match expressions -- Use type hints when practical -- Ternary operators for simple conditionals -- Keep functions focused and single-purpose - -#### CSS -- Use CSS variables for theming -- Nesting for component-scoped styles -- Grid for layout, not tables or excessive flexbox -- `clamp()` for responsive sizing -- Avoid pixel values where relative units work better - -#### Templates -- Escape output: `htmlspecialchars()` for user-generated content -- Short echo tags: `` -- Minimize logic in templates—prepare data beforehand - -### Performance Considerations -- Page load time displayed in footer (transparency and pride in performance) -- CSS versioned with MD5 hash for cache busting -- Minimal HTTP requests through direct includes -- No JavaScript means no parsing delay - -### Extensibility Patterns -- Third-party code goes in `/app/vendor/` -- Custom code goes in `/app/custom/` - -### List Views -When a directory contains subdirectories: -- Default list template generates automatic listings -- Each item shows title, date, optional cover image, optional summary -- Override with custom list template for specialized presentation - -## What This Framework Is Not - -- Not a CMS with an admin panel -- Not a single-page application -- Not a JavaScript framework - -## What This Framework Is - -- A simple, intuitive way to publish content -- A foundation that will work for decades +**Templates:** Escape output (`htmlspecialchars()` for UGC). Short echo tags (``). From 82b94a1eb736de87298beb0617509d9110619a97 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:25:42 +0100 Subject: [PATCH 13/50] Add petition form translations for English and Norwegian Add Norwegian region names for petition form Add email confirmation messages for petition form Add error handling messages for petition form Add signature display options for petition form --- custom/languages/en.ini | 59 +++++++++++++++++++++++++++++++++++++++++ custom/languages/no.ini | 59 +++++++++++++++++++++++++++++++++++++++++ 2 files changed, 118 insertions(+) diff --git a/custom/languages/en.ini b/custom/languages/en.ini index 66042a8..27a00db 100644 --- a/custom/languages/en.ini +++ b/custom/languages/en.ini @@ -18,3 +18,62 @@ footer_copyright = "Copyright" footer_follow_mastodon = "Follow us on Mastodon" footer_handcoded = "This website was hand-coded by Ruben Solvang using HTML, CSS and minimal doses of PHP. It took" footer_page_time = "ms to generate this page." + +; Petition form +petition.form_title = "Sign the Petition" +petition.firstname_label = "First name" +petition.firstname_placeholder = "Your first name" +petition.firstname_required = "First name is required" +petition.surname_label = "Surname" +petition.surname_placeholder = "Your surname" +petition.surname_required = "Surname is required" +petition.email_label = "Email" +petition.email_placeholder = "your@email.com" +petition.email_help = "Not shown publicly, only for confirmation" +petition.email_required = "Valid email is required" +petition.region_label = "Region" +petition.region_required = "Please select a region" +petition.region_placeholder = "Select region..." +petition.display_legend = "How should you appear in the list?" +petition.display_semi = "Show my first name and region (default)" +petition.display_anonymous = "Anonymous - only show my region" +petition.anonymous_name = "Anonymous" +petition.from_region = "from" +petition.display_full = "Show my full name and region" +petition.submit_button = "Sign the Petition" +petition.signatures_title = "Signatures" +petition.signature_count = "{count} signature" +petition.signature_count_plural = "{count} signatures" +petition.newest_first = "Newest first" +petition.error_csrf = "Security error. Please try again." +petition.error_honeypot = "Invalid submission." +petition.error_rate_limit = "Please wait a moment before submitting again." +petition.error_time_check = "Multiple signature attempts were sent from the same computer within a short time. Please wait a moment and try again." +petition.error_referrer = "Invalid request." +petition.error_validation = "Please correct the errors in the form." +petition.error_email_send = "Could not send confirmation email. Please try again later." +petition.error_already_signed = "This email address has already signed this petition." +petition.success_pending = "Thank you! Check your email to confirm your signature." +petition.confirm_success = "Thank you! Your signature has been confirmed and added to the list." +petition.confirm_error = "Invalid or expired confirmation link." +petition.confirm_already = "This signature has already been confirmed." +petition.email_subject = "Confirm your signature" +petition.email_greeting = "Hello {name}," +petition.email_thanks = "Thank you for signing the petition \"{title}\"." +petition.email_confirm = "Please confirm your signature by clicking this link:" +petition.email_ignore = "If you did not sign this petition, please ignore this email." +petition.email_signature = "Best regards" +petition.email_org = "Stop the Suffering" + +; Norwegian regions (fylker) - kept in Norwegian as they are proper nouns +regions.oslo = "Oslo" +regions.rogaland = "Rogaland" +regions.more_og_romsdal = "Møre og Romsdal" +regions.nordland = "Nordland" +regions.viken = "Viken" +regions.innlandet = "Innlandet" +regions.vestfold_og_telemark = "Vestfold og Telemark" +regions.agder = "Agder" +regions.vestland = "Vestland" +regions.trondelag = "Trøndelag" +regions.troms_og_finnmark = "Troms og Finnmark" diff --git a/custom/languages/no.ini b/custom/languages/no.ini index b699fcc..06ae11d 100644 --- a/custom/languages/no.ini +++ b/custom/languages/no.ini @@ -18,3 +18,62 @@ footer_copyright = "Opphavsrett" footer_follow_mastodon = "Følg oss på Mastodon" footer_handcoded = "Nettsiden er håndkodet av Ruben Solvang ved hjelp av HTML, CSS og minimale doser PHP. Det tok" footer_page_time = "ms å generere siden." + +; Petition form +petition.form_title = "Signer underskriftskampanjen" +petition.firstname_label = "Fornavn" +petition.firstname_placeholder = "Ditt fornavn" +petition.firstname_required = "Fornavn er påkrevd" +petition.surname_label = "Etternavn" +petition.surname_placeholder = "Ditt etternavn" +petition.surname_required = "Etternavn er påkrevd" +petition.email_label = "E-post" +petition.email_placeholder = "din@epost.no" +petition.email_help = "Vises ikke offentlig, kun for bekreftelse" +petition.email_required = "Gyldig e-post er påkrevd" +petition.region_label = "Fylke" +petition.region_required = "Velg fylke" +petition.region_placeholder = "Velg fylke..." +petition.display_legend = "Hvordan vil du vises i listen?" +petition.display_semi = "Vis mitt fornavn og fylke (standard)" +petition.display_anonymous = "Anonym - vis bare mitt fylke" +petition.anonymous_name = "Anonym" +petition.from_region = "fra" +petition.display_full = "Vis mitt fulle navn og fylke" +petition.submit_button = "Signer underskriftskampanjen" +petition.signatures_title = "Underskrifter" +petition.signature_count = "{count} underskrift" +petition.signature_count_plural = "{count} underskrifter" +petition.newest_first = "Nyeste først" +petition.error_csrf = "Sikkerhetsfeil. Vennligst prøv igjen." +petition.error_honeypot = "Ugyldig innsending." +petition.error_rate_limit = "Vennligst vent litt før du sender på nytt." +petition.error_time_check = "Flere underskrifter ble forsøkt levert fra samme PC innen et kort tidsrom. Vennligst vent en stund og prøv på nytt." +petition.error_referrer = "Ugyldig forespørsel." +petition.error_validation = "Vennligst rett opp feilene i skjemaet." +petition.error_email_send = "Kunne ikke sende bekreftelsesmail. Vennligst prøv igjen senere." +petition.error_already_signed = "Denne e-postadressen har allerede signert denne kampanjen." +petition.success_pending = "Takk! Sjekk din e-post for å bekrefte signaturen." +petition.confirm_success = "Takk! Din signatur er nå bekreftet og lagt til i listen." +petition.confirm_error = "Ugyldig eller utløpt bekreftelseslenke." +petition.confirm_already = "Denne signaturen er allerede bekreftet." +petition.email_subject = "Bekreft din signatur" +petition.email_greeting = "Hei {name}," +petition.email_thanks = "Takk for at du signerte underskriftskampanjen «{title}»." +petition.email_confirm = "Vennligst bekreft din signatur ved å klikke på denne lenken:" +petition.email_ignore = "Hvis du ikke signerte denne kampanjen, kan du ignorere denne e-posten." +petition.email_signature = "Med vennlig hilsen" +petition.email_org = "Stopp Lidelsen" + +; Norwegian regions (fylker) +regions.oslo = "Oslo" +regions.rogaland = "Rogaland" +regions.more_og_romsdal = "Møre og Romsdal" +regions.nordland = "Nordland" +regions.viken = "Viken" +regions.innlandet = "Innlandet" +regions.vestfold_og_telemark = "Vestfold og Telemark" +regions.agder = "Agder" +regions.vestland = "Vestland" +regions.trondelag = "Trøndelag" +regions.troms_og_finnmark = "Troms og Finnmark" From b1f19e2cdd2d71d13feebd716f936341b81ac3c1 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:25:51 +0100 Subject: [PATCH 14/50] Add inherit font to table elements --- custom/styles/base.css | 1 + 1 file changed, 1 insertion(+) diff --git a/custom/styles/base.css b/custom/styles/base.css index 6bf7e4a..f763f71 100644 --- a/custom/styles/base.css +++ b/custom/styles/base.css @@ -134,6 +134,7 @@ table { background-color: transparent; color: var(--color-grey); outline: .08rem var(--color-grey) solid; + font: inherit; &:hover { background-color: var(--color-grey); color: white; outline: none } &:active, &.active { background-color: var(--color-green); color: white; outline: none } &:focus { background-color: var(--color-green); color: white; outline: none } From fd1f152e55449d385d3cb3a57272e7de44f481ea Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 20:25:59 +0100 Subject: [PATCH 15/50] Update email validation to return false for invalid addresses Fix email validation to properly handle invalid addresses by returning false --- custom/vendor/PHPMailer.Lite.php | 5 +++-- 1 file changed, 3 insertions(+), 2 deletions(-) diff --git a/custom/vendor/PHPMailer.Lite.php b/custom/vendor/PHPMailer.Lite.php index c951fb5..8a15dde 100644 --- a/custom/vendor/PHPMailer.Lite.php +++ b/custom/vendor/PHPMailer.Lite.php @@ -613,9 +613,10 @@ class PHPMailerLite { if (!empty($str) && is_string($str)) { preg_match('/[A-Za-z0-9._%+-]+@[A-Za-z0-9.-]+\.[A-Za-z]{2,9}/', $str, $bk); - if (!empty($bk[0])) { - $email = $bk[0]; + if (empty($bk[0])) { + return false; } + $email = $bk[0]; $email = str_ireplace(["\r", "\n", "\t", '"', ",", "<", ">"], "", $email); if (filter_var($email, FILTER_VALIDATE_EMAIL) && self::IsValidEmail($email)) { return $email; From 5f8284041c191e6ad03f4d8fac7fbe1da9bb9504 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:15:18 +0100 Subject: [PATCH 16/50] Add development environment and workflow section Add edit instructions for AGENT.md file --- AGENT.md | 12 ++++++++++++ 1 file changed, 12 insertions(+) diff --git a/AGENT.md b/AGENT.md index 34d2d78..00e0ae1 100644 --- a/AGENT.md +++ b/AGENT.md @@ -1,6 +1,9 @@ ## Philosophy Minimal PHP for modern conveniences. Prioritize longevity (decade-scale maintainability) by avoiding volatile dependencies. Strictly add only what's essential—readable, simple, and future-proof. +## Edit instructions +All edits to this AGENT.md file should be done in a compressed shortform for LLM consumption. + ## Core Constraints **Minimalism:** Only essential tech (HTML, PHP 8.4+, CSS). No JS, frameworks, build tools, or package managers. Comments only for major sections. @@ -20,3 +23,12 @@ Minimal PHP for modern conveniences. Prioritize longevity (decade-scale maintain **CSS:** Variables, native nesting, grid layouts. `clamp()` over `@media`. Relative units > pixels. **Templates:** Escape output (`htmlspecialchars()` for UGC). Short echo tags (``). + +## Development Environment and workflow +**LLM Agent Testing Protocol:** +**Container isolation:** ALL test data (CSV, temp files, generated content) MUST remain inside container filesystem (not mounted volumes) +*Testing website:** `curl localhost:4040/path` to fetch pages, test forms with `curl -X POST -d "field=value" localhost:4040/path` +- **Test data paths:** Use `/tmp/` or `/var/test/` inside container—never write to `/var/www/html` or mounted dirs during tests +**Running tests:** `podman exec stopplidelsen.no php /path/to/test.php` or `podman-compose run --rm custom php /tmp/test-script.php` + **Syntax checks:** `podman exec stopplidelsen.no php -l /var/www/custom/file.php` + **Cleanup:** `podman-compose down && podman-compose up -d` between test runs From 7124812e4d45a5821739ba2b260e71e961454513 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:15:34 +0100 Subject: [PATCH 17/50] Rename Dockerfile to Containerfile --- Dockerfile => Containerfile | 0 1 file changed, 0 insertions(+), 0 deletions(-) rename Dockerfile => Containerfile (100%) diff --git a/Dockerfile b/Containerfile similarity index 100% rename from Dockerfile rename to Containerfile From 6682e9479800e13cbdce9777442c90b85a9796b7 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:15:43 +0100 Subject: [PATCH 18/50] Remove redundant article container and extra whitespace Remove unnecessary closing article tags and extra whitespace --- content/kontakt/01-kontaktskjema.en.php | 5 +---- content/kontakt/01-kontaktskjema.php | 5 +---- 2 files changed, 2 insertions(+), 8 deletions(-) diff --git a/content/kontakt/01-kontaktskjema.en.php b/content/kontakt/01-kontaktskjema.en.php index 4a6ca8d..739fcf1 100644 --- a/content/kontakt/01-kontaktskjema.en.php +++ b/content/kontakt/01-kontaktskjema.en.php @@ -192,8 +192,7 @@ if ($_SERVER['REQUEST_METHOD'] === 'POST' && isset($_POST['contact_form_submit'] $currentTime = time(); ?> -
-

Contact Form

+

Contact Form

Do you have questions, suggestions or want to participate in our work? Fill out the form below! But remember that it may take time before you get a response, we are not many and run everything on a voluntary basis.

@@ -273,5 +272,3 @@ $currentTime = time(); - -
diff --git a/content/kontakt/01-kontaktskjema.php b/content/kontakt/01-kontaktskjema.php index 985d8aa..710d749 100644 --- a/content/kontakt/01-kontaktskjema.php +++ b/content/kontakt/01-kontaktskjema.php @@ -192,8 +192,7 @@ if ($_SERVER['REQUEST_METHOD'] === 'POST' && isset($_POST['contact_form_submit'] $currentTime = time(); ?> -
-

Kontaktskjema

+

Kontaktskjema

Har du spørsmål, innspill eller ønsker å delta i arbeidet vårt? Fyll ut skjemaet nedenfor! Men husk at det kan ta tid før du får svar, vi er ikke så mange og driver alt på frivillig basis.

@@ -273,5 +272,3 @@ $currentTime = time(); - -
From 22717168ae60d79031936fc027f9c9506149f334 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:15:58 +0100 Subject: [PATCH 19/50] Update article structure and fix translation keys Fix translation keys in FAQ template Add article wrapper to page template --- content/nyheter/2025-11-28-hva-skjedde-i-okt-nov/article.html | 4 +--- custom/templates/list-faq.php | 4 ++-- custom/templates/page.php | 2 ++ 3 files changed, 5 insertions(+), 5 deletions(-) diff --git a/content/nyheter/2025-11-28-hva-skjedde-i-okt-nov/article.html b/content/nyheter/2025-11-28-hva-skjedde-i-okt-nov/article.html index 0e1f7d3..a5b12f6 100644 --- a/content/nyheter/2025-11-28-hva-skjedde-i-okt-nov/article.html +++ b/content/nyheter/2025-11-28-hva-skjedde-i-okt-nov/article.html @@ -1,5 +1,4 @@ -
-

Dette skjedde i oktober og november

+

Dette skjedde i oktober og november

Det har vært en hektisk høst, med møter og planlegging av neste års aktiviteter.

Politikere

@@ -18,4 +17,3 @@ Moderpartiene har hatt en travel høst med ny regjering og budsjettforhandlinger

Takk til dere alle

Til slutt vil vi takke dere alle for deres bidrag til å få dette til. Takk til dere som deler historien dere, takk til dere som engasjerer dere og sprer brosjyrer, takk til dere som liker og deler informasjon. Sammen er vi sterke!

-
diff --git a/custom/templates/list-faq.php b/custom/templates/list-faq.php index d2b7984..cbb3a41 100644 --- a/custom/templates/list-faq.php +++ b/custom/templates/list-faq.php @@ -14,9 +14,9 @@
-

+

- +
diff --git a/custom/templates/page.php b/custom/templates/page.php index 6ed654c..edff588 100644 --- a/custom/templates/page.php +++ b/custom/templates/page.php @@ -1,3 +1,4 @@ +
@@ -23,3 +24,4 @@ +
From 443c44d095fdd5acd001e941770e2b3a8cc625f5 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:16:14 +0100 Subject: [PATCH 20/50] Add section headers to language files and update petition messages Add GDPR-compliant expiration to confirmation links Add IP rate limiting error message Update region list to current Norwegian counties Add signature deletion functionality Add thank you email with deletion option Improve error messages and user feedback --- custom/languages/en.ini | 143 +++++++++++++++++++++------------------ custom/languages/no.ini | 144 ++++++++++++++++++++++------------------ 2 files changed, 156 insertions(+), 131 deletions(-) diff --git a/custom/languages/en.ini b/custom/languages/en.ini index 27a00db..aeb9ba8 100644 --- a/custom/languages/en.ini +++ b/custom/languages/en.ini @@ -8,72 +8,85 @@ language_name_no = "Norsk" categories = "Categories" tags = "Tags" -; FAQ -faq_summary_label = "In short:" -faq_read_full_answer = "Read full answer" +[faq] +summary_label = "In short:" +read_full_answer = "Read full answer" -; Footer -footer_social = "Follow us on Mastodon" -footer_copyright = "Copyright" -footer_follow_mastodon = "Follow us on Mastodon" -footer_handcoded = "This website was hand-coded by Ruben Solvang using HTML, CSS and minimal doses of PHP. It took" -footer_page_time = "ms to generate this page." +[footer] +social = "Follow us on Mastodon" +copyright = "Copyright" +follow_mastodon = "Follow us on Mastodon" +handcoded = "This website was hand-coded by Ruben Solvang using HTML, CSS and minimal doses of PHP. It took" +page_time = "ms to generate this page." -; Petition form -petition.form_title = "Sign the Petition" -petition.firstname_label = "First name" -petition.firstname_placeholder = "Your first name" -petition.firstname_required = "First name is required" -petition.surname_label = "Surname" -petition.surname_placeholder = "Your surname" -petition.surname_required = "Surname is required" -petition.email_label = "Email" -petition.email_placeholder = "your@email.com" -petition.email_help = "Not shown publicly, only for confirmation" -petition.email_required = "Valid email is required" -petition.region_label = "Region" -petition.region_required = "Please select a region" -petition.region_placeholder = "Select region..." -petition.display_legend = "How should you appear in the list?" -petition.display_semi = "Show my first name and region (default)" -petition.display_anonymous = "Anonymous - only show my region" -petition.anonymous_name = "Anonymous" -petition.from_region = "from" -petition.display_full = "Show my full name and region" -petition.submit_button = "Sign the Petition" -petition.signatures_title = "Signatures" -petition.signature_count = "{count} signature" -petition.signature_count_plural = "{count} signatures" -petition.newest_first = "Newest first" -petition.error_csrf = "Security error. Please try again." -petition.error_honeypot = "Invalid submission." -petition.error_rate_limit = "Please wait a moment before submitting again." -petition.error_time_check = "Multiple signature attempts were sent from the same computer within a short time. Please wait a moment and try again." -petition.error_referrer = "Invalid request." -petition.error_validation = "Please correct the errors in the form." -petition.error_email_send = "Could not send confirmation email. Please try again later." -petition.error_already_signed = "This email address has already signed this petition." -petition.success_pending = "Thank you! Check your email to confirm your signature." -petition.confirm_success = "Thank you! Your signature has been confirmed and added to the list." -petition.confirm_error = "Invalid or expired confirmation link." -petition.confirm_already = "This signature has already been confirmed." -petition.email_subject = "Confirm your signature" -petition.email_greeting = "Hello {name}," -petition.email_thanks = "Thank you for signing the petition \"{title}\"." -petition.email_confirm = "Please confirm your signature by clicking this link:" -petition.email_ignore = "If you did not sign this petition, please ignore this email." -petition.email_signature = "Best regards" -petition.email_org = "Stop the Suffering" +[petition] +form_title = "Sign the Petition" +firstname_label = "First name" +firstname_placeholder = "Your first name" +firstname_required = "First name is required" +surname_label = "Surname" +surname_placeholder = "Your surname" +surname_required = "Surname is required" +email_label = "Email" +email_placeholder = "your@email.com" +email_help = "Not shown publicly, only for confirmation" +email_required = "Valid email is required" +region_label = "Region" +region_required = "Please select a region" +region_placeholder = "Select region..." +display_legend = "How should you appear in the list?" +display_semi = "Show my first name and region (default)" +display_anonymous = "Anonymous - only show my region" +anonymous_name = "Anonymous" +from_region = "from" +display_full = "Show my full name and region" +submit_button = "Sign the Petition" +signatures_title = "Signatures" +signature_count = "{count} signature" +signature_count_plural = "{count} signatures" +newest_first = "Newest first" +error_csrf = "Security error. Please try again." +error_honeypot = "Invalid submission." +error_rate_limit = "Please wait a moment before submitting again." +error_ip_rate_limit = "Too many attempts from your IP address. Please wait 5 minutes before trying again." +error_time_check = "Multiple signature attempts were sent from the same computer within a short time. Please wait a moment and try again." +error_referrer = "Invalid request." +error_validation = "Please correct the errors in the form." +error_email_send = "Could not send confirmation email. Please try again later." +error_already_signed = "This email address has already signed this petition." +success_pending = "Thank you! Check your email to confirm your signature." +confirm_success = "Thank you! Your signature has been confirmed and added to the list." +confirm_error = "Invalid confirmation link." +confirm_expired = "This confirmation link has expired (max 30 days). Please sign the petition again if you still wish to support it." +confirm_already = "This signature has already been confirmed." +email_subject = "Confirm your signature" +email_greeting = "Hello {name}," +email_thanks = "Thank you for signing the petition \"{title}\"." +email_confirm = "Please confirm your signature by clicking this link:" +email_expiry_notice = "This link is valid for 30 days for privacy reasons (GDPR compliance)." +email_ignore = "If you did not sign this petition, please ignore this email." +email_signature = "Best regards" +email_org = "Stop the Suffering" +email_thankyou_subject = "Thank you for your signature" +email_thankyou_confirmed = "Your signature on the petition \"{title}\" has been confirmed and registered." +email_delete_info = "If you wish to withdraw your signature, you can do so at any time by clicking this link:" +delete_success = "Your signature has been deleted." +delete_error = "Could not delete the signature. The link may be invalid." ; Norwegian regions (fylker) - kept in Norwegian as they are proper nouns -regions.oslo = "Oslo" -regions.rogaland = "Rogaland" -regions.more_og_romsdal = "Møre og Romsdal" -regions.nordland = "Nordland" -regions.viken = "Viken" -regions.innlandet = "Innlandet" -regions.vestfold_og_telemark = "Vestfold og Telemark" -regions.agder = "Agder" -regions.vestland = "Vestland" -regions.trondelag = "Trøndelag" -regions.troms_og_finnmark = "Troms og Finnmark" +[regions] +agder = "Agder" +akershus = "Akershus" +buskerud = "Buskerud" +finnmark = "Finnmark" +innlandet = "Innlandet" +more_og_romsdal = "Møre og Romsdal" +nordland = "Nordland" +oslo = "Oslo" +rogaland = "Rogaland" +telemark = "Telemark" +troms = "Troms" +trondelag = "Trøndelag" +vestfold = "Vestfold" +vestland = "Vestland" +ostfold = "Østfold" diff --git a/custom/languages/no.ini b/custom/languages/no.ini index 06ae11d..0b90902 100644 --- a/custom/languages/no.ini +++ b/custom/languages/no.ini @@ -8,72 +8,84 @@ language_name_en = "English" categories = "Kategorier" tags = "Stikkord" -; FAQ -faq_summary_label = "Kort oppsumert:" -faq_read_full_answer = "Les hele svaret" +[faq] +summary_label = "Kort oppsumert:" +read_full_answer = "Les hele svaret" -; Footer -footer_social = "Følg oss på Facebook, Instagram og Mastodon" -footer_copyright = "Opphavsrett" -footer_follow_mastodon = "Følg oss på Mastodon" -footer_handcoded = "Nettsiden er håndkodet av Ruben Solvang ved hjelp av HTML, CSS og minimale doser PHP. Det tok" -footer_page_time = "ms å generere siden." +[footer] +social = "Følg oss på Facebook, Instagram og Mastodon" +copyright = "Opphavsrett" +follow_mastodon = "Følg oss på Mastodon" +handcoded = "Nettsiden er håndkodet av Ruben Solvang ved hjelp av HTML, CSS og minimale doser PHP. Det tok" +page_time = "ms å generere siden." -; Petition form -petition.form_title = "Signer underskriftskampanjen" -petition.firstname_label = "Fornavn" -petition.firstname_placeholder = "Ditt fornavn" -petition.firstname_required = "Fornavn er påkrevd" -petition.surname_label = "Etternavn" -petition.surname_placeholder = "Ditt etternavn" -petition.surname_required = "Etternavn er påkrevd" -petition.email_label = "E-post" -petition.email_placeholder = "din@epost.no" -petition.email_help = "Vises ikke offentlig, kun for bekreftelse" -petition.email_required = "Gyldig e-post er påkrevd" -petition.region_label = "Fylke" -petition.region_required = "Velg fylke" -petition.region_placeholder = "Velg fylke..." -petition.display_legend = "Hvordan vil du vises i listen?" -petition.display_semi = "Vis mitt fornavn og fylke (standard)" -petition.display_anonymous = "Anonym - vis bare mitt fylke" -petition.anonymous_name = "Anonym" -petition.from_region = "fra" -petition.display_full = "Vis mitt fulle navn og fylke" -petition.submit_button = "Signer underskriftskampanjen" -petition.signatures_title = "Underskrifter" -petition.signature_count = "{count} underskrift" -petition.signature_count_plural = "{count} underskrifter" -petition.newest_first = "Nyeste først" -petition.error_csrf = "Sikkerhetsfeil. Vennligst prøv igjen." -petition.error_honeypot = "Ugyldig innsending." -petition.error_rate_limit = "Vennligst vent litt før du sender på nytt." -petition.error_time_check = "Flere underskrifter ble forsøkt levert fra samme PC innen et kort tidsrom. Vennligst vent en stund og prøv på nytt." -petition.error_referrer = "Ugyldig forespørsel." -petition.error_validation = "Vennligst rett opp feilene i skjemaet." -petition.error_email_send = "Kunne ikke sende bekreftelsesmail. Vennligst prøv igjen senere." -petition.error_already_signed = "Denne e-postadressen har allerede signert denne kampanjen." -petition.success_pending = "Takk! Sjekk din e-post for å bekrefte signaturen." -petition.confirm_success = "Takk! Din signatur er nå bekreftet og lagt til i listen." -petition.confirm_error = "Ugyldig eller utløpt bekreftelseslenke." -petition.confirm_already = "Denne signaturen er allerede bekreftet." -petition.email_subject = "Bekreft din signatur" -petition.email_greeting = "Hei {name}," -petition.email_thanks = "Takk for at du signerte underskriftskampanjen «{title}»." -petition.email_confirm = "Vennligst bekreft din signatur ved å klikke på denne lenken:" -petition.email_ignore = "Hvis du ikke signerte denne kampanjen, kan du ignorere denne e-posten." -petition.email_signature = "Med vennlig hilsen" -petition.email_org = "Stopp Lidelsen" +[petition] +form_title = "Signer underskriftskampanjen" +firstname_label = "Fornavn" +firstname_placeholder = "Ditt fornavn" +firstname_required = "Fornavn er påkrevd" +surname_label = "Etternavn" +surname_placeholder = "Ditt etternavn" +surname_required = "Etternavn er påkrevd" +email_label = "E-post" +email_placeholder = "din@epost.no" +email_help = "Vises ikke offentlig, kun for bekreftelse" +email_required = "Gyldig e-post er påkrevd" +region_label = "Fylke" +region_required = "Velg fylke" +region_placeholder = "Velg fylke..." +display_legend = "Hvordan vil du vises i listen?" +display_semi = "Vis mitt fornavn og fylke (standard)" +display_anonymous = "Anonym - vis bare mitt fylke" +anonymous_name = "Anonym" +from_region = "fra" +display_full = "Vis mitt fulle navn og fylke" +submit_button = "Signer underskriftskampanjen" +signatures_title = "Underskrifter" +signature_count = "{count} underskrift" +signature_count_plural = "{count} underskrifter" +newest_first = "Nyeste først" +error_csrf = "Sikkerhetsfeil. Vennligst prøv igjen." +error_honeypot = "Ugyldig innsending." +error_rate_limit = "Vennligst vent litt før du sender på nytt." +error_ip_rate_limit = "For mange forsøk fra din IP-adresse. Vennligst vent 5 minutter før du prøver igjen." +error_time_check = "Flere underskrifter ble forsøkt levert fra samme PC innen et kort tidsrom. Vennligst vent en stund og prøv på nytt." +error_referrer = "Ugyldig forespørsel." +error_validation = "Vennligst rett opp feilene i skjemaet." +error_email_send = "Kunne ikke sende bekreftelsesmail. Vennligst prøv igjen senere." +error_already_signed = "Denne e-postadressen har allerede signert denne kampanjen." +success_pending = "Takk! Sjekk din e-post for å bekrefte signaturen." +confirm_success = "Takk! Din signatur er nå bekreftet og lagt til i listen." +confirm_error = "Ugyldig bekreftelseslenke." +confirm_expired = "Denne bekreftelseslenken har utløpt (maks 30 dager). Vennligst signer kampanjen på nytt hvis du fortsatt ønsker å støtte den." +confirm_already = "Denne signaturen er allerede bekreftet." +email_subject = "Bekreft din signatur" +email_greeting = "Hei {name}," +email_thanks = "Takk for at du signerte underskriftskampanjen «{title}»." +email_confirm = "Vennligst bekreft din signatur ved å klikke på denne lenken:" +email_expiry_notice = "Denne lenken er gyldig i 30 dager av personvernhensyn (GDPR)." +email_ignore = "Hvis du ikke signerte denne kampanjen, kan du ignorere denne e-posten." +email_signature = "Med vennlig hilsen" +email_org = "Stopp Lidelsen" +email_thankyou_subject = "Takk for din signatur" +email_thankyou_confirmed = "Din signatur på underskriftskampanjen «{title}» er nå bekreftet og registrert." +email_delete_info = "Hvis du ønsker å trekke tilbake din signatur, kan du gjøre det når som helst ved å klikke på denne lenken:" +delete_success = "Din signatur er nå slettet." +delete_error = "Kunne ikke slette signaturen. Lenken kan være ugyldig." -; Norwegian regions (fylker) -regions.oslo = "Oslo" -regions.rogaland = "Rogaland" -regions.more_og_romsdal = "Møre og Romsdal" -regions.nordland = "Nordland" -regions.viken = "Viken" -regions.innlandet = "Innlandet" -regions.vestfold_og_telemark = "Vestfold og Telemark" -regions.agder = "Agder" -regions.vestland = "Vestland" -regions.trondelag = "Trøndelag" -regions.troms_og_finnmark = "Troms og Finnmark" +[regions] +agder = "Agder" +akershus = "Akershus" +buskerud = "Buskerud" +finnmark = "Finnmark" +innlandet = "Innlandet" +more_og_romsdal = "Møre og Romsdal" +nordland = "Nordland" +oslo = "Oslo" +rogaland = "Rogaland" +telemark = "Telemark" +troms = "Troms" +trondelag = "Trøndelag" +vestfold = "Vestfold" +vestland = "Vestland" +ostfold = "Østfold" From b452c73de30c8e6a6db1a2245db501257ad6a4b2 Mon Sep 17 00:00:00 2001 From: Ruben Date: Wed, 14 Jan 2026 23:16:19 +0100 Subject: [PATCH 21/50] Update translation keys to use dot notation Update content rendering to use wrapped content fallback --- custom/templates/base.php | 10 +++++----- 1 file changed, 5 insertions(+), 5 deletions(-) diff --git a/custom/templates/base.php b/custom/templates/base.php index 4a1771f..e473327 100644 --- a/custom/templates/base.php +++ b/custom/templates/base.php @@ -123,17 +123,17 @@ function getActiveClass($href) { return rtrim(parse_url($_SERVER['REQUEST_URI'],
- +